Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
34500.0 | 2011-10-20 00:00:00 UTC | Mid-Day Update: Stocks Lower, Despite Positive Philly Fed Index Surprise | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-lower-despite-positive-philly-fed-index-surprise-2011-10-20 | nan | nan | Here's where markets stand at mid-day:
-NYSE down 43.95 (-0.64%) to 7,193.68
-DJIA down 79.99 (-0.68%) to 11,426.06
-S&P 500 down 0.78 (-1.37%) to 1,568.36
-Nasdaq down 34.90 (-1.34%) to 2,567.89
GLOBAL SENTIMENT
Nikkei down 1%
Hang Seng down 1.7%.
Shanghai Composite down 1.9%.
FTSE-100 down 0.4%.
DAX-30 down 0.7%.
MID-DAY NYSE INDEX WATCH
NYSE Energy down 0.54% at 11,874.82
NYSE Financial down 0.96% at 3,977.05
NYSE Health Care down 0.31% at 6,603.62
NYSE Arca Tech 100 down 1.55% at 1,057.00
UPSIDE MOVERS
(+) TZOO (+4.4%) beats with Q3 results.
(+) RVBD (+9.9%) continues evening jump that followed upbeat earnings.
(+) FITB (+6.5%) earnings beat.
(+) ERIC (+1.2%) earnings beat.
(+) LUV (+2.7%) earnings beat.
(+) YOKU (+4.2%) upgraded.
(+) WDC (+0.1%) downgraded.
DOWNSIDE MOVERS
(-) LLY (-0.9%) meets with EPS, guides in line.
(-) EBAY (-6.7%) continues evening fall that followed EPS in line, disappointing guidance.
(-) WYNN (-7%) continues evening fall that followed mixed results.
(-) CRUS (-17.6%) continues evening decline that followed weak earnings, revenue guidance.
(-) BIDU (-2.2%) downgraded.
MARKET DIRECTION
Stocks have slipped into negative territory as Europe worries return to center stage, overshadowing new data showing signs of life in regional manufacturing and a drop in first-time unemployment claims.
The U.S. Federal Reserve's Philly Fed index rose to 8.7 in October from negative 17.5 last month, MarketWatch noted in a report on the data. Economists had expected a negative 10 reading, the report said.
Also, the Labor Department said initial jobless claims fell by 6,000 to 403,000 in the week ended Oct. 15. Initial claims from two weeks ago were revised up to 409,000 from an original reading of 404,000, however. The average of new claims over the past four weeks, seen as a more accurate gauge of labor trends, fell by 6,250 to 403,000, the lowest since mid-April.
Overseas, an unexpected meeting between French President Nicolas Sarkozy and German Chancellor Angela Merkel and other international officials in Frankfurt late Wednesday fueled worries over a potential rift between Berlin and Paris over elements of a comprehensive package of reforms expected to be presented by euro-zone leaders at a Brussels summit meeting on Sunday, news reports said. There was no official comment from the Wednesday gathering, however.
U.S. economic news helped cement those early mild futures gains, though brought little fresh hope for aggressive labor market improvement.
In other company news:
Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. A Jefferies Group analyst noted that Merck & Co. ( MRK ), Roche ( RHHBY ) and Bayer ( BAYRY ) are potentially interested parties.
Shares of Apple ( AAPL ) are lower after the company reported that it held down costs for its iPhone 4S even as it made several design improvements, such as the capacity t be used with multiple wireless systems. The report cited an assessment from industry research firm IHS iSuppli.
Shares Neoprobe (NEOP) are sharply higher after it announced that its New Drug Application for Lymphoseek has been accepted for review by the U.S. Food and Drug Administration. Neoprobe submitted the Lymphoseek NDA last month.
Cisco (CSCO) is down after it today announced its intent to acquire privately-held BNI Video. Under the terms of the agreement, Cisco will pay $99 million in cash and retention-based incentives in exchange for all shares of BNI Video. The acquisition is subject to various standard closing conditions and is expected to be complete in the second quarter of Cisco's fiscal year 2012.
In earnings news:
--Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. However, revenue came in at $537.2 million, below expectations of $541 million.
--Shares of Philip Morris (PM) are up 2.79%, or $1.84, to $67.7 after the company issued its third quarter report. The company said Q3 EPS were $1.37, ahead of analyst expectations of $1.24. Revenue rose 26.4% from the year ago period to $8.36 billion, comfortably beating estimates of $7.57 billion. The company also says it sees FY11 EPS of $4.75-4.80, higher than estimates of $4.74.
--Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. Chief Executive Stephen Elop said despite the result, the firm's sales execution and inventory situation had improved, the report said.
Natural gas futures gained after a new report showed inventories rose 103 billion cubic feet for the week ended Oct. 14, less than analysts had predicted.
Commodities are down. December gold contracts fell 2.27% to $1,610 an ounce while December crude oil contacts are down $1.27 to $86.29 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 1.32% to $32.87 and the United States Natural Gas fund (UNG) is up 1.71%, to $8.91.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 1.91% to $156.81. Market Vectors Gold Miners (GDX) is down 1.68% to $52.65. iShares Silver Trust (SLV) is down 2.2% to $29.57.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. Stocks have slipped into negative territory as Europe worries return to center stage, overshadowing new data showing signs of life in regional manufacturing and a drop in first-time unemployment claims. Shares of Apple ( AAPL ) are lower after the company reported that it held down costs for its iPhone 4S even as it made several design improvements, such as the capacity t be used with multiple wireless systems. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. In earnings news: --Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. Natural gas futures gained after a new report showed inventories rose 103 billion cubic feet for the week ended Oct. 14, less than analysts had predicted. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. In earnings news: --Shares of The New York Times Co. (NYT) are higher after the media company reported Q3 EPS, excluding items, of $0.05 per share, ahead of the analyst consensus of $0.04 per share on Thomson Reuters. --Shares of Nokia (NOK) are higher after the mobile phone company reported a $93.1 million Q3 loss, which was less than analysts had expected, The New York Times reports. | In other company news: Abbott Laboratories ( ABT ) are higher on a Bloomberg report that the breakup of the drug maker into two separate firms will result in a $54 billion target for acquisitive drug makers. The U.S. Federal Reserve's Philly Fed index rose to 8.7 in October from negative 17.5 last month, MarketWatch noted in a report on the data. Revenue rose 26.4% from the year ago period to $8.36 billion, comfortably beating estimates of $7.57 billion. |
34501.0 | 2011-10-20 00:00:00 UTC | J&J Third-Quarter Earnings Fall: These 4 Other Drugmakers Reporting Soon | ABT | https://www.nasdaq.com/articles/jj-third-quarter-earnings-fall-these-4-other-drugmakers-reporting-soon-2011-10-20 | nan | nan | (Written by Alexander Crawford. EPS estimates sourced from Yahoo! Finance, data sourced from Finviz.)
On Tuesday Johnson & Johnson (JNJ) reported disappointing third-quarter profits, which slipped more than 6% from one year ago. The company blamed generic competition on several key drugs of theirs, as well as increased spending on marketing new drugs.
“Bottom line” net income dropped to $3.2 billion, or $1.15 a share, from $3.42 billion, or $1.23, a year earlier, reports Bloomberg.
Johnson & Johnson is currently facing generic competition on its antibiotic Levaquin and its attention deficit disorder medication Concerta, which together had generated almost 5% of revenue last year.
On a brighter note, J&J raised its lower-end forecast for 2011 profit, and its earnings adjusted for one-time items beat analyst expectations.
The generic competitors cost J&J “a few hundred million in sales,” said Jeff Jonas, a Gabelli & Co. analyst in an interview with Bloomberg before the company’s announcement. “And they’re still investing pretty heavily to launch their new drugs.”
This disappointing earnings report may make you question whether other drugmakers will meet the same fate. After all, generic competition is affecting virtually all major drugmakers in some way today.
For a look at other major drugmakers yet to report their third-quarter earnings, here is a list of four drugmakers soon to report:
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
1. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $81.63B. Earnings to be released on 10/19. Among 17 analysts surveyed, the average EPS estimate for this quarter is $1.17 vs. year-ago EPS at $1.05.
2. Eli Lilly & Co. (LLY): Develops, manufactures, and sells pharmaceutical products worldwide. Market cap of $44.56B. Earnings to be released on 10/20. Among 16 analysts surveyed, the average EPS estimate for this quarter is $1.12 vs. year-ago EPS at $1.21
3. Bristol-Myers Squibb Company (BMY): Develops, and delivers innovative medicines that help patients prevail over serious diseases. Market cap of $55.54B. Earnings to be released on 10/27. Among 17 analysts surveyed, the average EPS estimate for this quarter is $0.57 vs. year-ago EPS at $0.59.
4. Merck & Co. Inc. (MRK): Provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Market cap of $101.02B. Earnings to be released on 10/28. Among 18 analysts surveyed, the average EPS estimate for this quarter is $0.90 vs. year-ago EPS at $0.8
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. On a brighter note, J&J raised its lower-end forecast for 2011 profit, and its earnings adjusted for one-time items beat analyst expectations. The generic competitors cost J&J “a few hundred million in sales,” said Jeff Jonas, a Gabelli & Co. analyst in an interview with Bloomberg before the company’s announcement. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Among 17 analysts surveyed, the average EPS estimate for this quarter is $1.17 vs. year-ago EPS at $1.05. Among 18 analysts surveyed, the average EPS estimate for this quarter is $0.90 vs. year-ago EPS at $0.8 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Among 17 analysts surveyed, the average EPS estimate for this quarter is $1.17 vs. year-ago EPS at $1.05. Among 16 analysts surveyed, the average EPS estimate for this quarter is $1.12 vs. year-ago EPS at $1.21 3. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. EPS estimates sourced from Yahoo! Among 18 analysts surveyed, the average EPS estimate for this quarter is $0.90 vs. year-ago EPS at $0.8 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34502.0 | 2011-10-19 00:00:00 UTC | Abbott Labs’ Adjusted Q3 Net Beats View; Will Split into Two Companies in 2012 (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-adjusted-q3-net-beats-view-will-split-two-companies-2012-abt-2011-10-19 | nan | nan | Diversified healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected third quarter earnings and announced it would split into two separate publicly-traded companies next year.
The Abbott Park, IL-based company reported third quarter net income of $303 million, or 19 cents per share, compared with $891 million, or 57 cents per share, in the year-ago period. Excluding special items, adjusted profit was $1.18 per share.
Net sales rose 13% from last year to $1.85 billion.
On average, Wall Street analysts expected a smaller profit of $1.17 per share, on lower revenue of $9.64 billion.
Looking ahead, the company narrowed its full-year earnings forecast to a range of $4.64 to $4.66 per share, excluding items, while analysts expect $4.63 per share for the year.
Break-Up Planned
Separately, Abbott announced that it plans to split its business into two separate publicly traded companies. The two companies will be comprised of:
Diversified medical products, consisting of its generic pharma, devices, diagnostic, and nutritional businesses. This division will keep the Abbott name.
The other company will specialize in research-based pharmaceuticals, made up of its proprietary pharmaceuticals and biologics units. The name of this company will be determined at a later date, and will be headed by current executive VP of Global Pharmaceuticals Richard Gonzalez, a 30-year veteran of the company.
The transaction is expected to be completed by the end of 2012, and is subject to shareholder and regulatory approval.
Abbott shares jumped $4.12, or +7.9%, in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.66% dividend yield, based on last night's closing stock price of $52.44.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Diversified healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected third quarter earnings and announced it would split into two separate publicly-traded companies next year. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | Diversified healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected third quarter earnings and announced it would split into two separate publicly-traded companies next year. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | Diversified healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected third quarter earnings and announced it would split into two separate publicly-traded companies next year. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | Diversified healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected third quarter earnings and announced it would split into two separate publicly-traded companies next year. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. |
34503.0 | 2011-10-19 00:00:00 UTC | Market Wrap-Up for Oct.19 (AAPL, ABT, TRV, AEM, BLK, INTC, GG, more) | ABT | https://www.nasdaq.com/articles/market-wrap-oct19-aapl-abt-trv-aem-blk-intc-gg-more-2011-10-19 | nan | nan | The markets had been trading mixed into the early afternoon, but by the close sellers hit the tape with some decent force.
When first glancing at today's business coverage, you'd think Apple ( AAPL ) was the only company that reported relevant results. We have more on Apple and the theme of "good news being built into a story" below.
Let's start with the earnings winners that bucked the selling: Travelers ( TRV ), Diageo ( DEO ), and Intel Corp ( INTC ) all ended in the green. A name we currently like, Abbott Labs ( ABT ), was up following their results as well as news the company will be splitting itself into two separate publicly-traded companies by the end of 2012. A big loser on the day was Agnico-Eagle Mines ( AEM ) on news of a mine shutdown for the gold-mining company. Investors in gold-mining stocks were certainly spooked by the news, with shares of Barrick Gold ( ABX ) and GoldCorp ( GG ) getting hit hard, along with other miners.
As for stocks not resonating well with investors following their reports, BlackRock ( BLK ), M&T Bank ( MTB ), and Comerica ( CMA ) took it one the chin and closed lower on the day. Speaking of BlackRock, company executives were participating along with other market titans in a Senate hearing today regarding ETFs and the effects they are having on market prices (especially leveraged ETFs). Unfortunately, senator turnout was said to be light. It must be campaign season. Either that or the fact that politicians don't tend to pick up on serious issues until severe damage has already taken place.
Dangers of Good News Already Built In
The negative reaction to Apple's ( AAPL ) surprise earnings miss from last night caught many investors off guard. The event market the first time Apple missed estimates in several years, and analysts are in the midst of scrambling to justify their much-higher price targets as we speak.
There is always a danger when investor and analyst sentiment on a particular investment is overwhelmingly bullish. You may sometimes hear the term "narrow market" when a stock market pundit is talking about the state of the investing world. A narrow market occurs when crowds gather in a small group of stocks or commodities in a super-bullish way. At some point, bad news will come, and many investors fail to react when they probably should.
Some of the biggest momentum winners of the last few years such as Apple ( AAPL ), Amazon ( AMZN ), or Gold ( GLD ), the trade in these stocks can easily be described as "crowded." With Amazon, the worry is its high valuation and what will happen to the stock if there is even a slight disappointment. With gold, the yellow metal and other commodities have been recently hurt by a margin price hike to trade futures contracts. Further margin price moves could put an even bigger dent in investors' appetite for gold.
Of course, you can sometimes be lucky just focusing on a couple of momentum ideas that continue to have great runs, but at some point, you will need to do a deep evaluation as to what the share/commodity prices could be telling us. If you can discipline yourself to pull the sell trigger, then you will be fine, but for many investors, selling big winners is often the hardest trade to have to make.
The beauty of dividend investing is that we don't worry about manic momentum traders for the most part. We focus on the long term, and put our money to work in income-producing stocks that don't fluctuate in price the way day traders like. There's no point in putting our wealth plan in jeopardy over one earnings miss.
Caulk & Paint and Make It What It Ain't
Our heads are still spinning after going through the earnings results from the last couple of days. It's incredible to see all the write-offs from banks, revaluations of debt, and nine-figure SEC settlements. What a mess! Here we thought TARP was supposed to make all the bad news go away. Our cautious stance on the financial names continues despite the stocks holding up a bit recently.
I am certain there will be plenty of calls that financials have bottomed. This past weekend's Barron's, for instance, had a "Buy the Banks" story emblazoned on its cover. There is so much time focused on turnaround efforts, when instead you can be accumulating the "boring" stocks that go out each quarter and deliver earnings results after earnings results. Keep this in mind the next time you are lured into the spell of "value" play articles/headlines.
There's an old saying in the real estate world that goes "Caulk and paint make it what it ain't." It seems that some in the financial space have adopted this mantra in attempts to bolster perception of the health of some of our nation's biggest banks.
Stagflation Alert
Consumer Price Index data out this morning showed food prices rose 0.4 percent for the month of September, pushed up by big increases in the dairy, cereals, and fruits and vegetables categories. Many economists feel that so-called "stagflation" (higher prices despite lower economic growth and higher unemployment) won't appear if unemployment remains high and consumer demand remains contained. If they are wrong, the one way to beat stagflation will be to raise interest rates. Doing so in a shaky economy can be quite the task. We'll be monitoring the data closely, as these factors all could play into how we view the markets moving forward.
Social Security Payouts to Rise 3.6%
News is officially out this morning that social security recipients will be getting a 3.6% cost-of-living raise in payouts for 2012. This is the first increase since 2009, following no increases in 2010 or 2011. How much of the increase will stick depends on how much the medicare premiums will be increased. That news will be out later this month, and many expect those higher premiums to all but wipe out the COLA increase.
A Dividend Capture Strategy for Active Investors
We offer complete U.S. dividend data for all Dividend.com Premium members, so anyone that focuses on "Dividend Capture" trading strategies should have plenty of good stuff to research each day. Just check our enhanced Ex-Dividend Calendar , which is the best in the business, to search for upcoming payouts.
Speaking of dividend capture, Dividend.com Premium members can now access a 9 page report we published on the essential elements to any successful dividend capture strategy. Be sure to check it out!
Thanks for reading everybody. I'll see you tomorrow!
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A name we currently like, Abbott Labs ( ABT ), was up following their results as well as news the company will be splitting itself into two separate publicly-traded companies by the end of 2012. As for stocks not resonating well with investors following their reports, BlackRock ( BLK ), M&T Bank ( MTB ), and Comerica ( CMA ) took it one the chin and closed lower on the day. Dangers of Good News Already Built In The negative reaction to Apple's ( AAPL ) surprise earnings miss from last night caught many investors off guard. | A name we currently like, Abbott Labs ( ABT ), was up following their results as well as news the company will be splitting itself into two separate publicly-traded companies by the end of 2012. Many economists feel that so-called "stagflation" (higher prices despite lower economic growth and higher unemployment) won't appear if unemployment remains high and consumer demand remains contained. A Dividend Capture Strategy for Active Investors We offer complete U.S. dividend data for all Dividend.com Premium members, so anyone that focuses on "Dividend Capture" trading strategies should have plenty of good stuff to research each day. | A name we currently like, Abbott Labs ( ABT ), was up following their results as well as news the company will be splitting itself into two separate publicly-traded companies by the end of 2012. Speaking of BlackRock, company executives were participating along with other market titans in a Senate hearing today regarding ETFs and the effects they are having on market prices (especially leveraged ETFs). Dangers of Good News Already Built In The negative reaction to Apple's ( AAPL ) surprise earnings miss from last night caught many investors off guard. | A name we currently like, Abbott Labs ( ABT ), was up following their results as well as news the company will be splitting itself into two separate publicly-traded companies by the end of 2012. Some of the biggest momentum winners of the last few years such as Apple ( AAPL ), Amazon ( AMZN ), or Gold ( GLD ), the trade in these stocks can easily be described as "crowded." The beauty of dividend investing is that we don't worry about manic momentum traders for the most part. |
34504.0 | 2011-10-19 00:00:00 UTC | Thinking Beyond Today | ABT | https://www.nasdaq.com/articles/thinking-beyond-today-2011-10-19 | nan | nan | Most investors understand that stocks reflect activity anticipated 6 to 9 months from now. That's why some stocks go up when they report losses. It's because management announces new contracts or new cash flows that will create more profits in the future. Or investors simply boost a stock's price because they think the worst is over and future revenues and profits will increase. Banks are a good example of this, though they're still selling cheaply. Still most of them are well off their lows as their numbers are improving in certain areas such as loan losses.
With that in mind, here are a few ideas to anticipate that are beginning to grab some investors' interest and enticing them to start buying.
- Home Building stocks. These rallied for a while but then real facts took them back down. Now the builders themselves are showing signs of optimism. They're seeing more interest from buyers and anticipate low interest rates for some time will persuade home buyers to act. Builder confidence in the market for newly built, single-family homes rose four points to 18 on the National Association of Home Builders/Wells Fargo Housing Market Index (HMI) for October, which was released today (October 17). This is the largest one-month gain the index has seen since the home buyer tax credit program helped spur the market in April of 2010. Several stocks in the home building group include Beazer Homes (BZH), Pulte Homes (PHM), Centex (CTX), B.R. Horton (DHI), Lennar (LEN), KB Homes (KBH), and Hovnanian (HOV). Another way to invest in a broad index is through the iShares Dow Jones Home Construction Index (ITB). Its holdings include the major home builders that are publicly traded.
- Banks. Most of the larger banks reported earnings. Some of them were very good because of one time events (Bank of America: BAC). Others disappointed a little (Wells Fargo:WFC) because revenues were a little shy. Others did well because international business picked up (Citigroup: C). The thing to keep in mind is that not all banks are the same. They may all say bank in their names, but they are each trying to carve a niche, usually a big niche, to help differentiate themselves. If they don't, they simply compete with the next behemoth for commodity business, like single family, conforming mortgages. There isn't much money in commodity businesses. So they look for areas others don't do or can't do as well. Bank of New York, Mellon (BK), for example, is mostly a custodial bank. It focuses on wealth management and securities servicing. You can't walk into a branch ask for the loan department. They don't have one.
Banks have been beaten down. Most are selling well below book value. Earnings just out suggest there are areas of improvement, like business lending and refinancing for home mortgages. But there is a concern over net interest margin (NIM) weakening as lower interest rates are pushing down the amount of interest received on most loans. As NIM goes lower, so go the profits in most banks, if they do mostly lending. Again, BK, as one bank with a specific niche, doesn't. Another would be Goldman, Sachs (GS), more an investment bank than a normal bank, but still in the financial services group. It's selling below book value (71% of book at this writing). At one time, no one would have guessed that was possible. But we're in a new world now. Of course, it reported a loss this quarter for only the second time since going public. So investors are wary. Plus the new Volcker rule will prohibit it (and all banks) from using its capital for propietary trading so that source of income (or loss in a bad quarter) will go away. Don't be surprised if Goldman decides to leave the banking fraternity and go back to being an investment bank only.
The point is that the banking sector has some values, if you know which ones have prospered in these tough times. One is First Niagara (FNFG) (a stock written up this week in our Online Investor Income column: www.theonlineinvestor.com). It's expanding its footprint in New York and Connecticut, buying branches and still reporting solid profits. And it pays a good dividend.
- Drugs
Most people think of drug stocks as defensive, or they used to. Times have changed. With generic drugs nipping at the heels of all prescription pills, most major drug manufacturers are having a tough time. But not all. One that isn't: Abbott (ABT). Its best selling drug loooks like it will be protected for four or five years. And it has almost $9 billion in cash to develop more drugs, pay dividends, and buy other companies. Look deeper into the drug makers. Most have plenty of cash to keep R&D healthy and make acquisitions. Examples: Johnson & Johnson (JNJ) and Pfizer (PFE). Some of these have been dormant for years. But many pay decent dividends to assuage the pain of patience.
Don't think only of the now. Now is basically over. It's in the stock market. Think well beyond today. Think about the possibilities if certain outcomes prevail. Buying homebuilder stocks today requires that. But these are the times that give investors opportunities to make large gains when markets turn. Look in the sectors other investors have ignored or dumped. That's where the bargains are. And if you only buy a little of each and spread your risk, the rewards can be bountiful.
- Ted Allrich
October 18, 2011
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One that isn't: Abbott (ABT). Or investors simply boost a stock's price because they think the worst is over and future revenues and profits will increase. This is the largest one-month gain the index has seen since the home buyer tax credit program helped spur the market in April of 2010. | One that isn't: Abbott (ABT). They're seeing more interest from buyers and anticipate low interest rates for some time will persuade home buyers to act. Several stocks in the home building group include Beazer Homes (BZH), Pulte Homes (PHM), Centex (CTX), B.R. | One that isn't: Abbott (ABT). Builder confidence in the market for newly built, single-family homes rose four points to 18 on the National Association of Home Builders/Wells Fargo Housing Market Index (HMI) for October, which was released today (October 17). Several stocks in the home building group include Beazer Homes (BZH), Pulte Homes (PHM), Centex (CTX), B.R. | One that isn't: Abbott (ABT). - Banks. Its best selling drug loooks like it will be protected for four or five years. |
34505.0 | 2011-10-11 00:00:00 UTC | Update: Top unusual option activity | ABT | https://www.nasdaq.com/articles/update-top-unusual-option-activity-2011-10-11 | nan | nan | As of today's market close, here are the top 10 names showing unusual option activity on tradeMONSTER's LiveAction data system.
Pharmaceutical Product Development (PPDI): Option volume 4,260 percent above average. About 11,000 January 30 calls were sold and an equal number of January 32.50 calls were bought as an investor bet that upside will be limited. PPDI rose 0.40 percent to $32.37.
Accenture (ACN): Option volume 2,761 percent above average. Call activity surged as investors looked to reap the stock's quarterly dividend. Similar activity also appeared in Abbott Laboratories (ABT), where total option volume was 1,658 percent above average.
Dynegy (DYN): Option volume 2,606 percent above average. Investors bought the October 4 calls, the November 4 calls and the November 3 puts, looking for movement in the shares. DYN rose 6.35 percent to $3.85.
Seabridge Gold (SA): Option volume 1,272 percent above average. About 9,000 November 23 calls were bought for $1.40 to $2.50 as investors positioned for upside. SA rose 9.02 percent to $23.93.
Rounding out the top 10 are:
99 Cents Stores (NDN): Option volume 1,262 percent above average.
Targacept (TRGT): Option volume 1,219 percent above average.
Warner Chilcott (WCRX): Option volume 1,059 percent above average.
Harmony Gold (HMY): Option volume 1,051 percent above average.
Rydex Currencyshares British Pound (FXB): Option volume 1,031 percent above average.
(Chart courtesy of tradeMONSTER )
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Similar activity also appeared in Abbott Laboratories (ABT), where total option volume was 1,658 percent above average. As of today's market close, here are the top 10 names showing unusual option activity on tradeMONSTER's LiveAction data system. Call activity surged as investors looked to reap the stock's quarterly dividend. | Similar activity also appeared in Abbott Laboratories (ABT), where total option volume was 1,658 percent above average. Pharmaceutical Product Development (PPDI): Option volume 4,260 percent above average. Seabridge Gold (SA): Option volume 1,272 percent above average. | Similar activity also appeared in Abbott Laboratories (ABT), where total option volume was 1,658 percent above average. Accenture (ACN): Option volume 2,761 percent above average. Dynegy (DYN): Option volume 2,606 percent above average. | Similar activity also appeared in Abbott Laboratories (ABT), where total option volume was 1,658 percent above average. As of today's market close, here are the top 10 names showing unusual option activity on tradeMONSTER's LiveAction data system. PPDI rose 0.40 percent to $32.37. |
34506.0 | 2011-09-27 00:00:00 UTC | 5 Companies that Haven't Lost a Dime in the Past Decade | ABT | https://www.nasdaq.com/articles/5-companies-havent-lost-dime-past-decade-2011-09-27 | nan | nan | We're more than a decade removed from the dot-com crash, and many investors still recall those days with dread, when the market plunged almost daily, seemingly without end. That same mood pervades Wall Street today, and the fear is once again palpable. But between the dot-com crash and the current swoon, major gains were made by many companies.
In fact, a host of companies in the S&P 500 Index never lost a dime during the past decade and saw their share prices rise steadily higher. StreetAuthority Co-founder Paul Tracy likes tocall these stocks -- the kind that steadily gains over time through any kind of market -- "forever" stocks. And many of these stocks certainly fit the bill.
Thankfully, the recent market pullback has knocked these stocks off their perch, and they have given back a big chunk of the gains picked up in the last decade, creating a potential once in a decade opportunity to buy for the long haul.
[If you haven't already, I encourage you to take some time and watch a presentation Paul recently put together called " The 10 Best Stocks to Hold Forever ."]
During my research, I've found no less than 20 stocks that could fall into this "forever" category. Perhaps it's time to reload your portfolio with these rock-steady assets while they are stuck in the bargain bin. I'll begin by detailing the first five stocks in this group. (And stay tuned in the coming days for my follow-up on the next five...)
1. 3M ( MMM )
2002 sales: $16.3 billion
2011 sales (est.): $30.1 billion
Shares of this diversified blue chip steadily rose from $50 in 2001 to nearly $100 this spring, reflecting the fact that sales nearly doubled and earnings per share ( EPS ) rose roughly 140% (from $2.50 in 2002 to an estimated $6 this year). Yet since peaking this spring, shares have lost a quarter of their value, down to $74. That's where shares stood in 2004, even though 3M is far larger today. Trading at just 12 times projected 2011 profits, the forward price-to-earnings (P/E) ratio is right near the low end of the 10-year range.
2. Abbott Labs ( ABT )
2002 sales: $15.3 billion
2011E sales: $39 billion
This provider of medical devices, hospital supplies and pharmaceuticals has been expanding through the ups and downs of the economy . Sales have steadily grown and per share profits are really soaring now, expected to hit a company record $4.64 this year. Analysts think EPS can hit $5 in 2012. But that's cold comfort for investors. The stock has mostly been stuck in a $40-$60 range for the last decade, and now trades at $50. With the stock spinning its wheels and EPS rising ever-higher, investors now have a chance to pick up this health care blue chip for a decade-low 10 times forward (2012) earnings .
3. Archer-Daniels Midland ( ADM )
Fiscal (June) 2003 sales: $30.7 billion
Fiscal 2011 sales: $80.7 billion.
This is a tale of two half-decades. From fiscal 2003 to fiscal 2007, per share profits for this large agricultural concern rose from $0.70 to $3.30. But in the past four years, they've been stuck in the $3 range, thank to less-profitable hedging strategies in its food processing programs. This may explain why shares have fallen from $48 in early 2008 to a recent $25. Still, at the current price, you can own this stock for less than eight times projected fiscal (June) 2012 profits. Analysts think the stock is quite a bargain, trading for slightly less than book value : "This has historically represented a bottom for the stock and provided investors with an excellent entry point, in which the stock has produced returns ranging from 20%-130% over the next two years," note analysts at Citigroup.
4. Cisco Systems (Nasdaq: CSCO)
Fiscal (July) 2003 sales: $18.9 billion
Fiscal 2011 sales: $43 billion
What a wild ride this stock has been on. It peaked at $70 in 2001, slumped to $10 in 2003, rebounded back into the $20s for much of the rest of the decade, and has again fallen back to around $15. The downward-sloping stock chart simply doesn't jive with the upwardly sloping sales figures noted above. To be sure, per share profit growth has been more elusive, stuck in a $0.87-$1.33 range for the last seven years. [Note: if you look up these figures in Yahoo Finance, you'll notice a discrepancy between the numbers cited here, which are from Reuters and Cisco's 10-K .]
Yet looked at another way, $1 a share in annual earnings has really added up for Cisco: the networking giant has generated $60 billion on free cash flow during this time frame, pumping up to form the strongest balance sheet in the S&P 500. Cisco now carries a stunning $45 billion in cash, which is fueling massive stock buybacks. But in a cruel twist of fate, shares of Cisco were finally starting to win more converts on Wall Street and the stock began to move up from its multi-year low just as the mid-summer market rout began. Perhaps when the selling abates, shares will again find support and begin moving higher again. [You can read more of my recent analysis on Cisco here .]
5. Dell (Nasdaq: DELL)
Fiscal (Jan.) 2003 sales: $35.4 billion
Fiscal 2011 sales: $61.4 billion
This is a virtual mirror image of Cisco Systems: Strong sales growth has not fueled a commensurate level of profit growth (EPS of $1.35 in fiscal 2011 is slightly below levels seen five years earlier). But Dell has also been able to generate ample free cash flow from those flat profits, and now has more than $15 billion in cash (around $9 billion when you subtract debt, etc.). This works out to be more than 35% of the company's entire $25 billion market value . Dell was once a $50 stock (in early 2000), then a $40 stock in 2005, then a $30 stock in 2007, and these days can be had for less than $15. Back out the company's cash (and associated interest income), and this stock trades for just five times projected profits. [See " These Stocks are Producing Mountains of Cash "]
Risks to Consider: If the market stabilizes but fails to rebound in coming weeks and months, these stocks may languish until the investor mood improves. Earnings estimates cited may come down in coming weeks and months if the U.S. economy slips into recession , although the fallback in share prices seems to reflect just such a possibility, implying that further selling won't accompany downward revisions.
Action to Take --> These are solid companies with great long-term track records. Not a single one has lost money in the past decade -- neither on an annual basis or a quarterly basis. The fact that these shares are well off their highs and in some instances are back at levels seen a number of years ago creates a solid entry point for new investors.
-- David Sterman
Disclosure: Neither David Sterman nor StreetAuthority, LLC hold positions in any securities mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) 2002 sales: $15.3 billion 2011E sales: $39 billion This provider of medical devices, hospital supplies and pharmaceuticals has been expanding through the ups and downs of the economy . We're more than a decade removed from the dot-com crash, and many investors still recall those days with dread, when the market plunged almost daily, seemingly without end. With the stock spinning its wheels and EPS rising ever-higher, investors now have a chance to pick up this health care blue chip for a decade-low 10 times forward (2012) earnings . | Abbott Labs ( ABT ) 2002 sales: $15.3 billion 2011E sales: $39 billion This provider of medical devices, hospital supplies and pharmaceuticals has been expanding through the ups and downs of the economy . Archer-Daniels Midland ( ADM ) Fiscal (June) 2003 sales: $30.7 billion Fiscal 2011 sales: $80.7 billion. Cisco Systems (Nasdaq: CSCO) Fiscal (July) 2003 sales: $18.9 billion Fiscal 2011 sales: $43 billion What a wild ride this stock has been on. | Abbott Labs ( ABT ) 2002 sales: $15.3 billion 2011E sales: $39 billion This provider of medical devices, hospital supplies and pharmaceuticals has been expanding through the ups and downs of the economy . Analysts think the stock is quite a bargain, trading for slightly less than book value : "This has historically represented a bottom for the stock and provided investors with an excellent entry point, in which the stock has produced returns ranging from 20%-130% over the next two years," note analysts at Citigroup. Cisco Systems (Nasdaq: CSCO) Fiscal (July) 2003 sales: $18.9 billion Fiscal 2011 sales: $43 billion What a wild ride this stock has been on. | Abbott Labs ( ABT ) 2002 sales: $15.3 billion 2011E sales: $39 billion This provider of medical devices, hospital supplies and pharmaceuticals has been expanding through the ups and downs of the economy . ): $30.1 billion Shares of this diversified blue chip steadily rose from $50 in 2001 to nearly $100 this spring, reflecting the fact that sales nearly doubled and earnings per share ( EPS ) rose roughly 140% (from $2.50 in 2002 to an estimated $6 this year). The stock has mostly been stuck in a $40-$60 range for the last decade, and now trades at $50. |
34507.0 | 2011-09-27 00:00:00 UTC | Abbott Labs Cut to a “Neutral” at JPMorgan (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-cut-neutral-jpmorgan-abt-2011-09-27 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday caught a downgrade from analysts at JPMorgan.
The firm said it lowered its rating on ABT from "Overweight" to "Neutral," on a valuation call. JPMorgan noted the stock has easily outperformed its peers year-to-date and may not have much near-term upside left.
Abbott Labs shares, which have risen about 6% year-to-date, were unchanged in premarket trading Tuesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.78% dividend yield, based on last night's closing stock price of $50.75.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday caught a downgrade from analysts at JPMorgan. The firm said it lowered its rating on ABT from "Overweight" to "Neutral," on a valuation call. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday caught a downgrade from analysts at JPMorgan. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday caught a downgrade from analysts at JPMorgan. | The firm said it lowered its rating on ABT from "Overweight" to "Neutral," on a valuation call. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday caught a downgrade from analysts at JPMorgan. |
34508.0 | 2011-09-20 00:00:00 UTC | Abbott Labs Started as a “Buy” at Jefferies (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-started-buy-jefferies-abt-2011-09-20 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday saw its coverage started with a "Buy" rating by analysts at Jefferies & Co.
The firm also set a $60 price target on ABT shares, suggesting a 15% upside to the stock's Monday closing price of $51.99.
A Jefferies analyst commented, "Abbott carries an unwarranted discount versus its peers that undervalues the depth and breadth of the company's broad portfolio of products. Fears of new competition to Humira are overdone, in our view, and have clouded investors' ability to appreciate the company's growth potential. We see numerous R&D catalysts and above-consensus revenue and EPS projections which should unlock significant value over the next 12 months."
Abbott Labs shares were unchanged in premarket trading Tuesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.69% dividend yield, based on last night's closing stock price of $51.99.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday saw its coverage started with a "Buy" rating by analysts at Jefferies & Co. The firm also set a $60 price target on ABT shares, suggesting a 15% upside to the stock's Monday closing price of $51.99. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday saw its coverage started with a "Buy" rating by analysts at Jefferies & Co. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday saw its coverage started with a "Buy" rating by analysts at Jefferies & Co. | Healthcare products maker Abbott Laboratories ( ABT ) on Tuesday saw its coverage started with a "Buy" rating by analysts at Jefferies & Co. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. |
34509.0 | 2011-09-14 00:00:00 UTC | Rumor Roundup: Crazy Day in Europe | ABT | https://www.nasdaq.com/articles/rumor-roundup-crazy-day-europe-2011-09-14 | nan | nan | (Article by Becca Lipman. List compiled by Eben Esterhuizen, CFA. EPS data sourced from Yahoo! Finance.)
Tuesday bore witness to the unforgiving power of the rumor mill. Whispers of big announcements on Greece and French banks set the European markets on a roller coaster capable of leaving even the most hardened investors feeling dizzy.
It all happened before 8 AM EST. Here's how the markets played out:
1. The Wall Street Journal released an Op-Ed on French Banks. The gist of it being that French Banks were barred from borrowing U.S money market funds. According to WSJ's anonymous source, without access to the dollar "we're creating a market in euros. This is a first. . . . We hope it will work, otherwise the downward spiral will be hell. We will no longer be trusted at all and no one will lend to us anymore."
2. This report, as one could imagine, was followed by temporary panic and a rush of heavy selling.
3. People were so upset that French bank BNP Paribas vehemently issued a denial, assuring investors that they could still borrow in dollars. Selling subsided.
4. A report then came out that German Chancellor Angela Merkel and French President Nicolas Sarkozy plan to make a joint announcement regarding Greece. According to Business Insider, "Presumably it will just be something about providing "support" for Greece, but anything's better than throwing in the towel."
5. Markets soared in anticipation. Business Insider reported "markets seem to think something big might happen -- all the big European markets are rallying, making up early morning losses."
6. French Spokesman Franck Louvrier announced there will be no big announcement after all. Sarkozy might make a minor announcement later in the day, but hinted it would be nothing too notable.
7. Markets plunged.
8. Markets recovered. BNP Paribas, which took the brunt of the French borrowing rumor, finished the day up 7.2% at €28.00.
Europe's rumor mill clearly has the markets in overdrive. So how will this European crisis play out? And more importantly, how can you protect yourself from Europe's trouble?
UBS's US Equity Strategy team put together a list of 30 stocks that should do relatively well if Europe deteriorates further.
Specifically, these stocks tend to outperform when credit default swaps rise in the European periphery.
From this list of 30 stocks, we looked for companies that have proven themselves to be more profitable than their competitors over the last 12 months.
To further refine the quality of the list, we focused on companies that have seen an increase in their earnings projections over the last 30 days.
These companies have proven themselves to be resilient to the troubles in Europe, and analysts expect these companies to continue to be profitable. Do any of these stocks interest you?
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
1. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. TTM gross margin at 68.13% vs. industry average at 67.38%. TTM operating margin at 22.75% vs. industry average at 14.23%. TTM pretax margin at 14.97% vs. industry average at 9.39%. The EPS estimate for the company's current year increased from 4.63 to 4.64 over the last 30 days, an increase of 0.22%. This increase came during a time when the stock price changed by -0.38% (from 49.91 to 49.72 over the last 30 days).
2. DaVita, Inc. (DVA): Provides kidney dialysis services in the United States. TTM gross margin at 31.06% vs. industry average at 20.97%. TTM operating margin at 15.27% vs. industry average at 8.52%. TTM pretax margin at 10.81% vs. industry average at 7.01%. The EPS estimate for the company's current year increased from 4.72 to 4.82 over the last 30 days, an increase of 2.12%. This increase came during a time when the stock price changed by -5.63% (from 74.66 to 70.46 over the last 30 days).
3. Unitedhealth Group, Inc. (UNH): Provides healthcare services in the United States. TTM gross margin at 24.76% vs. industry average at 20.97%. TTM operating margin at 8.61% vs. industry average at 8.43%. TTM pretax margin at 7.92% vs. industry average at 6.91%. The EPS estimate for the company's current year increased from 4.35 to 4.37 over the last 30 days, an increase of 0.46%. This increase came during a time when the stock price changed by -0.87% (from 45.94 to 45.54 over the last 30 days).
4. Duke Energy Corporation (DUK): Operates as an energy company in the Americas. TTM gross margin at 34.78% vs. industry average at 27.9%. TTM operating margin at 22.55% vs. industry average at 19.31%. TTM pretax margin at 20.7% vs. industry average at 14.76%. The EPS estimate for the company's current year increased from 1.37 to 1.38 over the last 30 days, an increase of 0.73%. This increase came during a time when the stock price changed by 0.71% (from 18.4 to 18.53 over the last 30 days).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Whispers of big announcements on Greece and French banks set the European markets on a roller coaster capable of leaving even the most hardened investors feeling dizzy. People were so upset that French bank BNP Paribas vehemently issued a denial, assuring investors that they could still borrow in dollars. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. The EPS estimate for the company's current year increased from 4.63 to 4.64 over the last 30 days, an increase of 0.22%. The EPS estimate for the company's current year increased from 4.72 to 4.82 over the last 30 days, an increase of 2.12%. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Business Insider reported "markets seem to think something big might happen -- all the big European markets are rallying, making up early morning losses." The EPS estimate for the company's current year increased from 4.63 to 4.64 over the last 30 days, an increase of 0.22%. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Business Insider reported "markets seem to think something big might happen -- all the big European markets are rallying, making up early morning losses." Europe's rumor mill clearly has the markets in overdrive. |
34510.0 | 2011-09-11 00:00:00 UTC | Pfizer Poised to Introduce Blockbuster Arthritis Pill | ABT | https://www.nasdaq.com/articles/pfizer-poised-introduce-blockbuster-arthritis-pill-2011-09-11 | nan | nan | (Article and list compiled by Alexander Crawford. Data sourced by Finviz.)
Final Phase III data is in for Pfizer’s (PFE) new rheumatoid arthritis (RA) pill, and it appears to be as effective as blockbuster Humira, with no sign of new safety concerns. Some analysts see the drug bringing in $2.6 billion a year or more for Pfizer, welcomed at a time when the company soon expects patent expiration of its $10.7 billion-a-year Lipitor.
Although the studies used Abbott Laboratories’ (ABT) Humira alongside Pfizer’s pill tofacitinib, they were not designed for a true head-to-head comparison. Pfizer pointed out similar efficacy for both treatments, as well as no new safety issues.
“Pfizer believes the risk-benefit profile supports regulatory submission for both the 5- and 10-milligram dose,” Victoria Davis, a spokeswoman for Pfizer, told Bloomberg. “We are looking forward to filing in the U.S., EU and Japan by the end of the year.”
The pill is designed to compete with injectable RA medicines, such as Humira, Johnson & Johnson’s (JNJ) Remicade, and Amgen’s (AMGN) Enbrel (shared by Pfizer).
Analyst at Credit Suisse Catherine Arnold told Bloomberg, “the new drug may bring in more than $2.6 billion a year,” and even referred to the number as “likely conservative.” She also said Humira will reach peak sales of $8.5 billion in 2013 before sales decline as tofacitinib and other new drugs are accepted by doctors.
According to Bloomberg, three biotech companies are trying to catch up to Pfizer with similar RA treatments: Rigel Pharmaceuticals (RIGL), Incyte Corp. (INCY), and Vertex Pharmaceuticals (VRTX). Pfizer is the first to complete Phase III, however.
Do you think Pfizer will get FDA approval? Here we report interesting data on the stocks of companies mentioned above:
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
1. Pfizer Inc. (PFE): Offers prescription medicines for humans and animals worldwide. Market cap of $146.84B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.25%, current ratio at 1.98, and quick ratio at 1.7. The stock has gained 16.97% over the last year.
2. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $80.07B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.73%, current ratio at 1.52, and quick ratio at 1.3. The stock has gained 4.38% over the last year.
3. Johnson & Johnson (JNJ): Engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Market cap of $177.99B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.51%, current ratio at 2.51, and quick ratio at 2.2. The stock has gained 12.45% over the last year.
4. Amgen Inc. (AMGN): Develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Market cap of $51.11B. The stock has gained 2.83% over the last year.
5. Rigel Pharmaceuticals, Inc. (RIGL): Engages in the discovery and development of small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. Market cap of $535.57M. The stock is a short squeeze candidate, with a short float at 7.3% (equivalent to 9.94 days of average volume). The stock has lost 11.53% over the last year.
6. Incyte Corporation (INCY): Focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Market cap of $1.96B. This is a risky stock that is significantly more volatile than the overall market (beta = 2.43). The stock is a short squeeze candidate, with a short float at 12.05% (equivalent to 8.83 days of average volume). The stock has had a good month, gaining 11%.
7. Vertex Pharmaceuticals Incorporated (VRTX): Engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Market cap of $9.90B. The stock has had a couple of great days, gaining 5.08% over the last week.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although the studies used Abbott Laboratories’ (ABT) Humira alongside Pfizer’s pill tofacitinib, they were not designed for a true head-to-head comparison. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Final Phase III data is in for Pfizer’s (PFE) new rheumatoid arthritis (RA) pill, and it appears to be as effective as blockbuster Humira, with no sign of new safety concerns. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Although the studies used Abbott Laboratories’ (ABT) Humira alongside Pfizer’s pill tofacitinib, they were not designed for a true head-to-head comparison. According to Bloomberg, three biotech companies are trying to catch up to Pfizer with similar RA treatments: Rigel Pharmaceuticals (RIGL), Incyte Corp. (INCY), and Vertex Pharmaceuticals (VRTX). | Although the studies used Abbott Laboratories’ (ABT) Humira alongside Pfizer’s pill tofacitinib, they were not designed for a true head-to-head comparison. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Analyst at Credit Suisse Catherine Arnold told Bloomberg, “the new drug may bring in more than $2.6 billion a year,” and even referred to the number as “likely conservative.” She also said Humira will reach peak sales of $8.5 billion in 2013 before sales decline as tofacitinib and other new drugs are accepted by doctors. | Although the studies used Abbott Laboratories’ (ABT) Humira alongside Pfizer’s pill tofacitinib, they were not designed for a true head-to-head comparison. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Final Phase III data is in for Pfizer’s (PFE) new rheumatoid arthritis (RA) pill, and it appears to be as effective as blockbuster Humira, with no sign of new safety concerns. |
34511.0 | 2011-09-09 00:00:00 UTC | Sanofi Expresses Optimistic Earnings Outlook After Genzyme Acquisition | ABT | https://www.nasdaq.com/articles/sanofi-expresses-optimistic-earnings-outlook-after-genzyme-acquisition-2011-09-09 | nan | nan | (By Alexander Crawford. Data sourced from Finviz.)
Like many large drugmakers today, France’s Sanofi (SNY) is adapting to a patent cliff that has been taking a heavy swipe at its revenue. The company has just set out a strategy that they believe will raise earnings by 5% annually over the next four years – and trim costs by $2.8 billion.
According to Bloomberg, these forecasts are Sanofi’s first to include their $20.1 billion acquisition of Genzyme Corp. (GENZ) earlier this year. “The cost cuts will come from the integration of Genzyme, which will contribute $700 million, as well as “new initiatives” (via Bloomberg).
“The focus has shifted to 2015 as people try to gain a perspective on the dynamic of the company,” Sanofi CEO Chris Viehbacher said on a conference call with reporters. “We are essentially pointing out a new investment thesis. It is first and foremost based on a return to growth for Sanofi following the patent cliff.”
Sanofi is presenting six new medicines to regulators between July and next March, and as many as nineteen new drugs by 2015, according to the company’s statement.
The acquisition of Genzyme, arguably the first biotech company and today’s largest maker of medicines for rare genetic disorders, was designed to provide Sanofi with access to treatments that are less vulnerable to generic competition.
The company said last month that generic versions of Sanofi drugs (such as the Lovenox and Plavix blood thinners) cut 778 million euros from second quarter sales.
Do you think that Sanofi will continue to grow despite generic competition? Here we report some interesting data on the largest drugmakers, including Sanofi, traded in the US.
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize annual returns for all stocks mentioned
List sorted by market cap.
1. Johnson & Johnson (JNJ): Engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Market cap of $179.30B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.48%, current ratio at 2.51, and quick ratio at 2.2. The stock has gained 15.15% over the last year.
2. Pfizer Inc. (PFE): Offers prescription medicines for humans and animals worldwide. Market cap of $148.32B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.21%, current ratio at 1.98, and quick ratio at 1.7. The stock has had a good month, gaining 14.11%.
3. Novartis AG (NVS): Engages in the research, development, manufacture, and marketing of healthcare products worldwide. Market cap of $130.60B. The stock has gained 11.19% over the last year.
4. GlaxoSmithKline plc (GSK): Engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. Market cap of $107.18B. The stock has gained 13.86% over the last year.
5. Merck & Co. Inc. (MRK): Provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. Market cap of $101.54B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.61%, current ratio at 2.05, and quick ratio at 1.66. The stock has had a good month, gaining 10.09%.
6. Sanofi-Aventis (SNY): Engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. Market cap of $95.54B. 0The stock has gained 22.7% over the last year.
7. Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Market cap of $81.41B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.67%, current ratio at 1.52, and quick ratio at 1.3. The stock has gained 7.46% over the last year.
8. AstraZeneca PLC (AZN): Develops, and commercializes prescription medicines for cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation diseases worldwide. Market cap of $61.60B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 5.89%, current ratio at 1.47, and quick ratio at 1.35. The stock has had a good month, gaining 10.32%.
9. Bristol-Myers Squibb Company (BMY): Develops, and delivers innovative medicines that help patients prevail over serious diseases. Market cap of $51.02B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.41%, current ratio at 1.99, and quick ratio at 1.79. The stock has had a good month, gaining 13.38%.
10. Eli Lilly & Co. (LLY): Develops, manufactures, and sells pharmaceutical products worldwide. Market cap of $42.77B. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 5.31%, current ratio at 1.73, and quick ratio at 1.4. The stock has gained 12.08% over the last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. The acquisition of Genzyme, arguably the first biotech company and today’s largest maker of medicines for rare genetic disorders, was designed to provide Sanofi with access to treatments that are less vulnerable to generic competition. The company said last month that generic versions of Sanofi drugs (such as the Lovenox and Plavix blood thinners) cut 778 million euros from second quarter sales. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.48%, current ratio at 2.51, and quick ratio at 2.2. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.21%, current ratio at 1.98, and quick ratio at 1.7. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 3.48%, current ratio at 2.51, and quick ratio at 2.2. Offers a good dividend, and appears to have good liquidity to back it up--dividend yield at 4.21%, current ratio at 1.98, and quick ratio at 1.7. | Abbott Laboratories (ABT): Engages in the discovery, development, manufacture, and sale of health care products worldwide. Here we report some interesting data on the largest drugmakers, including Sanofi, traded in the US. Visualize annual returns for all stocks mentioned List sorted by market cap. |
34512.0 | 2011-09-08 00:00:00 UTC | Stocks Choppy Ahead of Obama's Address to Congress; Commodities Mixed | ABT | https://www.nasdaq.com/articles/stocks-choppy-ahead-obamas-address-congress-commodities-mixed-2011-09-08 | nan | nan | Stocks made a brief run into positive territory but have fallen back into the red at mid-day ahead of President Obama's speech on jobs to a joint session of Congress. New data released this morning showed a rise in jobless claims and set the tone for Obama's speech, which will outline a new spending to boost hiring in the sluggish economy.
Jobless claims rose to 414,000 from 412,000. Initial claims from two weeks ago were revised up from an original reading of 409,000. The average of new claims over the past four weeks, meanwhile, rose by 3,750 to 414,750, the highest level since mid-July.
Also reported this morning, the Commerce Department said the trade deficit narrowed to a seasonally adjusted $44.8 billion in July from $51.6 billion in June, a decline of 13.1% -- the largest percentage decline since February 2009.
Obama is slated to deliver a televised speech on jobs to Congress after markets have closed, at 7:00 p.m. ET. The president is expected to propose an extension of the expiring payroll-tax cuts and push for new spending on infrastructure.
Global investors are awaiting word from Washington on the possibility of more help for the economy. Federal Reserve Chairman Ben Bernanke is also slated to speak.
The cost of a 30-year fixed mortgage hit a new record for the third consecutive week, dropping to 4.35%, according to Bankrate.com's weekly national survey. The average 15-year fixed mortgage remained at 3.48% while the larger jumbo 30-year fixed rate set a new low of 4.86%.
Oil prices have turned lower, slipping below $89 a barrel, despite a new Energy Information Administration report that U.S. stockpiles fell sharply last week by 4 million barrels, three times as much as analysts predicted.
In company news:
Shares of Johnson & Johnson ( JNJ ) are higher in regular-session trade, sitting just off session highs, after Bloomberg reported that the drug and medical products maker, along with C.R. Bard, may be required to submit additional safety data on a surgical mesh the resulted in about 500 lawsuits. A panel of the U.S. Food and Drug Administration is meeting to discuss whether the mesh is safe and effective.
Shares of Cisco Systems ( CSCO ) are holding firm and building on pre-market gains after the stock was upgraded to Buy from Hold at Auriga. The price target for the firm was raised to $20 from $16. In his note, Auriga analyst Sandeep Shyamsukha wrote that the networking equipment maker is "now well positioned to gain market share in key segments like switching, routing and servers in both enterprise and service provider segments from competitors," MarketWatch report on the upgrade.
Shares of Pfizer ( PFE ) are higher after the company said its experimental pill to treat rheumatoid arthritis showed the medicine was as effective as Abbott's ( ABT ) injectable Humira drug, but more patients taking it had serious side effects.
Shares of Bank of America ( BAC ) are down in regular-session trading as the company is slated to close up to 600 branches as a part of its continued reorganization efforts, reports TheStreet.com.
Shares of Wal-Mart Stores (WMT) are higher Reuters reports the company has hired the former head of the largest food retailer in Russia, called X5, citing a company spokeswoman. The executive will be a senior vice-president and chief leverage officer. The move is seen as a sign that Russia has yet to abandon its plans to enter the Russian market.
Commodities are mixed. December gold contracts are up 2.41% to $1,861 an ounce while October crude oil contacts are down 0.67% to $88.78 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 0.12% to $34.67 and the United States Natural Gas fund (UNG) is up 1.71%, to $10.10.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 2.1% to $180.85. Market Vectors Gold Miners (GDX) is up 2.05% to $66.77. iShares Silver Trust (SLV) is up 1.95% to $41.32.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Pfizer ( PFE ) are higher after the company said its experimental pill to treat rheumatoid arthritis showed the medicine was as effective as Abbott's ( ABT ) injectable Humira drug, but more patients taking it had serious side effects. Stocks made a brief run into positive territory but have fallen back into the red at mid-day ahead of President Obama's speech on jobs to a joint session of Congress. New data released this morning showed a rise in jobless claims and set the tone for Obama's speech, which will outline a new spending to boost hiring in the sluggish economy. | Shares of Pfizer ( PFE ) are higher after the company said its experimental pill to treat rheumatoid arthritis showed the medicine was as effective as Abbott's ( ABT ) injectable Humira drug, but more patients taking it had serious side effects. In company news: Shares of Johnson & Johnson ( JNJ ) are higher in regular-session trade, sitting just off session highs, after Bloomberg reported that the drug and medical products maker, along with C.R. In energy ETFs, the United States Oil Fund (USO) is down 0.12% to $34.67 and the United States Natural Gas fund (UNG) is up 1.71%, to $10.10. | Shares of Pfizer ( PFE ) are higher after the company said its experimental pill to treat rheumatoid arthritis showed the medicine was as effective as Abbott's ( ABT ) injectable Humira drug, but more patients taking it had serious side effects. New data released this morning showed a rise in jobless claims and set the tone for Obama's speech, which will outline a new spending to boost hiring in the sluggish economy. Oil prices have turned lower, slipping below $89 a barrel, despite a new Energy Information Administration report that U.S. stockpiles fell sharply last week by 4 million barrels, three times as much as analysts predicted. | Shares of Pfizer ( PFE ) are higher after the company said its experimental pill to treat rheumatoid arthritis showed the medicine was as effective as Abbott's ( ABT ) injectable Humira drug, but more patients taking it had serious side effects. Obama is slated to deliver a televised speech on jobs to Congress after markets have closed, at 7:00 p.m. The cost of a 30-year fixed mortgage hit a new record for the third consecutive week, dropping to 4.35%, according to Bankrate.com's weekly national survey. |
34513.0 | 2011-08-24 00:00:00 UTC | Abbott Labs’ Rating, Target Cut at Morgan Keegan (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-rating-target-cut-morgan-keegan-abt-2011-08-24 | nan | nan | Medical device maker Abbott Laboratories ( ABT ) on Wednesday caught a downgrade from analysts at Morgan Keegan.
The firm said it cut its rating on ABT from "Outperform" to "Market Perform" and lowered its price target from $60 to $57. That new target suggests a smaller 13% upside to the stock's Tuesday closing price of $50.51.
Abbott Labs shares fell 25 cents, or -0.5%, in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.80% dividend yield, based on last night's closing stock price of $50.51.
Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical device maker Abbott Laboratories ( ABT ) on Wednesday caught a downgrade from analysts at Morgan Keegan. The firm said it cut its rating on ABT from "Outperform" to "Market Perform" and lowered its price target from $60 to $57. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Medical device maker Abbott Laboratories ( ABT ) on Wednesday caught a downgrade from analysts at Morgan Keegan. The firm said it cut its rating on ABT from "Outperform" to "Market Perform" and lowered its price target from $60 to $57. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Medical device maker Abbott Laboratories ( ABT ) on Wednesday caught a downgrade from analysts at Morgan Keegan. | Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Medical device maker Abbott Laboratories ( ABT ) on Wednesday caught a downgrade from analysts at Morgan Keegan. The firm said it cut its rating on ABT from "Outperform" to "Market Perform" and lowered its price target from $60 to $57. |
34514.0 | 2011-08-10 00:00:00 UTC | Stocks Down, But Off Lows; Crude Futures Find Feet After Two-Day Decline | ABT | https://www.nasdaq.com/articles/stocks-down-lows-crude-futures-find-feet-after-two-day-decline-2011-08-10 | nan | nan | Stocks are backtracking sharply for the second time in three sessions at mid-day, with concern over European banks spreading gloom to U.S. equities markets and overshadowing a rise in job ads. With theeconomic calendarrelatively light, investors are eying corporate earnings, including Dow Jones Industrial component Walt Disney Co. ( DIS ), and the U.S. Federal Reserve's policy statement yesterday.
Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. Revenue was $10.67 billion compared with the mean analyst consensus for $10.45 billion on Thomson Reuters. Third quarter profits were buoyed by deferred revenue moved from the fourth quarter to the third quarter, noted Reuters. Excluding that item, results missed most analysts' expectations, the report said.
On the economic front, U.S. wholesaler inventories rose less-than-expected at 0.6% in June, which signals a cautionary stance from business.
In company news:
Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension.
Apple ( AAPL ) shares are down after Reuters reported a court in Germany temporarily halted Samsung Electronics from selling its Galaxy tablet in most of the European Union, handing Apple a victory in its intellectual property fight against the Korean firm. Last week, Samsung was forced to delay the Galaxy launch in Australia.
Shares of Goldman Sachs ( GS ) are sharply lower after The Wall Street Journal reported that U.S. securities regulators are investigating the securities firm under the U.S. Foreign Corrupt Practices Act related to its dealings with Libya's sovereign-wealth fund. Banking stocks are down across the board.
Wal-Mart ( WMT ) is down 2.86% at mid-day, after Digital Music News reports that Walmart Music Downloads Store located at MP3.walmart.com will close on August 28. All content in the Store will be disabled and no longer available for download from the store. The service was reportedly unable to compete with Apple's ( AAPL ) iTunes online music store.
Shares of Johnson & Johnson (JNJ) are down after Bloomberg reports that the health care products giant has reached an agreement to settle a misdemeanor criminal charge related to marketing of its antipsychotic drug Risperdal.
Commodities are higher as December gold contracts are up 3.04% to $1,796 an ounce while September crude oil contacts are up 1.29% to $80.36 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 0.66% to $31.41 and the United States Natural Gas fund (UNG) is up 0.99%, to $10.23.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 3% at $173.67. Market Vectors Gold Miners (GDX) is up 2.19% to $58.96. iShares Silver Trust (SLV) is up 4.41% to $37.92.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Stocks are backtracking sharply for the second time in three sessions at mid-day, with concern over European banks spreading gloom to U.S. equities markets and overshadowing a rise in job ads. With theeconomic calendarrelatively light, investors are eying corporate earnings, including Dow Jones Industrial component Walt Disney Co. ( DIS ), and the U.S. Federal Reserve's policy statement yesterday. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. Wal-Mart ( WMT ) is down 2.86% at mid-day, after Digital Music News reports that Walmart Music Downloads Store located at MP3.walmart.com will close on August 28. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. Apple ( AAPL ) shares are down after Reuters reported a court in Germany temporarily halted Samsung Electronics from selling its Galaxy tablet in most of the European Union, handing Apple a victory in its intellectual property fight against the Korean firm. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. The service was reportedly unable to compete with Apple's ( AAPL ) iTunes online music store. |
34515.0 | 2011-08-10 00:00:00 UTC | Mid-Day Update: Stocks Off Lows; Job Ads Rise, But Banking Concerns Weigh | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-lows-job-ads-rise-banking-concerns-weigh-2011-08-10 | nan | nan | Here's where markets stand at mid-day:
-NYSE down 249.03 (-3.43%) to 7,009.01
-DJIA down 373.54 (-3.32%) to 10,866.23
-S&P 500 down 33.97 (-2.9%) to 1,138.92
-Nasdaq down 62.09 (-2.52%) to 2,420.54
GLOBAL SENTIMENT
Nikkei up 1%.
Hang Seng up 2%.
Shanghai Composite up 0.9%.
FTSE-100 up 0.5%.
MID-DAY NYSE INDEX WATCH
NYSE Energy down 2.7% at 11,369.94
NYSE Financial down 4.45% at 4,046.24
NYSE Health Care down 2.73% at 6,279.91
NYSE Arca Tech 100 down 2.42% at 1,002.38
UPSIDE MOVERS
(+) RL (+6.3%) easily beats Q1 earnings estimates.
(+) COF (+1.3%) is buying HSBC's domestic credit card business. HBC (+0.4%)
(+) CREE (+15.7%) continues eventual sharp evening gain that followed Q4 beat, mixed guidance.
(+) BCON (+6.9%) inks deal.
(+) ADLR (+0.01%) jumps on study results.
(+) FOSL (-3.7%) gives up early gain; upgraded today after guidance miss on Tuesday.
DOWNSIDE MOVERS
(-) BAC (-6.9%) reportedly selling part of mortgage business: WSJ
(-) M (-2.1%) beats with Q2 results and sees FY EPS beating Street.
(-) WMT (-2.6%) brings its VUDU movie streaming to iPad.
(-) DIS (-9.2%) downgraded; gained in evening session after earnings beat.
(-) MOTR (-53%) continues evening plunge that followed Q2 miss, worrisome revenue view.
(-) SATC (-18.9%) misses Q2 estimates, guides for sales miss.
MARKET DIRECTION
Stocks are backtracking sharply for the second time in three sessions at mid-day, with concern over European banks spreading gloom to U.S. equities markets and overshadowing a rise in job ads. With theeconomic calendarrelatively light, investors are eying corporate earnings, including Dow Jones Industrial component Walt Disney Co. ( DIS ), and the U.S. Federal Reserve's policy statement yesterday.
Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. Revenue was $10.67 billion compared with the mean analyst consensus for $10.45 billion on Thomson Reuters. Third quarter profits were buoyed by deferred revenue moved from the fourth quarter to the third quarter, noted Reuters. Excluding that item, results missed most analysts' expectations, the report said.
On the economic front, U.S. wholesaler inventories rose less-than-expected at 0.6% in June, which signals a cautionary stance from business.
In company news:
Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension.
Apple ( AAPL ) shares are down after Reuters reported a court in Germany temporarily halted Samsung Electronics from selling its Galaxy tablet in most of the European Union, handing Apple a victory in its intellectual property fight against the Korean firm. Last week, Samsung was forced to delay the Galaxy launch in Australia.
Shares of Goldman Sachs ( GS ) are sharply lower after The Wall Street Journal reported that U.S. securities regulators are investigating the securities firm under the U.S. Foreign Corrupt Practices Act related to its dealings with Libya's sovereign-wealth fund. Banking stocks are down across the board.
Wal-Mart ( WMT ) is down 2.86% at mid-day, after Digital Music News reports that Walmart Music Downloads Store located at MP3.walmart.com will close on August 28. All content in the Store will be disabled and no longer available for download from the store. The service was reportedly unable to compete with Apple's ( AAPL ) iTunes online music store.
Shares of Johnson & Johnson (JNJ) are down after Bloomberg reports that the health care products giant has reached an agreement to settle a misdemeanor criminal charge related to marketing of its antipsychotic drug Risperdal.
Commodities are higher as December gold contracts are up 3.04% to $1,796 an ounce while September crude oil contacts are up 1.29% to $80.36 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 0.66% to $31.41 and the United States Natural Gas fund (UNG) is up 0.99%, to $10.23.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 3% at $173.67. Market Vectors Gold Miners (GDX) is up 2.19% to $58.96. iShares Silver Trust (SLV) is up 4.41% to $37.92.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Stocks are backtracking sharply for the second time in three sessions at mid-day, with concern over European banks spreading gloom to U.S. equities markets and overshadowing a rise in job ads. With theeconomic calendarrelatively light, investors are eying corporate earnings, including Dow Jones Industrial component Walt Disney Co. ( DIS ), and the U.S. Federal Reserve's policy statement yesterday. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. Shares of Walt Disney Co. ( DIS ) are down sharply after the company said late yesterday that Q3 EPS was $0.78, excluding charges, compared to expectations of $0.73 per share. Wal-Mart ( WMT ) is down 2.86% at mid-day, after Digital Music News reports that Walmart Music Downloads Store located at MP3.walmart.com will close on August 28. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. (-) BAC (-6.9%) reportedly selling part of mortgage business: WSJ (-) M (-2.1%) beats with Q2 results and sees FY EPS beating Street. Apple ( AAPL ) shares are down after Reuters reported a court in Germany temporarily halted Samsung Electronics from selling its Galaxy tablet in most of the European Union, handing Apple a victory in its intellectual property fight against the Korean firm. | In company news: Abbott Laboratories ( ABT ) said that it has received U.S. Food and Drug Administration approval for its RX Herculink Elite Renal Stent System for the treatment of renal artery stenosis, or the narrowing of the main arteries supplying blood to the kidneys, in patients with uncontrolled hypertension. (-) DIS (-9.2%) downgraded; gained in evening session after earnings beat. (-) MOTR (-53%) continues evening plunge that followed Q2 miss, worrisome revenue view. |
34516.0 | 2011-08-09 00:00:00 UTC | Stocks Rally; All Eyes Turn to Fed Statement This Afternoon | ABT | https://www.nasdaq.com/articles/stocks-rally-all-eyes-turn-to-fed-statement-this-afternoon-2011-08-09 | nan | nan | Stocks are rallying at mid-day, with the tech-heavy Nasdaq up 3% and other indexes up near 2%, after the bloodbath in the prior session. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message.
The Federal Reserve is due to release a post-meeting statement at 2:15 p.m. ET today. It was once expected to be a mostly formulaic meeting for Wall Street. That changed in the wake of a recent round of weak economic data, the U.S. credit downgrade and continuing concern over European sovereign debt. Investors will be scrutinizing every word of the Fed's statement for any hint of another round of quantitative easing to prop up the recovery.
Before the market opened, productivity data eased and revealed a sharp rise in a key inflation measure within the report -- unit labor costs jumped 2.2%.
In company news:
Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. The study demonstrated significant reductions in annualized relapse rate and meets key secondary endpoints.
Shares of Citigroup ( C ) are surging, paring some of their heavy prior-session losses. Citigroup CEO Vikram Pandit said the bank has "unparalleled resources" to withstand the market upheaval, Bloomberg reported. In his comments, Pandit said the current market turmoil is different from that during the financial crisis.
Ford ( F ) is up 9.21% to $10.85, after the company said its July sales totaled 180,865 vehicles, up 9% versus a year ago - driven by 13% higher Ford brand sales and 40% higher sales for Lincoln.
Meanwhile, shares of Pfizer ( PFE ) are higher after Bloomberg reported that Nestle may be putting together a bid for the drug makers baby-food division. The move comes as Nestle is said to be looking to foster momentum in China. the move would push Nestle to No. 3 from No. 6 in China's infant-nutrition market, the report said. Also this morning, Goldman Sachs upgraded Pfizer ( PFE ) to Conviction Buy from Buy. It has a price target of $22.
Bank of America (BAC) is up after Chief Financial Officer Bruce Thompson told Nomura Holdings Inc. analysts that the bank won't need to raise extra capital to meet new international standards, Bloomberg reported.
Shares of Apple (AAPL) are seeing support after Bloomberg reported the computer maker's patent-infringement complaint against HTC Corp. will received a review from a U.S. trade agency that has the power to block imports of HTC's mobile phones and tablet computers. Apple accuses HTC of infringing on five patents connected to software architecture and user interfaces on portable devices, the report said.
Commodities are mixed. December gold contracts are up 1.61% to $1,740 an ounce while September crude oil contacts are up 1.51% to $82.57 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 2.28% to $32.06 and the United States Natural Gas fund (UNG) is up 1.9%, to $10.17.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 1.23% at $169.17. Market Vectors Gold Miners (GDX) is up 1.26% to $56.14. iShares Silver Trust (SLV) is down 2.63% to $36.97.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message. That changed in the wake of a recent round of weak economic data, the U.S. credit downgrade and continuing concern over European sovereign debt. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message. Meanwhile, shares of Pfizer ( PFE ) are higher after Bloomberg reported that Nestle may be putting together a bid for the drug makers baby-food division. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. Before the market opened, productivity data eased and revealed a sharp rise in a key inflation measure within the report -- unit labor costs jumped 2.2%. Meanwhile, shares of Pfizer ( PFE ) are higher after Bloomberg reported that Nestle may be putting together a bid for the drug makers baby-food division. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. Citigroup CEO Vikram Pandit said the bank has "unparalleled resources" to withstand the market upheaval, Bloomberg reported. Meanwhile, shares of Pfizer ( PFE ) are higher after Bloomberg reported that Nestle may be putting together a bid for the drug makers baby-food division. |
34517.0 | 2011-08-09 00:00:00 UTC | Mid-Day Update: Stocks Surge Ahead of FOMC Statement | ABT | https://www.nasdaq.com/articles/mid-day-update%3A-stocks-surge-ahead-of-fomc-statement-2011-08-09 | nan | nan | Here's where markets stand at mid-day:
-NYSE up 218.01 (+3.16%) to 7,113.98
-DJIA up 220.62 (+2.04%) to 11,030.47
-S&P 500 up 30.61 (+2.75%) to 1,150.27
-Nasdaq up 82.23 (+3.53%) to 2,440.91
GLOBAL SENTIMENT
Nikkei down 1.7%.
Hang Seng down 5.6%.
Shanghai Composite down 0.03%.
FTSE-100 down 0.4%.
MID-DAY NYSE INDEX WATCH
NYSE Energy up 3.51% at 11,520.18
NYSE Financial up 4.51% at 4,117.84
NYSE Health Care up 2.94% at 6,383.10
NYSE Arca Tech 100 up 3.43% at 1,012.34
UPSIDE MOVERS
(+) GLW (+4.7%) upgraded.
(+) WFC (+5.4%) upgraded.
(+) UA (+6.3%) upgraded.
(+) XIN (+14.3%) beats estimates, raises outlook.
(+) TA (+7.1%) reports improved results vs year ago.
(+) SFI (+29.3%) sets buyback.
(+) ATPG (+0.9%) beats with sales.
(+) MRK (+3.1%) upgraded.
(+) PFE (+4.3%) added to Goldman's Conviction Buy list.
(+) UA (+6.2%) upgraded.
(+) XIN (+14.3%) beats with earnings, raises outlook.
(+) SOL (+10.9%) guides for sales miss.
DOWNSIDE MOVERS
(-) FOSL (-17.4%) beats with results but guides for FY miss.
(-) LLNW (-33.6%) downgraded.
MARKET DIRECTION
Stocks are rallying at mid-day, with the tech-heavy Nasdaq up 3% and other indexes up near 2%, after the bloodbath in the prior session. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message.
The Federal Reserve is due to release a post-meeting statement at 2:15 p.m. ET today. It was once expected to be a mostly formulaic meeting for Wall Street. That changed in the wake of a recent round of weak economic data, the U.S. credit downgrade and continuing concern over European sovereign debt. Investors will be scrutinizing every word of the Fed's statement for any hint of another round of quantitative easing to prop up the recovery.
Before the market opened, productivity data eased and revealed a sharp rise in a key inflation measure within the report -- unit labor costs jumped 2.2%.
In company news:
Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. The study demonstrated significant reductions in annualized relapse rate and meets key secondary endpoints.
Shares of Citigroup ( C ) are surging, paring some of their heavy prior-session losses. Citigroup CEO Vikram Pandit said the bank has "unparalleled resources" to withstand the market upheaval, Bloomberg reported. In his comments, Pandit said the current market turmoil is different from that during the financial crisis.
Ford ( F ) is up 9.21% to $10.85, after the company said its July sales totaled 180,865 vehicles, up 9% versus a year ago - driven by 13% higher Ford brand sales and 40% higher sales for Lincoln.
Meanwhile, shares of Pfizer ( PFE ) are higher after Bloomberg reported that Nestle may be putting together a bid for the drug makers baby-food division. The move comes as Nestle is said to be looking to foster momentum in China. the move would push Nestle to No. 3 from No. 6 in China's infant-nutrition market, the report said. Also this morning, Goldman Sachs upgraded Pfizer ( PFE ) to Conviction Buy from Buy. It has a price target of $22.
Bank of America (BAC) is up after Chief Financial Officer Bruce Thompson told Nomura Holdings Inc. analysts that the bank won't need to raise extra capital to meet new international standards, Bloomberg reported.
Shares of Apple (AAPL) are seeing support after Bloomberg reported the computer maker's patent-infringement complaint against HTC Corp. will received a review from a U.S. trade agency that has the power to block imports of HTC's mobile phones and tablet computers. Apple accuses HTC of infringing on five patents connected to software architecture and user interfaces on portable devices, the report said.
Commodities are mixed. December gold contracts are up 1.61% to $1,740 an ounce while September crude oil contacts are up 1.51% to $82.57 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 2.28% to $32.06 and the United States Natural Gas fund (UNG) is up 1.9%, to $10.17.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 1.23% at $169.17. Market Vectors Gold Miners (GDX) is up 1.26% to $56.14. iShares Silver Trust (SLV) is down 2.63% to $36.97.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message. That changed in the wake of a recent round of weak economic data, the U.S. credit downgrade and continuing concern over European sovereign debt. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. Ford ( F ) is up 9.21% to $10.85, after the company said its July sales totaled 180,865 vehicles, up 9% versus a year ago - driven by 13% higher Ford brand sales and 40% higher sales for Lincoln. Also this morning, Goldman Sachs upgraded Pfizer ( PFE ) to Conviction Buy from Buy. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. Before the market opened, productivity data eased and revealed a sharp rise in a key inflation measure within the report -- unit labor costs jumped 2.2%. Ford ( F ) is up 9.21% to $10.85, after the company said its July sales totaled 180,865 vehicles, up 9% versus a year ago - driven by 13% higher Ford brand sales and 40% higher sales for Lincoln. | In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. 6 in China's infant-nutrition market, the report said. Also this morning, Goldman Sachs upgraded Pfizer ( PFE ) to Conviction Buy from Buy. |
34518.0 | 2011-07-26 00:00:00 UTC | These Tiny Companies Could Cure Cancer and Make You Wealthy | ABT | https://www.nasdaq.com/articles/these-tiny-companies-could-cure-cancer-and-make-you-wealthy-2011-07-26 | nan | nan | A gain of 25%... 50%... even more than 100% in a single trading day?
It's rare. But it does happen.
Take Dendreon Corp. (Nasdaq: DNDN) , for example. Dendreon has a new drug called Provenge that taps into the immune system to fight prostate cancer. A single course of treatment costs $93,000.
You read that correctly. It's $93,000 for just one cycle of one drug. Between March 2009 and April 2010 -- during which Provenge was going through late rounds of trials -- Dendreon'sshares rose 1,764%.
On just one day -- April 14, 2009 -- Dendreon's stock shot up 132%. And it almost doubled again two weeks later on April 29, 2009, when the shares made another one-day jump of 94%.
Shares of biotechnology company Clinical Data (Nasdaq: CLDA) rose 68% on January 24, 2011, following news the Food and Drug Administration (FDA) approved its antidepressant drug.
And then there's XenoPort (Nasdaq: XNPT) , whose shares soared 56% on April 7 of this year, after the biopharmaceutical company got the nod from the FDA for its treatment of restless leg syndrome.
It's easy to see that when major medical breakthroughs occur, the benefit can be two-fold -- not only do patients get help for life-altering illnesses, but investors can also earn overnight profits.
And I don't know if there is anywhere the opportunity is more pronounced than in the field of treating cancer.
The American Cancer Society estimates that one in two American men and one in four American women will be diagnosed with some sort of cancer in their lifetimes. More than 500,000 Americans will succumb to the disease this year alone, equal to roughly one-third of the 1.5 million new cases expected to be diagnosed in 2011.
But it wasn't that long ago that a diagnosis of cancer was an automatic death sentence, and a terribly painful one at that. Now, a generation later, many types of cancer are curable and others are manageable. New drugs and treatments will take cancer from a killer disease to a chronic condition within my lifetime.
This means there will be companies along the way that profit from creating the drugs that beat cancer.
This is all well and good, but what's the best way for the average investor to find the next quick gainer that will soar from the fight against cancer?
First, forget the household names. It may well be the case that the next miracle drug will come from Pfizer ( PFE ) , Abbott Labs ( ABT ) or Eli Lilly ( LLY ) -- and more power to them.
But from an investing standpoint, we have to respect the law of large numbers. That is, a blockbuster drug matters a lot more to the share price of a $500 million company than a $50 billion company.
The challenge for investors, then, is knowing where to look for small companies with promise, and what to look for.
I've been doing a lot research into this area. I've found a total of 39 companies with cancer drugs in phase III of trials -- this is the step before FDA approval. When a drug passes phase III trials, it is given a pretty good chance (80%) of being approved by the FDA. It was Provenge's passage of phase III trials that started Dendreon's run.
Now, investors must go into this situation with their eyes fully open. There are never any guarantees in the field of drug approval (many stocks have dropped sharply on news a drug wasn't approved). But for the better part of a month I've been digging through the list of cancer drugs currently in phase III trials. And I think a handful of the companies are showing promise.
This means they are small companies with big potential for FDA approval, and they're working on products that target large segments of national health care spending.
This list includes some big names, including Pfizer, Amgen (Nasdaq: AMGN) , and Bristol-Myers Squibb ( BMY ) . But mixed in are smaller names like Halozyme Therapeutics (Nasdaq: HALO) . This $700 million biopharma company has two cancer drugs in late-stage trials, one for breast cancer and the other for follicular lymphoma.
Action to Take --> If one of these drugs is approved, a big one-day jump in the shares isn't out of the question.
And if we're able to make money while also battling against one of nature's most vile diseases, I can't see a negative.
Note: As I said, for the better part of a month I've researched the companies that could be the next big winners in the treatment of cancer for my Game-Changing Stocks advisory. To learn more about my results -- including the 5 stocks I think show the most promise -- visit this link.
--Andy Obermueller
Disclosure: Neither Andy Obermueller nor StreetAuthority, LLC hold positions in any securities mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It may well be the case that the next miracle drug will come from Pfizer ( PFE ) , Abbott Labs ( ABT ) or Eli Lilly ( LLY ) -- and more power to them. And then there's XenoPort (Nasdaq: XNPT) , whose shares soared 56% on April 7 of this year, after the biopharmaceutical company got the nod from the FDA for its treatment of restless leg syndrome. It's easy to see that when major medical breakthroughs occur, the benefit can be two-fold -- not only do patients get help for life-altering illnesses, but investors can also earn overnight profits. | It may well be the case that the next miracle drug will come from Pfizer ( PFE ) , Abbott Labs ( ABT ) or Eli Lilly ( LLY ) -- and more power to them. This list includes some big names, including Pfizer, Amgen (Nasdaq: AMGN) , and Bristol-Myers Squibb ( BMY ) . Action to Take --> If one of these drugs is approved, a big one-day jump in the shares isn't out of the question. | It may well be the case that the next miracle drug will come from Pfizer ( PFE ) , Abbott Labs ( ABT ) or Eli Lilly ( LLY ) -- and more power to them. Shares of biotechnology company Clinical Data (Nasdaq: CLDA) rose 68% on January 24, 2011, following news the Food and Drug Administration (FDA) approved its antidepressant drug. I've found a total of 39 companies with cancer drugs in phase III of trials -- this is the step before FDA approval. | It may well be the case that the next miracle drug will come from Pfizer ( PFE ) , Abbott Labs ( ABT ) or Eli Lilly ( LLY ) -- and more power to them. On just one day -- April 14, 2009 -- Dendreon's stock shot up 132%. It was Provenge's passage of phase III trials that started Dendreon's run. |
34519.0 | 2011-07-20 00:00:00 UTC | Abbott Labs’ Q2 Profit Surges 50% on Higher Sales (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-q2-profit-surges-50-higher-sales-abt-2011-07-20 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected second quarter profit and boosted its full-year earnings outlook.
The Abbott Park, IL-based company reported second quarter net income of $1.94 billion, or $1.23 per share, compared with $1.29 billion, or 83 cents, per share, in the year-ago period.
Revenue rose 9% from last year to $9.62 billion.
On average, Wall Street analysts expected a much smaller profit of $1.11 per share, on lower revenue of $9.54 billion.
Looking ahead, the company boosted its full-year earnings outlook by 4 cents, to a range of $4.58 to $4.68 per share. Analysts are currently looking for $4.60 per share for the year.
Abbott Labs shares rose 56 cents, or +1.1%, in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.8, 2011, when the stock was trading at $46.32. The company has a 3.63% dividend yield, based on last night's closing stock price of $52.89.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected second quarter profit and boosted its full-year earnings outlook. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.8, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected second quarter profit and boosted its full-year earnings outlook. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.8, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.8, 2011, when the stock was trading at $46.32. Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected second quarter profit and boosted its full-year earnings outlook. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday posted better-than-expected second quarter profit and boosted its full-year earnings outlook. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.8, 2011, when the stock was trading at $46.32. |
34520.0 | 2011-07-12 00:00:00 UTC | Abbott Labs’ Estimates Boosted at UBS (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-estimates-boosted-ubs-abt-2011-07-12 | nan | nan | Medical products maker Abbott Laboratories ( ABT ) on Tuesday saw its earnings estimates raised by analysts at UBS.
The firm said it lifted its estimates for ABT through 2012, citing currency trends that are driving earnings upside. UBS maintained its "Buy" rating and $59 price target, which suggests an 11% upside to the stock's Monday closing price of $53.18.
Abbott Labs shares were mostly flat in premarket trading Tuesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.61% dividend yield, based on last night's closing stock price of $53.18.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medical products maker Abbott Laboratories ( ABT ) on Tuesday saw its earnings estimates raised by analysts at UBS. The firm said it lifted its estimates for ABT through 2012, citing currency trends that are driving earnings upside. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. | Medical products maker Abbott Laboratories ( ABT ) on Tuesday saw its earnings estimates raised by analysts at UBS. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Medical products maker Abbott Laboratories ( ABT ) on Tuesday saw its earnings estimates raised by analysts at UBS. | Medical products maker Abbott Laboratories ( ABT ) on Tuesday saw its earnings estimates raised by analysts at UBS. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. The firm said it lifted its estimates for ABT through 2012, citing currency trends that are driving earnings upside. |
34521.0 | 2011-07-12 00:00:00 UTC | Update: Top unusual option activity | ABT | https://www.nasdaq.com/articles/update-top-unusual-option-activity-2011-07-12 | nan | nan | As of today's close, here are the top 10 names showing unusual option activity on tradeMONSTER's LiveAction data system.
Two Harbors Investment (TWO): Option volume 4,451 percent above average. An investor sold 12,000 August 5 calls for $5.62. TWO fell 1.84 percent to $10.65.
Mohawk Industries (MHK): Option volume 4,390 percent above average. Investors bought more than 9,000 August 55 puts for $2.10 to $2.25, positioning for a drop. MHK fell 0.95 percent to $55.53.
Abbott Laboratories (ABT): Option volume 4,239 percent above average. Call activity surged as investors looked to reap the company's cash dividend.
Telestone Technologies (TSTC): Option volume 2,412 percent above average. Positions in the July 10 calls and July 10 puts were rolled forward by one month. TSTC fell 1.94 percent to 6.08.
Vanguard MSCI Europe ETF (VGK): Option volume 2,058 percent above average. A block of 5,000 September 53 puts was sold for $3.60. VGK fell 0.96 percent to $50.31.
Rounding out the rest of the top 10 are:
Edison International (EIX): Option volume 1,622 percent above average.
Freescale Semiconductor (FSL): Option volume 1,573 percent above average.
General Growth Properties (GGP): Option volume 1,552 percent above average.
Foot Locker (FL): Option volume 1,410 percent above average.
iShares Barclays 7-10 Yrs Treasury Bond Fund (IEF): Option volume 1,409 percent above average.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Option volume 4,239 percent above average. As of today's close, here are the top 10 names showing unusual option activity on tradeMONSTER's LiveAction data system. Rounding out the rest of the top 10 are: Edison International (EIX): Option volume 1,622 percent above average. | Abbott Laboratories (ABT): Option volume 4,239 percent above average. Mohawk Industries (MHK): Option volume 4,390 percent above average. Telestone Technologies (TSTC): Option volume 2,412 percent above average. | Abbott Laboratories (ABT): Option volume 4,239 percent above average. Two Harbors Investment (TWO): Option volume 4,451 percent above average. Mohawk Industries (MHK): Option volume 4,390 percent above average. | Abbott Laboratories (ABT): Option volume 4,239 percent above average. Two Harbors Investment (TWO): Option volume 4,451 percent above average. An investor sold 12,000 August 5 calls for $5.62. |
34522.0 | 2011-06-24 00:00:00 UTC | Stocks Slump, But Off Lows, as Investors Eye Revised GDP Data; Commodities in Red | ABT | https://www.nasdaq.com/articles/stocks-slump-lows-investors-eye-revised-gdp-data-commodities-red-2011-06-24 | nan | nan | Stocks are lower for the second session in a row after new data showed the US economy grew slower than analysts had expected, and reports from two tech names failed to inspire investor confidence.
The U.S. economy grew at a slightly faster 1.9% clip in Q1 compared to 1.8% revealed in the initial reading, although a touch shy of Wall Street expectations for a revised 2%. In Europe, just as progress on Greek aid cheered investors, a suspension in Italian banking share trade rattled markets anew.
Trading in Italian bank stocks was suspended Friday after a sudden drop in share prices, MarketWatch reports. A spokeswoman for Borsa Italiana said the suspension was temporary and was triggered by "technical problems about volatility."
In earnings, Oracle (ORCL) is down after the company reported a rise in fiscal Q4 profit that topped analyst expectations. However, traders look to be focusing on the report's details. Hardware sales dropped during the quarter in contrast to Oracle's previous forecast of a rise of up to 12%.
On its conference call, ORCL said it expects Q1 revenue growth in the range of of 9% to 12%. Non-GAAP EPS is seen in the range of $0.45 to $0.48 per share. The Street is at 9% revenue growth and earnings of $0.46 per share. Earlier, the company reported Q4 revenue of $10.77 bln, just ahead of the analyst consensus of $10.74 bln on Thomson Reuters. EPS $0.75, vs. expectations of $0.71 per share.
Also, Micron (MU) is lower after it reports late Thursday Q3 sales of $2.13 billion, below the analyst consensus of $2.36 billion on Thomson Reuters. EPS was $0.07 per share, vs. expectations of $0.16 per share.
Elsewhere in company news:
NYSE Euronext (NYX) and Deutsche Boerse AG will pay $910 million in dividends to shareholders to settle lawsuits challenging the $9.53 billion buyout of the parent company of the New York Stock Exchange, according to court papers, Bloomberg reports.
Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. The stude showed that bardoxolone bolstered kidney performance by about 30 percent.
Blackboard ( BBBB ) gains after the WSJ reports that it is in exclusive talks with Providence Equity Partners. The acquisition may happen next week, the WSJ said.
Baidu ( BIDU ) says it will make a US$306 million strategic investment in Qunar, which will make BIDU the majority shareholder. The parties currently expect that the transaction will close in Q3.
Pfizer (PFE) and Pain Therapeutics ( PTIE ) shares are lower as the U.S. Food and Drug Administration delayed approval of a new pain killer for the second time. The companies announced that a complete response letter was received from the U.S. Food and Drug Administration on the resubmission to the new drug application for REMOXY (oxycodone) Extended-Release Capsules CII. Pfizer said it is working to evaluate the issues described in the letter and plans to have further discussions with FDA around them.
Bank of Ireland Plc ( IRE ) slips after it says it may raise a total of 2.5 billion euros from its offer to swap subordinated debt for equity or cash, according to Glas Securities, Bloomberg reports.
Commodities are down. August gold contracts are down 0.65% to $1,511 an ounce while August crude oil contacts are down 0.23% to $90.78 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 1.17% to $35.59 and the United States Natural Gas fund (UNG) is down 0.01%, to $10.70.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 0.87% at $147.04. Market Vectors Gold Miners (GDX) is down 1.98% to $52.94. iShares Silver Trust (SLV) is down 1.08% to $34.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. Stocks are lower for the second session in a row after new data showed the US economy grew slower than analysts had expected, and reports from two tech names failed to inspire investor confidence. The U.S. economy grew at a slightly faster 1.9% clip in Q1 compared to 1.8% revealed in the initial reading, although a touch shy of Wall Street expectations for a revised 2%. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. In Europe, just as progress on Greek aid cheered investors, a suspension in Italian banking share trade rattled markets anew. Also, Micron (MU) is lower after it reports late Thursday Q3 sales of $2.13 billion, below the analyst consensus of $2.36 billion on Thomson Reuters. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. Stocks are lower for the second session in a row after new data showed the US economy grew slower than analysts had expected, and reports from two tech names failed to inspire investor confidence. EPS was $0.07 per share, vs. expectations of $0.16 per share. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. The Street is at 9% revenue growth and earnings of $0.46 per share. Also, Micron (MU) is lower after it reports late Thursday Q3 sales of $2.13 billion, below the analyst consensus of $2.36 billion on Thomson Reuters. |
34523.0 | 2011-06-24 00:00:00 UTC | Mid-Day Update: Stocks Lower; Earnings, GDP Data Disappoint | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-lower-earnings-gdp-data-disappoint-2011-06-24 | nan | nan | Here's where markets stand at mid-day:
-NYSE down 51.51 (-0.64%) to 8,002.38
-DJIA down 84.28 (-0.7%) to 11,965.72
-S&P 500 down 9.73 (-0.75%) to 1,273.81
-Nasdaq down 21.74 (-0.81%) to 2,665.03
GLOBAL SENTIMENT
Nikkei up 0.9%.
Hang Seng up 1.9%.
Shanghai Composite up 2.2%.
FTSE-100 up 0.9%.
MID-DAY NYSE INDEX WATCH
NYSE Energy down 0.85% at 12,832.44
NYSE Financial down 0.85% at 4,717.27
NYSE Health Care down 1.18% at 7,110.05
NYSE Arca Tech 100 down 0.87% at 1,128.61
UPSIDE MOVERS
(+) SUG (+16.9%) continues evening gain that followed Williams' $39 per-share offer.
(+) SSN (+5.2%) buying additional Bakken acreage.
(+) CMCSA (+0.02%) upgraded.
(+) DO (+0.8%) upgraded.
(+) KOG (+0.7%) upgraded.
(+) BBBB (+6.5%) reportedly in talks to be bought.
(+) TIF (+0.6%) downgraded.
DOWNSIDE MOVERS
(-) PTIE (-39.7%) along with PFE and DRRX get complete response letter on Remoxy.
(-) DRRX (-32.0%) along with PFE and PTIE get complete response letter on Remoxy.
(-) AEGR (-4.1%) prices shares.
(-) IRE (-2.6%) may raise money in swap.
(-) LUX (-1.5%) downgraded.
(-) MU (-12.7%) misses with earnings.
(-) ORCL (-3.4%) beats with earnings but guides in line and key sales figures disappoint.
MARKET DIRECTION
Stocks are lower for the second session in a row after new data showed the US economy grew slower than analysts had expected, and reports from two tech names failed to inspire investor confidence.
The U.S. economy grew at a slightly faster 1.9% clip in Q1 compared to 1.8% revealed in the initial reading, although a touch shy of Wall Street expectations for a revised 2%. In Europe, just as progress on Greek aid cheered investors, a suspension in Italian banking share trade rattled markets anew.
Trading in Italian bank stocks was suspended Friday after a sudden drop in share prices, MarketWatch reports. A spokeswoman for Borsa Italiana said the suspension was temporary and was triggered by "technical problems about volatility."
In earnings, Oracle (ORCL) is down after the company reported a rise in fiscal Q4 profit that topped analyst expectations. However, traders look to be focusing on the report's details. Hardware sales dropped during the quarter in contrast to Oracle's previous forecast of a rise of up to 12%.
On its conference call, ORCL said it expects Q1 revenue growth in the range of of 9% to 12%. Non-GAAP EPS is seen in the range of $0.45 to $0.48 per share. The Street is at 9% revenue growth and earnings of $0.46 per share. Earlier, the company reported Q4 revenue of $10.77 bln, just ahead of the analyst consensus of $10.74 bln on Thomson Reuters. EPS $0.75, vs. expectations of $0.71 per share.
Also, Micron (MU) is lower after it reports late Thursday Q3 sales of $2.13 billion, below the analyst consensus of $2.36 billion on Thomson Reuters. EPS was $0.07 per share, vs. expectations of $0.16 per share.
Elsewhere in company news:
NYSE Euronext (NYX) and Deutsche Boerse AG will pay $910 million in dividends to shareholders to settle lawsuits challenging the $9.53 billion buyout of the parent company of the New York Stock Exchange, according to court papers, Bloomberg reports.
Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. The stude showed that bardoxolone bolstered kidney performance by about 30 percent.
Blackboard ( BBBB ) gains after the WSJ reports that it is in exclusive talks with Providence Equity Partners. The acquisition may happen next week, the WSJ said.
Baidu ( BIDU ) says it will make a US$306 million strategic investment in Qunar, which will make BIDU the majority shareholder. The parties currently expect that the transaction will close in Q3.
Pfizer (PFE) and Pain Therapeutics ( PTIE ) shares are lower as the U.S. Food and Drug Administration delayed approval of a new pain killer for the second time. The companies announced that a complete response letter was received from the U.S. Food and Drug Administration on the resubmission to the new drug application for REMOXY (oxycodone) Extended-Release Capsules CII. Pfizer said it is working to evaluate the issues described in the letter and plans to have further discussions with FDA around them.
Bank of Ireland Plc ( IRE ) slips after it says it may raise a total of 2.5 billion euros from its offer to swap subordinated debt for equity or cash, according to Glas Securities, Bloomberg reports.
Commodities are down. August gold contracts are down 0.65% to $1,511 an ounce while August crude oil contacts are down 0.23% to $90.78 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 1.17% to $35.59 and the United States Natural Gas fund (UNG) is down 0.01%, to $10.70.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 0.87% at $147.04. Market Vectors Gold Miners (GDX) is down 1.98% to $52.94. iShares Silver Trust (SLV) is down 1.08% to $34.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. Stocks are lower for the second session in a row after new data showed the US economy grew slower than analysts had expected, and reports from two tech names failed to inspire investor confidence. The U.S. economy grew at a slightly faster 1.9% clip in Q1 compared to 1.8% revealed in the initial reading, although a touch shy of Wall Street expectations for a revised 2%. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. Also, Micron (MU) is lower after it reports late Thursday Q3 sales of $2.13 billion, below the analyst consensus of $2.36 billion on Thomson Reuters. Pfizer (PFE) and Pain Therapeutics ( PTIE ) shares are lower as the U.S. Food and Drug Administration delayed approval of a new pain killer for the second time. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. In earnings, Oracle (ORCL) is down after the company reported a rise in fiscal Q4 profit that topped analyst expectations. EPS was $0.07 per share, vs. expectations of $0.16 per share. | Shares of Abbott Laboratories ( ABT ) are down even as new data showed that an experimental drug from Abbott and Reata Pharmaceuticals reversed declining kidney function in diabetics, the companies said in a statement. In earnings, Oracle (ORCL) is down after the company reported a rise in fiscal Q4 profit that topped analyst expectations. The Street is at 9% revenue growth and earnings of $0.46 per share. |
34524.0 | 2011-06-20 00:00:00 UTC | Mid-Day Update: Stocks Shake Off Greece Worries to Sit Higher at Session's Half; Commodities Mixed | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-shake-greece-worries-sit-higher-sessions-half-commodities-mixed-2011 | nan | nan | Here's where markets stand at mid-day:
-NYSE up 40.78 (+0.51%) to 8,040.89
-DJIA up 88.89 (+0.74%) to 12,093.25
-S&P 500 up 7.96 (+0.63%) to 1,279.66
-Nasdaq up 14.93 (+0.57%) to 2,631.30
GLOBAL SENTIMENT
Nikkei up 0.03%.
Hang Seng down 0.4%.
Shanghai Composite down 0.8%.
FTSE-100 down 0.9%.
MID-DAY NYSE INDEX WATCH
NYSE Energy down 10.49% at 12,885.67
NYSE Financial up 0.17% at 4,780.37
NYSE Health Care up 5.23% at 7,180.64
NYSE Arca Tech 100 up 0.57% at 1,110.78
UPSIDE MOVERS
(+) HRBN (+61.5%) sold for $24 a share; off early highs.
(+) BTU (+0.8%) upgraded.
(+) BA (+0.3%) reporting new orders from Paris Air Show.
(+) CBS (+2.8%) is subject of favorable Barron's coverage.
(+) ACUR (+26.6%) with PFE gets clearance for Oxecta pain medicationl; PFE slips.
(+) MOS (+1.0%) upgraded.
(+) PSTI (+4.9%) inks deal, gets upfront payment with United Therapeutics.
(+) CRIS (+2.5%) reports positive trial data.
(+) AGU (+3.3%) raises outlook.
(+) F (+1.8%) spending $1 bln on Lincoln unit.
(+/-) CNX (0.0%) upgraded.
(+) MSFT (+1.3%) subject of Barron's piece detailing growth over value.
DOWNSIDE MOVERS
(-) DATE (-3.8%) started with favorable coverage.
(-) PBTH (-1.5%) upgraded.
(-) PNC (-2.1%) buying RBC's U.S. unit for $3.45 bln.
(-) LPL (-0.9%) upgraded.
(-) SWKS (-5.1%) downgraded.
(-) NBR (-2.0%) warns for profit.
(-) GE (-0.01%) inks tentative deal with leading unions.
MARKET DIRECTION
Stocks are higher in mid-session trading as deal news provides support in the absence of new economic data. Stocks have pared the early losses that followed Greece's failure to win support for immediate debt relief. Inaction stoked simmering worries over the European Union's handling of the crisis there.
European officials delayed the final decision for releasing the next $16.8 billion tranche of a $155 billion aid package until Greece has implemented further austerity measures. Market observers were hoping the tranche would be immediately released over the weekend and markets had gained at times last week on optimism for quick action. That next installment is key to preventing debt default in Greece, reports say this morning.
In deal news:
The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. With approximately $25 billion of assets, Raleigh, N.C.-based RBC Bank ( USA ) has 424 branches in North Carolina, Florida, Alabama, Georgia, Virginia and South Carolina. When combined with PNC's existing network, the company will have 2,870 branches, ranking it 5th among U.S. banks.
Also, EBay Inc. ( EBAY ) says it completed its previously announced acquisition of GSI Commerce Inc. ( GSIC ), a provider of e-commerce and ineractive marketing services, following the approval of GSIC stockholders of the merger agreement. eBay will acquire all shares outstanding of GSI for $29.25 per share in cash, for a total consideration price of $2.4 bln.
In company news:
Shares of Wal-Mart Stores (WMT) are higher as the retail giant wins that a gender-bias case before the US Supreme Court. The case had aimed cover every woman who worked at any of Wal-Mart's branded stores or associated chains at any time since December of 1998. The case had been viewed closely by businesses. Wal-Mart stores was being sued for discrimination on behalf of nearly a million female workers, Bloomberg noted in a report on the win. Ultimately, justices said lawyers for for plaintiffs did not identify a common corporate policy that led to gender discrimination against the workers.
Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform. Shares are up over 3% in mid-session trading.
Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. Approval of a new six-month formulation means that physicians and patients who have chosen Lupron Depot now have an additional treatment option. Patients can now chose to receive their treatments every six months, providing additional dosing flexibility for patients with advanced prostate cancer.
Shares of Goldman Sachs (GS) are down as Bloomberg reports the bank was fined $40,000 by the ICE Futures Europe exchange due to "disorderly" oil trading, the exchange said. The trades are related to price spikes in the April 2011 contract price of Brent crude that were late found to result from several large market orders, the report said.
Shares of Pfizer (PFE) and Acura Pharmaceuticals ( ACUR ) are mixed as the two announce the marketing approval from the FDA for OXECTATM tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
Commodities are mixed as August gold contracts are flat at $1,539 an ounce while July crude oil contacts are down 0.2% to $92.86 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.08% to $36.67 and the United States Natural Gas fund (UNG) is down 0.27%, to $11.01.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 0.04% at $150. Market Vectors Gold Miners (GDX) is up 0.75% to $52.36. iShares Silver Trust (SLV) is up 0.17% to $35.01.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. In company news: Shares of Wal-Mart Stores (WMT) are higher as the retail giant wins that a gender-bias case before the US Supreme Court. Shares of Pfizer (PFE) and Acura Pharmaceuticals ( ACUR ) are mixed as the two announce the marketing approval from the FDA for OXECTATM tablets CII. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. Stocks are higher in mid-session trading as deal news provides support in the absence of new economic data. In deal news: The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. In deal news: The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform. Shares are up over 3% in mid-session trading. |
34525.0 | 2011-06-20 00:00:00 UTC | US Indexes Gains Despite Greece Worries; Commodities Mixed at the Session's Half | ABT | https://www.nasdaq.com/articles/us-indexes-gains-despite-greece-worries-commodities-mixed-sessions-half-2011-06-20 | nan | nan | Stocks are higher in mid-session trading as deal news provides support in the absence of new economic data. Stocks have pared the early losses that followed Greece's failure to win support for immediate debt relief. Inaction stoked simmering worries over the European Union's handling of the crisis there.
European officials delayed the final decision for releasing the next $16.8 billion tranche of a $155 billion aid package until Greece has implemented further austerity measures. Market observers were hoping the tranche would be immediately released over the weekend and markets had gained at times last week on optimism for quick action. That next installment is key to preventing debt default in Greece, reports say this morning.
In deal news:
The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. With approximately $25 billion of assets, Raleigh, N.C.-based RBC Bank ( USA ) has 424 branches in North Carolina, Florida, Alabama, Georgia, Virginia and South Carolina. When combined with PNC's existing network, the company will have 2,870 branches, ranking it 5th among U.S. banks.
Also, EBay Inc. ( EBAY ) says it completed its previously announced acquisition of GSI Commerce Inc. ( GSIC ), a provider of e-commerce and ineractive marketing services, following the approval of GSIC stockholders of the merger agreement. eBay will acquire all shares outstanding of GSI for $29.25 per share in cash, for a total consideration price of $2.4 bln.
In company news:
Shares of Wal-Mart Stores (WMT) are higher as the retail giant wins that a gender-bias case before the US Supreme Court. The case had aimed cover every woman who worked at any of Wal-Mart's branded stores or associated chains at any time since December of 1998. The case had been viewed closely by businesses. Wal-Mart stores was being sued for discrimination on behalf of nearly a million female workers, Bloomberg noted in a report on the win. Ultimately, justices said lawyers for for plaintiffs did not identify a common corporate policy that led to gender discrimination against the workers.
Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform. Shares are up over 3% in mid-session trading.
Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. Approval of a new six-month formulation means that physicians and patients who have chosen Lupron Depot now have an additional treatment option. Patients can now chose to receive their treatments every six months, providing additional dosing flexibility for patients with advanced prostate cancer.
Shares of Goldman Sachs (GS) are down as Bloomberg reports the bank was fined $40,000 by the ICE Futures Europe exchange due to "disorderly" oil trading, the exchange said. The trades are related to price spikes in the April 2011 contract price of Brent crude that were late found to result from several large market orders, the report said.
Shares of Pfizer (PFE) and Acura Pharmaceuticals ( ACUR ) are mixed as the two announce the marketing approval from the FDA for OXECTATM tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
Commodities are mixed as August gold contracts are flat at $1,539 an ounce while July crude oil contacts are down 0.2% to $92.86 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.08% to $36.67 and the United States Natural Gas fund (UNG) is down 0.27%, to $11.01.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 0.04% at $150. Market Vectors Gold Miners (GDX) is up 0.75% to $52.36. iShares Silver Trust (SLV) is up 0.17% to $35.01.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. In company news: Shares of Wal-Mart Stores (WMT) are higher as the retail giant wins that a gender-bias case before the US Supreme Court. Wal-Mart stores was being sued for discrimination on behalf of nearly a million female workers, Bloomberg noted in a report on the win. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. Stocks are higher in mid-session trading as deal news provides support in the absence of new economic data. In deal news: The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. In deal news: The PNC Financial Services Group, Inc. (PNC) and Royal Bank of Canada (RY have signed a definitive agreement for PNC to acquire RBC Bank ( USA ), the U.S. retail banking subsidiary of Royal Bank of Canada, for $3.45 billion, or $112 million discount to tangible book value. Whole Foods (WFMI) shares are higher after it was reportedly upgraded by BMO Capital Markets to Outperform from Market Perform. | Abbott Laboratories ( ABT ) shares are higher as the company said the U.S. Food and Drug Administration approved a new 45 mg for six-month administration formulation of Lupron Depot, a medication used for the palliative treatment of advanced prostate cancer. The case had been viewed closely by businesses. Wal-Mart stores was being sued for discrimination on behalf of nearly a million female workers, Bloomberg noted in a report on the win. |
34526.0 | 2011-06-17 00:00:00 UTC | Abbott Labs Started as an “Outperform” at Morgan Keegan (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-started-outperform-morgan-keegan-abt-2011-06-17 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Friday saw its coverage initiated with an "Outperform" rating by analysts at Morgan Keegan.
The firm also set a $61 price target on ABT shares, which suggests a 19% upside to the stock's Thursday closing price of $51.31.
Morgan Keegan noted the company's geographic expansion can be a big driver for sales growth.
Abbott shares were mostly flat in premarket trading Friday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.74% dividend yield, based on last night's closing stock price of $51.31.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Friday saw its coverage initiated with an "Outperform" rating by analysts at Morgan Keegan. The firm also set a $61 price target on ABT shares, which suggests a 19% upside to the stock's Thursday closing price of $51.31. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. | Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Friday saw its coverage initiated with an "Outperform" rating by analysts at Morgan Keegan. The firm also set a $61 price target on ABT shares, which suggests a 19% upside to the stock's Thursday closing price of $51.31. | The firm also set a $61 price target on ABT shares, which suggests a 19% upside to the stock's Thursday closing price of $51.31. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) on Friday saw its coverage initiated with an "Outperform" rating by analysts at Morgan Keegan. The firm also set a $61 price target on ABT shares, which suggests a 19% upside to the stock's Thursday closing price of $51.31. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars. |
34527.0 | 2011-06-09 00:00:00 UTC | Mid-Day Update: Stocks Rally Despite Disappointing Jobs Data; Trade Deficit Narrows | ABT | https://www.nasdaq.com/articles/mid-day-update%3A-stocks-rally-despite-disappointing-jobs-data-trade-deficit-narrows-2011-06 | nan | nan | Here's where markets stand at mid-day:
-NYSE up 77.52 (+0.96%) to 8,158.87
-DJIA up 117.76 (+0.98%) to 12,166.70
-S&P 500 up 12.18 (+0.95%) to 1,291.93
-Nasdaq up 12.04 (+0.45%) to 2,687.38
GLOBAL SENTIMENT
Nikkei up 0.2%.
Hang Seng down 0.2%.
Shanghai Composite down 1.7%.
FTSE-100 flat.
MID-DAY NYSE INDEX WATCH
NYSE Energy down 7.08% at 13,376.23
NYSE Financial up 0.86% at 4,824.73
NYSE Health Care up 6.9% at 7,294.69
NYSE Arca Tech 100 up 0.52% at 1,135.48
UPSIDE MOVERS
(+) AIG (+3.6%) gets favorable analyst coverage.
(+) GM (+1.6%) reportedly considering putting up Opel for sale.
(+) TXN (+0.8%) improves after initial drop on Q2 warning.
(+) M (+1.9%) upgraded.
(+) OAS (+3.5%) upgraded.
(+) TITN (+7.9%) beats with earnings.
(+) ELN (+6.1%) upgraded.
(+) CBAK (+9.9%) reports strong demand for e-Bike battery.
(+) CSTR (+0.3%) inks kiosk deal with Safeway.
(+) HWD (+2.0%) misses with Q1 results.
DOWNSIDE MOVERS
(-) VRTX (-9.1%) says drugs show promise in Cystic Fibrosis.
(-) RPC (-12.3%) reports weaker Q1 than year ago.
(-) WLL (-1.0%) downgraded.
(-) ITG (-1.6%) downgraded.
(-) V (-0.3%) makes acquisition.
MARKET DIRECTION
Stocks are rallying at mid-day, with the Dow up more than 100 points after a six-day slide, as despite disappointing weekly jobless figures were offset by the prospect of an interest rate hike in Europe, which is lifting banking stocks. Investors may also be shopping for bargains.
Weighing on the market early, applications for unemployment increased by 1,000 to a seasonally adjusted 427,000 in the week ended June 4, according to the Labor Department. Economists surveyed by MarketWatch had expected new requests to decline to 419,000. But on the positive side, the four-week rolling average of new claims, which smooths out volatility, dipped 2,750 to 424,000.
The U.S. trade deficit narrowed sharply in April after imports from Japan were curtailed due to the earthquake, the Commerce Department reported. The trade deficit narrowed 6.7% in April to $43.7 billion from a revised $46.8 billion in March.
In company news:
Citigroup Inc. ( C ) is showing little downside from a report this morning that hackers were able to phish credit card information on North American customers. The major online security breach affects about 200,000 accounts, according to the Financial Times, which broke the story. Citi has more than 21 million credit card customers in North America, according to its 2010 annual report. Hackers reportedly reaped names, account numbers and contact information, but did not get access to social security numbers, birth dates, card expiry dates or card security codes.
Nokia (NOK) is up 1% after shaking off a Standard & Poor's downgrade of its credit in the face of what is expected to be weaker financial results. On the heels of a Fitch Ratings cut yesterday, S&P analyst Matthias Raab dropped Nokia's borrower rating to b BBB+/A-2b3 from b A-/A-1b3, and placed the firm's ratings on b CreditWatch with negative implications.
Shares of Abbott Laboratories ( ABT ) are higher after the company reported on the interim efficacy and safety results from its long-term, 54-week, Phase III study of its investigational treatment of Parkinson's disease.The treatment is for patients with levodopa-carbidopa intestinal gel, or LCIG. The study showed that patients treated for 12 weeks with LCIG showed decreased "off" times, when re-emergence of the disease results in loss of mobility, and increased "on" times, periods wherein the disease is manageable, without dyskinesias, the company said.
Shares of Microsoft (MSFT) have turned higher at mid-day, following a Wall Street Journal reported that the US Supreme Court upheld a patent-infringement verdict worth $290 million against the company, rejecting the software firm's effort to make it more difficult to sue it for patent claims. The case stems from a case against Toronto technology company i4i Inc. Microsoft argued the company should not have won a verdict involving a patent claim related to document editing in its Word word processing software. the report said.
Radient Pharmaceuticals ( RPC ) is sharply lower after it said late Wednesday Q1 sales fell to $30,655, from $36,842 a year ago. Net loss was $0.13 per share, wider than the $0.11 loss a year earlier. Its quarterly report includes a "going concern" explanatory disclosure which expresses doubt, based upon current financial resources, as to whether RPC can meet its continuing obligations without access to additional working capital. It says it intends to raise additional capital and pursue expense reductions to ensure its ongoing financial viability.
General Motors ( GM ) shares are higher after the company considers putting its European arm Opel up for sale again. According to Auto Bild and Spiegel Online, possible buyers could be Chinese carmakers or Germany's Volkswagen, Reuters reports.
Commodities are higher. August gold contracts are up 0.66%, to $1,549 an ounce while July crude oil contacts are up 1.58% to $102.33 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 1.2% to $40.33 and the United States Natural Gas fund (UNG) is down 1.46%, to $12.14.
In precious metal ETFs, the SPDR Gold Trust ( GLD ) is UP 0.63% at $150.76. Market Vectors Gold Miners (GDX) is up 2.17% to $54.69. iShares Silver Trust (SLV) is up 1.55% to $36.59.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of Abbott Laboratories ( ABT ) are higher after the company reported on the interim efficacy and safety results from its long-term, 54-week, Phase III study of its investigational treatment of Parkinson's disease.The treatment is for patients with levodopa-carbidopa intestinal gel, or LCIG. In company news: Citigroup Inc. ( C ) is showing little downside from a report this morning that hackers were able to phish credit card information on North American customers. Shares of Microsoft (MSFT) have turned higher at mid-day, following a Wall Street Journal reported that the US Supreme Court upheld a patent-infringement verdict worth $290 million against the company, rejecting the software firm's effort to make it more difficult to sue it for patent claims. | Shares of Abbott Laboratories ( ABT ) are higher after the company reported on the interim efficacy and safety results from its long-term, 54-week, Phase III study of its investigational treatment of Parkinson's disease.The treatment is for patients with levodopa-carbidopa intestinal gel, or LCIG. (-) RPC (-12.3%) reports weaker Q1 than year ago. Hackers reportedly reaped names, account numbers and contact information, but did not get access to social security numbers, birth dates, card expiry dates or card security codes. | Shares of Abbott Laboratories ( ABT ) are higher after the company reported on the interim efficacy and safety results from its long-term, 54-week, Phase III study of its investigational treatment of Parkinson's disease.The treatment is for patients with levodopa-carbidopa intestinal gel, or LCIG. The study showed that patients treated for 12 weeks with LCIG showed decreased "off" times, when re-emergence of the disease results in loss of mobility, and increased "on" times, periods wherein the disease is manageable, without dyskinesias, the company said. Shares of Microsoft (MSFT) have turned higher at mid-day, following a Wall Street Journal reported that the US Supreme Court upheld a patent-infringement verdict worth $290 million against the company, rejecting the software firm's effort to make it more difficult to sue it for patent claims. | Shares of Abbott Laboratories ( ABT ) are higher after the company reported on the interim efficacy and safety results from its long-term, 54-week, Phase III study of its investigational treatment of Parkinson's disease.The treatment is for patients with levodopa-carbidopa intestinal gel, or LCIG. Nokia (NOK) is up 1% after shaking off a Standard & Poor's downgrade of its credit in the face of what is expected to be weaker financial results. The study showed that patients treated for 12 weeks with LCIG showed decreased "off" times, when re-emergence of the disease results in loss of mobility, and increased "on" times, periods wherein the disease is manageable, without dyskinesias, the company said. |
34528.0 | 2011-05-31 00:00:00 UTC | Will Corporate Tax Reform Help or Hurt Your Stocks? | ABT | https://www.nasdaq.com/articles/will-corporate-tax-reform-help-or-hurt-your-stocks-2011-05-31 | nan | nan | With the United States a little financially strapped right now, lawmakers are including all kinds of remedies -- including a major overhaul of corporate tax laws.
Our current system's odd features often leave observers scratching their heads or shaking their fists. For companies and individuals alike, the sheer complexity of the tax code is a problem in and of itself. ExxonMobil , with tax returns running 20,000 pages, houses 35 full-time IRS employees at its headquarters just to help it stay in compliance. The tax returns of Warren Buffett's Berkshire Hathaway take up roughly 14,000 pages. Simplifying the tax code would save many companies considerable time and money.
A 25% solution
One reform that many have suggested, and which is currently being considered, involves lowering the corporate tax rate from its current 35% rate, while eliminating many corporate tax breaks. You might think that the business world would rejoice at such a reduction, but many businesses enjoy so many tax breaks and deductions that they effectively pay far less than 25% already.
According to the angry-about-corporate-taxes organization Pay Up Now, for example, Abbott Labs ( ABT ) paid the equivalent of a U.S. tax rate of 15% between 2008 and 2010, while Caterpillar ( CAT ) paid 5%. Companies that may see their tax bills shrink include MedcoHealth Solutions ( MHS ) , with a 2008-to-2010 rate of 38%, and Lowe's , paying 33%.
If reforms truly wipe out government subsidies and tax breaks, certain industries will really get pinched, particularly alternative energy companies . JA Solar (Nasdaq: JASO) , for instance, paid a 12% tax rate in 2010.
Getting territorial
Another reform on the table would make our corporate tax system "territorial," like those of many other nations. A fully territorial system would exempt profits generated abroad from taxation in the U.S. As you might imagine, many global giants are salivating at this thought. After all, in 2010, 93% of Citigroup's ( C ) profits were generated outside the U.S., while that number was 64% for General Electric ( GE ) and more than 88% for Cisco Systems (Nasdaq: CSCO) .
The corporate tax laws might not become fully territorial, but it's possible that they may become somewhat so.
A simpler tax system could be much less expensive to operate, and may generate more much-needed revenue for our country. But it's far from a sure thing, given the influence of massive corporate lobbying. Still, if big changes do make it into law, many otherwise excellent investments might get whacked hard.
Grab profitable tax tips in ourTax Center, and learnabouttwo compelling small-cap companies the government won't let fail in thisspecial report.
Longtime Fool contributorSelena Maranjianowns shares of Berkshire Hathaway.Click hereto see her holdings and a short bio. The Motley Fool owns shares of Abbott Labs, Berkshire Hathaway, and MedcoHealth Solutions, and has created a bull call spread position on Cisco.Motley Fool newsletter serviceshave recommended buying shares of Cisco, Abbott Labs, Berkshire Hathaway, Lowe's, and MedcoHealth Solutions, as well as writing covered calls in Lowe's. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to the angry-about-corporate-taxes organization Pay Up Now, for example, Abbott Labs ( ABT ) paid the equivalent of a U.S. tax rate of 15% between 2008 and 2010, while Caterpillar ( CAT ) paid 5%. A fully territorial system would exempt profits generated abroad from taxation in the U.S. As you might imagine, many global giants are salivating at this thought. Grab profitable tax tips in ourTax Center, and learnabouttwo compelling small-cap companies the government won't let fail in thisspecial report. | According to the angry-about-corporate-taxes organization Pay Up Now, for example, Abbott Labs ( ABT ) paid the equivalent of a U.S. tax rate of 15% between 2008 and 2010, while Caterpillar ( CAT ) paid 5%. A 25% solution One reform that many have suggested, and which is currently being considered, involves lowering the corporate tax rate from its current 35% rate, while eliminating many corporate tax breaks. Getting territorial Another reform on the table would make our corporate tax system "territorial," like those of many other nations. | According to the angry-about-corporate-taxes organization Pay Up Now, for example, Abbott Labs ( ABT ) paid the equivalent of a U.S. tax rate of 15% between 2008 and 2010, while Caterpillar ( CAT ) paid 5%. A 25% solution One reform that many have suggested, and which is currently being considered, involves lowering the corporate tax rate from its current 35% rate, while eliminating many corporate tax breaks. Getting territorial Another reform on the table would make our corporate tax system "territorial," like those of many other nations. | According to the angry-about-corporate-taxes organization Pay Up Now, for example, Abbott Labs ( ABT ) paid the equivalent of a U.S. tax rate of 15% between 2008 and 2010, while Caterpillar ( CAT ) paid 5%. A 25% solution One reform that many have suggested, and which is currently being considered, involves lowering the corporate tax rate from its current 35% rate, while eliminating many corporate tax breaks. The corporate tax laws might not become fully territorial, but it's possible that they may become somewhat so. |
34529.0 | 2011-05-10 00:00:00 UTC | Mid-Day Update: China Trade Data Supporting Stock Advance Through Session's Half; Import Price Log Increase | ABT | https://www.nasdaq.com/articles/mid-day-update-china-trade-data-supporting-stock-advance-through-sessions-half-import | nan | nan | Here's where markets stand at mid-day:
-NYSE up 47.30 (+0.56%) to 8,525.49
-DJIA up 52.82 (+0.42%) to 12,737.50
-S&P 500 up 7.03 (+0.52%) to 1,353.45
-Nasdaq up 16.36 (+0.58%) to 2,859.63
GLOBAL SENTIMENT
Nikkei up 0.3%.
Hang Seng closed.
Shanghai Composite up 0.6%.
FTSE-100 up 1.3%.
MID-DAY NYSE INDEX WATCH
NYSE Energy up 0.46% at 13,761.12
NYSE Financial down 0.72% at 5,165.99
NYSE Health Care up 0.06% at 7,331.54
NYSE Arca Tech 100 up 0.58% at 1,194.23
UPSIDE MOVERS
(+) TASR (+3.4) inks new orders.
(+) NXG (+5.3%) gains after results.
(+) CSCO (+1.1%) started with Buy rating.
(+) JASO (+5.6%) beats with results.
(+) EBAY (+2.7%) had maintained investment in former unit Skype.
(+) CNIT (+1.9%) beats year-ago quarter.
(+) CMFO (+1.7%) beats year-ago quarter.
(+) FOSL (+11.9%) beats with Q1 but guides for Q2 miss.
(+) ALKS (+2.2%) upgraded.
(+) FONR (+24.3%) reports improved quarter.
(+) DF (+11%) beats with earnings, raises outlook.
DOWNSIDE MOVERS
(-) ROSE (-0.1%) upgraded.
(-) NTWK (-0.02%) raises outlook.
(-) KNDL (-0.3%) upgraded.
(-) MY (-2.8%) reports improved results.
(-) MSFT (-1.4%) buying Skype
(-) PAL (-20.1%) cuts production outlook
(-) CNK (-3.3%) prices shares.
(-) GMXR (-6.5%) swings to loss.
(-) USAT (-12.6%) issues mixed results.
(-) HEAT (-26.9%) swings to loss.
(-) MNKD (-12.5%) continues evening decline that followed drug update.
(-) AEO (-0.6%) downgraded.
MARKET DIRECTION
Stocks are logging gains through to the session's half as new data on China's trade helped to quell concerns over easing economic activity for the world's second largest economy. Deal news from the tech sector and import price data also added to the mix.
China logged a $11.4 billion trade surplus in April, which was nearly four times higher than expected, reports Business Spectator.
Also, U.S. import prices rose 2.2% in April, according to statistics from the US Labor Department. The move is the first time prices have risen over 2% in consecutive months since June 2008, MarketWatch noted. The move also follows a 2.7% rise in March and beats the 1.6% rise that economists had expected.
In deal news:
Microsoft ( MSFT ) is just lower after it says it will buy Skype for $8.5 billion. Microsoft said it will continue to support Skype on other software platforms. The sellers include eBay ( EBAY ) and private equity firms Silver Lake and Andreessen Horowitz. EBAY was last up 2.84%.
Elsewhere in company news:
Shares of Abbot Laboratories ( ABT ) near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. In the results, the company said 16.5 percent of patients who were treated with Humira went into clinical remission compared to 9.3 percent on placebo.
Google Inc. ( GOOG ) is off its early high of $541.65, but still holding fractional gains after a report that it could begin offering music downloads as early as today. The Wall Street Journal, citing people familiar with the matter, reported that Google could announce the service, which would compete with Apple ( AAPL ) and Amazon.com (AMZN) music services, at its annual Google I/O developers conference in San Francisco.
Whirlpool (WHR) today announced that the United States District Court in Chicago refused to award any relief to LG on the last remaining claim in a lawsuit filed by LG in 2008. The Court found that "Whirlpool has established that its dryers do, in fact, use steam", and that "LG did not introduce expert testimony or credible evidence of even a single Whirlpool customer, retailer, or trade representative who expressed confusion."
Boston Scientific (BSX) announced that Ray Elliott will retire as President and Chief Executive Officer on December 31, 2011. The Board has created a special CEO search committee, on which Elliott will serve as a member, to select the company's next President and CEO.
Goldman Sachs (GS) shares are higher as Bloomberg reports the fifth-largest US bank cut its estimated losses due to legal claims by 21 percent for the first quarter. The firm's quarterly filing with the US Securities and Exchange Commission shows "reasonably possible" losses from lawsuits dropped from $3.4 billion to $2.7 billion at the end of March, the report said.
Wal-Mart Stores (WMT) shares are higher as Reuters reports South Africa's government may demand local procurement targets in the retailer's acquisition attempt for retailer Massmart--potentially derailing the deal. Officials in South Africa are hearing testimony until next week on whether Wal-Mart should be allowed to proceed with its buy.
In earnings news:
--Wendy's/Arby's (WEN) eases after it says Q1 adjusted EPS were a penny per share, a penny below the Thomson Reuters mean. Sales of $847.8 million topped forecasts for $845.6 million.
--Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. Adjusted revenues were $52.9 million compared to the prior year's $43.9 million. Net income however plummeted to $0.73 million, or $0.02 per share, versus the prior-year quarter's $19.73 million, or $0.63 per share. Adjusted net income was $10.61 million, or $0.27 per share, a penny below the Thomson Reuters EPS mean of $0.28.
--Dean Foods (DF) rises after it says Q1 adjusted EPS were $0.14 compared to $0.24 a year earlier but better than the Thomson Reuters mean estimate for $0.06. Net sales rose 3% to $3.05 billion, about in line with the Street view.
Commodities are higher as June gold contracts are up 0.68%, to $1,513 an ounce while June crude oil contacts are up 0.48% to $103.15 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.32% to $41 and the United States Natural Gas fund (UNG) is up 0.46%, to $10.82.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 0.26% at $147.77. Market Vectors Gold Miners (GDX) is down 0.35% to $57.01. iShares Silver Trust (SLV) is up 1.41% to $37.50.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. Stocks are logging gains through to the session's half as new data on China's trade helped to quell concerns over easing economic activity for the world's second largest economy. Goldman Sachs (GS) shares are higher as Bloomberg reports the fifth-largest US bank cut its estimated losses due to legal claims by 21 percent for the first quarter. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. --Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. Adjusted net income was $10.61 million, or $0.27 per share, a penny below the Thomson Reuters EPS mean of $0.28. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. Goldman Sachs (GS) shares are higher as Bloomberg reports the fifth-largest US bank cut its estimated losses due to legal claims by 21 percent for the first quarter. --Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. (+) JASO (+5.6%) beats with results. The firm's quarterly filing with the US Securities and Exchange Commission shows "reasonably possible" losses from lawsuits dropped from $3.4 billion to $2.7 billion at the end of March, the report said. |
34530.0 | 2011-05-10 00:00:00 UTC | US Indexes Sitting Higher as Chinese Trade Data Eases Slowdown Concerns; Deal News Continues | ABT | https://www.nasdaq.com/articles/us-indexes-sitting-higher-chinese-trade-data-eases-slowdown-concerns-deal-news-continues | nan | nan | Stocks are logging gains through to the session's half as new data on China's trade helped to quell concerns over easing economic activity for the world's second largest economy. Deal news from the tech sector and import price data also added to the mix.
China logged an $11.4 billion trade surplus in April, which was nearly four times higher than expected, reports Business Spectator.
Also, U.S. import prices rose 2.2% in April, according to statistics from the US Labor Department. The move is the first time prices have risen over 2% in consecutive months since June 2008, MarketWatch noted. The move also follows a 2.7% rise in March and beats the 1.6% rise that economists had expected.
In deal news:
Microsoft ( MSFT ) is just lower after it says it will buy Skype for $8.5 billion. Microsoft said it will continue to support Skype on other software platforms. The sellers include eBay ( EBAY ) and private equity firms Silver Lake and Andreessen Horowitz. EBAY was last up 2.84%.
Elsewhere in company news:
Shares of Abbot Laboratories ( ABT ) are near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. In the results, the company said 16.5 percent of patients who were treated with Humira went into clinical remission compared to 9.3 percent on placebo.
Google Inc. ( GOOG ) is off its early high of $541.65, but still holding fractional gains after a report that it could begin offering music downloads as early as today. The Wall Street Journal, citing people familiar with the matter, reported that Google could announce the service, which would compete with Apple ( AAPL ) and Amazon.com (AMZN) music services, at its annual Google I/O developers conference in San Francisco.
Whirlpool (WHR) today announced that the United States District Court in Chicago refused to award any relief to LG on the last remaining claim in a lawsuit filed by LG in 2008. The Court found that "Whirlpool has established that its dryers do, in fact, use steam", and that "LG did not introduce expert testimony or credible evidence of even a single Whirlpool customer, retailer, or trade representative who expressed confusion."
Boston Scientific (BSX) announced that Ray Elliott will retire as President and Chief Executive Officer on December 31, 2011. The Board has created a special CEO search committee, on which Elliott will serve as a member, to select the company's next President and CEO.
Goldman Sachs (GS) shares are higher as Bloomberg reports the fifth-largest US bank cut its estimated losses due to legal claims by 21 percent for the first quarter. The firm's quarterly filing with the US Securities and Exchange Commission shows "reasonably possible" losses from lawsuits dropped from $3.4 billion to $2.7 billion at the end of March, the report said.
Wal-Mart Stores (WMT) shares are higher as Reuters reports South Africa's government may demand local procurement targets in the retailer's acquisition attempt for retailer Massmart--potentially derailing the deal. Officials in South Africa are hearing testimony until next week on whether Wal-Mart should be allowed to proceed with its buy.
In earnings news:
--Wendy's/Arby's (WEN) eases after it says Q1 adjusted EPS were a penny per share, a penny below the Thomson Reuters mean. Sales of $847.8 million topped forecasts for $845.6 million.
--Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. Adjusted revenues were $52.9 million compared to the prior year's $43.9 million. Net income however plummeted to $0.73 million, or $0.02 per share, versus the prior-year quarter's $19.73 million, or $0.63 per share. Adjusted net income was $10.61 million, or $0.27 per share, a penny below the Thomson Reuters EPS mean of $0.28.
--Dean Foods (DF) rises after it says Q1 adjusted EPS were $0.14 compared to $0.24 a year earlier but better than the Thomson Reuters mean estimate for $0.06. Net sales rose 3% to $3.05 billion, about in line with the Street view.
Commodities are higher as June gold contracts are up 0.68%, to $1,513 an ounce while June crude oil contacts are up 0.48% to $103.15 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.32% to $41 and the United States Natural Gas fund (UNG) is up 0.46%, to $10.82.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 0.26% at $147.77. Market Vectors Gold Miners (GDX) is down 0.35% to $57.01. iShares Silver Trust (SLV) is up 1.41% to $37.50.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) are near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. Stocks are logging gains through to the session's half as new data on China's trade helped to quell concerns over easing economic activity for the world's second largest economy. Goldman Sachs (GS) shares are higher as Bloomberg reports the fifth-largest US bank cut its estimated losses due to legal claims by 21 percent for the first quarter. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) are near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. --Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. Adjusted net income was $10.61 million, or $0.27 per share, a penny below the Thomson Reuters EPS mean of $0.28. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) are near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. Wal-Mart Stores (WMT) shares are higher as Reuters reports South Africa's government may demand local procurement targets in the retailer's acquisition attempt for retailer Massmart--potentially derailing the deal. --Independent energy company, Carrizo Oil & Gas (CRZO) reported an increase in Q1 revenues to $44.06 million compared to Q1 2010's $38.96 million. | Elsewhere in company news: Shares of Abbot Laboratories ( ABT ) are near the flatline as Reuters reports that the drugmaker's Humira, to treat ulcerative colitis--a bowel disease--met the main goal of a late-stage trial. In deal news: Microsoft ( MSFT ) is just lower after it says it will buy Skype for $8.5 billion. Adjusted net income was $10.61 million, or $0.27 per share, a penny below the Thomson Reuters EPS mean of $0.28. |
34531.0 | 2011-04-20 00:00:00 UTC | Abbott Labs’ Profit Falls 14% on Items; Adjusted Net Beats View (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-profit-falls-14-items-adjusted-net-beats-view-abt-2011-04-20 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday said its first quarter profit fell 14% from last year due to one-time costs, but its adjusted results edged out analyst expectations.
The Abbott Park, IL-based company reported first quarter net income of $864 million, or 55 cents per share, compared with $1 billion, or 64 cents per share, in the year-ago period. Excluding one-time items, adjusted profit was 91 cents per share.
Net sales jumped 17% from last year to $9.04 billion.
On average, Wall Street analysts expected a smaller profit of 90 cents per share on lower revenue of $8.83 billion.
Abbott Labs shares were mostly flat in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on last night's closing stock price of $51.09.
Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday said its first quarter profit fell 14% from last year due to one-time costs, but its adjusted results edged out analyst expectations. Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on last night's closing stock price of $51.09. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday said its first quarter profit fell 14% from last year due to one-time costs, but its adjusted results edged out analyst expectations. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on last night's closing stock price of $51.09. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday said its first quarter profit fell 14% from last year due to one-time costs, but its adjusted results edged out analyst expectations. Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on last night's closing stock price of $51.09. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011. Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on last night's closing stock price of $51.09. Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday said its first quarter profit fell 14% from last year due to one-time costs, but its adjusted results edged out analyst expectations. |
34532.0 | 2011-04-15 00:00:00 UTC | Stocks Higher Ahead Next Week's Earnings; Economic Data Supports | ABT | https://www.nasdaq.com/articles/stocks-higher-ahead-next-weeks-earnings-economic-data-supports-2011-04-15 | nan | nan | Stocks are seeing some support as the week draws to a close, supported by economic data showing a rise in consumer sentiment and tame inflation, excluding gas and food, which seemed to encourage market bulls. Also, investors are looking ahead to next week when corporate earnings season kicks into high gear.
U.S. consumer prices rose 0.5% in March, with higher gas and food costs accounting for three-quarters of the increase, according to Labor Department data. Core prices, which strip out volatile food and energy costs, rose 0.1%, the government reported Friday. Economists surveyed by MarketWatch had forecast CPI to rise 0.5% overall, with a 0.2% increase in the core rate.
Consumer prices are up 2.7% over the last 12 months. In a separate report, Labor said real average hourly earnings of U.S. workers fell by 0.6% in March, owing to the increase in higher consumer prices. Also, the Empire State manufacturing survey rose for a fifth consecutive month in April, with general business conditions increasing over four points to a reading of 21.7, the Federal Reserve Bank of New York said. It's the highest reading in a year.
The Thomson Reuters/University of Michigan index of consumer sentiment climbed to 69.6, from last month's 67.5 reading and topping economists' expectations for a rise to 68.8, according to a Bloomberg News survey. Among consumer-oriented stocks, WMT is flat, BBBY os up 0.7%, TGT is up 0.7%, DIS is up 0.7%.
In company news:
Pfizer ( PFE ) today announced that in the top-line results from its ORAL Scan Phase 3 study, the rheumatoid arthritis drug, tofacitinib, was able to meet all primary endpoints at a 10 mg twice daily dose. Some analysts anticipate that tofacitinib, if approved, could earn peak annual sales of $2 billion or more. It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson ( JNJ ) Reuters reported.
Oracle Corp. ( ORCL ) today announced its intention to no longer offer commercial versions of Open Office, instead making OpenOffice.org into an open source project that is community-based. This is a reaffirmation of Oracle's continued support of adopting, developing and supporting open source products.
Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. In a statement, Merck said Warburg Pincus Private Equity, which owns approximately 28 percent of the outstanding shares of Inspire, has agreed, among other things, to tender all of its shares in the tender offer.
Bronco Drilling (BRNC) is higher after its says it will be bought by Chesapeake Energy (CHK) for $11 per share cash, or approximately $315 million, including debt, net working capital and outstanding warrants.
Altria Group's (MO) Philip Morris USA announced today that it has made its annual Master Settlement Agreement payment of approximately $3.5 billion. The amount includes approximately $267 million that Philip Morris disputes it owes as a result of the 2008 Non-Participating Manufacturer Adjustment.
Goldman Sachs (GS) shares are down as Bloomberg reports that US government prosecutors indicated they were willing and ready to call Goldman president Gary Cohn as a witness to rebut the defense of Galleon Group LLC co-founder Raj Rajaratnam's defense in his insider-trading trial.
In earnings news:
--Google (GOOG) is down after it reported late Thursday Q1 revenue of $8.58 bln, up 27% vs. year ago levels. Traffic Acquisition Costs, the portion of revenues shared with Google's partners, increased to $2.04 billion in the first quarter of 2011, compared to TAC of $1.71 billion in the first quarter of 2010. Ex TAC, revenue looks to have been $6.54 bln. Non-GAAP EPS was $8.08 per share, vs. $6.76 per share last year. The Street view was $6.32 bln in revenue and EPS of $8.10 per share.
--Bank of America Corporation (BAC) reported Q1 EPS of $0.17 compared to $0.28 a year ago but below the Thomson Reuters mean analyst estimate for $0.27. Revenue of $27.1 billion is down from $32.3 billion a year ago. The Street looked for $26.69 billion.
Commodities are higher. June gold contracts are up $14, or 0.94%, to $1,486 an ounce while May crude oil contacts are up 1.18%, or $1.28, at $109.39 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.97% to $43.70 and the United States Natural Gas fund (UNG) is down $0.02, or 0.17%, to $11.04.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 0.68% at $144.82. Market Vectors Gold Miners (GDX) is down 0.1% to $61.58. iShares Silver Trust (SLV) is up 1.61% to $41.73.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson ( JNJ ) Reuters reported. Also, the Empire State manufacturing survey rose for a fifth consecutive month in April, with general business conditions increasing over four points to a reading of 21.7, the Federal Reserve Bank of New York said. In company news: Pfizer ( PFE ) today announced that in the top-line results from its ORAL Scan Phase 3 study, the rheumatoid arthritis drug, tofacitinib, was able to meet all primary endpoints at a 10 mg twice daily dose. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson ( JNJ ) Reuters reported. U.S. consumer prices rose 0.5% in March, with higher gas and food costs accounting for three-quarters of the increase, according to Labor Department data. Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson ( JNJ ) Reuters reported. Stocks are seeing some support as the week draws to a close, supported by economic data showing a rise in consumer sentiment and tame inflation, excluding gas and food, which seemed to encourage market bulls. Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson ( JNJ ) Reuters reported. U.S. consumer prices rose 0.5% in March, with higher gas and food costs accounting for three-quarters of the increase, according to Labor Department data. The Street view was $6.32 bln in revenue and EPS of $8.10 per share. |
34533.0 | 2011-04-15 00:00:00 UTC | Mid-Day Update: Stocks Firmer Following Data Deluge, Corporate Earnings | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-firmer-following-data-deluge-corporate-earnings-2011-04-15 | nan | nan | Here's where markets stand at mid-day:
-NYSE up 24.35 (+0.29%) to 8,398.51
-DJIA up 51.38 (+0.42%) to 12,336.53
-S&P 500 up 6.98 (+0.53%) to 1,321.50
-Nasdaq up 4.66 (+0.17%) to 2,764.96
GLOBAL SENTIMENT
Hang Seng down 0.02%
Nikkei down 0.02%
FTSE up 0.54%
MID-DAY NYSE INDEX WATCH
NYSE Energy up 0.56% at 13,966.94
NYSE Financial up 0.02% at 5,142.49
NYSE Health Care up 0.97% at 6,999.17
NYSE Arca Tech 100 up 0.59% at 1,154.31
UPSIDE MOVERS
(-) BAC (-0.9%) improves during pre-market trading after EPS miss.
(+) MRK (+2.8%) backs outlook.
(+) AGO (+26.5%) settles with BofA.
(+) AMLN (+13.1%) secures European approval Bydureon with partners Lilly ( LLY ) and Alkermes ( ALKS ).
(+) ATVI (+0.1%) initiated with Buy rating.
(-) AEN (-24.8%) reports favorable study results.
(+) POZN (+5.7%) wins preliminary injunction against Par Pharma.
(+) ULU (+3.5%) to present Altrazeal data at conference.
(+) BRNC (+5.7%) sold to Chesapeake for $315 mln.
(+) LPH (+7%) issues upbeat yearly forecast.
(-) HOG (-0.2%) upgraded.
(-) AEN (-24.8%) gains on study results.
(+) CDE (+5.3%) says not subject to proposed nationalization in Bolivia.
(+) MAT (+4.8%) beats with Q1 results.
DOWNSIDE MOVERS
(-) CTCT (-3.8%) downgraded.
(-) GOOG (-6.9%) continues decline that followed mixed results.
(-) CSCO (-6.9%) downgraded.
(-) PFE (-0.2%) down despite saying arthritis drug meets endpoints.
(-) URBN (-2.8%) downgraded.
(-) INFY (-15.6%) misses with revenue despite EPS beat, sets mixed guidance.
MARKET DIRECTION
Stocks are seeing some support as the week draws to a close, supported by economic data showing a rise in consumer sentiment and tame inflation, excluding gas and food, which seemed to encourage market bulls. Also, investors are looking ahead to next week when corporate earnings season kicks into high gear.
U.S. consumer prices rose 0.5% in March, with higher gas and food costs accounting for three-quarters of the increase, according to Labor Department data. Core prices, which strip out volatile food and energy costs, rose 0.1%, the government reported Friday. Economists surveyed by MarketWatch had forecast CPI to rise 0.5% overall, with a 0.2% increase in the core rate.
Consumer prices are up 2.7% over the last 12 months. In a separate report, Labor said real average hourly earnings of U.S. workers fell by 0.6% in March, owing to the increase in higher consumer prices. Also, the Empire State manufacturing survey rose for a fifth consecutive month in April, with general business conditions increasing over four points to a reading of 21.7, the Federal Reserve Bank of New York said. It's the highest reading in a year.
The Thomson Reuters/University of Michigan index of consumer sentiment climbed to 69.6, from last month's 67.5 reading and topping economists' expectations for a rise to 68.8, according to a Bloomberg News survey. Among consumer-oriented stocks, WMT is flat, BBBY os up 0.7%, TGT is up 0.7%, DIS is up 0.7%.
In company news:
Pfizer ( PFE ) today announced that in the top-line results from its ORAL Scan Phase 3 study, the rheumatoid arthritis drug, tofacitinib, was able to meet all primary endpoints at a 10 mg twice daily dose. Some analysts anticipate that tofacitinib, if approved, could earn peak annual sales of $2 billion or more. It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson (JNJ) Reuters reported.
Oracle Corp. (ORCL) today announced its intention to no longer offer commercial versions of Open Office, instead making OpenOffice.org into an open source project that is community-based. This is a reaffirmation of Oracle's continued support of adopting, developing and supporting open source products.
Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. In a statement, Merck said Warburg Pincus Private Equity, which owns approximately 28 percent of the outstanding shares of Inspire, has agreed, among other things, to tender all of its shares in the tender offer.
Bronco Drilling (BRNC) is higher after its says it will be bought by Chesapeake Energy (CHK) for $11 per share cash, or approximately $315 million, including debt, net working capital and outstanding warrants.
Altria Group's (MO) Philip Morris USA announced today that it has made its annual Master Settlement Agreement payment of approximately $3.5 billion. The amount includes approximately $267 million that Philip Morris disputes it owes as a result of the 2008 Non-Participating Manufacturer Adjustment.
Goldman Sachs (GS) shares are down as Bloomberg reports that US government prosecutors indicated they were willing and ready to call Goldman president Gary Cohn as a witness to rebut the defense of Galleon Group LLC co-founder Raj Rajaratnam's defense in his insider-trading trial.
In earnings news:
--Google (GOOG) is down after it reported late Thursday Q1 revenue of $8.58 bln, up 27% vs. year ago levels. Traffic Acquisition Costs, the portion of revenues shared with Google's partners, increased to $2.04 billion in the first quarter of 2011, compared to TAC of $1.71 billion in the first quarter of 2010. Ex TAC, revenue looks to have been $6.54 bln. Non-GAAP EPS was $8.08 per share, vs. $6.76 per share last year. The Street view was $6.32 bln in revenue and EPS of $8.10 per share.
--Bank of America Corporation (BAC) reported Q1 EPS of $0.17 compared to $0.28 a year ago but below the Thomson Reuters mean analyst estimate for $0.27. Revenue of $27.1 billion is down from $32.3 billion a year ago. The Street looked for $26.69 billion.
Commodities are higher. June gold contracts are up $14, or 0.94%, to $1,486 an ounce while May crude oil contacts are up 1.18%, or $1.28, at $109.39 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.97% to $43.70 and the United States Natural Gas fund (UNG) is down $0.02, or 0.17%, to $11.04.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 0.68% at $144.82. Market Vectors Gold Miners (GDX) is down 0.1% to $61.58. iShares Silver Trust (SLV) is up 1.61% to $41.73.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson (JNJ) Reuters reported. Also, the Empire State manufacturing survey rose for a fifth consecutive month in April, with general business conditions increasing over four points to a reading of 21.7, the Federal Reserve Bank of New York said. In company news: Pfizer ( PFE ) today announced that in the top-line results from its ORAL Scan Phase 3 study, the rheumatoid arthritis drug, tofacitinib, was able to meet all primary endpoints at a 10 mg twice daily dose. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson (JNJ) Reuters reported. U.S. consumer prices rose 0.5% in March, with higher gas and food costs accounting for three-quarters of the increase, according to Labor Department data. Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson (JNJ) Reuters reported. Stocks are seeing some support as the week draws to a close, supported by economic data showing a rise in consumer sentiment and tame inflation, excluding gas and food, which seemed to encourage market bulls. Shares of Merck & Co. (MRK) are higher after the drug maker announced a tender offer for all outstanding shares of Inspire Pharmaceuticals (ISPH) for $5.00 per share in cash without interest and less any applicable withholding taxes. | It will compete with rheumatoid arthritis drugs by Abbott Laboratories ( ABT ), Amgen ( AMGN ) and Johnson & Johnson (JNJ) Reuters reported. Non-GAAP EPS was $8.08 per share, vs. $6.76 per share last year. The Street view was $6.32 bln in revenue and EPS of $8.10 per share. |
34534.0 | 2011-04-12 00:00:00 UTC | Why More Stocks are Likely to Pay Dividends | ABT | https://www.nasdaq.com/articles/why-more-stocks-are-likely-pay-dividends-2011-04-12 | nan | nan | By Chloe Lutts
---
A few months ago, we surveyed you, our Investment of the Week readers, and asked what types of investments you wanted to read about. Small company stocks, technology stocks and oil and gas stocks were all popular choices. However, the investment class with the most votes by far, with 69% of readers expressing interest in it, was dividend-paying stocks.
The subscribers to my Dick Davis Dividend Digest were among those surveyed, and they're obviously interested in income-generating investments. However, they represented far less than 69% of the sample, leading me to conclude this is a topic of broad interest among you.
One of the likely reasons for high interest in dividend payers is the increasing number of Americans-and my readers-approaching or at retirement age. Owning dividend-paying stocks is a great way to keep receiving regular income after you retire. Consequently, I suspect that these investments will only increase in popularity as the baby boomer generation retires. Those of you already invested in dividend payers will benefit as their increasing popularity drives up prices. And investors looking to add an income component to their portfolios will probably see even more options in coming years, as demand drives younger blue chip-type stocks like Cisco ( CSCO ) to introduce dividends for the first time. I also expect some companies that currently pay only small dividends to increase their payouts to attract more retiree investors.
--- Advertisement ---
Get the Most Profitable Investment Advice-All in One Place
Have you ever wanted to cherry-pick the best investment ideas, from the smartest people on Wall Street? Now you can with Dick Davis Investment Digest.
At Dick Davis Investment Digest, we pore over hundreds of financial newsletters and institutional research reports to cull the shrewdest advice with the greatest potential to make you money. Pick the brains of Wall Street's A-list advisors for only 35 cents a day!
---
Of course, there are already plenty of great dividend payers out there. The most reliable are the S&P 500 Dividend Aristocrats: Companies that have increased their dividends for at least 25 consecutive years. Typically, a so-called Dividend Aristocrat is, by its very nature, a large and relatively stable blue-chip company with a healthy balance sheet. A Dividend Aristocrat is considered the "gold standard" for dividend-generating stocks and, as such, income investors seek them out. A lot of companies, particularly financials, fell off this hallowed list in 2008 and 2009, so the ones left are truly the crème de la crème of dividend payers. Many of them are featured in the Dividend Digest regularly.
Today, I'd like to share a few of the most recent recommendations from the list. They're all great options for investors looking to create or add to an income-generating portfolio:
Insurer and Dividend Aristocrat The Chubb Corporation ( CB ) was originally recommended in the Dividend Digest over a year ago, on February 10, 2010, at 48.40 by John Eade of the Argus Weekly Staff Report. At that time, he wrote: "We expect a well-managed combined loss and expense ratio and an aggressive stock buyback program to drive results, as the top line takes a couple more quarters to revive. The company's balance sheet is in solid shape, with industry-low debt levels. CB shares are now trading at near parity to book value, which is historically an attractive valuation."
In a follow-up published in the Dividend Digest almost exactly a year later, on February 9, 2011, Eade wrote: "We are maintaining our BUY rating and $65 target price on Focus List selection The Chubb Corp. Chubb is doing a good job managing what it can control-the noncatastrophe combined loss and expense ratio- and its aggressive stock buyback program is also driving results."
In February 2011, CB was trading around 59. It has since crept up a bit to 62, and on March 16 it paid a 39-cent dividend, its highest ever. Think insurance companies are boring? Think again. Well-managed insurers can be insanely profitable-and they produce most of their profits by investing customers' premiums themselves, often in income-generating securities. That's why owning top-quality insurance stocks like CB is a great way to generate reliable and growing income.
Exxon Mobil ( XOM ) is the S&P 500 Dividend Aristocrat Index's seventh-largest constituent by market cap. XOM's performance has been nothing less than stellar over the last six months. It was last recommended in the Dividend Digest on January 12, 2011, when it was selected as a Top Pick for 2011 by Stephen Todd, Editor of the Todd Market Forecast. He wrote:
"The stock's current yield is 2.3%, and the appreciation potential should be excellent. This is because 2011 is likely to see an economic growth spurt and the Obama Administration seems anti-oil. This will prevent drilling at a time when demand increases. The rise in oil prices should be a boon to ExxonMobil."
Four months later, oil prices have indeed risen, and XOM is 14% higher, trading around 85. The yield has fallen closer to 2% thanks to the price increase, but Exxon usually increases its dividend for the second quarter, which will be paid in May.
Abbott Laboratories ( ABT ) is definitely an income investor favorite; I see it recommended by one of our contributors at least once every month. Ingrid Hendershot, CFA, editor of Hendershot Investments, also chose it for the January Top Picks issue. She wrote:
"Abbott Laboratories (ABT 47.86 NYSE - yield 3.70%) is a global, broad-based health care company. Abbott's primary businesses include pharmaceuticals, with key therapeutic areas including immunology, cardiology and infectious diseases; nutritional products for infants, children and adults with special dietary needs; and medical products, including vascular, laboratory and molecular diagnostics, vision care and diabetes. The company markets its products in more than 130 countries. Abbott is expanding its overseas presence, most recently with the acquisition of Piramal Healthcare Solutions, one of the biggest generic pharmaceutical suppliers in India.
"Abbott generates strong cash flow from its operations. Free cash flow has more than doubled from $3 billion in 2004 to over $6 billion in 2009. Free cash flow through the first nine months of 2010 increased 24% to $5.7 billion. The company returned $2.9 billion of the cash to shareholders in the form of $2 billion in dividends and $866 million in share repurchases. The dividend currently yields an attractive 3.7%. Abbott has paid a dividend every year since 1924 and increased the dividend for 38 consecutive years. With market leadership positions across multiple growth areas, a strong financial position, record cash flows and highly profitable operations, Abbott is a HI-quality company. With an expected 13% free cash flow yield, Abbott is attractively valued and well-positioned to continue to increase its dividend thanks to its bountiful cash flows. Long-term investors should consider injecting Abbott into their portfolio for healthy long-term total returns."
Abbot just increased its dividend, to be paid May 16, to 48 cents, giving it a yield of 3.80% at today's price of 50. As Top Picks, the Abbott and Exxon recommendations will both be updated in this summer's special issue of Dividend Digest Top Picks Update.
Johnson & Johnson ( JNJ ) is another popular recommendation among Dividend Digest contributors. Mark Deschaine, editor of Deschaine & Company's Viewpoint, was the last expert to recommend it in the Digest on October 10, 2010. He wrote:
"Johnson & Johnson may seem out of fashion in today's frivolous, hyperactive, and alpha-starved investment environment; but this $170 billion dollar health care and personal product empire has been a wealth creating, income producing, compounding machine for well over a century. … Johnson & Johnson makes and markets thousands of diverse health care and personal care products, including such household medicine cabinet staples as Tylenol and Listerine, as well as some of the world's most sophisticated medical devices and diagnostic equipment. JNJ has been paying a dividend since 1944 and has increased it annually for over 47 years. … For every share you might have bought in 1979 at $0.85, you would now be receiving $2.16 in annual dividends, or more than 2.5 times your initial investment-each and every year- and growing to boot! Going forward, you can be sure we do not anticipate this kind of supercharged income growth. However, our analysis indicates that Johnson & Johnson should be able to continue to generate positive cash flow from its stable of products and continue to pay and increase its dividends for years to come. As long as that's the case, and the price of the stock remains reasonable by our valuation measures; we'll continue utilizing the dividend and dividend growth attributes of JNJ to provide growing income to our clients."
At today's price near 59, JNJ is currently yielding 3.63%.
Most recently, Patrick McKeough, editor of the Wall Street Stock Forecaster, recommended Dividend Aristocrat The McGraw-Hill Companies (MHP) in the March 9, 2011, Dividend Digest. He wrote:
"McGraw-Hill gets 70% of its earnings and 45% of its revenue from its Standard & Poor's division, which provides financial information, including credit ratings on bonds. The company also publishes textbooks and magazines, and owns nine television stations. In 2010, McGraw-Hill's revenue rose 3.6%, to $6.2 billion from $6.0 billion. Revenue from Standard & Poor's rose 8.3%, as businesses took advantage of low interest rates to issue more bonds. The textbook division's revenue rose 1.9%, thanks to higher college enrollment and rising demand for electronic versions of its books. That offset slower demand for new elementary and high school textbooks. Revenue at McGraw-Hill's media operations fell 4.9%, mainly because the company sold BusinessWeek magazine in 2009. Without this sale, this division's revenue would have risen 6.2%.
"Earnings rose 13.2% in 2010, to $840.0 million, or $2.69 a share. The company earned $742.2 million, or $2.37 a share, in 2009. These figures exclude gains on the sale of BusinessWeek and other assets, as well costs to restructure the textbook and media businesses. McGraw-Hill continues to buy related companies. It recently paid roughly $300 million for TheMarkets.com, a privately held firm that sellsinvestment researchand data to hedge funds and other institutional investors. The company can easily afford to keep making purchases like this. Its long-term debt of $1.2 billion is just 10% of its market cap, and it holds cash of $1.5 billion, or $4.97 a share. Continued falling demand for elementary and high school textbooks could hold back McGraw-Hill's earnings growth in 2011. Still, the stock trades at a reasonable 13.3 times the company's likely 2011 earnings of $2.85 a share. McGraw-Hill also raised its quarterly dividend for the 38th consecutive year, to $0.25 a share, up 6.4% from $0.235. The new annual rate of $1.00 yields 2.6%. McGraw-Hill is a buy."
To learn more about Dividend Aristocrats like CB, XOM, ABT, JNJ and MHP, check out Dick Davis Dividend Digest, where top income-generating stocks are recommended each and every month. Learn more here.
Wishing you success in your investing and beyond,
Chloe Lutts
Editor of Investment of the Week
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is definitely an income investor favorite; I see it recommended by one of our contributors at least once every month. She wrote: "Abbott Laboratories (ABT 47.86 NYSE - yield 3.70%) is a global, broad-based health care company. To learn more about Dividend Aristocrats like CB, XOM, ABT, JNJ and MHP, check out Dick Davis Dividend Digest, where top income-generating stocks are recommended each and every month. | To learn more about Dividend Aristocrats like CB, XOM, ABT, JNJ and MHP, check out Dick Davis Dividend Digest, where top income-generating stocks are recommended each and every month. Abbott Laboratories ( ABT ) is definitely an income investor favorite; I see it recommended by one of our contributors at least once every month. She wrote: "Abbott Laboratories (ABT 47.86 NYSE - yield 3.70%) is a global, broad-based health care company. | To learn more about Dividend Aristocrats like CB, XOM, ABT, JNJ and MHP, check out Dick Davis Dividend Digest, where top income-generating stocks are recommended each and every month. Abbott Laboratories ( ABT ) is definitely an income investor favorite; I see it recommended by one of our contributors at least once every month. She wrote: "Abbott Laboratories (ABT 47.86 NYSE - yield 3.70%) is a global, broad-based health care company. | To learn more about Dividend Aristocrats like CB, XOM, ABT, JNJ and MHP, check out Dick Davis Dividend Digest, where top income-generating stocks are recommended each and every month. Abbott Laboratories ( ABT ) is definitely an income investor favorite; I see it recommended by one of our contributors at least once every month. She wrote: "Abbott Laboratories (ABT 47.86 NYSE - yield 3.70%) is a global, broad-based health care company. |
34535.0 | 2011-04-07 00:00:00 UTC | Abbott Labs Started as a “Hold” at Deutsche Bank (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-started-hold-deutsche-bank-abt-2011-04-07 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Thursday saw its coverage initiated with a "Hold" rating by analysts at Deutsche Bank.
The firm also set a $53 price target on ABT, which suggests a 5% upside to the stock's Monday closing price of $50.68.
A Deutsche analyst commented, "ABT's success over the last 6 years can largely be attributed to surging sales of its largest drug, Humira, with revs expected to exceed $7B this year. ABT has further expanded its dominant pharma segment via acquisitions, and is diversified into Medical Products and Nutritionals. However, slowing Humira sales, impending new competitors, and an absence of new drugs, have depressed ABT's multiple. As growth shifts from the top line to bottom line (margin leverage from merger synergies), we see little impetus for multiple expansion and rate the shares Hold."
Abbott Labs shares were mostly flat in premarket trading Thursday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.79% dividend yield, based on last night's closing stock price of $50.68.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Thursday saw its coverage initiated with a "Hold" rating by analysts at Deutsche Bank. ABT has further expanded its dominant pharma segment via acquisitions, and is diversified into Medical Products and Nutritionals. The firm also set a $53 price target on ABT, which suggests a 5% upside to the stock's Monday closing price of $50.68. | The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) on Thursday saw its coverage initiated with a "Hold" rating by analysts at Deutsche Bank. | Healthcare products maker Abbott Laboratories ( ABT ) on Thursday saw its coverage initiated with a "Hold" rating by analysts at Deutsche Bank. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) on Thursday saw its coverage initiated with a "Hold" rating by analysts at Deutsche Bank. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. |
34536.0 | 2011-03-30 00:00:00 UTC | Abbott Labs’ Price Target Upped at Morgan Stanley (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-price-target-upped-morgan-stanley-abt-2011-03-30 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday saw its price target boosted by analysts at Morgan Stanley.
The firm said it now expects ABT shares to reach $55, suggesting a 14% upside to the stock's Tuesday closing price of $48.38.
Morgan Stanley noted that although the company's popular Humira rheumatoid arthritis drug is facing increased competition, but that fact has already been largely priced into the stock. The analyst also maintained its "Overweight" rating on ABT.
Abbott Labs shares were mostly flat in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. The company has a 3.97% dividend yield, based on last night's closing stock price of $48.38.
Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday saw its price target boosted by analysts at Morgan Stanley. The firm said it now expects ABT shares to reach $55, suggesting a 14% upside to the stock's Tuesday closing price of $48.38. The analyst also maintained its "Overweight" rating on ABT. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday saw its price target boosted by analysts at Morgan Stanley. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday saw its price target boosted by analysts at Morgan Stanley. The Bottom Line We have been recommending shares of Abbott Labs ( ABT ) since Feb.18, 2011, when the stock was trading at $46.32. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) on Wednesday saw its price target boosted by analysts at Morgan Stanley. Abbott Laboratories ( ABT ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. The firm said it now expects ABT shares to reach $55, suggesting a 14% upside to the stock's Tuesday closing price of $48.38. |
34537.0 | 2011-02-24 00:00:00 UTC | 7 Health Care Stocks to Sell | ABT | https://www.nasdaq.com/articles/7-health-care-stocks-sell-2011-02-24 | nan | nan | Big pharma is in big trouble, with looming patent expirations and drug generic competition weighing on health care stocks. While many health care companies are still soundly profitable, there's no doubt that investors are thinking twice about drugmakers and pharmaceutical stocks in the long term.
Looking at the fundamentals, there are 7 big pharma health care stocks that I see as big losers in the weeks and months ahead. These drug stocks should be sold immediately.
Abbott Laboratories : The first big pharma stock worth selling is Abbott Laboratories (NYSE: ABT ), which has dropped -14% in the last year, compared to gains by the broader markets. The stock may have rebounded in October, but has since dropped -10%, putting it right above its 52-week low of $44.59
Bristol-Myers Squibb : Global pharmaceutical company Bristol-Myers Squibb (NYSE: BMY ) has watched its stock price fall -6% since the start of October. Analysts are also projecting a three cent drop in earnings this quarter compared to last year. Ignore this stock until it proves it can turn it around.
GlaxoSmithKline : Vaccine and OTC medicine producer GlaxoSmithKline (NYSE: GSK ) posted a dismal quarterly revenue growth of -11% in its last income statement, year-over-year. Not helping matters is GSK's dwindling stock price, down -9% since mid-October.
Johnson & Johnson : Consumer staple Johnson & Johnson (NYSE: JNJ ) is in the midst of its second large stock swoon of the past calendar year, down -5% since November. Earnings wise, analysts are expecting a four cent drop in EPS compared to this quarter last year. Just because you own JNJ products doesn't mean you should own this stock.
Merck & Co : Over the past 12 months, Merck & Co. (NYSE: MRK ) has dropped -13% overall, and the stock is down -11% since the start of 2011. Stockholders can't be pleased with the company's net profit margin, which sat at -4% last quarter.
Novartis : Switzerland-based Novartis AG (NYSE: NVS ) may have had a nice finish to 2010, but is down -3% since the start of 2011. Experts predict that NVS will also miss its EPS from last year by 12 cents this quarter.
Teva Pharmaceutical : Last on the list is Teva Pharmaceutical Industries (NASDAQ: TEVA ) which has posted a loss of -15% in the last 52 weeks. After bouncing back towards the end of 2010, TEVA has since declined another -2%.
As of this writing, Louis Navellier did not own a position in any of the stocks named here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories : The first big pharma stock worth selling is Abbott Laboratories (NYSE: ABT ), which has dropped -14% in the last year, compared to gains by the broader markets. While many health care companies are still soundly profitable, there's no doubt that investors are thinking twice about drugmakers and pharmaceutical stocks in the long term. Earnings wise, analysts are expecting a four cent drop in EPS compared to this quarter last year. | Abbott Laboratories : The first big pharma stock worth selling is Abbott Laboratories (NYSE: ABT ), which has dropped -14% in the last year, compared to gains by the broader markets. Looking at the fundamentals, there are 7 big pharma health care stocks that I see as big losers in the weeks and months ahead. The stock may have rebounded in October, but has since dropped -10%, putting it right above its 52-week low of $44.59 Bristol-Myers Squibb : Global pharmaceutical company Bristol-Myers Squibb (NYSE: BMY ) has watched its stock price fall -6% since the start of October. | Abbott Laboratories : The first big pharma stock worth selling is Abbott Laboratories (NYSE: ABT ), which has dropped -14% in the last year, compared to gains by the broader markets. The stock may have rebounded in October, but has since dropped -10%, putting it right above its 52-week low of $44.59 Bristol-Myers Squibb : Global pharmaceutical company Bristol-Myers Squibb (NYSE: BMY ) has watched its stock price fall -6% since the start of October. Johnson & Johnson : Consumer staple Johnson & Johnson (NYSE: JNJ ) is in the midst of its second large stock swoon of the past calendar year, down -5% since November. | Abbott Laboratories : The first big pharma stock worth selling is Abbott Laboratories (NYSE: ABT ), which has dropped -14% in the last year, compared to gains by the broader markets. Big pharma is in big trouble, with looming patent expirations and drug generic competition weighing on health care stocks. Stockholders can't be pleased with the company's net profit margin, which sat at -4% last quarter. |
34538.0 | 2011-02-16 00:00:00 UTC | How to Earn 13.0% Yields From Stocks Paying 6.2% | ABT | https://www.nasdaq.com/articles/how-earn-130-yields-stocks-paying-62-2011-02-16 | nan | nan | The story was picked up by the major news sources last year as a "cute" human interest feature. You might have seen the headlines like "How a Secretary Made and Gave Away $7 Million."
But for me, this wasn't some light news piece. This was a story that resonated deeply with me.
I didn't know Grace Groner, from Lake Forest, Ill. From the stories, she was a woman who lived frugally. Her passing was of interest because her threeshares of Abbott Laboratories ( ABT ) grew into more than 100,000shares through decades ofdividend reinvestment.In total, her estate became worth roughly $7 million .
And while I didn't know Grace Groner, I did know Lillian Calistri.
The last time I saw Aunt Lillian was in 1990. I remember that a nephew had the misfortune of addressing her as "Lillian." She promptly looked us all in the eye and said, "You will continue to call me Aunt Lillian." We were all more than 25 years old at the time, but in Lillian's world, adulthood was no excuse for bad manners.
Aunt Lillian taught homeeconomics at Charleroi High School in Pennsylvania. After she retired in the 1950s, she moved to Tucson, Ariz. I remember thinking it was nice that Lillian had been able to live comfortably in her golden years -- aided by a teacher's retirement and a nest egg from the 1952 sale of the family's ice cream business.
Here's the kicker: When Lillian died in 1993, her estate was worth north of $5 million. Her broker was the only one who wasn't shocked. "They should have that kind of discipline on Wall Street," he said. Dividend reinvestment? You bet.
But there's something else to this story. And it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace did.
They may not have realized it at the time, but the women in these stories chose their investments wisely.
Abbott Laboratories paid its first dividend in 1983. Adjusted for stock splits, the pharmaceutical company initially paid a dividend of $0.01562 per share, representing a yield of just 1.1%. But during Ms. Groner's lifetime, Abbott consistently grew its dividend. Its latest dividend was $0.44 a share -- 2,717% greater than the original payout.
One of Aunt Lillian's investments was International Business Machines ( IBM ) . IBM dished out its first dividend in 1962. Since then, it has grown its dividend by 64,900%.
Neither Abbott nor IBM had a particularly juicy yield at the time these women bought their shares . But they had something equally powerful: a corporate culture dedicated to dividend growth. Throughout Grace and Lillian's lifetime, these companies never cut their dividend. In good economic times and challenging times, these companies found a way to deliver ever-increasing income to their shareholders.
And those extra dividends add up a lot quicker than you'd think.
In my Daily Paycheck portfolio, I already have two lifetime dividend achievers. AT&T ( T ) and Altria ( MO ) .
If you put $5,000 into AT&T five years ago, you'd have earned a 4.7% yield at the time. That's $242 a year. But today, that $5,000 investment would be paying $405 a year if you simply reinvested your dividends. That's an 8.1% yield on your original investment.
Altria is an even better story. Right now the shares pay a solid 6.2%. It's nothing to sneeze at, but thanks to the company's commitment to dividend growth, $5,000 invested just five years ago -- plus reinvested dividends -- is now earning 13.0%, or about $650 every year.
Action to Take--> It's doubtful most of us will have decades and decades to invest like Grace Groner or Aunt Lillian. But that doesn't mean we can't see our dividends grow enormously in a span of just a few short years by reinvesting dividends. Stocks like AT&T and Altria are perfectly capable of doing this again, but you should also look for other securities that could deliver a big paycheck down the road.
-- Amy Calistri
P.S. -- I mentioned above that AT&T and Altria are both in my Daily Paycheck portfolio. But it takes a few more ideas to build a portfolio that pays you daily...
So far the daily strategy has been working like a charm. In January I earned $1,663.30 from 25 dividend payments. To learn how to get started creating your own Daily Paycheck portfolio, I invite you to read this memo.
Disclosure: Neither Amy Calistri nor StreetAuthority, LLC hold positions in any securities mentioned in this article.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Her passing was of interest because her threeshares of Abbott Laboratories ( ABT ) grew into more than 100,000shares through decades ofdividend reinvestment.In total, her estate became worth roughly $7 million . I remember thinking it was nice that Lillian had been able to live comfortably in her golden years -- aided by a teacher's retirement and a nest egg from the 1952 sale of the family's ice cream business. Adjusted for stock splits, the pharmaceutical company initially paid a dividend of $0.01562 per share, representing a yield of just 1.1%. | Her passing was of interest because her threeshares of Abbott Laboratories ( ABT ) grew into more than 100,000shares through decades ofdividend reinvestment.In total, her estate became worth roughly $7 million . It's nothing to sneeze at, but thanks to the company's commitment to dividend growth, $5,000 invested just five years ago -- plus reinvested dividends -- is now earning 13.0%, or about $650 every year. Action to Take--> It's doubtful most of us will have decades and decades to invest like Grace Groner or Aunt Lillian. | Her passing was of interest because her threeshares of Abbott Laboratories ( ABT ) grew into more than 100,000shares through decades ofdividend reinvestment.In total, her estate became worth roughly $7 million . And it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace did. It's nothing to sneeze at, but thanks to the company's commitment to dividend growth, $5,000 invested just five years ago -- plus reinvested dividends -- is now earning 13.0%, or about $650 every year. | Her passing was of interest because her threeshares of Abbott Laboratories ( ABT ) grew into more than 100,000shares through decades ofdividend reinvestment.In total, her estate became worth roughly $7 million . And it's something that can help you earn larger dividends soon -- helpful if you don't have a lifetime to invest as Aunt Lillian and Grace did. Neither Abbott nor IBM had a particularly juicy yield at the time these women bought their shares . |
34539.0 | 2011-01-26 00:00:00 UTC | Stocks Higher Ahead of Fed Meeting; Generally Positive Home Sales Data Supports | ABT | https://www.nasdaq.com/articles/stocks-higher-ahead-fed-meeting-generally-positive-home-sales-data-supports-2011-01-26 | nan | nan | Stocks are just higher at mid-day amid a week filled with earnings news as investors eye the conclusion of the Federal Reserve's monetary policy meeting today. Adding to the mix is generally positive news about the housing market.
In the Fed announcement, due at 2:15 p.m. EST, no policy change is expected but the Street wants to hear the central bank's latest growth and inflation assessment and any clues on a future change in policy.
In the most recent data from the real estate sector, the US Commerce Department said sales of new single-family homes rose in December to an annual rate of 329,000. That is the highest level seen since April, when a federal tax credit gave housing a shot in the arm. November sales, however, were revised down 280,000 from 290,000.
In company news:
Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. This is in addition to 3,000 job cuts, or 3.2% of its global workforce, in September due to its purchase of Solvay Pharmaceuticals last year, the company stated. The changes are also in response to U.S. health-care reform and the challenging regulatory environment. Also, Abbott just beat the Street's Q4 view.
ADRs of Toyota Motor ( TM ) are lower after the automaker said it was recalling more than 1.7 million vehicles worldwide to fix problems including fuel-system defects. The recall affects approximately 1.2 million cars, according to reports. The second recall is for 280,000 units and involves a pressure sensor on the fuel delivery pipe.
Starbucks shares are down despite market expectation of an 18% jump in 2010 Q4 earnings. The company is set to report its earning after the market close today. Analysts' mean estimate is earnings of $294.5 million, or $0.39 per share. Revenue is expected to be $2.93 billion.
Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. Revenue fell 3.9% to $13.44 billion against $13.98 billion in the year-ago period. The company sees full-year 2011 net income of at least $6.30 per share. The Street is at $6.58. WellPoint saw a boost from frugal Americans who deferred doctor visits and medical treatment due to the economy, Bloomberg noted. The trend has trimmed expenses for all health insurers in the past two years.
In M&A news, Cisco ( CSCO ) announced today that it plans to purchase privately-held Pari Networks, a provider of network configuration and change management (NCCM) and compliance management solutions. The acquisition is expected to complement CSCO's smart service capabilities. Pari Networks' technology is planned to integrate into the company's smart services and help accelerate the ability of CSCO and its partners to manage the health and stability of customer networks through proactive, personalized services.
ADRs of Barclays ( BCS ) are lower as the bank says it plans to cut about 1,000 jobs in the UK as it looks to stop offering financial planning advice in its branch locations, Reuters reports. The move is seen as another example of the bank making cuts to improve lagging profitability. The cuts are reportedly to occur across the UK. The bank will focus financial advice to online customers.
Shares of computer maker Dell Inc. (DELL) are trending higher as Bloomberg reported comments made by company founder Michael Dell regarding Hewlett-Packard's (HPQ) acquisition of storage company 3Par. Dell had engaged in a bidding battle with HP for 3Par. Dell acquired another storage company, Compellent Technologies, for $960 million. HP paid $2.35 billion for 3Par. "We showed a good discipline and didn't take an emotional decision," Bloomberg quoted Dell as saying to a crow at the World Economic Forum in Davos. "I think HP paid way too much for 3Par."
Elsewhere in earnings news:
--Xerox Corp. (XRX) is down nearly 8% after the bell today after providing Q1 guidance that was below analyst consensus opinion. It said earnings should be in a range between $0.20 to $0.22 a share -- or $0.01 under the Street call. Full-year 2011 guidance was in-line with forecasts as were Q4 earnings and revenues.
--ConocoPhillips (COP) says Q4 adjusted EPS were $1.32, meeting estimates.
--Valero Energy (VLO) reports Q4 ex items earnings of about $0.39 per share, ahead of the Street view of $0.34 per share. Revenue was $22.1 bln, vs. expectations of $21.2 bln.
--St. Jude Medical (STJ) reports Q4 adjusted EPS of $0.75 compared to $0.64 a year earlier and just topping the Thomson Reuters mean analyst estimate for $0.74. Q4 sales of $1.35 billion top the $1.2 billion reported a year earlier. The Street looked for $1.32 billion.
--Flagstar Bancorp (FBC) says its Q4 net loss widened to $0.74 per share from a loss of $0.15 in Q3.
--First Cash Financial Services (FCFS) says Q4 EPS from continuing operations were $0.59, above the Thomson Reuters mean for $0.54. Sales were $129.6 million, beating forecasts for $122 million. FY11 EPS are seen between $2.02 to $2.10 per share, above estimates for $1.71.
--Shares of SAP AG (SAP) are up after it released its fourth quarter results, with revenue surpassing estimates. Fourth quarter revenue was up 27% at $4.09 billion, year-over-year, surpassing the average estimate of $3.81 billion.
Commodities are mixed as February gold contracts--still the most active--are down $6, or 0.49%, to $1,326 an ounce while March crude oil contacts are up 0.77%, or $0.62, at $86.81 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.5% to $36.45 and the United States Natural Gas fund (UNG) is down 0.82% to $6.04.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 0.45% to $129.52. Market Vectors Gold Miners (GDX) is up 0.47% to $53.37. iShares Silver Trust (SLV) is down 0.42% to $26.12.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Stocks are just higher at mid-day amid a week filled with earnings news as investors eye the conclusion of the Federal Reserve's monetary policy meeting today. ADRs of Toyota Motor ( TM ) are lower after the automaker said it was recalling more than 1.7 million vehicles worldwide to fix problems including fuel-system defects. | In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. In M&A news, Cisco ( CSCO ) announced today that it plans to purchase privately-held Pari Networks, a provider of network configuration and change management (NCCM) and compliance management solutions. | In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. Shares of computer maker Dell Inc. (DELL) are trending higher as Bloomberg reported comments made by company founder Michael Dell regarding Hewlett-Packard's (HPQ) acquisition of storage company 3Par. | In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Analysts' mean estimate is earnings of $294.5 million, or $0.39 per share. Revenue is expected to be $2.93 billion. |
34540.0 | 2011-01-26 00:00:00 UTC | Mid-Day Update: Stocks Higher Amid Heavy Earnings Week; Investors Await Fed Meeting | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-higher-amid-heavy-earnings-week-investors-await-fed-meeting-2011-01 | nan | nan | Here's where markets stand at mid-day:
-NYSE up 31.02 (+0.38%) to 8,172.15
-DJIA up 2.84 (+0.02%) to 11,980.03
-S&P 500 up 4.29 (+0.36%) to 1,295.80
-Nasdaq up 16.51 (+0.61%) to 2,735.92
GLOBAL SENTIMENT
Hang Seng up 0.23%
Nikkei down 0.6%
FTSE up 0.87%
MID-DAY NYSE INDEX WATCH
NYSE Energy up 1.22% at 13,077.54
NYSE Financial down 0.02% at 5,142.74
NYSE Health Care up 0.09% at 6,590.75
NYSE Arca Tech 100 up 0.74% at 1,118.53
UPSIDE MOVERS
(+) JNPR (+6.1%) rebounds from evening drop; company beats with earnings but may disappoint in coming quarterly report.
(+) GLW (+3.2%) upgraded.
(+) ERIC (+2.3%) inks new deals.
(+) APCVZ (+22.9%) secures deal with Teva.
(+) UAL (+7.6%) beats earnings estimates.
(+) CSX (+1.3%) upgraded.
(+) RHT (+4.7%) upgraded.
DOWNSIDE MOVERS
(-) UTX (-0.6%) beats with earnings.
(-) JASO (-4.9%) upgraded.
(-) GD (-0.6) beats with earnings.
(-) STJ (-2.2) beats with earnings.
(-) ABT (-1.9%) beats with earnings.
(-) GIGM (-1.4%) guides for return to Q2 profitability.
(-) XRX (-7.9%) EPS beat by a penny.
(-) LM (-4.2%) results top year-ago levels.
(-) TM (-1.9%) announces recall.
(-) EK (-16.8%) misses with Q4 results.
(-) YHOO (-2.8%) continues evening decline that followed revenue warning.
(-) RFMD (-8.8%) continues evening decline that followed revenue warning.
(-) MIPS (-10.6%) continues sharp evening slide that followed revenue miss.
(-) BA (-3.5%) misses with revenue.
MARKET DIRECTION
Stocks are just higher at mid-day amid a week filled with earnings news as investors eye the conclusion of the Federal Reserve's monetary policy meeting today. Adding to the mix is generally positive news about the housing market.
In the Fed announcement, due at 2:15 p.m. EST, no policy change is expected but the Street wants to hear the central bank's latest growth and inflation assessment and any clues on a future change in policy.
In the most recent data from the real estate sector, the US Commerce Department said sales of new single-family homes rose in December to an annual rate of 329,000. That is the highest level seen since April, when a federal tax credit gave housing a shot in the arm. November sales, however, were revised down 280,000 from 290,000.
In company news:
Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. This is in addition to 3,000 job cuts, or 3.2% of its global workforce, in September due to its purchase of Solvay Pharmaceuticals last year, the company stated. The changes are also in response to U.S. health-care reform and the challenging regulatory environment. Also, Abbott just beat the Street's Q4 view.
ADRs of Toyota Motor ( TM ) are lower after the automaker said it was recalling more than 1.7 million vehicles worldwide to fix problems including fuel-system defects. The recall affects approximately 1.2 million cars, according to reports. The second recall is for 280,000 units and involves a pressure sensor on the fuel delivery pipe.
Starbucks shares are down despite market expectation of an 18% jump in 2010 Q4 earnings. The company is set to report its earning after the market close today. Analysts' mean estimate is earnings of $294.5 million, or $0.39 per share. Revenue is expected to be $2.93 billion.
Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. Revenue fell 3.9% to $13.44 billion against $13.98 billion in the year-ago period. The company sees full-year 2011 net income of at least $6.30 per share. The Street is at $6.58. WellPoint saw a boost from frugal Americans who deferred doctor visits and medical treatment due to the economy, Bloomberg noted. The trend has trimmed expenses for all health insurers in the past two years.
In M&A news, Cisco ( CSCO ) announced today that it plans to purchase privately-held Pari Networks, a provider of network configuration and change management (NCCM) and compliance management solutions. The acquisition is expected to complement CSCO's smart service capabilities. Pari Networks' technology is planned to integrate into the company's smart services and help accelerate the ability of CSCO and its partners to manage the health and stability of customer networks through proactive, personalized services.
ADRs of Barclays ( BCS ) are lower as the bank says it plans to cut about 1,000 jobs in the UK as it looks to stop offering financial planning advice in its branch locations, Reuters reports. The move is seen as another example of the bank making cuts to improve lagging profitability. The cuts are reportedly to occur across the UK. The bank will focus financial advice to online customers.
Shares of computer maker Dell Inc. (DELL) are trending higher as Bloomberg reported comments made by company founder Michael Dell regarding Hewlett-Packard's (HPQ) acquisition of storage company 3Par. Dell had engaged in a bidding battle with HP for 3Par. Dell acquired another storage company, Compellent Technologies, for $960 million. HP paid $2.35 billion for 3Par. "We showed a good discipline and didn't take an emotional decision," Bloomberg quoted Dell as saying to a crow at the World Economic Forum in Davos. "I think HP paid way too much for 3Par."
Elsewhere in earnings news:
--Xerox Corp. (XRX) is down nearly 8% after the bell today after providing Q1 guidance that was below analyst consensus opinion. It said earnings should be in a range between $0.20 to $0.22 a share -- or $0.01 under the Street call. Full-year 2011 guidance was in-line with forecasts as were Q4 earnings and revenues.
--ConocoPhillips (COP) says Q4 adjusted EPS were $1.32, meeting estimates.
--Valero Energy (VLO) reports Q4 ex items earnings of about $0.39 per share, ahead of the Street view of $0.34 per share. Revenue was $22.1 bln, vs. expectations of $21.2 bln.
--St. Jude Medical (STJ) reports Q4 adjusted EPS of $0.75 compared to $0.64 a year earlier and just topping the Thomson Reuters mean analyst estimate for $0.74. Q4 sales of $1.35 billion top the $1.2 billion reported a year earlier. The Street looked for $1.32 billion.
--Flagstar Bancorp (FBC) says its Q4 net loss widened to $0.74 per share from a loss of $0.15 in Q3.
--First Cash Financial Services (FCFS) says Q4 EPS from continuing operations were $0.59, above the Thomson Reuters mean for $0.54. Sales were $129.6 million, beating forecasts for $122 million. FY11 EPS are seen between $2.02 to $2.10 per share, above estimates for $1.71.
--Shares of SAP AG (SAP) are up after it released its fourth quarter results, with revenue surpassing estimates. Fourth quarter revenue was up 27% at $4.09 billion, year-over-year, surpassing the average estimate of $3.81 billion.
Commodities are mixed as February gold contracts--still the most active--are down $6, or 0.49%, to $1,326 an ounce while March crude oil contacts are up 0.77%, or $0.62, at $86.81 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.5% to $36.45 and the United States Natural Gas fund (UNG) is down 0.82% to $6.04.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 0.45% to $129.52. Market Vectors Gold Miners (GDX) is up 0.47% to $53.37. iShares Silver Trust (SLV) is down 0.42% to $26.12.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) ABT (-1.9%) beats with earnings. In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Stocks are just higher at mid-day amid a week filled with earnings news as investors eye the conclusion of the Federal Reserve's monetary policy meeting today. | (-) ABT (-1.9%) beats with earnings. In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. | (-) ABT (-1.9%) beats with earnings. In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Shares of WellPoint ( WLP ) are higher as the healthcare company reported Q4 adjusted EPS of $1.33 compared to $1.16 a year earlier and above the Street view for $1.23. | (-) ABT (-1.9%) beats with earnings. In company news: Abbott Laboratories ( ABT ) announced today that it plans to restructure its pharmaceutical business and cut 1,900 jobs or 2% of its workforce. Analysts' mean estimate is earnings of $294.5 million, or $0.39 per share. |
34541.0 | 2011-01-26 00:00:00 UTC | Market Wrap-Up for Jan.26 (ROK, BA, COP, ABT, DD, more) | ABT | https://www.nasdaq.com/articles/market-wrap-jan26-rok-ba-cop-abt-dd-more-2011-01-26 | nan | nan | I'm sure most people could have written the script we heard last night on what the U.S. needs to do to turn things around. The problems are obvious (lack of jobs), but the solutions are not. Unfortunately the problem with politicians is that most of the time, they recant the issues we already know - get the standard applause when they say things need to change - but rarely offer up any solutions.
I find it fairly comical how the mood shifts occur and all of a sudden what the President is saying is good for the market. I've got news for everybody: the market already expected what the President was going to talk about. Folks, we have gone from Dow 6600 to Dow 12,000 in a matter of 20 months. What, you didn't think the President would get business-friendly? I have never met a politician that hasn't changed his/her stripes to get on the right side of the track when their political career is on the line.
If you toughed out the bear market by just putting capital into names that were still on our recommended list at the time, your returns would be unbelievable right now. Despite the recent rally, we are still looking for more buying opportunities going forward. The job of putting capital to work never stops and neither does our job in finding the best dividend stocks for your investment portfolio. I remember my baseball coach yelling at one of the kids at our team that loved to get on base by just watching pitches and walking. If you don't swing the bat, you'll never know how special a player you can become, and that holds true for investors too! Sitting in cash is the equivalent of just taking walks. Don't worry about getting an uptick the minute you buy shares, or waiting for that magical perfect entry point. Just get back in the game already!
Speaking of swinging the bat, we added two new names to our recommended list today (there have been a total of six new names added this week). Be sure to check the link below for the names in case you didn't read the e-mail alert we sent out earlier.
The markets briefly touched over Dow 12K on the back of the State of the Union euphoria as well as the Federal Reserve deciding to leave rates once again (certainly not a surprise to many). Winners on the earnings side today included Rockwell Automation ( ROK ), ConocoPhillips ( COP ), and Dupont ( DD ). ROK is a name we added to our aggressive list early last month in the high $60′s and the stock just broke above $80 today. It is certainly nice to catch a quick move like that, but we never try and bet on big short-term movements. As for earnings movers to the downside today, sellers were active in names like Boeing ( BA ), Abbott Labs ( ABT ), and Altera Corp ( ALTR ).
Let's continue this week's series on investing strategy anecdotes.
Investing Strategy #11 - "Let your setups come to you - do not chase. There will always be another day, another setup."
While the setup term applies a bit more to trading, the "don't chase" part is the more important focus for investors. That's why I don't like our subscribers buying new recommendations we make the minute they get their email alert about the upgrades. Lots of times, investors want to jump in on any news headline that comes out, which usually means you're buying emotion - which is never a good idea.
Investing Strategy #12 - "Stay the course until evidence proves the other way around."
If you have a sell discipline and you stick to it, you will avoid taking any major losses that would put a big dent in your plans to build wealth. The stocks that have done well for you will likely continue to do so, unless outside technological, economic, or cultural factors begin working against them.
Investing Strategy #13 - "The importance of having a system and sticking to it especially when your emotions are working against you."
It pays to have a game plan on what you want to be buying with your new monies each month, even if the market is going through a rocky period. There are almost always a place you can get your money in the markets to get working for you.
Investing Strategy #14 - "Inaction due to fear of the unknown is the worst thing one can do."
This goes back to the above and what I said about swinging the bat. Fear is the biggest factor that holds investors back. Fear of losing, fear having an opinion others may not like, fear the stock you buy may go down, etc. Don't let fear stop you from taking advantage of every opportunity life can give you, beyond just investing.
Investing Strategy #15 - "You only need to be correct on one or two themes per year and overweight them to have acceptable performance."
This is certainly possible, but I tend to lean toward capping any one stock at no more than 10% of any particular portfolio. You can certainly let a winner run a bit more than that, but you can also take some of those winnings and likely find another name or two to consider buying. Often times, there could be stocks that drift down to attractive levels where the dividend yield is too juicy to ignore.
Check out the first 10 investing strategy anecdotes put up in Monday and Tuesday's daily newsletter and be sure to read more of these as the week goes on.
Don't forget to check out our library of "Learn to Be Rich" articles which give you snippets about personal finance matters you should educate yourself about. And as always, check out our industry-leading "Best Dividend Stocks" List for the top dividend names to put money into right now.
Thanks for reading, and I'll see you tomorrow!
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As for earnings movers to the downside today, sellers were active in names like Boeing ( BA ), Abbott Labs ( ABT ), and Altera Corp ( ALTR ). The markets briefly touched over Dow 12K on the back of the State of the Union euphoria as well as the Federal Reserve deciding to leave rates once again (certainly not a surprise to many). If you have a sell discipline and you stick to it, you will avoid taking any major losses that would put a big dent in your plans to build wealth. | As for earnings movers to the downside today, sellers were active in names like Boeing ( BA ), Abbott Labs ( ABT ), and Altera Corp ( ALTR ). And as always, check out our industry-leading "Best Dividend Stocks" List for the top dividend names to put money into right now. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As for earnings movers to the downside today, sellers were active in names like Boeing ( BA ), Abbott Labs ( ABT ), and Altera Corp ( ALTR ). The job of putting capital to work never stops and neither does our job in finding the best dividend stocks for your investment portfolio. Fear of losing, fear having an opinion others may not like, fear the stock you buy may go down, etc. | As for earnings movers to the downside today, sellers were active in names like Boeing ( BA ), Abbott Labs ( ABT ), and Altera Corp ( ALTR ). The job of putting capital to work never stops and neither does our job in finding the best dividend stocks for your investment portfolio. Investing Strategy #13 - "The importance of having a system and sticking to it especially when your emotions are working against you." |
34542.0 | 2011-01-14 00:00:00 UTC | Stocks Turn Positive at Mid-Day as Industrial Production Buoys Investors | ABT | https://www.nasdaq.com/articles/stocks-turn-positive-mid-day-industrial-production-buoys-investors-2011-01-14 | nan | nan | Stocks turned positive at mid-session after a new report showed a jump in industrial production in December by the the biggest amount in five months, suggesting that the economic recovery has momentum going into the new year.
The report offset disappointing data on US business inventories and consumer sentiment. Inventories rose less than expected, showing that demand for goods could be stabilizing, and consumer sentiment unexpectedly declined in a preliminary sampling by Thomson Reuters and the University of Michigan. The index came in at 72.7, down from 75.2 the month before and below expectations for an increase to 76.0.
Output of the nation's factories, mines and utilities rose 0.8% last month, the Federal Reserve said. Overall industrial activity is up 11% since hitting its recession low in June 2009. But it is still 6% below its Sept. 2007 peak.
Meanwhile, U.S. business inventories rose 0.2% in November, the Commerce Department said, below economists' expectations. Sales at U.S. businesses rose 1.2%. The inventory-to-sales ratio, an indication of demand, fell to 1.25 in November from 1.27 in October. Economists surveyed by MarketWatch were expecting inventories to rise by 0.5% in November.
Also, Lackluster retail sales reports also contributing to profit-taking ahead of the three-day Martin Luther King Jr. holiday weekend. Sales rose 0.6% last month to $381 billion, less than analysts expected, although a 13.5% gain over the recession low in Dec. 2008. On the year, sales rose 6.7% over last year, the biggest annual increase since 1999.
Overseas, China raised bank reserve requirements in a move widely interpreted to indicate the government is determined to cool the economy.
In company news:
Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. The firm developed to treat a skin condition called psoriasis,. Abbott said regulators could want more research..
With shares of most semiconductor makers soaring after Intel's ( INTC ) blow-out results last night, chip equipment suppliers such as Cymer Inc. ( CYMI ) and Varian Semiconductor Equipment ssociates Inc. ( VSEA ) also are up sharply this morning.
ADRs of Smith & Nephew ( SNN ) are down after the maker of knee and hip replacements said its not in talks that could lead to a merger or takeover, Bloomberg reports. The UK's Daily Telegraph reported that the company is going to start informal negotiations with Biomet. "Smith & Nephew has a long-standing policy of not commenting on press speculation, unless there is a regulatory obligation to do so," Smith & Nephew said in a statement.
Apple (AAPL) and News Corp. (NWS) are delaying the launch of the latter's digital newspaper for the iPad, according to a report in The Wall Street Journal, citing people familiar with the matter. The newspaper, called The Daily, was supposed to be released next Wednesday. Both have reportedly decided they need more time to test it.
Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. The warrants were given to taxpayers in return for bailing out the bank during the financial crisis. The warrant sale "would represent Treasury's disposition of its remaining holdings," the Treasury Department said in a statement.
Borders (BGP) is up by double digits after the New York Times reports the company may be close to securing refinancing from GE Capital and other lenders.
Shares of Chevron (CVX) are up as the oil major resumed flow through its pipeline in the southern Niger River delta in Nigeria a month after it was overtaken by militants, Bloomberg reports. The line that was impacted os fixed and operations there have returned to normal, a Chevron spokesman noted.
CVS Caremark (CVS) has been sued by North Carolina pharmacies, which have alleged that CVS violated the North Carolina Pharmacy of Choice Act, as well as committing unfair and deceptive business practices.
The Trans Alaska Pipeline is set to be shut down today to install a bypass on the system, which was shut down earlier this week due to a leak. The leak force BP (BP), ConocoPhillips (COP) and Exxon Mobil (XOM) to suspend 95% of production from Alaska's North Slope area.
Gold Resource Corp (GORO) is off sharply, giving back all of yesterday's gains -- and then some -- following CEO William Reid's appearance Thursday on CNBC. Today's decline also is likely due to the 2% fall in gold prices today.
In earnings news:
--Coinstar (CSTR) has shed nearly a quarter of its market value, after saying Q4 EPS and revenues would be well below its prior guidance.
--JPMorgan Chase (JPM) shares are higher after it reported Q4 EPS of $1.12 per share, up from $0.74 per share in the year ago quarter. Revenue was $26.7 billion, up from $25.2 billion a year ago. The analyst consensus was $1.00 per share in earnings on revenue of $24.3 billion, according to Thomson Reuters.
--Hasbro Inc. (HAS) is down about 3% this morning after the toy company said Q4 and full-year revenues will fall about $100 mln short of the Thomson Reuters average by analysts.
Commodities are lower. February gold contracts are down $29, or 2.08%, to $1,358 an ounce while February crude oil contacts are down 0.32%, or $0.29, at $91.14 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.1% to $38.68 and the United States Natural Gas fund (UNG) is up 0.5% to $6.01.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 1.05% to $132.64. Market Vectors Gold Miners (GDX) is down 2.3% to $54.76. iShares Silver Trust (SLV) is down 1.39% to $27.61.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Stocks turned positive at mid-session after a new report showed a jump in industrial production in December by the the biggest amount in five months, suggesting that the economic recovery has momentum going into the new year. Shares of Chevron (CVX) are up as the oil major resumed flow through its pipeline in the southern Niger River delta in Nigeria a month after it was overtaken by militants, Bloomberg reports. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Sales rose 0.6% last month to $381 billion, less than analysts expected, although a 13.5% gain over the recession low in Dec. 2008. Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Sales rose 0.6% last month to $381 billion, less than analysts expected, although a 13.5% gain over the recession low in Dec. 2008. Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Meanwhile, U.S. business inventories rose 0.2% in November, the Commerce Department said, below economists' expectations. Sales at U.S. businesses rose 1.2%. |
34543.0 | 2011-01-14 00:00:00 UTC | Mid-Day Update: Stocks Turn Positive as Dec. Industrial Production Jumps; China Tempers Gains | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-turn-positive-dec-industrial-production-jumps-china-tempers-gains | nan | nan | Here's where markets stand at mid-day:
-NYSE up 24.95 (+0.31%) to 8,144.38
-DJIA up 33 (+0.28%) to 11,764.90
-S&P 500 up 5.43 (+0.42%) to 1,289.23
-Nasdaq up 10.56 (+0.39%) to 2,745.84
GLOBAL SENTIMENT
Hang Seng up 0.18%
Nikkei down 0.86%
FTSE down 0.36%
MID-DAY NYSE INDEX WATCH
NYSE Energy up 0.29% at 12,898.23
NYSE Financial up 1.03% at 5,183.98
NYSE Health Care down 0.13% at 6,585.97
NYSE Arca Tech 100 up 0.67% at 1,135.37
UPSIDE MOVERS
(+) CT (+5.7%) continues sharp move; company has no comment on share activity.
(+) BGP (+23.8%) reportedly close to refinancing deal.
(+) COCO (+9.2%) upgraded.
(+) JPM (+2.6%) gains then declines after earnings beat.
DOWNSIDE MOVERS
(-) HAS (-0.9%) guides for full year and Q4 revenue just below Street view; backs 2011 guidance.
(-) NVO (-1.7%) downgraded.
(-) PCX (-6.1%) downgraded.
(-) CSTR (-24.6%) continues sharp evening slide seen in wake of slashed Q4 guidance.
(-) TSTC (-4.4%) responds to fraud allegations, considers legal action in response to article.
(-) LIFE (-1.1%) downgraded.
(-) ILMN (-0.9%) downgraded.
(-) JASO (-5.5%) downgraded.
(-) GENZ (-0.4%) gains as Sanofi-Aventis reportedly set to offer $76 per share for company.
(-) INTC (-0.9%) continues upside response to evening earnings beat, upbeat revenue guidance.
MARKET DIRECTION
Stocks turned positive at mid-session after a new report showed a jump in industrial production in December by the the biggest amount in five months, suggesting that the economic recovery has momentum going into the new year.
The report offset disappointing data on US business inventory and consumer sentiment, Inventories rose less than expected, showing that demand for goods could be stabilizing and consumer sentiment unexpectedly declined in a preliminary sampling by Thomson Reuters and the University of Michigan. The index came in at 72.7, down from 75.2 the month before and below expectations for an increase to 76.0.
Output of the nation's factories, mines and utilities rose 0.8% last month, the Federal Reserve said. Overall industrial activity is up 11% since hitting its recession low in June 2009. But it is still 6% below its Sept. 2007 peak.
Meanwhile, U.S. business inventories rose 0.2% in November, the Commerce Department said, below economists' expectations. Sales at U.S. businesses rose 1.2%. The inventory-to-sales ratio, an indication of demand, fell to 1.25 in November from 1.27 in October. Economists surveyed by MarketWatch were expecting inventories to rise by 0.5% in November.
Also, Lackluster retail sales reports also contributing to profit-taking ahead of the three-day Martin Luther King Jr. holiday weekend. Sales rose 0.6% last month to $381 billion, less than analysts expected, although a 13.5% gain over the recession low in Dec. 2008. On the year, sales rose 6.7% over last year, the biggest annual increase since 1999.
Overseas, China raised bank reserve requirements in a move widely interpreted to indicate the government is determined to cool the economy.
In company news:
Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. The firm developed to treat a skin condition called psoriasis,. Abbott said regulators could want more research..
With shares of most semiconductor makers soaring after Intel's ( INTC ) blow-out results last night, chip equipment suppliers such as Cymer Inc. ( CYMI ) and Varian Semiconductor Equipment ssociates Inc. ( VSEA ) also are up sharply this morning.
ADRs of Smith & Nephew ( SNN ) are down after the maker of knee and hip replacements said its not in talks that could lead to a merger or takeover, Bloomberg reports. The UK's Daily Telegraph reported that the company is going to start informal negotiations with Biomet. "Smith & Nephew has a long-standing policy of not commenting on press speculation, unless there is a regulatory obligation to do so," Smith & Nephew said in a statement.
Apple (AAPL) and News Corp. (NWS) are delaying the launch of the latter's digital newspaper for the iPad, according to a report in The Wall Street Journal, citing people familiar with the matter. The newspaper, called The Daily, was supposed to be released next Wednesday. Both have reportedly decided they need more time to test it.
Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. The warrants were given to taxpayers in return for bailing out the bank during the financial crisis. The warrant sale "would represent Treasury's disposition of its remaining holdings," the Treasury Department said in a statement.
Borders (BGP) is up by double digits after the New York Times reports the company may be close to securing refinancing from GE Capital and other lenders.
Shares of Chevron (CVX) are up as the oil major resumed flow through its pipeline in the southern Niger River delta in Nigeria a month after it was overtaken by militants, Bloomberg reports. The line that was impacted os fixed and operations there have returned to normal, a Chevron spokesman noted.
CVS Caremark (CVS) has been sued by North Carolina pharmacies, which have alleged that CVS violated the North Carolina Pharmacy of Choice Act, as well as committing unfair and deceptive business practices.
The Trans Alaska Pipeline is set to be shut down today to install a bypass on the system, which was shut down earlier this week due to a leak. The leak force BP (BP), ConocoPhillips (COP) and Exxon Mobil (XOM) to suspend 95% of production from Alaska's North Slope area.
Gold Resource Corp (GORO) is off sharply, giving back all of yesterday's gains -- and then some -- following CEO William Reid's appearance Thursday on CNBC. Today's decline also is likely due to the 2% fall in gold prices today.
In earnings news:
--Coinstar (CSTR) has shed nearly a quarter of its market value, after saying Q4 EPS and revenues would be well below its prior guidance.
--JPMorgan Chase (JPM) shares are higher after it reported Q4 EPS of $1.12 per share, up from $0.74 per share in the year ago quarter. Revenue was $26.7 billion, up from $25.2 billion a year ago. The analyst consensus was $1.00 per share in earnings on revenue of $24.3 billion, according to Thomson Reuters.
--Hasbro Inc. (HAS) is down about 3% this morning after the toy company said Q4 and full-year revenues will fall about $100 mln short of the Thomson Reuters average by analysts.
Commodities are lower. February gold contracts are down $29, or 2.08%, to $1,358 an ounce while February crude oil contacts are down 0.32%, or $0.29, at $91.14 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 0.1% to $38.68 and the United States Natural Gas fund (UNG) is up 0.5% to $6.01.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 1.05% to $132.64. Market Vectors Gold Miners (GDX) is down 2.3% to $54.76. iShares Silver Trust (SLV) is down 1.39% to $27.61.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Stocks turned positive at mid-session after a new report showed a jump in industrial production in December by the the biggest amount in five months, suggesting that the economic recovery has momentum going into the new year. Apple (AAPL) and News Corp. (NWS) are delaying the launch of the latter's digital newspaper for the iPad, according to a report in The Wall Street Journal, citing people familiar with the matter. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. (-) INTC (-0.9%) continues upside response to evening earnings beat, upbeat revenue guidance. The report offset disappointing data on US business inventory and consumer sentiment, Inventories rose less than expected, showing that demand for goods could be stabilizing and consumer sentiment unexpectedly declined in a preliminary sampling by Thomson Reuters and the University of Michigan. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. The report offset disappointing data on US business inventory and consumer sentiment, Inventories rose less than expected, showing that demand for goods could be stabilizing and consumer sentiment unexpectedly declined in a preliminary sampling by Thomson Reuters and the University of Michigan. Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. | In company news: Shares of Abbott Laboratories ( ABT ) are down after a Wall Street Journal report that it withdrew its U.S. and European applications for an experimental drug called briakinumab. Sales rose 0.6% last month to $381 billion, less than analysts expected, although a 13.5% gain over the recession low in Dec. 2008. Shares of Citigroup (C) are higher following news that the bank will sell warrants this quarter in bank, Bloomberg reports. |
34544.0 | 2011-01-14 00:00:00 UTC | The Top 20 Most Undervalued Healthcare Stocks By Target Price | ABT | https://www.nasdaq.com/articles/top-20-most-undervalued-healthcare-stocks-target-price-2011-01-14 | nan | nan | Compiled by Luis Gonzalez: The following is a list of the most undervalued healthcare stocks, when comparing the current price against the average analyst target price (used as a proxy for fair value).
Yes, this is a crude way to find undervalued companies, but the goal here is to give you a starting point for your own analysis. Full details below.
All data sourced from Finviz.
Analyze These Ideas (Tools Will Open In A New Window)
1. Access a thorough description of all companies mentioned
2. Compare analyst ratings for all stocks mentioned below
3. Visualize monthly and annual returns for all stocks mentioned
The list has been sorted by the average discount to target price.
1. Inspire Pharmaceuticals, Inc. (ISPH): Drug Manufacturers Industry. Market cap of $335.5M. Price at time of writing $4.12 vs. target price of $6.75 (discount of 38.96%). Short float at 4.05%, which implies a short ratio of 2.59 days. The stock has lost -40.44% over the last year.
2. Corcept Therapeutics Inc. (CORT): Biotechnology Industry. Market cap of $315.58M. Price at time of writing $4.35 vs. target price of $6.58 (discount of 33.89%). Short float at 2.84%, which implies a short ratio of 4.97 days. The stock has gained 45.33% over the last year.
3. Halozyme Therapeutics, Inc. (HALO): Biotechnology Industry. Market cap of $767.29M. Price at time of writing $7.49 vs. target price of $11.29 (discount of 33.66%). Short float at 4.19%, which implies a short ratio of 8.15 days. The stock has gained 29.05% over the last year.
4. PROLOR Biotech, Inc. (PBTH): Biotechnology Industry. Market cap of $331.5M. Price at time of writing $6.18 vs. target price of $8.5 (discount of 27.29%). Short float at 2.33%, which implies a short ratio of 8.48 days. The stock has gained 159.58% over the last year.
5. Thoratec Corp. (THOR): Medical Instruments & Supplies Industry. Market cap of $1.66B. Price at time of writing $28.35 vs. target price of $38.41 (discount of 26.19%). Short float at 9.46%, which implies a short ratio of 3.69 days. The stock has gained 1.25% over the last year.
6.Human Genome Sciences Inc. (HGSI): Biotechnology Industry. Market cap of $5.07B. Price at time of writing $26.70 vs. target price of $35.17 (discount of 24.08%). Short float at 8.11%, which implies a short ratio of 4.07 days. The stock has lost -10.85% over the last year.
7. Incyte Corporation (INCY): Biotechnology Industry. Market cap of $1.97B. Price at time of writing $16.06 vs. target price of $21.08 (discount of 23.81%). Short float at 12.87%, which implies a short ratio of 8.59 days. The stock has gained 57.09% over the last year.
8. Optimer Pharmaceuticals, Inc. (OPTR): Biotechnology Industry. Market cap of $452.94M. Price at time of writing $11.79 vs. target price of $15.33 (discount of 23.09%). Short float at 6.38%, which implies a short ratio of 12.61 days. The stock has lost -11.73% over the last year.
9. Abbott Laboratories (ABT): Drug Manufacturers Industry. Market cap of $73.23B. Price at time of writing $46.96 vs. target price of $59.73 (discount of 21.38%). Short float at 0.55%, which implies a short ratio of 1 days. The stock has lost -11.36% over the last year.
10. American Medical Systems Holdings Inc. (AMMD): Medical Appliances & Equipment Industry. Market cap of $1.48B. Price at time of writing $19.09 vs. target price of $24.1 (discount of 20.79%). Short float at 8.6%, which implies a short ratio of 7.52 days. The stock has lost -4.01% over the last year.
11. Eurand N.V. (EURX): Biotechnology Industry. Market cap of $570.M. Price at time of writing $11.89 vs. target price of $15.0 (discount of 20.73%). Short float at 3.78%, which implies a short ratio of 1.74 days. The stock has lost -1.9% over the last year.
12. Healthways Inc. (HWAY): Specialized Health Services Industry. Market cap of $379.47M. Price at time of writing $10.90 vs. target price of $13.69 (discount of 20.38%). Short float at 4.62%, which implies a short ratio of 6.24 days. The stock has lost -38.42% over the last year.
13. BioMimetic Therapeutics Inc. (BMTI): Medical Instruments & Supplies Industry. Market cap of $400.89M. Price at time of writing $14.06 vs. target price of $17.63 (discount of 20.25%). Short float at 9.07%, which implies a short ratio of 17.24 days. The stock has gained 16.68% over the last year.
14. Orthofix International NV (OFIX): Medical Appliances & Equipment Industry. Market cap of $555.84M. Price at time of writing $31.20 vs. target price of $39.0 (discount of 20.%). Short float at 5.17%, which implies a short ratio of 6.27 days. The stock has lost -4.91% over the last year.
15. Acorda Therapeutics, Inc. (ACOR): Biotechnology Industry. Market cap of $1.07B. Price at time of writing $26.90 vs. target price of $33.58 (discount of 19.89%). Short float at 16.96%, which implies a short ratio of 8.48 days. The stock has gained 5.74% over the last year.
16. Cephalon Inc. (CEPH): Biotechnology Industry. Market cap of $4.51B. Price at time of writing $59.59 vs. target price of $74.21 (discount of 19.7%). Short float at 14.75%, which implies a short ratio of 9.58 days. The stock has lost -6.55% over the last year.
17. China Medical Technologies Inc. (CMED): Medical Instruments & Supplies Industry. Market cap of $388.53M. Price at time of writing $12.11 vs. target price of $15.04 (discount of 19.48%). Short float at 21.47%, which implies a short ratio of 17.39 days. The stock has lost -20.53% over the last year.
18. Warner Chilcott plc (WCRX): Drug Manufacturers - Other Industry. Market cap of $6.04B. Price at time of writing $23.83 vs. target price of $29.42 (discount of 19.%). Short float at 1.24%, which implies a short ratio of 1.26 days. The stock has gained 18.17% over the last year.
19. Mindray Medical International Limited (MR): Medical Instruments & Supplies Industry. Market cap of $2.74B. Price at time of writing $26.44 vs. target price of $32.46 (discount of 18.55%). Short float at 20.62%, which implies a short ratio of 20.32 days. The stock has lost -31.98% over the last year.
20. NPS Pharmaceuticals, Inc. (NPSP): Biotechnology Industry. Market cap of $550.16M. Price at time of writing $8.20 vs. target price of $10.06 (discount of 18.49%). Short float at 3.92%, which implies a short ratio of 5.94 days. The stock has gained 140.35% over the last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT): Drug Manufacturers Industry. Yes, this is a crude way to find undervalued companies, but the goal here is to give you a starting point for your own analysis. Visualize monthly and annual returns for all stocks mentioned The list has been sorted by the average discount to target price. | Abbott Laboratories (ABT): Drug Manufacturers Industry. Compiled by Luis Gonzalez: The following is a list of the most undervalued healthcare stocks, when comparing the current price against the average analyst target price (used as a proxy for fair value). BioMimetic Therapeutics Inc. (BMTI): Medical Instruments & Supplies Industry. | Abbott Laboratories (ABT): Drug Manufacturers Industry. Price at time of writing $4.12 vs. target price of $6.75 (discount of 38.96%). China Medical Technologies Inc. (CMED): Medical Instruments & Supplies Industry. | Abbott Laboratories (ABT): Drug Manufacturers Industry. Compare analyst ratings for all stocks mentioned below 3. Visualize monthly and annual returns for all stocks mentioned The list has been sorted by the average discount to target price. |
34545.0 | 2011-01-04 00:00:00 UTC | Stocks Slip Despite Positive Economic News; Investors Look to Fed Minutes This Afternoon | ABT | https://www.nasdaq.com/articles/stocks-slip-despite-positive-economic-news-investors-look-fed-minutes-afternoon-2011-01-04 | nan | nan | Stocks are mixed at mid-session after Inflation in Europe overshadowed new economic reports that saw an unexpected jump in factory orders and an increase in Christmas retail sales--both suggesting economic expansion. Investor attention will be focused on the Federal Reserve's December monetary policy meeting minutes, which will be issued this afternoon.
US retailers saw sales rise 3.6% last week compared to the year-earlier period as shoppers took advantage of post-Christmas discounts according to an index of sales released by Goldman Sachs and the International Council of Shopping Centers.
November factory orders in the US rose 0.7% compared with a forecast for a 0.1% drop. Demand for capital equipment drove gains.
At 2 p.m. ET, the Fed's December monetary policy meeting minutes will be released. Investors will be closely watching for a central bank assessment that at least matches the general enthusiasm that Wall Street has shown over the economy in recent weeks. Optimistic sentiment has sent the averages to multiyear highs without much of a consolidation phase.
In company news:
General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. The automaker sold 224,185 cars and trucks. Ex discontinued brands, sales of GM's four remaining lines jumped 15.5% to 223,932 vehicles last month. Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%,
Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. The product generated about $1.37 billion in sales in 2009.
Coffee chain Starbucks ( SBUX ) is down following a Bloomberg report that says the company could miss a jump in home brewing unless it can break a pact that links it to Kraft Food's Tassimo machine, which competes with the best-selling Keurig home brewer. Under terms of the agreement, Starbucks can't put its coffee in the Keurig.
Dell Inc.( DELL ) announced Tuesday its plans to acquire information-security services firm SecureWorks, Inc. The acquisition comes three weeks after DELL's announcement that it had agreed to acquire Compellent Technologies (CML) for $820 million. Financial terms for the ShareWroks deal, however, were not disclosed.
American Express (AXP) is up as shares get support from Jim Cramer at CNBC, who named the stock as one of his Dow Leaders in 2011. According to Cramer, AXP could jump 40% to $60 by the end of 2011 in a broad based advance for financial companies, based on improved overseas growth. The stock recently reported a 17% increase in year-over-year revenues, although Cramer cautioned that AXP is still "misunderstood and underestimated."
Shares of Celgene (CELG) are down after the biotech firm said it has submitted new marketing applications for its blood cancer drugs Revlimid and Istodax, Reuters reported. Revmid--in combination with other drugs--treats multiple myloma. Istodax is for patients with peripheral T-cell lymphoma.
Apple's (AAPL) iOS--the operating system for its iPhone smartphone--is still the No. 1 mobile operating system over Google's Android OS, according to the latest survey from Nielsen, as reported by Bizjournals.com Apple's iOS has 28.6% of the smartphone market. That was narrowly ahead of Research in Motion's (RIMM) Blackberry OS at 26.1% and Google's (GOOG) Android at 25.8%. Still, Google's Android is said to be the most popular among new smartphone buyers.
American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported. AIG has been trying to sell the unit for 15 months. The proposal from home security company Taiwan Secom Group is seen as pleasing regulators but likely is contrary to what AIG is aiming to do.
BP (BP) ADRs are just higher following an earlier report from London's Daily Mail that Royal Dutch Shell (RDS.A) is mulling an opportunistic takeover of BP because of its vulnerability following the Gulf of Mexico spill. The report says Shell's board decided against a bid due to its concern over legal liabilities but that it remains interested in a merger.
Commodities are down. February gold contracts are down $38, or 2.66%, to $1,385 an ounce while February crude oil contacts are down 2.58%, or $2.36, at $89.19 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 2.87% to $37.93 and the United States Natural Gas fund (UNG) is down 0.48% to $6.28.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 2.11% to $135.09. Market Vectors Gold Miners (GDX) is down 3.14% to $58.83. iShares Silver Trust (SLV) is down 2.6% to $29.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. Investors will be closely watching for a central bank assessment that at least matches the general enthusiasm that Wall Street has shown over the economy in recent weeks. Shares of Celgene (CELG) are down after the biotech firm said it has submitted new marketing applications for its blood cancer drugs Revlimid and Istodax, Reuters reported. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. Investor attention will be focused on the Federal Reserve's December monetary policy meeting minutes, which will be issued this afternoon. In company news: General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. In company news: General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. Investor attention will be focused on the Federal Reserve's December monetary policy meeting minutes, which will be issued this afternoon. AIG has been trying to sell the unit for 15 months. |
34546.0 | 2011-01-04 00:00:00 UTC | Mid-Day Update: Stocks Lower After Europe Inflation Overshadows Upbeat Retail Sales, Factory Orders; Fed Meeting Minutes on Tap | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-lower-after-europe-inflation-overshadows-upbeat-retail-sales-factory | nan | nan | Here's where markets stand at mid-day:
-NYSE down 46.05 (-0.57%) to 7,997.92
-DJIA down 9.99 (-0.09%) to 11,660.76
-S&P 500 down 6.46 (-0.51%) to 1,265.34
-Nasdaq down 22.82 (-0.85%) to 2,2668.74
GLOBAL SENTIMENT
Hang Seng up 0.99%
Nikkei up 1.65%
FTSE up 1.93%
MID-DAY NYSE INDEX WATCH
NYSE Energy down 0.67% at 12,555.26
NYSE Financial down 0.64% at 5,010.71
NYSE Health Care up 0.07% at 6,556.38
NYSE Arca Tech 100 down 0.81% at 1,091.22
UPSIDE MOVERS
(+) BP (+2.1%) gaining but off early highs; subject of article about interest from Shell, reacting to presumed resumption of Gulf of Mexico drilling.
(+) WAG (+0.9%) added to Goldman's Conviction Buy list.
(+) XOMA (+22.6%) inks development commercialization pact.
(+) VECO (+0.9%) upgraded.
(+) PLUG (+15.9%) offers upbeat sales comments.
(+) CCL (+0.6%) upgraded.
(+) RBS (+1.1%) upgraded.
(+) DRYS (+1.5%) inks new contracts.
(+) NTWK (+2.3%) inks strategic understanding with SANY auto finance.
(+) RPC (+28%) remains active gainer over several sessions.
DOWNSIDE MOVERS
(-) NKE (-2.4%) removed from Goldman's Conviction Buy list.
(-) BGP (-9.4%) down as financial situation remains in focus; some execs leaving; gets delivery pledge from vendor.
(-) NLY (-2.6%) continues evening decline that followed planned share issuance.
(-) SJM (-3.1) downgraded, price target lowered.
(-) OPTR (-1.8%) gets orphan drug status for Fidaxomicin.
MARKET DIRECTION
Stocks are mixed at mid-session after Inflation in Europe overshadowed new economic reports that saw an unexpected jump in factory orders and an increase in Christmas retail sales--both suggesting economic expansion. Investor attention will be focused on the Federal Reserve's December monetary policy meeting minutes, which will be issued this afternoon.
US retailers saw sales rise 3.6% last week compared to the year-earlier period as shoppers took advantage of post-Christmas discounts according to an index of sales released by Goldman Sachs and the International Council of Shopping Centers.
November factory orders in the US rose 0.7% compared with a forecast for a 0.1% drop. Demand for capital equipment drove gains.
At 2 p.m. ET, the Fed's December monetary policy meeting minutes will be released. Investors will be closely watching for a central bank assessment that at least matches the general enthusiasm that Wall Street has shown over the economy in recent weeks. Optimistic sentiment has sent the averages to multiyear highs without much of a consolidation phase.
In company news:
General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. The automaker sold 224,185 cars and trucks. Ex discontinued brands, sales of GM's four remaining lines jumped 15.5% to 223,932 vehicles last month. Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%,
Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. The product generated about $1.37 billion in sales in 2009.
Coffee chain Starbucks ( SBUX ) is down following a Bloomberg report that says the company could miss a jump in home brewing unless it can break a pact that links it to Kraft Food's Tassimo machine, which competes with the best-selling Keurig home brewer. Under terms of the agreement, Starbucks can't put its coffee in the Keurig.
Dell Inc.( DELL ) announced Tuesday its plans to acquire information-security services firm SecureWorks, Inc. The acquisition comes three weeks after DELL's announcement that it had agreed to acquire Compellent Technologies (CML) for $820 million. Financial terms for the ShareWroks deal, however, were not disclosed.
American Express (AXP) is up as shares get support from Jim Cramer at CNBC, who named the stock as one of his Dow Leaders in 2011. According to Cramer, AXP could jump 40% to $60 by the end of 2011 in a broad based advance for financial companies, based on improved overseas growth. The stock recently reported a 17% increase in year-over-year revenues, although Cramer cautioned that AXP is still "misunderstood and underestimated."
Shares of Celgene (CELG) are down after the biotech firm said it has submitted new marketing applications for its blood cancer drugs Revlimid and Istodax, Reuters reported. Revmid--in combination with other drugs--treats multiple myloma. Istodax is for patients with peripheral T-cell lymphoma.
Apple's (AAPL) iOS--the operating system for its iPhone smartphone--is still the No. 1 mobile operating system over Google's Android OS, according to the latest survey from Nielsen, as reported by Bizjournals.com Apple's iOS has 28.6% of the smartphone market. That was narrowly ahead of Research in Motion's (RIMM) Blackberry OS at 26.1% and Google's (GOOG) Android at 25.8%. Still, Google's Android is said to be the most popular among new smartphone buyers.
American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported. AIG has been trying to sell the unit for 15 months. The proposal from home security company Taiwan Secom Group is seen as pleasing regulators but likely is contrary to what AIG is aiming to do.
BP (BP) ADRs are just higher following an earlier report from London's Daily Mail that Royal Dutch Shell (RDS.A) is mulling an opportunistic takeover of BP because of its vulnerability following the Gulf of Mexico spill. The report says Shell's board decided against a bid due to its concern over legal liabilities but that it remains interested in a merger.
Commodities are down. February gold contracts are down $38, or 2.66%, to $1,385 an ounce while February crude oil contacts are down 2.58%, or $2.36, at $89.19 a barrel.
In energy ETFs, the United States Oil Fund (USO) is down 2.87% to $37.93 and the United States Natural Gas fund (UNG) is down 0.48% to $6.28.
In precious metal ETFs, the SPDR Gold Trust (GLD) is down 2.11% to $135.09. Market Vectors Gold Miners (GDX) is down 3.14% to $58.83. iShares Silver Trust (SLV) is down 2.6% to $29.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. Investors will be closely watching for a central bank assessment that at least matches the general enthusiasm that Wall Street has shown over the economy in recent weeks. Shares of Celgene (CELG) are down after the biotech firm said it has submitted new marketing applications for its blood cancer drugs Revlimid and Istodax, Reuters reported. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. In company news: General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. In company news: General Motors ( GM ) shares are higher after it reported a 7.5% increase in December domestic sales, lifting sales on the year to 2.22 million, up from 2.08 million last year. American International Group (AIG) shares are down after the firm received a proposal from a local Taiwan company to buy a stake in AIG's Taiwan unit, Reuters reported. | Meanwhile, shares of Ford Motor ( F ) are just higher after the automaker reported that December sales jumped about 7%, Shares of Abbott Laboratories ( ABT ) are higher even as copyright protection for the company's HIV drug Kaletra was rejected in India, which will allow other generic drug companies to manufacture copies, Bloomberg reports. (+) BP (+2.1%) gaining but off early highs; subject of article about interest from Shell, reacting to presumed resumption of Gulf of Mexico drilling. AIG has been trying to sell the unit for 15 months. |
34547.0 | 2010-12-31 00:00:00 UTC | Stocks Mixed as 2010 Comes to a Close; Market Near Two-Year Highs | ABT | https://www.nasdaq.com/articles/stocks-mixed-2010-comes-close-market-near-two-year-highs-2010-12-31 | nan | nan | Stocks are mixed at mid-day in ho-hum session that is capping off an otherwise strong year for stocks that sent prices to two-year highs. With no economic news scheduled for release and a relatively slow, year-end trickle of corporate news, investors turned to prognostication about potential stock market catalysts for 2011 and consolidated gains.
In the latest news:
EBay Auction Co. said Friday its merger with fellow eBay Inc. ( EBAY ) unit eBay Gmarket Co. has been delayed. EBay Auction said in a regulatory filing it will later notify the market of the timeline for the merger process. The firms were initially scheduled to merge by Nov. 1, but eBay Auction didn't give a reason for the delay. The two eBay units are South Korea's largest online auction Web sites, Dow Jones Newswires reports. EBay took control of Gmarket last year.
Abbott Laboratories ( ABT ) is up on speculation the medical technology company will again soon raise its dividend. According to Seeking Alpha, ABT raised its dividend 10% to $0.44 a share in April 2010, following an 11% increase in 2009. In fact, ABT has increased its dividend for 38 consecutive years and there's little evidence the string will snap in 2011. The stock is currently yielding 3.7%.
Imax Corp. ( IMAX ) shares are higher on reports Sony Corp ( SNE ) may be interested in acquiring the company for as much as $40 a share. The (U.K.) Daily Mail, citing London traders, reports that Walt Disney Co. ( DIS ) also may be interested in buying the giant-screen exhibitor.
Clearwire Corp. (CLWR) shares are alternating between trading flat to slightly down after disclosing in regulatory documents last night that Board Chairman Craig McCaw plans to step down at year's end. McCaw, 61, informed CLWR executives of his plans earlier this week. There was no disagreement, the company said. The Wall Street Journal reported that Clearwater faces the challenges of smoothing its relations with its parent, Sprint Nextel Corp. (S) and in raising funds to build out its network. Eagle River, McCaw's holding company, which the WSJ says owns 4% of Clearwire, nominated Benjamin Wolff as chairman to succeed McCaw.
In banking news, shares of Deutsche Bank (DB) are higher as Bloomberg notes that the German bank climbed three slots to become the No. 2 global corporate bond underwriter, just under JPMorgan. JPMorgan has sat atop that list for three years.
Pier 1 Imports (PIR) and Chase Bank USA N.A. (JPM) are revising a 2006 marketing and services agreement for Pier 1's private label credit card. Under the new deal, PIR will receive an undisclosed lump-sum payment from the bank as well as ongoing payments based on credit card sales.
Molycorp (MCP) is down after Reuters reports that the CEO said the company is in discussions with a number of potential joint-venture partners and customers scrambling to find other suppliers of the critical minerals in the wake of China's supply cut. In an interview, Chief Executive Mark Smith said the company was "absolutely" in negotiations to reach deals similar to the ones it announced earlier this month with Hitachi Metals Ltd and Sumitomo Corp.
Transocean (RIG) shares are up fractionally at mid-day, after the offshore contract provider of oil well drilling services said a federal panel that investigated the fatal 2005 Texas refinery blast that ended with a $50 million fine for BP (BP) doesn't have the authority to investigate the Gulf of Mexico disaster, Bloomberg reported.
JPMorgan Chase & Co. (JPM) is trading higher despite opening the regular session in the red on a report that a court-appointed receiver is trying to recover funds from the bank for victims of Tom Petters' Ponzi scheme.
Apache (APA) and Woodside Petroleum (WOPEY) shares are trading higher despite a Bloomberg report that the two halted Western Australia oil field production because a tropical low system was forecast to become a cyclone.
Commodities are higher. February gold contracts are up $13, or 0.9%, to $1,419 an ounce while February crude oil contacts are up 1.08%, or $0.97, at $90.81 a barrel.
In energy ETFs, the United States Oil Fund (USO) is up 2.18% to $38.95 and the United States Natural Gas fund (UNG) is up 2.12% to $6.01.
In precious metal ETFs, the SPDR Gold Trust (GLD) is up 1.06% to $138.48. Market Vectors Gold Miners (GDX) is up 1.17% to $60.67. iShares Silver Trust (SLV) is up 1.4% to $30.17.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is up on speculation the medical technology company will again soon raise its dividend. According to Seeking Alpha, ABT raised its dividend 10% to $0.44 a share in April 2010, following an 11% increase in 2009. In fact, ABT has increased its dividend for 38 consecutive years and there's little evidence the string will snap in 2011. | Abbott Laboratories ( ABT ) is up on speculation the medical technology company will again soon raise its dividend. According to Seeking Alpha, ABT raised its dividend 10% to $0.44 a share in April 2010, following an 11% increase in 2009. In fact, ABT has increased its dividend for 38 consecutive years and there's little evidence the string will snap in 2011. | Abbott Laboratories ( ABT ) is up on speculation the medical technology company will again soon raise its dividend. According to Seeking Alpha, ABT raised its dividend 10% to $0.44 a share in April 2010, following an 11% increase in 2009. In fact, ABT has increased its dividend for 38 consecutive years and there's little evidence the string will snap in 2011. | Abbott Laboratories ( ABT ) is up on speculation the medical technology company will again soon raise its dividend. According to Seeking Alpha, ABT raised its dividend 10% to $0.44 a share in April 2010, following an 11% increase in 2009. In fact, ABT has increased its dividend for 38 consecutive years and there's little evidence the string will snap in 2011. |
34548.0 | 2010-11-29 00:00:00 UTC | Abbott Laboratories’ Price Target Slashed at Goldman Sachs (ABT) | ABT | https://www.nasdaq.com/articles/abbott-laboratories-price-target-slashed-goldman-sachs-abt-2010-11-29 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) on Monday saw its price target cut by analysts at Goldman Sachs.
The firm said it now expected ABT shares to reach $54, which implies a smaller 15% upside to the stock's Friday closing price of $46.80. Goldman maintained its "Neutral" rating on the stock.
The analyst cited expectations of lower Humira sales for the move. Humira is Abbott's flagship rheumatoid arthritis treatment drug.
Abbott shares were mostly flat in premarket trading Monday.
The Bottom Line
Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on Friday's closing stock price of $46.80. The stock has technical support in the $42-$44 price area. If the shares can firm up, we see overhead resistance around the $50 price level.
Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) on Monday saw its price target cut by analysts at Goldman Sachs. The firm said it now expected ABT shares to reach $54, which implies a smaller 15% upside to the stock's Friday closing price of $46.80. The Bottom Line Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on Friday's closing stock price of $46.80. | The firm said it now expected ABT shares to reach $54, which implies a smaller 15% upside to the stock's Friday closing price of $46.80. The Bottom Line Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on Friday's closing stock price of $46.80. Healthcare products maker Abbott Laboratories ( ABT ) on Monday saw its price target cut by analysts at Goldman Sachs. | Healthcare products maker Abbott Laboratories ( ABT ) on Monday saw its price target cut by analysts at Goldman Sachs. The firm said it now expected ABT shares to reach $54, which implies a smaller 15% upside to the stock's Friday closing price of $46.80. The Bottom Line Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on Friday's closing stock price of $46.80. | Healthcare products maker Abbott Laboratories ( ABT ) on Monday saw its price target cut by analysts at Goldman Sachs. The firm said it now expected ABT shares to reach $54, which implies a smaller 15% upside to the stock's Friday closing price of $46.80. The Bottom Line Shares of Abbott Labs ( ABT ) have a 3.76% dividend yield, based on Friday's closing stock price of $46.80. |
34549.0 | 2010-11-09 00:00:00 UTC | 5 Famous Pharma Stocks to Sell Now | ABT | https://www.nasdaq.com/articles/5-famous-pharma-stocks-sell-now-2010-11-09 | nan | nan | There's a lot of talk about the recently passed health-care reforms in the wake of the election, and some investors are wondering if provisions of the legislation could be rolled back. I won't pretend to know what's going to happen in Washington in the future, but I can tell you that no matter what happens to the so-called "Obamacare" initiative, a number of health-care stocks are in dire straits - and no amount of politicking is going to help them.
Specifically, I'm talking about a group of battered drug makers that have seen poor earnings performances lately and are up against looming patent expirations and fierce competition in emerging markets.
Here are five famous pharmaceutical stocks that you should sell immediately:
Abbott Laboratories ( ABT )
Abbott Laboratories (NYSE: ABT ) is engaged in the discovery, development, manufacture and sale of a variety of health-care products. Since January, ABT stock has dropped 6.6%, compared to gains of 9.5% and 9.3% for the S&P 500 and Dow Jones, respectively. While the stock regained slightly in September, ABT has lost 3.5% since October. While ABT has outperformed earnings estimates for four consecutive quarters, it has been by only one cent each quarter. Abbott stock currently trades at $50.45.
Sanofi-Aventis S.A. ADS ( SNY )
Sanofi-Aventis (NYSE: SNY ) is also involved with the research, development, manufacture and marketing of health-care products. The company is known for its pharmaceuticals, including vaccines, as well as its animal health-care products. Year-to-date, SNY stock has slid 9.4%. Additionally, Sanofi-Aventis has missed earnings estimates two of the last three quarters. While the stock has regained slightly in the last few months, it is still down from its 52-week high of $41.59, with a current price of $35.62
Teva Pharmaceutical Industries ( TEVA )
Global pharmaceutical company Teva Pharmaceutical Industries (NASDAQ: TEVA ) produces and markets a wide range of generic drugs. Its major products are Copaxone for multiple sclerosis and Azilect for Parkinson's disease. Since January, TEVA is down 9.6%, compared to gains by the broader markets. After a productive September, TEVA has dropped 3.7% since the start of October. Trading at $50.80, TEVA is only a few dollars removed from its 52-week low of $46.99.
GlaxoSmithKline PLC ADS ( GSK )
GlaxoSmithKline (NYSE: GSK ) works with vaccines, over-the-counter medications and various other health-care consumer products. The company's main products deal with the following: respiratory system, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatalogicals and vaccines. GSK stock is down 4.1% in 2010, despite seeing gains in September and October. Additionally, GSK reported a quarterly earnings drop of 3.5% in its last income statement, which certainly has disappointed shareholders.
Pfizer Inc. ( PFE )
Research-based, global pharmaceutical company Pfizer Inc. (NYSE: PFE ) rounds out the list of big pharma stocks to sell. Year-to-date, Pfizer has watched its stock decrease 6.5%, compared to gains by the broader markets. Analysts aren't buying into Pfizer, as they have downgraded their earnings estimates to 47 cents a share this quarter after and actual EPS of 54 cents a share last quarter. A quarterly earnings decline of nearly 70% is another reason why Pfizer is a stock worth selling.
As of this writing, Louis Navellier did not own a position in any of the stocks named here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are five famous pharmaceutical stocks that you should sell immediately: Abbott Laboratories ( ABT ) Abbott Laboratories (NYSE: ABT ) is engaged in the discovery, development, manufacture and sale of a variety of health-care products. Since January, ABT stock has dropped 6.6%, compared to gains of 9.5% and 9.3% for the S&P 500 and Dow Jones, respectively. While the stock regained slightly in September, ABT has lost 3.5% since October. | Here are five famous pharmaceutical stocks that you should sell immediately: Abbott Laboratories ( ABT ) Abbott Laboratories (NYSE: ABT ) is engaged in the discovery, development, manufacture and sale of a variety of health-care products. Since January, ABT stock has dropped 6.6%, compared to gains of 9.5% and 9.3% for the S&P 500 and Dow Jones, respectively. While the stock regained slightly in September, ABT has lost 3.5% since October. | Here are five famous pharmaceutical stocks that you should sell immediately: Abbott Laboratories ( ABT ) Abbott Laboratories (NYSE: ABT ) is engaged in the discovery, development, manufacture and sale of a variety of health-care products. Since January, ABT stock has dropped 6.6%, compared to gains of 9.5% and 9.3% for the S&P 500 and Dow Jones, respectively. While the stock regained slightly in September, ABT has lost 3.5% since October. | Here are five famous pharmaceutical stocks that you should sell immediately: Abbott Laboratories ( ABT ) Abbott Laboratories (NYSE: ABT ) is engaged in the discovery, development, manufacture and sale of a variety of health-care products. Since January, ABT stock has dropped 6.6%, compared to gains of 9.5% and 9.3% for the S&P 500 and Dow Jones, respectively. While the stock regained slightly in September, ABT has lost 3.5% since October. |
34550.0 | 2010-10-26 00:00:00 UTC | Stocks Trending Higher as Indexes Move Into Positive Territory; Consumer Confidence Provides Lift | ABT | https://www.nasdaq.com/articles/stocks-trending-higher-as-indexes-move-into-positive-territory-consumer-confidence | nan | nan | Stocks are turning positive at mid-day but remain choppy amid a spate of earnings news and disappointing housing data. Positive consumer confidence numbers, however, are providing some support for the broader market.
U.S. consumer confidence rose in October to 50.2, according to the Conference Board. Economists had expected a reading of 50, according to a MarketWatch poll. Confidence for September was revised up to 48.6, from a prior estimate of 48.5. The barometer on consumers' expectations rose to 67.8 in October from 65.5 in September, while consumers' assessment of current conditions rose to 23.9 from 23.3.
The U.S. August Case-Shiller home price index, released before the bell, fell 0.2% but is up 1.7% in the past year.
In company news, BHP Billiton ( BHP ) plans to challenge a shareholder rights plan set up at Saskatchewan's Potash ( POT ) at regulatory hearing on Nov. 8, Reuters reported. BHP is looking to suspend the plan, which has been set up as an anti-takeover defense, commonly called a "poison pill" after BHP began a hostile $39 billion bid for the company.
Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease.
IBM ( IBM ) is up after it says its Board approved $10 billion in additional funds for its stock buyback program. This amount is in addition to approximately $2.3 billion remaining at the end of September from a prior authorization. IBM expects to request additional share repurchase authorization at the April 2011 board meeting. It also declared a regular quarterly cash dividend of $0.65 per common share, payable December 10 to stockholders of record November 10.
Lexmark ( LXK ) shares are sharply lower after the printer maker said its longtime CEO Paul Curlander plans to retire in the spring of 2011, according to a statement. Curlander will assume the role of executive chairman. Also, Lexmark reported Q3 non-GAAP EPS of $1.09, ahead of Street estimates of $0.98 per share. Revenue was $1.02 billion, vs. expectations of $1.04 billion.
American International Group, Inc. ( AIG ) announced that its President and Chief Executive Officer, Robert H. Benmosche, has been diagnosed with cancer and is undergoing aggressive chemotherapy. "The good news is that I feel fine, and I continue to work according to my normal schedule. As for my long-term prognosis I will have a better idea over the next couple of months of what that will look like as I continue to undergo treatment and my doctors refine their diagnosis," Benmosche said.
Deutsche Bank ( DB ) is suing a former client for $1.8 million in unpaid debts, after suffering losses on investments connected to Citigroup ( C ), Bloomberg reported. Chang Tse Wen is countersuing for $49 million from Deutsche Bank, saying he was induced to open a private banking accountin in Aug. 2007 and that the bank was negligent in its advice and made fraudulent misrepresentations, the report said.
Sony ( SNE ) shares rose almost 3%, retreated and are advancing again, amid speculation that Apple Inc. ( AAPL ) is eying it as an acquisition, Reuters reported. Analysts dismissed the speculation, the report said. The speculation started with a Saturday report in Barron's that Apple, which has $51 billion in cash, is thinking about making a big acquisition.
MGM Resort International ( MGM ) is holding a fractional gain in choppy morning trade, after Moody's Investors Service bumped up the company's rating outlook to positive from stable and affirmed its Caa1 corporate family rating. "The outlook revision to positive reflects the favorable impact on MGM's liquidity following the company's recent $511 million equity issuance and the new $500 million senior secured bond offering," the ratings agency said in a statement.
In the latest earnings news:
--Sherwin-Williams Co. ( SHW ) is down after flat Q3 earnings on an 8.8% increase in revenue in the face of rising commodity costs disappointed the Street.
--Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. Ex items, the company reported earning 74 cents a share, ahead of the Street's consensus for 70 cents. Revenue came in at $949.3 million, compared with $1.01 billion last year, but just ahead of the Street's call for $944.7 million.
--Bristol-Myers Squibb ( BMY ) reported Q3 EPS of $0.59, ahead of expectations of $0.53 per share. Sales were $4.79 billion, vs. expectations of $4.91 billion. Looking forward, the company affirmed its 2010 EPS guidance range of $2.10 to $2.20 per share. The Street is at $2.10 per share.
--Ford ( F ) is just higher after it reported Q3 net income of $0.43 per share and pre-tax operating profit of $0.48, vs. Street estimates of $0.38 per share. Revenue was $29 bln, in line with the analyst consensus on Thomson Reuters.
--Texas Instruments ( TXN ) reported Q3 revs of $3.74 billion, better than the analyst consensus of $3.69 billion on Thomson Reuters. EPS was $0.71 per share, vs. expectations of $0.69 per share.
--U.S. Steel ( X ) reported Q3 sales of $4.5 billion, down 4% from year ago levels but above the analyst consensus of $4.43 billion on Thomson Reuters. Loss for the quarter was $0.35 per share, vs. a year ago loss of $2.11 per share. The Street was expecting a profit of $0.22 per share.
--DuPont ( DD ) reported Q3 EPS of $0.40 compared to $0.45 a year earlier though topping the Thomson Reuters mean analyst estimate for $0.34. Sales of $7 billion were up from $5.96 billion a year earlier. The Street expected $6.72 billion. The company lifts FY EPS guidance to around $3.10. The Street is at $3.04.
Commodities are higher as December gold contracts are up $2, or 0.18%, to $1,342 an ounce while December crude contacts are up 0.17%, or $0.14, at $82.63 a barrel.
In energy ETFs, the United States Oil Fund ( USO ) is up 0.45% to $35.64 and the United States Natural Gas fund ( UNG ) is up 1.69% to $5.43.
In precious metal ETFs, the SPDR Gold Trust ( GLD ) is up 0.16% to $131.06. Market Vectors Gold Miners ( GDX ) is up 0.48% to $56.01. iShares Silver Trust ( SLV ) is up 1.30% to $23.40.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. Lexmark ( LXK ) shares are sharply lower after the printer maker said its longtime CEO Paul Curlander plans to retire in the spring of 2011, according to a statement. American International Group, Inc. ( AIG ) announced that its President and Chief Executive Officer, Robert H. Benmosche, has been diagnosed with cancer and is undergoing aggressive chemotherapy. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. --Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. Ex items, the company reported earning 74 cents a share, ahead of the Street's consensus for 70 cents. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. --Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. --Ford ( F ) is just higher after it reported Q3 net income of $0.43 per share and pre-tax operating profit of $0.48, vs. Street estimates of $0.38 per share. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. Also, Lexmark reported Q3 non-GAAP EPS of $1.09, ahead of Street estimates of $0.98 per share. Revenue came in at $949.3 million, compared with $1.01 billion last year, but just ahead of the Street's call for $944.7 million. |
34551.0 | 2010-10-26 00:00:00 UTC | Mid-Day Update: Consumer Confidence Rise Lifts Stocks Off Lows; Indexes Just Higher | ABT | https://www.nasdaq.com/articles/mid-day-update%3A-consumer-confidence-rise-lifts-stocks-off-lows-indexes-just-higher-2010-10 | nan | nan | Here's where markets stand at mid-day:
-NYSE down 9.97 (-0.13%) to 7,536.40
-DJIA up 2.65 (+0.02%) to 11,166.70
-S&P 500 up 0.50 (+0.04%) to 1,186.16
-Nasdaq up 9.88 (+0.40%) to 2,500.68
GLOBAL SENTIMENT
Hang Seng down 0.11%
Nikkei down -0.25%
FTSE down 0.78%
MID-DAY NYSE INDEX WATCH
NYSE Energy up 0.2% at 11,239.33
NYSE Financial down 0.37% at 4,764.66
NYSE Health Care down 0.47% at 6,480.59
NYSE Arca Tech 100 up 0.26% at 1,008.24
UPSIDE MOVERS
(+) NTRS (+4.6%) gains as reports says HSBC may make a bid.
(+) JASO (+2.4%) projects better-than-expected Q3.
(+) COH (+11.9%) beats with Q1 results.
(+) SUPG (+18.9%) continues evening gain after earnings top year-ago levels.
(+) MIPS (+23.7%) continues strong evening upside in wake of earnings beat.
(+) F (+1.9%) loses early bid that followed earnings beat.
DOWNSIDE MOVERS
(-) DD (-1.8%) gives up early gain to turn just lower; beats with weaker earnings, raises guidance.
(-) TXN (-0.7%) continues evening decline that followed Q3 estimates, Q4 guidance that straddles Street view.
(-) UBS (-5.5%) investment side performance clouds earnings beat.
(-) RF (-7.4%) misses loss expectations.
(-) TLAB (-14.1%) guides for revenue miss.
(-) ARMH (-4.2%) dented by Q3 results.
(-) X (-3.8%) earnings disappoint.
(-) ZRAN (-20.2%) warns for Q4 after Q3 revenue miss.
(-) VLTR (-1.9%) downgraded.
MARKET DIRECTION
Stocks are turning positive at mid-day but remain choppy amid a spate of earnings news and disappointing housing data. Positive consumer confidence numbers, however, are providing some support for the broader market.
U.S. consumer confidence rose in October to 50.2, according to the Conference Board. Economists had expected a reading of 50, according to a MarketWatch poll. Confidence for September was revised up to 48.6, from a prior estimate of 48.5. The barometer on consumers' expectations rose to 67.8 in October from 65.5 in September, while consumers' assessment of current conditions rose to 23.9 from 23.3.
The U.S. August Case-Shiller home price index, released before the bell, fell 0.2% but is up 1.7% in the past year.
In company news, BHP Billiton ( BHP ) plans to challenge a shareholder rights plan set up at Saskatchewan's Potash ( POT ) at regulatory hearing on Nov. 8, Reuters reported. BHP is looking to suspend the plan, which has been set up as an anti-takeover defense, commonly called a "poison pill" after BHP began a hostile $39 billion bid for the company.
Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease.
IBM ( IBM ) is up after it says its Board approved $10 billion in additional funds for its stock buyback program. This amount is in addition to approximately $2.3 billion remaining at the end of September from a prior authorization. IBM expects to request additional share repurchase authorization at the April 2011 board meeting. It also declared a regular quarterly cash dividend of $0.65 per common share, payable December 10 to stockholders of record November 10.
Lexmark ( LXK ) shares are sharply lower after the printer maker said its longtime CEO Paul Curlander plans to retire in the spring of 2011, according to a statement. Curlander will assume the role of executive chairman. Also, Lexmark reported Q3 non-GAAP EPS of $1.09, ahead of Street estimates of $0.98 per share. Revenue was $1.02 billion, vs. expectations of $1.04 billion.
American International Group, Inc. ( AIG ) announced that its President and Chief Executive Officer, Robert H. Benmosche, has been diagnosed with cancer and is undergoing aggressive chemotherapy. "The good news is that I feel fine, and I continue to work according to my normal schedule. As for my long-term prognosis I will have a better idea over the next couple of months of what that will look like as I continue to undergo treatment and my doctors refine their diagnosis," Benmosche said.
Deutsche Bank ( DB ) is suing a former client for $1.8 million in unpaid debts, after suffering losses on investments connected to Citigroup ( C ), Bloomberg reported. Chang Tse Wen is countersuing for $49 million from Deutsche Bank, saying he was induced to open a private banking accountin in Aug. 2007 and that the bank was negligent in its advice and made fraudulent misrepresentations, the report said.
Sony ( SNE ) shares rose almost 3%, retreated and are advancing again, amid speculation that Apple Inc. ( AAPL ) is eying it as an acquisition, Reuters reported. Analysts dismissed the speculation, the report said. The speculation started with a Saturday report in Barron's that Apple, which has $51 billion in cash, is thinking about making a big acquisition.
MGM Resort International ( MGM ) is holding a fractional gain in choppy morning trade, after Moody's Investors Service bumped up the company's rating outlook to positive from stable and affirmed its Caa1 corporate family rating. "The outlook revision to positive reflects the favorable impact on MGM's liquidity following the company's recent $511 million equity issuance and the new $500 million senior secured bond offering," the ratings agency said in a statement.
In the latest earnings news:
--Sherwin-Williams Co. ( SHW ) is down after flat Q3 earnings on an 8.8% increase in revenue in the face of rising commodity costs disappointed the Street.
--Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. Ex items, the company reported earning 74 cents a share, ahead of the Street's consensus for 70 cents. Revenue came in at $949.3 million, compared with $1.01 billion last year, but just ahead of the Street's call for $944.7 million.
--Bristol-Myers Squibb ( BMY ) reported Q3 EPS of $0.59, ahead of expectations of $0.53 per share. Sales were $4.79 billion, vs. expectations of $4.91 billion. Looking forward, the company affirmed its 2010 EPS guidance range of $2.10 to $2.20 per share. The Street is at $2.10 per share.
--Ford ( F ) is just higher after it reported Q3 net income of $0.43 per share and pre-tax operating profit of $0.48, vs. Street estimates of $0.38 per share. Revenue was $29 bln, in line with the analyst consensus on Thomson Reuters.
--Texas Instruments ( TXN ) reported Q3 revs of $3.74 billion, better than the analyst consensus of $3.69 billion on Thomson Reuters. EPS was $0.71 per share, vs. expectations of $0.69 per share.
--U.S. Steel ( X ) reported Q3 sales of $4.5 billion, down 4% from year ago levels but above the analyst consensus of $4.43 billion on Thomson Reuters. Loss for the quarter was $0.35 per share, vs. a year ago loss of $2.11 per share. The Street was expecting a profit of $0.22 per share.
--DuPont ( DD ) reported Q3 EPS of $0.40 compared to $0.45 a year earlier though topping the Thomson Reuters mean analyst estimate for $0.34. Sales of $7 billion were up from $5.96 billion a year earlier. The Street expected $6.72 billion. The company lifts FY EPS guidance to around $3.10. The Street is at $3.04.
Commodities are higher as December gold contracts are up $2, or 0.18%, to $1,342 an ounce while December crude contacts are up 0.17%, or $0.14, at $82.63 a barrel.
In energy ETFs, the United States Oil Fund ( USO ) is up 0.45% to $35.64 and the United States Natural Gas fund ( UNG ) is up 1.69% to $5.43.
In precious metal ETFs, the SPDR Gold Trust ( GLD ) is up 0.16% to $131.06. Market Vectors Gold Miners ( GDX ) is up 0.48% to $56.01. iShares Silver Trust ( SLV ) is up 1.30% to $23.40.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. Lexmark ( LXK ) shares are sharply lower after the printer maker said its longtime CEO Paul Curlander plans to retire in the spring of 2011, according to a statement. American International Group, Inc. ( AIG ) announced that its President and Chief Executive Officer, Robert H. Benmosche, has been diagnosed with cancer and is undergoing aggressive chemotherapy. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. Ex items, the company reported earning 74 cents a share, ahead of the Street's consensus for 70 cents. --U.S. Steel ( X ) reported Q3 sales of $4.5 billion, down 4% from year ago levels but above the analyst consensus of $4.43 billion on Thomson Reuters. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. --Hospira Inc. ( HSP ) is higher on reported Q3 earnings of $71.4 million, or 42 cents per share, down from $116.2 million, or 71 cents per share, last year. Ex items, the company reported earning 74 cents a share, ahead of the Street's consensus for 70 cents. | Abbott Laboratories ( ABT ) filed suit against Anchen Pharmaceuticals, a generic drug maker, in federal court in Delaware, saying it had infringed on a U.S. patent for Zemplar, a drug used to treat people with kidney disease. Revenue was $1.02 billion, vs. expectations of $1.04 billion. Revenue came in at $949.3 million, compared with $1.01 billion last year, but just ahead of the Street's call for $944.7 million. |
34552.0 | 2010-10-21 00:00:00 UTC | My Top 10 Super Companies | ABT | https://www.nasdaq.com/articles/my-top-10-super-companies-2010-10-21 | nan | nan | I often get asked if investing exclusively in dividend-paying companies will bring the best results. There is no simple answer, but history shows that dividend income is an important part of your total return when investing in common stocks. Increasing stock prices help to build your wealth and beat inflation, but dividends provide a steady return on your investment through thick and thin.
I also receive questions from investors asking me to compile a list of stocks to begin building their initial portfolios. Whether you are a new investor or an old pro, or whether you are young or old, I usually advise that you include some ultra-conservative companies in your portfolio. I call them core holdings. Owning conservative companies will not only allow you to sleep at night, but will also provide you with modest appreciation and dividend income for many years into the future. When asked how long an investor should hold a stock, Warren Buffett's answer is: "Our favorite holding period is forever."
Dividend paying stocks offer two ways to make money with your stocks: The price of the stock can appreciate and the dividend can provide income. Invest in companies with histories of well-founded growth that will continue during the next several years and even decades. A company's history of steady sales and earnings growth will usually lead to relatively steady appreciation and frequent dividend increases.
Dividends are the regular cash payments that a company sends to you or to your brokerage account. You can, however, instruct the company or your broker to reinvest your dividends into additional shares or fractional shares. Reinvesting your dividends makes sense, because the effects of compounding your dividends will make your investment grow faster.
Many investors focus exclusively on speculative gains (the appreciation), going so far as ignoring dividend payments when reportingstock market resultsover long periods of time. You might be pleasantly surprised, though, if you include your dividends when you calculate your total return. You will also see that dividend-paying stocks tend to decline noticeably less than stocks with no dividends.
Dividends are hard-earned cash, and a company's ability to continually pay them provides concrete evidence that the company is performing well. Accounting malfeasance is harder, or impossible, if a large transfer of cash is going to shareholders on a regular basis. Don't include companies paying really low dividends, because I am referring to companies paying dividends yielding more than 1% per year (calculated by dividing the annual dividend by the current stock price).
There is another common pitfall to be aware of when evaluating dividends and yields. The dividend payout is the ratio of dividends per share compared to earnings per share (DPS divided by EPS). The payout ratio indicates if earnings can support the dividend. A growth company that pays a small dividend will tend to have a lower dividend payout ratio than a well-established "blue chip" company that has a higher dividend payout.
As a rule of thumb, most successful dividend investors avoid companies with a dividend payout ratio above 50% or 60%. Anything above that mark means the company may not be investing enough capital back into the organization. Even though a company's growth has slowed, it is still critical to reinvest a portion of earnings back into the organization.
--- Advertisement ---
10 High-Yield Winners for 2011
Did you know that dividend stocks have out-performed non-dividend stocks by four to one over the past 35 years?
That's because dividends usually increase each year. In fact, more than 137 years of data point to the inescapable conclusion that owning dividend-paying stocks-and then re-investing those dividends-beats other investment approaches hands down.
And for a limited time, if you subscribe to Dick Davis Dividend Digest , you'll receive our top high-yield picks for 2011!
---
My top 10 "super" companies listed below offer dividends, which on average, exceed the current 10-year U.S. Treasury bond rate of 2.5%. In addition to generous dividend payments, investors can expect steady long-term earnings and dividend growth of about 10% per year. All of the companies maintain strong balance sheets with low debt and lots of cash. Annual dividend increases are common for all of the companies and have averaged 15% annual increases during the past 10 years.
We expect the size of dividend increases to diminish somewhat during future years. The average dividend payout ratio for our 10 companies is 36%, which is well below our 50% to 60% limit. And best of all, high-quality companies have been neglected by investors during the past several years and now sell at very reasonable prices.
In my opinion, the following companies should be included in your portfolio:
Abbott Laboratories ( ABT ) produces a wide range of drugs, diagnostic products, medical testing products, test analysis and nutritional products. Sales and earnings growth have been aided by expanding international sales and by recent acquisitions. Sales, earnings and dividends increased 8% to 10% during the past 10 years. We believe future growth will be the same or slightly better based upon rising international sales, additional sales to the ageing population of America and new acquisitions. ABT shares are undervalued at 12.1 times current EPS. Dividends have been paid since 1926 and currently provide a yield of 3.3%.
Aflac ( AFL ) is the world's largest supplemental insurance provider. The company derives 75% of its business from Japan, where it also sells life and health insurance. Sales have increased 10% to 12% per year during the past 10 years, and dividends have increased an impressive 22% per year. We forecast sales growth of 10% and earnings and dividend growth of 12 to 15% during the next five years. New products and an improving economy in Japan should produce considerable excess cash. AFL shares are undervalued at 9.6 times forward 12-month EPS. Dividends have been paid since 1973 and currently provide a yield of 2.2%.
Colgate-Palmolive ( CL ) , a leading consumer products company, continues to benefit from a very successful restructuring program. Leading products include Ajax, Fab and Murphy cleaners, Colgate toothpaste, Irish Spring soap, Mennen shave cream and Hill's pet food. Sales and earnings increased 7% to 9% per year during the past 10 years, while dividends were boosted 12% per year. Further success in Latin America, new products and new acquisitions will keep earnings and dividends moving forward at a 10% pace during the next five years. CL shares are reasonably priced at 14.6 times forward EPS. Dividends have been paid since 1895 and currently provide a yield of 2.8%.
General Dynamics ( GD ) makes electronics for land, sea and air weapons systems. GD manufactures cargo ships and Gulfstream business jets. It also makes armored combat vehicles, submarines and destroyers. The company sells primarily to the U.S. Department of Defense including the U.S. Army and Navy. General Dynamic's sales, earnings and dividends increased 10% to 12% per year during the past 10 years. We expect sales and earnings to increase at an 8% clip during the next five years, but the company will likely increase dividends by 12% per year. Sales to the military will probably slow, but sales generated from General Dynamic's other units, including Gulfstream, will likely pick up steam. GD shares are undervalued at 8.9 times 12-month forward EPS. Dividends have been paid since 1979 and currently provide a yield of 2.7%.
International Business Machines ( IBM ) is the world's largest information technology company. IBM is taking advantage of increasing demand for software services from overseas corporations, which make up 65% of total sales. Revenues, earnings and dividends increased 5%, 10% and 15% respectively during the past 10 years. We expect IBM to increase EPS and dividends by 11% to 12% during the next five years. The company is poised to take advantage of the anticipated up-cycle in technology. IBM shares are reasonably priced at 11.6 times forward EPS. Dividends have been paid since 1916 and currently provide a yield of 1.9%.
Johnson & Johnson ( JNJ ) is the world's largest and most diversified health care company. The company produces a large variety of drugs, medical and diagnostic equipment, and consumer products. After experiencing slower growth during the past couple of years, Johnson & Johnson is now focused on faster growing health care segments and on divesting underperforming divisions. Sales and earnings growth of 8% to 9% per year during the past 10 years was accompanied by 14% dividend growth. Acquisitions and new product introductions will help sales and earnings grow by 6% to 7% during the next five years. Dividends will probably increase 8% per year. JNJ shares are reasonably priced at 12.6 times forward EPS. Dividends have been paid since 1944 and currently provide a yield of 3.5%.
McDonald's ( MCD ) operates 32,000 fast-food restaurants in 118 countries and generates $23 billion in sales. Sales in Europe have been surprisingly strong, while sales in the U.S. are not nearly as weak as other restaurants because Americans are eating at less expensive restaurants, such as McDonald's, to save money. Sales and earnings increased 8% to 10% per year during the past 10 years, and dividends jumped 25% per year. We forecast sales, earnings, and dividend growth of 9% to 10% per year during the next five years. MCD's ability to innovate ahead of competitors should keep growth intact. MCD shares are reasonably priced at 15.6 times forward 12-month EPS. Dividends have been paid since 1976 and currently provide a yield of 3.2%.
PepsiCo ( PEP ) is a global leader in the soft drink and snack food industries. The company is expanding in international markets and focusing on health and wellness beverages and foods. Annual revenues, earnings and dividends increased 8%, 10% and 12% respectively during the past 10 years. We expect Pepsi to increase sales, earnings, and dividends by 10% to 12% during the next five years. New products and further expansion into emerging markets will spur future business. The stock is reasonably priced at 15.0 times next 12-month EPS. Dividends have been paid since 1952 and currently provide a yield of 2.9%.
Walgreen ( WAG ) , a leading drug store retailer, is adding worksite and homecare facilities to its pharmacy business. The company has also become more active in acquiring small competitors. New management is renovating existing stores and cutting operating costs. Sales, earnings, and dividends increased 11% to 12% per year during the past 10 years. We foresee sales, earnings and dividend growth of 8%, 12% and 15% during the next five years. New acquisitions and the expected rapid growth of the drug store industry will spark strong results. WAG shares are reasonably priced at 14.5 times forward 12-month EPS. Dividends have been paid since 1933 and currently provide a yield of 2.1%.
Wal-Mart Stores ( WMT ) is the world's largest retailer with 8,500 stores, two million employees, and $400 billion total sales. Groceries now account for 51% of sales. Shoppers seeking low retail prices and one-stop shopping are boosting Wal-Mart's sales. Sales and earnings increased 10% while dividends jumped 20% per year during the past 10 years. We expect sales and earnings to increase 10% per year and dividends to advance 12% per year during the next five years. WMT shares are undervalued at 12.5 times forward EPS. Dividends have been paid since 1973 and currently provide a yield of 2.2%.
I will continue to follow my top 10 "super" companies, and other blue-chip, high-quality companies in my Cabot Benjamin Graham Value Letter. My next issue, coming soon, will focus on undervalued stocks with low price-to-book-value ratios. I hope you won't miss it!
Sincerely,
J. Royden Ward
For Cabot Wealth Advisory
Editor's Note: You can find additional dividend-paying stocks selling at bargain prices in the Cabot Benjamin Graham Value Letter. In every issue, you'll find my legendary Maximum Buy and Minimum Sell Prices for over 250 stocks. Click here to get started today!
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In my opinion, the following companies should be included in your portfolio: Abbott Laboratories ( ABT ) produces a wide range of drugs, diagnostic products, medical testing products, test analysis and nutritional products. ABT shares are undervalued at 12.1 times current EPS. Many investors focus exclusively on speculative gains (the appreciation), going so far as ignoring dividend payments when reportingstock market resultsover long periods of time. | In my opinion, the following companies should be included in your portfolio: Abbott Laboratories ( ABT ) produces a wide range of drugs, diagnostic products, medical testing products, test analysis and nutritional products. ABT shares are undervalued at 12.1 times current EPS. Dividend paying stocks offer two ways to make money with your stocks: The price of the stock can appreciate and the dividend can provide income. | In my opinion, the following companies should be included in your portfolio: Abbott Laboratories ( ABT ) produces a wide range of drugs, diagnostic products, medical testing products, test analysis and nutritional products. ABT shares are undervalued at 12.1 times current EPS. Don't include companies paying really low dividends, because I am referring to companies paying dividends yielding more than 1% per year (calculated by dividing the annual dividend by the current stock price). | In my opinion, the following companies should be included in your portfolio: Abbott Laboratories ( ABT ) produces a wide range of drugs, diagnostic products, medical testing products, test analysis and nutritional products. ABT shares are undervalued at 12.1 times current EPS. Dividend paying stocks offer two ways to make money with your stocks: The price of the stock can appreciate and the dividend can provide income. |
34553.0 | 2010-10-20 00:00:00 UTC | Major Indexes in Positive Territory as Earnings Season Presses On; Fed Beige Book on Tap | ABT | https://www.nasdaq.com/articles/major-indexes-positive-territory-earnings-season-presses-fed-beige-book-tap-2010-10-20 | nan | nan | Stocks are broadly in positive territory following upbeat earnings news ahead of key releases from the U.S. Federal Reserve Bank this afternoon. The triple-digit move for the Dow Jones Industrial Average pares some of yesterday's losses and showed positive sentiment wasn't entirely sapped after bloodletting in the prior session.
The Fed Beige Book for October will be released at 2 p.m. ET. Speeches are also expected from Charles Plosser, president of the Federal Reserve Bank of Philadelphia, and Jeffrey Lacker, president of the Federal Reserve Bank of Richmond.
In company news, Pfizer ( PFE ) hormone replacement therapy treatment Prempro nearly doubled the risk of death from breast cancer, according to findings in a U.S. study reported by Bloomberg. The findings are the first to tie Pfizer's hormone replacement therapy to tumor mortality rate, the report said. The study comes from Women's Health Initiative.
Novo Nordisk AS ( NVO ) is up by double digits on the NYSE after federal regulators rejected a diabetes drug being developed by rivals. A diabetes injection, Bydureon, which has been jointly developed by Amylin Pharmaceuticals ( AMLN ), Alkermes Inc. ( ALKS ) and Eli Lilly & Co ( LLY ) was denied approval by the FDA for the second time Monday afternoon.
Meanwhile, Google's ( GOOG ) market share in China fell to its lowest level in nearly three years, Bloomberg reported, citing the Internet search company's recent dispute with that government over censorship. Google accounted for 24.6% of China's Internet search market in Q3, the report said, citing research firm iResearch Inc.
A group of lawyers who performed most of the work on lawsuits related to Merck & Co.'s ( MRK ) Vioxx painkiller litigation will get $315.3 million, Bloomberg reported, citing a judge's ruling. Other lawyers who filed suits will receive $1.24 billion, the report said. Merck won 11 of 16 Vioxx suits at trial before the company agreed to settle all remaining claims in 2007, the report noted.
Marathon Oil ( MRO ) said it took a stake in four exploration blocks in Kurdistan, making the company's first entry into Iraq, Reuters reported. The Houston-based company signed production-sharing agreements to operate and take an 80% stake in two open blocks the report said. No specific value was placed on the deal.
Earnings season pressed on before the bell this morning, moving stocks throughout the first half of the regular session.
Shares of Wells Fargo & Co. ( WFC ) are higher following the company's third-quarter earnings report this morning. The bank reported Q3 EPS of $0.60 per share, a nickel better than the Street view. Revenue was $20.87 billion, vs. expectations of $20.94 billion. "Wells Fargo continues to be one of our top picks," said Christopher Kotowski, an analyst with Oppenheimer & Co., in a Sept. 20 report, as reported by Bloomberg. "Near term, the continued improvement in asset quality will be the driver."
Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations. Altera ( ALTR ), the largest U.S. tobacco company, reported Q3 EPS of 69 cents per share compared to Street estimates of 65 cents a share. Revenue of $527.5 million is higher than Street estimates of $525.98. For Q4, company sees sales growth up 3% to 6%. Profit rose by higher prices for its Marlboro cigarettes and snuff sales, Bloomberg reported. Altera shares are down 0.59%, or $0.18, to $29.32.
Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. Sales of $8.7 billion are up from $7.8 billion. The Street looked for $8.9 billion. ABT sees adjusted 2010 EPS at $4.16 to $4.18. The Street is at $4.16.
Yahoo Inc. ( YHOO ) is higher, even though the Internet group reported disappointing revenue growth for the fourth quarter. The company expects revenue to reach between $1.125 billion to $1.225 billion, while analysts polled by Thomson Reuters on average had expected the figure to reach $1.26 billion. As a result, speculation is growing that Yahoo may consider a buyout and start discussions with private equity firms.
Airline stocks are trending higher following positive earnings numbers.
Delta ( DAL ) posted a profit of $929 million, or $1.10 a share excluding one-time items, having posted a loss of $161 million, or 19 cents a share, a year ago. Analysts polled by Thomson Reuters on average had expected earnings of 94 cents a share.
US Airways ( LCC ), meanwhile, reported a profit of $243 million, or $1.23 a share, which was above the $1.17 a share expected by analysts.
Commodities are higher as December gold contracts rose $7, or 0.52%, to $1,343 an ounce while November crude contacts are up 1.85%, or $1.47, at $81.65 a barrel.
In energy ETFs, the United States Oil Fund ( USO ) is up 2.02% to $35.32 and the United States Natural Gas fund ( UNG ) was up 0.62% to $5.64.
In precious metal ETFs, the SPDR Gold Trust ( GLD ) is up 0.76% to $131.10. Market Vectors Gold Miners ( GDX ) is up 1.54% to $55.37. iShares Silver Trust ( SLV ) is up 1.75% to $23.24.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. In company news, Pfizer ( PFE ) hormone replacement therapy treatment Prempro nearly doubled the risk of death from breast cancer, according to findings in a U.S. study reported by Bloomberg. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Meanwhile, Google's ( GOOG ) market share in China fell to its lowest level in nearly three years, Bloomberg reported, citing the Internet search company's recent dispute with that government over censorship. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Stocks are broadly in positive territory following upbeat earnings news ahead of key releases from the U.S. Federal Reserve Bank this afternoon. |
34554.0 | 2010-10-20 00:00:00 UTC | Mid-Day Update: Stocks In Strong Advance; Eyes Ahead to Fed's Beige Book | ABT | https://www.nasdaq.com/articles/mid-day-update-stocks-strong-advance-eyes-ahead-feds-beige-book-2010-10-20 | nan | nan | Here's where markets stand at mid-day:
-NYSE up 112.03 (+1.51%) to 7,534.74
-DJIA up 147.51 (+1.34%) to 11,126.13
-S&P 500 up 15.11 (+1.3%) to 1,181.01
-Nasdaq up 30.32 (+1.24%) to 2,467.27
GLOBAL SENTIMENT
Hang Seng down 0.87%
Nikkei down 1.65%
FTSE up 0.44%
MID-DAY NYSE INDEX WATCH
NYSE Energy up 1.59% at 11,252.23
NYSE Financial up 1.41% at 4,814.36
NYSE Health Care up 1.6% at 6,524.08
NYSE Arca Tech 100 up 1.42% at 989.53
UPSIDE MOVERS
(+) YHOO (+3.6%) early gains matching evening move after results top year-ago quarter.
(+) BA (+2.4%) beats with earnings, raises guidance.
(+) BDSI (+3.6%) gets European approval for BEMA Fentanyl.
(+) DEAR (+22.9%) swings to profit.
(+) HTZ (+3.3%) raises guidance.
(+) JNPR (+5%) twisting around even mark after evening decline that followed inline Q3 results.
(+) WFC (+3.3%) gained initially but falls; EPS beat by a nickel, meets with revenue.
DOWNSIDE MOVERS
(-) AMLN (-47.1%) tumbling with partners after getting negative FDA complete response letter for BYDUREON.
(-) ALKS (-28%) falling in step with AMLN on drug news.
(-) BAC (-2.4%) remains under pressure amid mortgage market concerns, mixed sector earnings.
(-) CREE (-5.6%) issues revenue warning after revenue miss.
(-) MS (-1.3%) earnings below year-ago results.
(-) GNBT (-17.1%) to delist.
(-) CTIC (-9.4%) selling shares.
(-) PPHM (-2.0%) falls despite favorable data.
(-) ALTR (-1.3%) lower after post-bell earnings beat.
MARKET DIRECTION
Stocks are broadly in positive territory following upbeat earnings news ahead of key releases from the U.S. Federal Reserve Bank this afternoon. The triple-digit move for the Dow Jones Industrial Average pares some of yesterday's losses and showed positive sentiment wasn't entirely sapped after bloodletting in the prior session.
The Fed Beige Book for October will be released at 2 p.m. ET. Speeches are also expected from Charles Plosser, president of the Federal Reserve Bank of Philadelphia, and Jeffrey Lacker, president of the Federal Reserve Bank of Richmond.
In company news, Pfizer ( PFE ) hormone replacement therapy treatment Prempro nearly doubled the risk of death from breast cancer, according to findings in a U.S. study reported by Bloomberg. The findings are the first to tie Pfizer's hormone replacement therapy to tumor mortality rate, the report said. The study comes from Women's Health Initiative.
Novo Nordisk AS ( NVO ) is up by double digits on the NYSE after federal regulators rejected a diabetes drug being developed by rivals. A diabetes injection, Bydureon, which has been jointly developed by Amylin Pharmaceuticals ( AMLN ), Alkermes Inc. ( ALKS ) and Eli Lilly & Co ( LLY ) was denied approval by the FDA for the second time Monday afternoon.
Meanwhile, Google's ( GOOG ) market share in China fell to its lowest level in nearly three years, Bloomberg reported, citing the Internet search company's recent dispute with that government over censorship. Google accounted for 24.6% of China's Internet search market in Q3, the report said, citing research firm iResearch Inc.
A group of lawyers who performed most of the work on lawsuits related to Merck & Co.'s ( MRK ) Vioxx painkiller litigation will get $315.3 million, Bloomberg reported, citing a judge's ruling. Other lawyers who filed suits will receive $1.24 billion, the report said. Merck won 11 of 16 Vioxx suits at trial before the company agreed to settle all remaining claims in 2007, the report noted.
Marathon Oil ( MRO ) said it took a stake in four exploration blocks in Kurdistan, making the company's first entry into Iraq, Reuters reported. The Houston-based company signed production-sharing agreements to operate and take an 80% stake in two open blocks the report said. No specific value was placed on the deal.
Earnings season pressed on before the bell this morning, moving stocks throughout the first half of the regular session.
Shares of Wells Fargo & Co. ( WFC ) are higher following the company's third-quarter earnings report this morning. The bank reported Q3 EPS of $0.60 per share, a nickel better than the Street view. Revenue was $20.87 billion, vs. expectations of $20.94 billion. "Wells Fargo continues to be one of our top picks," said Christopher Kotowski, an analyst with Oppenheimer & Co., in a Sept. 20 report, as reported by Bloomberg. "Near term, the continued improvement in asset quality will be the driver."
Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations. Altera ( ALTR ), the largest U.S. tobacco company, reported Q3 EPS of 69 cents per share compared to Street estimates of 65 cents a share. Revenue of $527.5 million is higher than Street estimates of $525.98. For Q4, company sees sales growth up 3% to 6%. Profit rose by higher prices for its Marlboro cigarettes and snuff sales, Bloomberg reported. Altera shares are down 0.59%, or $0.18, to $29.32.
Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. Sales of $8.7 billion are up from $7.8 billion. The Street looked for $8.9 billion. ABT sees adjusted 2010 EPS at $4.16 to $4.18. The Street is at $4.16.
Yahoo Inc. ( YHOO ) is higher, even though the Internet group reported disappointing revenue growth for the fourth quarter. The company expects revenue to reach between $1.125 billion to $1.225 billion, while analysts polled by Thomson Reuters on average had expected the figure to reach $1.26 billion. As a result, speculation is growing that Yahoo may consider a buyout and start discussions with private equity firms.
Airline stocks are trending higher following positive earnings numbers.
Delta ( DAL ) posted a profit of $929 million, or $1.10 a share excluding one-time items, having posted a loss of $161 million, or 19 cents a share, a year ago. Analysts polled by Thomson Reuters on average had expected earnings of 94 cents a share.
US Airways ( LCC ), meanwhile, reported a profit of $243 million, or $1.23 a share, which was above the $1.17 a share expected by analysts.
Commodities are higher as December gold contracts rose $7, or 0.52%, to $1,343 an ounce while November crude contacts are up 1.85%, or $1.47, at $81.65 a barrel.
In energy ETFs, the United States Oil Fund ( USO ) is up 2.02% to $35.32 and the United States Natural Gas fund ( UNG ) was up 0.62% to $5.64.
In precious metal ETFs, the SPDR Gold Trust ( GLD ) is up 0.76% to $131.10. Market Vectors Gold Miners ( GDX ) is up 1.54% to $55.37. iShares Silver Trust ( SLV ) is up 1.75% to $23.24.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. In company news, Pfizer ( PFE ) hormone replacement therapy treatment Prempro nearly doubled the risk of death from breast cancer, according to findings in a U.S. study reported by Bloomberg. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. Shares of Altera ( ALTR ) are lower even after the company reported third quarter earnings results that beat Street expectations. | Abbott Labs ( ABT ) reports Q3 adjusted EPS at $1.05, just topping the Thomson Reuters mean analyst estimate for $1.04. ABT sees adjusted 2010 EPS at $4.16 to $4.18. (+) WFC (+3.3%) gained initially but falls; EPS beat by a nickel, meets with revenue. |
34555.0 | 2010-09-16 00:00:00 UTC | 9 Stocks that Have Consistently Raised Dividends for 25 Years or More | ABT | https://www.nasdaq.com/articles/9-stocks-have-consistently-raised-dividends-25-years-or-more-2010-09-16 | nan | nan | As income investors, we can get caught up in yields... almost to a fault. But there is something else you should be studying that could make just as big a difference to your long-term returns: dividend growth.
That's because dividend growth can make even lower-yielding stocks into big income producers over time. Take a look below at the income streams from a stock yielding 7% but not growing dividends, versus a 5% yielder that hikes payments +10% every year. If you held 1,000 shares trading at a $10 share price, here is the income stream each would produce over a year:
In just five years, that 5% yield would actually be worth more than the 7% yield. And just two years later, your income stream would grow to be +27% more than the stock yielding 7%! Keep in mind, this doesn't take into account rising share prices. If both yields stayed the same, the share price of the 5% yielder would have to grow to $17.72 -- a +77% gain.
Buying stocks that increase dividends allows you to take advantage of one of the most powerful tools in the investors' arsenal -- the wealth-building effect of compounding . And consistent dividend growth is like jet fuel for the compounding engine.
But there are more advantages to companies able to consistently grow dividend payments. One often overlooked "plus" is that they tend to be safer investments. Dividends are a litmus test of a company's true financial strength. Only companies able to grow earnings through good times and bad will commit to consistently raising dividends. And these are the types of business that tend to see more stability in their shares.
The best measure of their value is how dividend growers perform over time. And the best proof lies in a special index created by Standard & Poor's, called the "Dividend Aristocrats." Every company on this list must that have posted increased dividends in each of the past 25 years.
According to S&P data, the Dividend Aristocrats have consistently outperformed the broader S&P 500. Dividend Aristocrats fell only -22% during the 2008 market crash, much less than the -37% decline for the S&P 500. Moreover, the group rebounded +27% the following year, slightly better than the +26% gain on the S&P 500.
As you would guess, the ranks of Dividend Aristocrats are exclusive -- only 42 of the 500 companies in the S&P made the list this year (about 8% of the index). I used this list of 42 companies as my starting point and then looked at nine companies that were raising payments the fastest:
Pitney Bowes ( PBI )
Yield: 7.0%
Pitney Bowes yields 7.0% and has recorded 28 consecutive years of dividend growth. Its business is boring -- it makes postage meters and mail processing equipment, but its dividend growth is anything but. Dividends have grown +10% a year since Pitney Bowes began paying investors in 1982. The 2010 increase of about +1.5% was a below average, but it did raise the annual payment to $1.46 per share.
Eli Lilly ( LLY )
Yield: 5.5%
Healthcare is less impacted by recession than other sectors, so it's no surprise to find multiple healthcare companies on the list of dividend growers. Eli Lilly is a leading global drug maker and has an uninterrupted record of roughly 40 years of dividend growth. In the last decade, Lilly has grown its dividend +8% a year. The company last increased the dividend by +3% to a $1.96 annual payment in 2009, meaning a dividend increase is likely in the next quarter if Eli Lilly wants to maintain its track record.
Cincinnati Financial Corp (Nasdaq: CINF)
Yield: 5.4%
The only financial company that made the list above is property/casualty insurance provider, Cincinnati Financial. This company has raised dividends 49 years in a row, setting the stage for a wonderful half-century of increasing payments. Dividend increases of late have slowed in line with the overall economic outlook, but consider that in 1999 the company paid just about $0.60 a share, compared to today's $1.60 annual rate.
Leggett & Platt ( LEG )
Yield: 5.0%
Fixture and furniture manufacturer Leggett & Platt is seeing a rebound in its markets and signaled confidence in its future prospects in August by hiking the dividend +4% to a $1.08 per share annual rate. The company now boasts an impressive track record of 39 years of dividend growth.
Johnson & Johnson ( JNJ )
Yield: 3.5%
Johnson & Johnson's 3.7% yield isn't likely to "wow" you -- but remember the example above when it comes to growing dividend payments. The company has increased dividends 48 years in a row. The last increase, announced in April, boosted the dividend by +10% to a $2.16 annual rate. [ Read my colleague Tom Hutchinson's take on JNJ ]
Abbott Labs ( ABT )
Yield: 3.4%
Drug manufacturer Abbott Labs has grown dividends for 38 years running. Like Johnson & Johnson, it's another medical company that doesn't pay a high "headline" yield, but it can grow payments. In the past decade, dividend growth has averaged nearly +9% a year. The last hike, announced in February, was a +10% increase. Abbot now pays a $1.76 annual dividend, up from just $0.74 in 2000.
Automatic Data Processing (Nasdaq: ADP)
Yield: 3.3%
Automatic Data Processing provides payroll processing services to thousands of businesses nationwide. Even with unemployment now at a high, this company has been able to hike dividends every year for 35 years straight. The last increase raised the payment by +3% to a $1.36 annual rate. In the past decade, annual dividend growth has been an impressive +15%.
McGraw-Hill ( MHP )
Yield: 3.1%
You might not know it, but McGraw-Hill actually owns Standard & Poor's, so it is only fitting this company makes S&P's Dividend Aristocrats list. McGraw-Hill's ranking comes thanks to 37 straight years of dividend growth. In the last decade, dividends have grown +7% a year. This includes the last dividend hike, announced in January, to a $0.94 annual rate.
PPG Industries ( PPG )
Yield: 3.1%
PPG Industries is a new member to the list, with "only" 25 years of dividend increases -- but it has paid 448 consecutive dividends. This maker of sealants and window coatings also stands out as the only Dividend Aristocrat to raise dividends twice in the past year. The last hike in July was by a penny per quarter to a $2.20 annual rate.
Action to Take --> Before investing in any of the ideas above, I would want to examine each in more detail, considering factors like business outlook and financial strength. Still, the combination of dividend increases and a solid yield makes this list an interesting starting point for further research.
-- Carla Pasternak
Carla Pasternak has nearly 30 years of income investing experience, including serving as the Director of Research for High-Yield Investing and High-Yield International. Read More...
Disclosure: Neither Carla Pasternak nor StreetAuthority, LLC hold positions in any securities mentioned in this article.
StreetAuthority
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | [ Read my colleague Tom Hutchinson's take on JNJ ] Abbott Labs ( ABT ) Yield: 3.4% Drug manufacturer Abbott Labs has grown dividends for 38 years running. Take a look below at the income streams from a stock yielding 7% but not growing dividends, versus a 5% yielder that hikes payments +10% every year. Buying stocks that increase dividends allows you to take advantage of one of the most powerful tools in the investors' arsenal -- the wealth-building effect of compounding . | [ Read my colleague Tom Hutchinson's take on JNJ ] Abbott Labs ( ABT ) Yield: 3.4% Drug manufacturer Abbott Labs has grown dividends for 38 years running. I used this list of 42 companies as my starting point and then looked at nine companies that were raising payments the fastest: Pitney Bowes ( PBI ) Yield: 7.0% Pitney Bowes yields 7.0% and has recorded 28 consecutive years of dividend growth. Johnson & Johnson ( JNJ ) Yield: 3.5% Johnson & Johnson's 3.7% yield isn't likely to "wow" you -- but remember the example above when it comes to growing dividend payments. | [ Read my colleague Tom Hutchinson's take on JNJ ] Abbott Labs ( ABT ) Yield: 3.4% Drug manufacturer Abbott Labs has grown dividends for 38 years running. I used this list of 42 companies as my starting point and then looked at nine companies that were raising payments the fastest: Pitney Bowes ( PBI ) Yield: 7.0% Pitney Bowes yields 7.0% and has recorded 28 consecutive years of dividend growth. The company last increased the dividend by +3% to a $1.96 annual payment in 2009, meaning a dividend increase is likely in the next quarter if Eli Lilly wants to maintain its track record. | [ Read my colleague Tom Hutchinson's take on JNJ ] Abbott Labs ( ABT ) Yield: 3.4% Drug manufacturer Abbott Labs has grown dividends for 38 years running. Every company on this list must that have posted increased dividends in each of the past 25 years. The 2010 increase of about +1.5% was a below average, but it did raise the annual payment to $1.46 per share. |
34556.0 | 2010-08-30 00:00:00 UTC | The 20 Highest Paid CEOs in America | ABT | https://www.nasdaq.com/articles/the-20-highest-paid-ceos-in-america | nan | nan | It's good to be king, particularly in corporate America. When we take a look at the 20 highest paid chief executive officers, we find familiar names, some names not as well-known, some whose pay is justified by increased shareholder value and some with pay packages that will make your blood boil.
The CEOs on our list are widely spread among a variety of industries, including: Technology (3), Media (3), Financial Services (3), Pharmaceuticals/Healthcare (3), Defense (3), Energy (2), Automotive (1), Consumer Staples (1) and Telecommunications (1).
Of the 20 companies with high-earning CEOs, 18 are listed on the NYSE and 2 are listed on the Nasdaq. Only eight are Dow component companies (to get the full list of Dow components, click here). No women made the list in 2009.
Starting at the top, here are the 20 highest paid executives in America:
Larry Ellison, Oracle (Nasdaq: ORCL)
2009 Total Compensation: $84.5 million
Ellison is usually somewhere toward the top of this list in any given year. Being critical of Ellison's pay is difficult for a couple of reasons. First, he founded Oracle, so this is his ship. Second, the performance of the stock seems to justify the pay -- Oracle was up more than +33% in 2009 and has returned almost +10,000% since going public in 1988.
[Ellison doesn't just make a ton of money; he also gives away a ton of money. See what Ellison can teach you about being a billionaire in one of the month's most popular articles, 3 Billionaire Habits for Non-Billionaires .]
Ray Elliott, Boston Scientific ( BSX )
2009 Total Compensation: $33.4 million
Elliott took the helm at Boston Scientific in July 2009, so one could argue he needs more time to get the medical device maker headed in the right direction. But detractors will tell you that $33 million is far too much to pay the CEO of a company whose shares have lost more than -50% in the past year and now trade for around $5.
Ray Irani, Occidental Petroleum ( OXY )
2009 Total Compensation: $31.4 million
Bigger isn't always better in terms of executive pay in the oil patch. Irani regularly appears near the top of this list despite the fact that Occidental is just the fourth-largest U.S. oil company. Irani and Occidental have both come under fire lately from shareholders concerned about executive pay and lack of a clear succession plan. But, Irani has been CEO of Occidental since 1990, and in that time its stock is up more than +400%.
Mark Hurd, Hewlett Packard ( HPQ )
2009 Total Compensation: $24.2 million
Hurd is the former CEO of the world's largest personal computer maker following a scandal involving his inability to properly fill out expense reports. In addition to pay, Hurd was lavishly compensated in other ways. He had access to the company jet and HP shareholders even paid for his personal financial advisor. Yes, HP stock almost doubled in Hurd's five-year tenure, but shares are down -18.5% in the past two years, making it difficult to justify the recent size of Hurd's deal.
James Hackett, Anadarko Petroleum ( APC )
2009 Total Compensation: $23.5 million
Hackett deserves credit for transforming Anadarko from a sleepy oil and gas producer to a major player on the global energy stage. The company doesn't just do business in the U.S.; it has exposure to exotic markets all over the world, and Hackett has overseen that transformation. He took over as CEO in December 2003, and despite the punishment Anadarko shares have endured recently for the company's exposure to the Gulf of Mexico oil spill, the stock has doubled from January 2004 through today.
A.G. Lafley, Procter & Gamble ( PG )
2009 Total Compensation: $23.5 million
Lafley retired in February, which may be a relief to P&G shareholders. He earned $71 million during the past three years while the stock barely moved. Yes, the dividend was raised on Lafley's watch, but P&G has raised its dividend annually for more than 50 consecutive years, so Lafley doesn't deserve credit for that. In my opinion, this has been an example of too much pay for too little performance.
William Weldon, Johnson & Johnson ( JNJ )
2009 Total Compensation: $22.8 Million
Like P&G, Johnson & Johnson is another prodigious dividend raiser. They've been raising payouts for so long that it almost doesn't matter who the CEO is because that person wouldn't want to be the one who ends the streak. Weldon hass been at the helm since 2002 and has presided over J&J's dismal 5-year return of -10%.
Miles White, Abbott Labs ( ABT )
Total 2009 Compensation: $21.9 Million
At least we can say Miles White delivers more for his shareholders than William Weldon does for his. Abbott is up +10% in five years. White is the longest tenured Big Pharma CEO and he has a tricky gauntlet to run as profitable patents like that for its blockbuster drug Depakote expire. This is when we'll see if his big pay benefits shareholders.
Bob Iger, Walt Disney ( DIS )
2009 Total Compensation: $21.6 million
It's hard to argue with this one. Iger has led Disney to a +20% gain in the past year, quadruple the Dow's performance. Not only that, but Iger has been instrumental in restoring investor confidence in Disney. The stock is up about +30% in the past five years, but compared to the flat Dow, Iger looks pretty deserving of his pay.
Samuel Palmisano, IBM ( IBM )
2009 Total Compensation: $21.2 Million
IBM is up only +5% in the past year and shareholders have been grumbling that the company could commit more cash to its dividend than it does. IBM did just take advantage of ridiculously low interest rates to raise $1.5 billion in bonds, so maybe some of that money will find its way back to shareholders in the form of dividends or share buybacks.
[A recent InvestingAnswers article from former IBM analyst and current income investing expert, Amy Calistri, looks at whether IBM's financing indicates that interest rates have bottomed. Read more here: One of America's Largest Companies Flashes a Warning Sign for Income Investors .]
Robert Stevens, Lockheed Martin ( LMT )
2009 Total Compensation $20.5 Million
This one is tricky. In the past year, rival Boeing ( BA ) has sharply outperformed Lockheed (+23.8% vs. -3.6%). But if we look at a five-year history (Stevens has run the show at Lockheed for six years), Lockheed's +17.4% return handily beats Boeing's -3.4%.
Randall Stephenson, AT&T ( T )
2009 Total Compensation: $20.3 million
AT&T shares are essentially flat in the past year, but this is one of the more predictable blue chips out there. AT&T takes its dividend seriously and in a volatile market environment a CEO that provides stable growth and a solid dividend is worth rewarding.
Jay Fishman, Travelers Companies ( TRV )
2009 Total Compensation: $20.1 million
Give Fishman credit: The financial crisis severely punished big insurance companies, but Travelers never suffered in the same way as American International Group ( AIG ) or Hartford Financial ( HIG ). Outperforming your rivals is key to commanding big-time paydays and Fishman has done just that.
Jeffrey Bewkes, Time Warner ( TWX )
2009 Total Compensation: $19.4 million
Considering the discrepancy in their respective stocks' performance, the difference between Bewkes and Iger's pay at Disney may not be big enough. Time Warner has trailed Disney in terms of stock appreciation by so much (+7.0% vs. +20%) that it can be argued that the $2.2 million gap between Bewkes and Iger isn't nearly enough.
John Stumpf, Wells Fargo ( WFC )
2009 Total Compensation: $18.8 million
Considering that Wells Fargo has been a solid performer under Stumpf's leadership and that the stock was one of many financials that rallied off the March 2009 market lows, Stumpf's big pay-day can be given a pass for now. But investors will be looking for the dividend to be restored soon, so that some of that big money can be funneled into their pockets instead of Stumpf's.
James Cracchiolo, Ameriprise Financial ( AMP )
Total 2009 Compensation: $18.2 million
Ameriprise tripled off its March 2009 low, so we'll give our seal of approval to Cracchiolo's pay and performance. The market was certainly favorable to financials for much of 2009, but a triple in 18 months is still pretty impressive.
Rupert Murdoch, News Corp. (Nasdaq: NWSA)
Total 2009 Compensation: $18 million
Murdoch built News Corp, and it's hard to think of anyone who would get in the way of a man being paid by his own company. But in all fairness, News Corp stock almost doubled in 2009, even taking into account a tough media and advertising environment. A pretty impressive performance.
Ronald Sugar, Northrup Grumman ( NOC )
Total 2009 Compensation: $17.9 million
Considering how sharply Northrup Grumman has outperformed Lockheed Martin in the past 52 weeks (+13.5% vs. -3.6%), it might be fair to say Sugar was underpaid compared to Stevens. Even so, the point is moot: Sugar stepped down as CEO and chairman at the end of 2009 and officially retired in June 2010.
Alan Mulally, Ford Motor ( F )
Total 2009 Compensation: $17.9 million
We'll make this one short and sweet: Given Ford's dramatic turnaround in both operating and share price performance under Mulally's stewardship, it can certainly be argued that this man is underpaid.
Louis Chenevert, United Technologies ( UTX )
Total 2009 Compensation: $17.9 million
United Technologies has been one of the better performing industrial conglomerates over the past year +11.6% and the stock has outperformed the Dow, its home index . Blue chips across the board have largely lagged United Technologies, so the money spent on this CEO seems well worth it.
If you'd like to read about how some of the richest people in the world invest their money, click here to see one of InvestingAnswers' most popular articles of the month, 5 Astonishing Billionaire Portfolios .
InvestingAnswers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Miles White, Abbott Labs ( ABT ) Total 2009 Compensation: $21.9 Million At least we can say Miles White delivers more for his shareholders than William Weldon does for his. The CEOs on our list are widely spread among a variety of industries, including: Technology (3), Media (3), Financial Services (3), Pharmaceuticals/Healthcare (3), Defense (3), Energy (2), Automotive (1), Consumer Staples (1) and Telecommunications (1). He took over as CEO in December 2003, and despite the punishment Anadarko shares have endured recently for the company's exposure to the Gulf of Mexico oil spill, the stock has doubled from January 2004 through today. | Miles White, Abbott Labs ( ABT ) Total 2009 Compensation: $21.9 Million At least we can say Miles White delivers more for his shareholders than William Weldon does for his. James Hackett, Anadarko Petroleum ( APC ) 2009 Total Compensation: $23.5 million Hackett deserves credit for transforming Anadarko from a sleepy oil and gas producer to a major player on the global energy stage. Jay Fishman, Travelers Companies ( TRV ) 2009 Total Compensation: $20.1 million Give Fishman credit: The financial crisis severely punished big insurance companies, but Travelers never suffered in the same way as American International Group ( AIG ) or Hartford Financial ( HIG ). | Miles White, Abbott Labs ( ABT ) Total 2009 Compensation: $21.9 Million At least we can say Miles White delivers more for his shareholders than William Weldon does for his. Starting at the top, here are the 20 highest paid executives in America: Larry Ellison, Oracle (Nasdaq: ORCL) 2009 Total Compensation: $84.5 million Ellison is usually somewhere toward the top of this list in any given year. Samuel Palmisano, IBM ( IBM ) 2009 Total Compensation: $21.2 Million IBM is up only +5% in the past year and shareholders have been grumbling that the company could commit more cash to its dividend than it does. | Miles White, Abbott Labs ( ABT ) Total 2009 Compensation: $21.9 Million At least we can say Miles White delivers more for his shareholders than William Weldon does for his. Second, the performance of the stock seems to justify the pay -- Oracle was up more than +33% in 2009 and has returned almost +10,000% since going public in 1988. In my opinion, this has been an example of too much pay for too little performance. |
34557.0 | 2010-07-21 00:00:00 UTC | Opening View: DJIA, SPX Bulls Optimistic Ahead of Bernanke Testimony | ABT | https://www.nasdaq.com/articles/opening-view-djia-spx-bulls-optimistic-ahead-bernanke-testimony-2010-07-21 | nan | nan | Despite plunging to a triple-digit loss early in the session, the Dow Jones Industrial Average (DJIA) came roaring back to finish Tuesday with a gain of roughly 75 points. The bulls are looking to extend the rally this morning, drawing strength from strong earnings from Apple Inc. and expectations that Federal Reserve Chairman Ben Bernanke may announce policy accommodation measures in testimony before the U.S. Senate Banking Committee later today. The DJIA could find resistance out of the gate this morning, with former support at the 10,250 level looming large as a potential hurdle. Above this area, the 10,400 level could cap any extended rallies by the blue-chip barometer. As for the S&P 500 Index (SPX), the index rebounded from its May "flash crash" low yesterday, and is now challenging former support/resistance near 1,085. Should the SPX push past this hurdle, longer-term resistance remains overhead at the 1,100 level. Heading into the open, the DJIA and the SPX are trading 13 points and 2.5 points above fair value, respectively, pointing toward a flat-to-higher open.
In earnings news, Apple Inc. ( AAPL ) said that strong demand for iPhones and iPads lifted third-quarter earnings to $3.25 billion, or $3.51 per share, compared with earnings of $1.83 billion, or $2.01 per share, last year. Revenue soared 61% to $15.7 billion. Analysts were expecting earnings of $3.11 per share on revenue of $14.75 billion. Looking ahead to the fourth quarter, Apple said it expects revenue of $18 billion with earnings of $3.44 per share, versus Wall Street's view for earnings of $3.82 per share on revenue of $17.03 billion. AAPL shares are up nearly 4% in pre-market trading.
Elsewhere, Yahoo! Inc. ( YHOO ) reported second-quarter net income of $213.3 million, or 15 cents per share, on revenue of $1.13 billion. Analysts had expected Yahoo! to post earnings of 14 cents per share on $1.16 billion in net revenue. YHOO was off nearly 7% in electronic trading at last check.
Finally, EMC Corp. ( EMC ) reported a second-quarter profit of $426 million, or 20 cents per share, as sales rose 24% to $4.02 billion. Earnings, excluding one-time items, came in at 28 cents per share. Analysts were expecting earnings of 28 cents per share on sales of $3.99 billion. Looking ahead, EMC said it expects to exceed its prior 2010 sales outlook of $16.5 billion. Still, EMC shares are off roughly 1.3% in pre-market trading.
Earnings Preview
On the earnings front Abbott Laboratories ( ABT ), The Coca-Cola Co. ( KO ), Wells Fargo & Co. ( WFC ), Baidu Inc. ( BIDU ), CA Inc. ( CA ), eBay Inc. ( EBAY ), Netflix Inc. ( NFLX ), QUALCOMM Inc. ( QCOM ), Starbucks Corp. ( SBUX ), Western Digital Corp. ( WDC ), and Xilinx Inc. ( XLNX ) are scheduled to release their quarterly earnings report today. Keep your browser at SchaeffersResearch.com for more news as it breaks.
Economic Calendar
The market will be graced with the weekly report on U.S. petroleum supplies today, while weekly initial jobless claims will be joined by June's existing home sales and June's leading economic indicators tomorrow. Friday ends the week as it began, with no reports slated for release.
Market Statistics
Equity option activity on the Chicago Board Options Exchange ( CBOE ) saw 1,246,606 call contracts traded on Tuesday, compared to 661,150 put contracts. The resultant single-session put/call ratio arrived at 0.53, while the 21-day moving average held at 0.64.
**The volume data shown above is from the Nasdaq and NYSE exchanges only. It does not include regional volume activity, which means that other daily volume quotes you see may be higher.**
Every morning, our research staff analyzes the prior day and the overnight markets, and monitors the morning wires to give you an accurate preview of the day to come. If you enjoyed today's edition of Opening View, sign up here for free daily delivery, straight to your inbox, before the opening bell.
Overseas Trading
Overseas trading looks strong this morning, as nine of the 10 foreign indexes that we track are in positive territory. The cumulative average return on the collective stands at a gain of 0.90%. In Asia, steel stocks led a broad rally in China after the government announced that it is working to consolidate local industry. Meanwhile, Japan retreated in the wake of a strengthening yen. Across the pond in Europe, strength in commodities is driving solid gains in regional markets, pushing stocks toward the end of a four-session losing streak.
Currencies and Commodities
The U.S. dollar continues to gain ground in overseas trading this week. Heading into the open this morning, the U.S. Dollar Index has advanced 0.26% to trade at 82.96. Elsewhere, commodities are shaking off the greenback's rise, with gold futures up $1.70 at $1,193.40 in London, while crude oil has added 34 cents to trade at $77.92 per barrel in electronic trading.
Unusual Put and Call Activity:
For an explanation of how to use this information, check out our Education Center topics on Option Volume and Open Interest Configurations .
Click here for the new spring issue of SENTIMENT magazine
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
All Rights Reserved. Unauthorized reproduction of any SIR publication is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Earnings Preview On the earnings front Abbott Laboratories ( ABT ), The Coca-Cola Co. ( KO ), Wells Fargo & Co. ( WFC ), Baidu Inc. ( BIDU ), CA Inc. ( CA ), eBay Inc. ( EBAY ), Netflix Inc. ( NFLX ), QUALCOMM Inc. ( QCOM ), Starbucks Corp. ( SBUX ), Western Digital Corp. ( WDC ), and Xilinx Inc. ( XLNX ) are scheduled to release their quarterly earnings report today. Despite plunging to a triple-digit loss early in the session, the Dow Jones Industrial Average (DJIA) came roaring back to finish Tuesday with a gain of roughly 75 points. The bulls are looking to extend the rally this morning, drawing strength from strong earnings from Apple Inc. and expectations that Federal Reserve Chairman Ben Bernanke may announce policy accommodation measures in testimony before the U.S. Senate Banking Committee later today. | Earnings Preview On the earnings front Abbott Laboratories ( ABT ), The Coca-Cola Co. ( KO ), Wells Fargo & Co. ( WFC ), Baidu Inc. ( BIDU ), CA Inc. ( CA ), eBay Inc. ( EBAY ), Netflix Inc. ( NFLX ), QUALCOMM Inc. ( QCOM ), Starbucks Corp. ( SBUX ), Western Digital Corp. ( WDC ), and Xilinx Inc. ( XLNX ) are scheduled to release their quarterly earnings report today. Looking ahead to the fourth quarter, Apple said it expects revenue of $18 billion with earnings of $3.44 per share, versus Wall Street's view for earnings of $3.82 per share on revenue of $17.03 billion. Inc. ( YHOO ) reported second-quarter net income of $213.3 million, or 15 cents per share, on revenue of $1.13 billion. | Earnings Preview On the earnings front Abbott Laboratories ( ABT ), The Coca-Cola Co. ( KO ), Wells Fargo & Co. ( WFC ), Baidu Inc. ( BIDU ), CA Inc. ( CA ), eBay Inc. ( EBAY ), Netflix Inc. ( NFLX ), QUALCOMM Inc. ( QCOM ), Starbucks Corp. ( SBUX ), Western Digital Corp. ( WDC ), and Xilinx Inc. ( XLNX ) are scheduled to release their quarterly earnings report today. In earnings news, Apple Inc. ( AAPL ) said that strong demand for iPhones and iPads lifted third-quarter earnings to $3.25 billion, or $3.51 per share, compared with earnings of $1.83 billion, or $2.01 per share, last year. Looking ahead to the fourth quarter, Apple said it expects revenue of $18 billion with earnings of $3.44 per share, versus Wall Street's view for earnings of $3.82 per share on revenue of $17.03 billion. | Earnings Preview On the earnings front Abbott Laboratories ( ABT ), The Coca-Cola Co. ( KO ), Wells Fargo & Co. ( WFC ), Baidu Inc. ( BIDU ), CA Inc. ( CA ), eBay Inc. ( EBAY ), Netflix Inc. ( NFLX ), QUALCOMM Inc. ( QCOM ), Starbucks Corp. ( SBUX ), Western Digital Corp. ( WDC ), and Xilinx Inc. ( XLNX ) are scheduled to release their quarterly earnings report today. In earnings news, Apple Inc. ( AAPL ) said that strong demand for iPhones and iPads lifted third-quarter earnings to $3.25 billion, or $3.51 per share, compared with earnings of $1.83 billion, or $2.01 per share, last year. Currencies and Commodities The U.S. dollar continues to gain ground in overseas trading this week. |
34558.0 | 2010-06-17 00:00:00 UTC | Thursday Winners: Neurocrine Biosciences, Pier One and Winnebago | ABT | https://www.nasdaq.com/articles/thursday-winners-neurocrine-biosciences-pier-one-and-winnebago-2010-06-17 | nan | nan | Among the biggest winners in Thursday's early trading are Neurocrine Biosciences, (Nasdaq: NBIX ) , Pier One (NYSE: PIR ) and Winnebago (NYSE: WGO ) .
A Key Positive for Consumer Spending
Raise your hand if you thought demand for mobile homes would snap back very quickly while unemployment remains so high. Me neither. Winnebago (NYSE: WGO ) just announced that it doubled the amount of mobile homes and campers it made in its fiscal third quarter compared with a year earlier. Results were especially lousy last year, but this business is clearly rebounding faster than most expected. Sales of its most expensive "Class A" motor homes were notably robust. That's in keeping with positive retail reports from firms like Saks (NYSE: SKS ) that also cater to the well-heeled set. Winnebago is up +16% on the bullish news.
This marks the second straight quarter that Winnebago has made money, after a six-quarter losing streak. Can it be sustained? Management says that inventories are fairly lean, down -14% from a year ago, and it's increasingly clear that spending has returned among upper income consumers.
What's not clear is how strong a rebound Winnebago can expect. The company routinely earned $1 to $2 a share from 2001 through 2007. To get back to that level, the company needs to hope that the expanded pool of aging baby boomers likes to drive the blue highways. Yet as long as unemployment stays high, customers of more marginal financial means probably need to hold off on such an expensive purchase.
Action to Take --> Look for analysts to raise their 2011 fiscal forecasts from the current $0.54 per share to around $1. Shares appear reasonably priced at around 13 times that figure. It may take several years for per-share profits to move past the $1.50 mark, but long-term investors should find this stock to be a bargain in that context. Shares rose sharply after the last quarterly report, and then fell sharply. This time around, shares should hold their gains -- and then some.
------------------------------------
Pier One Follow-up
In early June, we noted that retailer Pier One (NYSE: PIR ) posted impressive sales results, and we anticipated a fairly robust profit report when the company ultimately released quarterly results. The news is in, and it's good: Instead of an anticipated minor loss, Pier One eked out a profit, which is atypical for the retailer in this seasonally slow quarter.
Sales at stores open more than one year rose +14% from a year ago. That's what reduced competition can do for you. And fewer rivals means fewer price wars: gross margins rose a hefty 700 basis points to 37.4%.
Action to Take --> As we noted a few weeks ago, earnings estimates are likely to rise, and shares, even after this morning's 5% gain, are still quite attractive. We stand by our earlier sentiment that "with less competition to worry about, this retailer could keep rising from the ashes, and shares could move into the low teens." That's a +30% to +40% gain from current levels.
------------------------------------
A Key Endorsement for Neurocrine Biosciences
For the second day in a row, we're highlighting robust gains for Neurocrine Biosciences (Nasdaq: NBIX ) . On Wednesday, the company secured an impressive agreement with Abbott Labs (NYSE: ABT ) .
A mere day later, Neurocrine has signed another partner to help develop and market a separate promising drug. Germany's Boehringer Ingelheim will pay $10 million now, and up to $225 million later, to help bring Neurocrine's diabetes-fighting molecular research to fruition. This effort is not as far along as the drug being jointly developed with Abbott Labs, so shares are posting a more muted 5% gain, after rising 14% on Wednesday. Yet you can argue that two partners and two promising research efforts make shares even more appealing, as it reduces the odds that the company will strike out as it wends further into clinical trials. A two-trick pony is better than one.
Action to Take --> We suggested Wednesday that "the near-term gains have been made in the stock, and you couldn't be faulted for taking profits." And we were wrong. We added that investors may be able to get in on a share price pullback. Now, such a pullback looks less likely. We're hesitant to place a value on these shares, but this week's flurry of deal-making is pretty darn impressive, and should make Neurocrine a household name among biotech investors.
-- David Sterman
Staff Writer
StreetAuthority
Disclosure: David Sterman owns shares of Neither StreetAuthority and LCC nor the editor hold positions in any securities mentioned in this report..
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Wednesday, the company secured an impressive agreement with Abbott Labs (NYSE: ABT ) . A Key Positive for Consumer Spending Raise your hand if you thought demand for mobile homes would snap back very quickly while unemployment remains so high. Winnebago (NYSE: WGO ) just announced that it doubled the amount of mobile homes and campers it made in its fiscal third quarter compared with a year earlier. | On Wednesday, the company secured an impressive agreement with Abbott Labs (NYSE: ABT ) . Among the biggest winners in Thursday's early trading are Neurocrine Biosciences, (Nasdaq: NBIX ) , Pier One (NYSE: PIR ) and Winnebago (NYSE: WGO ) . ------------------------------------ Pier One Follow-up In early June, we noted that retailer Pier One (NYSE: PIR ) posted impressive sales results, and we anticipated a fairly robust profit report when the company ultimately released quarterly results. | On Wednesday, the company secured an impressive agreement with Abbott Labs (NYSE: ABT ) . Among the biggest winners in Thursday's early trading are Neurocrine Biosciences, (Nasdaq: NBIX ) , Pier One (NYSE: PIR ) and Winnebago (NYSE: WGO ) . Winnebago (NYSE: WGO ) just announced that it doubled the amount of mobile homes and campers it made in its fiscal third quarter compared with a year earlier. | On Wednesday, the company secured an impressive agreement with Abbott Labs (NYSE: ABT ) . This time around, shares should hold their gains -- and then some. ------------------------------------ Pier One Follow-up In early June, we noted that retailer Pier One (NYSE: PIR ) posted impressive sales results, and we anticipated a fairly robust profit report when the company ultimately released quarterly results. |
34559.0 | 2010-06-16 00:00:00 UTC | Wednesday Winners: Neurocrine Biosciences, Sunoco and Ener1 | ABT | https://www.nasdaq.com/articles/wednesday-winners-neurocrine-biosciences-sunoco-and-ener1-2010-06-16 | nan | nan | Among the biggest winners in Wednesday's early trading are Neurocrine Biosciences (Nasdaq: NBIX ) , Sunoco (NYSE: SUN ) and Ener1 (NYSE: HEV ) .
A Key Endorsement
Small biotech firms have two goals: prove that their drugs are effective and safe, and find a large partner to help bring the drugs to market. Neurocrine Biosciences (Nasdaq: NBIX ) has met both of those goals in just three weeks. We told you on May 25 that the company's drug that boosts fertility of otherwise infertile women showed very strong results in Phase II clinical testing. We concluded our assessment by noting that, "A large partnership agreement stands as the next near-term catalyst. Shares should be bought in advance of such an agreement."
That window has just closed. Abbott Labs (NYSE: ABT ) has announced a wide-ranging partnership that will net Neurocrine $75 million now, and up to $500 million more down the road. Neurocrine still must complete Phase III trials, which is often the hardest hurdle to pass. But if successful, this drug should find a fairly large potential market, as no competing approaches exist. The Abbott imprimatur is pushing shares up +10% today.
Action to Take --> The near-term gains have been made in the stock, and you couldn't be faulted for taking profits if you followed our advice. As time passes, shares may pull back in the face of market weakness, which would create a better entry point.
------------------------------------
Sunoco Unlocks Value
Over the last few decades, a wide range of conglomerates sought to break themselves into smaller pieces as they realized that investors failed to fully grasp the value of disparate businesses. This was known as "the conglomerate discount." Sunoco (NYSE: SUN ) has belatedly realized that breaking up is the path to a higher stock price. Shares have fallen sharply from their 2006 peak of $95. But they're up +8% in Wednesday trading to a two-year high as Sunoco announced plans to spin off its coking business. Coke is a high-grade form of coal used to generate intense heat at steel-making plants.
The coking business was one of the few bright spots on Sunoco's income statement . It's oil refinery and gas station businesses have been in the midst of a tough slog, though management notes that operation are improving their as well.
Action to Take --> Sunoco will be increasingly reliant on its oil refinery activities. And that industry has been characterized by very low profit margins thanks to weakening demand for gasoline. As cars and trucks are expected to get even more efficient in coming years, demand for gasoline is unlikely to sharply rebound, making this a fairly unappealing investment.
------------------------------------
Good Call, Bad Timing
In late May, we suggested that investors had been too harsh in dumping shares of advanced battery makers A123 Systems (Nasdaq: AONE ) and Ener1 (NYSE: HEV ) .
Shares slumped further from there, but have bounced back nicely this week. Shares of Ener1 are up nearly +5% to $3.60 on Wednesday after a +12% gain on Tuesday. Analysts at Needham & Co. initiated coverage of the stock on Monday with a $6 price target, noting that "the company is positioned to become a major supplier of lithium-ion (li-ion) battery systems into a growing passenger vehicle market."
Ener1 already has key relationships with Norwegian electric car maker THINK, Volvo and China's largest battery manufacturer. As production volumes ramp up to support those relationships, Needham's Michael Lew thinks other auto makers will sign on as customers as well.
Action to Take --> These stocks have taken quite a drubbing and remain close to their 52-week lows. Their outlooks are quite bright, and if you stay focused on the long-term, you may see considerable upside as the electric and hybrid car markets take off.
-- David Sterman
Staff Writer
StreetAuthority
Disclosure: David Sterman owns shares of Neither StreetAuthority and LCC nor the editor hold positions in any securities mentioned in this report..
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© Copyright 2001-2010 StreetAuthority, LLC. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (NYSE: ABT ) has announced a wide-ranging partnership that will net Neurocrine $75 million now, and up to $500 million more down the road. ------------------------------------ Sunoco Unlocks Value Over the last few decades, a wide range of conglomerates sought to break themselves into smaller pieces as they realized that investors failed to fully grasp the value of disparate businesses. ------------------------------------ Good Call, Bad Timing In late May, we suggested that investors had been too harsh in dumping shares of advanced battery makers A123 Systems (Nasdaq: AONE ) and Ener1 (NYSE: HEV ) . | Abbott Labs (NYSE: ABT ) has announced a wide-ranging partnership that will net Neurocrine $75 million now, and up to $500 million more down the road. Among the biggest winners in Wednesday's early trading are Neurocrine Biosciences (Nasdaq: NBIX ) , Sunoco (NYSE: SUN ) and Ener1 (NYSE: HEV ) . ------------------------------------ Good Call, Bad Timing In late May, we suggested that investors had been too harsh in dumping shares of advanced battery makers A123 Systems (Nasdaq: AONE ) and Ener1 (NYSE: HEV ) . | Abbott Labs (NYSE: ABT ) has announced a wide-ranging partnership that will net Neurocrine $75 million now, and up to $500 million more down the road. Among the biggest winners in Wednesday's early trading are Neurocrine Biosciences (Nasdaq: NBIX ) , Sunoco (NYSE: SUN ) and Ener1 (NYSE: HEV ) . ------------------------------------ Good Call, Bad Timing In late May, we suggested that investors had been too harsh in dumping shares of advanced battery makers A123 Systems (Nasdaq: AONE ) and Ener1 (NYSE: HEV ) . | Abbott Labs (NYSE: ABT ) has announced a wide-ranging partnership that will net Neurocrine $75 million now, and up to $500 million more down the road. Among the biggest winners in Wednesday's early trading are Neurocrine Biosciences (Nasdaq: NBIX ) , Sunoco (NYSE: SUN ) and Ener1 (NYSE: HEV ) . Ener1 already has key relationships with Norwegian electric car maker THINK, Volvo and China's largest battery manufacturer. |
34560.0 | 2010-06-07 00:00:00 UTC | Abbott Labs Downgraded at Goldman Sachs (ABT) | ABT | https://www.nasdaq.com/articles/abbott-labs-downgraded-goldman-sachs-abt-2010-06-07 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) saw its rating cut on Monday by analysts at Goldman Sachs.
The firm lowered its rating on ABT to "Neutral" from "Buy," but maintained its $69 price target on the stock. That target represents a more than 48% upside to Abbott's Friday closing price of $46.53.
Goldman noted that it sees a better combination of upside potential and earnings catalysts for Abbott's competitor, Bristol Myers ( BMY ) , which the firm upgraded to a "Buy" today.
Abbott Labs shares fell 33 cents, or -0.7%, in premarket trading Monday.
The Bottom Line
We had removed shares of ABT from our recommended list back on Apr.27, when the stock was trading at $50.37. The company has a 3.78% dividend yield, based on Friday's closing stock price of $ 46.53. The stock has technical support in the $43-$44 price area. If the shares can firm up, we see overhead resistance around the $50 price level. We would remain on the sidelines for now.
Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) saw its rating cut on Monday by analysts at Goldman Sachs. The Bottom Line We had removed shares of ABT from our recommended list back on Apr.27, when the stock was trading at $50.37. The firm lowered its rating on ABT to "Neutral" from "Buy," but maintained its $69 price target on the stock. | Healthcare products maker Abbott Laboratories ( ABT ) saw its rating cut on Monday by analysts at Goldman Sachs. The firm lowered its rating on ABT to "Neutral" from "Buy," but maintained its $69 price target on the stock. The Bottom Line We had removed shares of ABT from our recommended list back on Apr.27, when the stock was trading at $50.37. | Healthcare products maker Abbott Laboratories ( ABT ) saw its rating cut on Monday by analysts at Goldman Sachs. The firm lowered its rating on ABT to "Neutral" from "Buy," but maintained its $69 price target on the stock. The Bottom Line We had removed shares of ABT from our recommended list back on Apr.27, when the stock was trading at $50.37. | The firm lowered its rating on ABT to "Neutral" from "Buy," but maintained its $69 price target on the stock. Abbott Laboratories ( ABT ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Healthcare products maker Abbott Laboratories ( ABT ) saw its rating cut on Monday by analysts at Goldman Sachs. |
34561.0 | 2010-05-21 00:00:00 UTC | 5 Booming Blue Chip Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/5-booming-blue-chip-stocks-buy-now-2010-05-21 | nan | nan | 5 Top Small Cap Stocks
5 Top Blue Chip Stocks to Buy Now
The stock market wasn't kind to investors in May, with the major indexes taking a tumble. But if you think this is a sign the bull market is over and that you should "sell in May and go away," think again. The recent correction on Wall Street provides a big buying opportunity in a number of fundamentally superior U.S. companies.
In fact, I believe the "euro crisis" centered in Greece and China's recent inflationary boom both present more benefits than challenges for investors, at least in the longer term. Troubles elsewhere have been driving buying pressure behind stable American blue chip stocks, as well as supporting the U.S. bond and currency markets. This has provided a measure of stability for investors - as well as big profit opportunities in stocks that just showed their strength after earnings.
Here are five booming blue chip stocks that will provide stability to your portfolio in the short-term and big profits in the months ahead.
NEXT - Blue Chip Stock to Buy #1
5 Top Small Cap Stocks
Blue Chip Stock to Buy #1 - AmerisourceBergen Corp.
AmerisourceBergen Corp. (NYSE: ABC ) is a Pennsylvania-based company that acts as an intermediary between pharmaceutical companies and health care providers such as hospitals and drugstores that dispense drugs. The company operates mostly in Canada and the United States, distributing both prescription and over-the-counter drugs, as well as some medical supplies.
This recession-proof business hasn't missed a beat in the last year and has recently gained even more momentum due to health care reform measures that would broaden drug coverage. ABC has grown its earnings for each of the last four consecutive quarters and has topped Wall Street expectations in each of those periods by an average of almost 12%. That's fundamental strength unmatched by other health care blue chips.
NEXT - Blue Chip Stock to Buy #2
5 Top Small Cap Stocks
Blue Chip Stock to Buy #2 - Hospira, Inc.
Illinois health care company Hospira, Inc. (NYSE: HSP ) is another great blue chip stock to buy. HSP stock was spun off from drug stock Abbott Laboratories (NYSE: ABT ) and makes specialty injectable pharmaceuticals (primarily generics) and other drug delivery-related equipment. Almost half of Hospira's sales are to group purchasing organizations (GPOs), including Premier, Broadlane and Novation, which means it can see a sales windfall in a hurry by virtue of a big order.
As with ABC, health care reform has been kind to Hospira. The company's latest earnings report at the end of April blew away forecasts by more than 30%. That would be impressive enough, but it's the fourth-straight earnings surprise of over 20% for HSP stock. Investors can rely on earnings strength like that in any market.
NEXT - Blue Chip Stock to Buy #3
5 Top Small Cap Stocks
Blue Chip Stock to Buy #3 - Colgate-Palmolive
U.S. blue chip Colgate-Palmolive Company (NYSE: CL ) needs no introduction since it is the top seller of toothpaste and a world leader in oral care products. The company also makes personal care items that include deodorants, shampoos and soaps, as well as household cleaners and pet nutrition products.
Colgate has grown both its revenue and sales for each of the last four consecutive quarters and is ready for another strong showing on July 29 when it releases its next earnings report. Shares have drifted downwards in May with the broader market, but this presents an excellent buying opportunity for investors ahead of their earnings report. I expect CL stock to bounce back nicely after releasing its numbers this summer.
NEXT - Blue Chip Stock to Buy #4
5 Top Small Cap Stocks
Blue Chip Stock to Buy #4 - Express Scripts
Express Scripts, Inc. (NASDAQ: ESRX ) is St. Louis-based provider of pharmacy benefit management services across North America. Some of its customers include third-party administrators, health insurers and employers. Besides providing customers with home delivery, benefit design consultation and disease management services, it also provides various specialty services like patient care and even marketing.
As the need for prescription drugs has increased due to expanded drug coverage, ESRX has shown strength over the last several months. On April 27, Barclays Capital upgraded the stock, and back in February, Caris & Company initiated coverage with a buy rating. I expect further success from this stock - buy it now.
NEXT - Blue Chip Stock to Buy #5
5 Top Small Cap Stocks
Blue Chip Stock to Buy #5 - Seagate Technology
Seagate Technology (NASDAQ: STX ) is a leading manufacturer of hard drives used in a wide variety of gadgets from personal computers and consumer electronics to high-end servers and mainframes. About two-thirds of Seagate's sales are to computer hardware manufacturers, which include Hewlett-Packard, Dell, EMC, IBM and Sun Microsystems, while distributors and retailers account for the rest.
Seagate has seen dramatic earnings growth across the last four consecutive quarters, coupled with four straight earnings surprises by as much as 150%. This company has the fundamentals necessary to succeed in any market, and it is a great investment after the recent market correction.
5 Top Small Cap Stocks - Free from Louis Navellier !
Small, innovative companies are watching their earnings explode - and they are the next ten-baggers. Investing pro Louis Navellier reveals his secrets to identifying these small cap innovators, plus five of his favorite small cap stocks - download your FREE profit guide here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | HSP stock was spun off from drug stock Abbott Laboratories (NYSE: ABT ) and makes specialty injectable pharmaceuticals (primarily generics) and other drug delivery-related equipment. In fact, I believe the "euro crisis" centered in Greece and China's recent inflationary boom both present more benefits than challenges for investors, at least in the longer term. This recession-proof business hasn't missed a beat in the last year and has recently gained even more momentum due to health care reform measures that would broaden drug coverage. | HSP stock was spun off from drug stock Abbott Laboratories (NYSE: ABT ) and makes specialty injectable pharmaceuticals (primarily generics) and other drug delivery-related equipment. NEXT - Blue Chip Stock to Buy #2 5 Top Small Cap Stocks Blue Chip Stock to Buy #2 - Hospira, Inc. Illinois health care company Hospira, Inc. (NYSE: HSP ) is another great blue chip stock to buy. NEXT - Blue Chip Stock to Buy #3 5 Top Small Cap Stocks Blue Chip Stock to Buy #3 - Colgate-Palmolive U.S. blue chip Colgate-Palmolive Company (NYSE: CL ) needs no introduction since it is the top seller of toothpaste and a world leader in oral care products. | HSP stock was spun off from drug stock Abbott Laboratories (NYSE: ABT ) and makes specialty injectable pharmaceuticals (primarily generics) and other drug delivery-related equipment. NEXT - Blue Chip Stock to Buy #1 5 Top Small Cap Stocks Blue Chip Stock to Buy #1 - AmerisourceBergen Corp. AmerisourceBergen Corp. (NYSE: ABC ) is a Pennsylvania-based company that acts as an intermediary between pharmaceutical companies and health care providers such as hospitals and drugstores that dispense drugs. NEXT - Blue Chip Stock to Buy #2 5 Top Small Cap Stocks Blue Chip Stock to Buy #2 - Hospira, Inc. Illinois health care company Hospira, Inc. (NYSE: HSP ) is another great blue chip stock to buy. | HSP stock was spun off from drug stock Abbott Laboratories (NYSE: ABT ) and makes specialty injectable pharmaceuticals (primarily generics) and other drug delivery-related equipment. NEXT - Blue Chip Stock to Buy #2 5 Top Small Cap Stocks Blue Chip Stock to Buy #2 - Hospira, Inc. Illinois health care company Hospira, Inc. (NYSE: HSP ) is another great blue chip stock to buy. Shares have drifted downwards in May with the broader market, but this presents an excellent buying opportunity for investors ahead of their earnings report. |
34562.0 | 2010-04-21 00:00:00 UTC | Abbott Laboratories Q1 Profit Surges 30%, Beating View (ABT) | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q1-profit-surges-30-beating-view-abt-2010-04-21 | nan | nan | Healthcare products maker Abbott Laboratories ( ABT ) said Wednesday that its first quarter profit fell 30% from last year, despite sharply higher revenue, as adjusted results beat analysts expectations.
The North Chicago, IL-based company reported first quarter net income of $1 billion, or 64 cents per share, compared with $1.44 billion, or 92 cents per share, in the year-ago period. Excluding one-time items, adjusted profit was 81 cents per share.
Revenue rose 15% from last year, to $7.7 billion, aided by 36% higher sales of its inflammatory disease drug, Humira.
On average, Wall Street analysts expected a slightly smaller profit of 80 cents per share, on slightly higher revenue of $7.73 billion.
Abbott Labs shares were mostly flat in premarket trading Wednesday.
The Bottom Line
We have been recommending shares of ABT since Oct.14, when the stock was trading at $49.65. The company has a 3.32% dividend yield, based on last night's closing stock price of $53.06.
Abbott Laboratories ( ABT ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Created by Dividend.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare products maker Abbott Laboratories ( ABT ) said Wednesday that its first quarter profit fell 30% from last year, despite sharply higher revenue, as adjusted results beat analysts expectations. The Bottom Line We have been recommending shares of ABT since Oct.14, when the stock was trading at $49.65. Abbott Laboratories ( ABT ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) said Wednesday that its first quarter profit fell 30% from last year, despite sharply higher revenue, as adjusted results beat analysts expectations. Abbott Laboratories ( ABT ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. The Bottom Line We have been recommending shares of ABT since Oct.14, when the stock was trading at $49.65. | Healthcare products maker Abbott Laboratories ( ABT ) said Wednesday that its first quarter profit fell 30% from last year, despite sharply higher revenue, as adjusted results beat analysts expectations. The Bottom Line We have been recommending shares of ABT since Oct.14, when the stock was trading at $49.65. Abbott Laboratories ( ABT ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. | Healthcare products maker Abbott Laboratories ( ABT ) said Wednesday that its first quarter profit fell 30% from last year, despite sharply higher revenue, as adjusted results beat analysts expectations. Abbott Laboratories ( ABT ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars. The Bottom Line We have been recommending shares of ABT since Oct.14, when the stock was trading at $49.65. |
34563.0 | 2010-04-20 00:00:00 UTC | Medicated Gains | ABT | https://www.nasdaq.com/articles/medicated-gains-2010-04-20 | nan | nan | The contentious debate over the shape of health care reform has finally drawn to a close, and despite the dire predictions, the industry has emerged intact. In fact, the legislation could present a unique opportunity for health care companies to grow revenues at the fastest pace in decades.
After a year of intense debate and acrimony, Congress has finally finished its work on health care reform. In its final form, the legislation is expected to reduce the uninsured population by 30 million by 2019 through a mandate that will require almost every American to carry health insurance. This individual mandate should boost consumption of health care goods and services substantially.
Although the pharmaceutical industry is on the hook to pay $85 billion into the program over the next ten years, its early involvement in the process and willingness to negotiate won it concessions on stronger patent protections and spared it the pain negotiating directly with the government over prices for federally administered programs.
One name that stands to benefit is Abbott Laboratories ( ABT ), a leading pharmaceutical company that also offers nutritional, diagnostic and vascular products. A diverse product line and strong international business are reason enough to invest in the company, but analysts forecast that health care reform could expand the company's US revenues by as much as 20 percent over the next decade.
And Abbott Laboratories doesn't face any major patent expirations; the company's last major loss came in 2008, when the patent on epilepsy drug Depakote expired. Abbott has coped well with the challenge, reformulating the drug for extended release--a move that should delay any major challenge from generic manufacturers for at least a few years.
The firm's only major drawback is its weakness in developing its drug pipeline internally. Abbott pursues an aggressive acquisition strategy, buying up smaller firms with promising products and businesses. Its most recent acquisition, STARLIMS Technologies, provides entrée into the medical information technology field, and last year's acquisitions of Advanced Medical Optics and Visiogen give Abbott a strong presence in the eye-care market, especially the rapidly growing field of LASIK vision corrective surgery. Abbott's purchase of Belgian pharmaceutical maker Solvay also deepened its drug pipeline while greatly expanding its presence in Europe and emerging markets.
That being said, Abbott does have a strong pipeline of drugs. One of its best candidates addresses Crohn's Disease and psoriasis. It also has several early- and mid-stage oncology treatments, as well as compounds in immunology, neuroscience, pain management and infectious diseases.
Abbott's acquisitions and strong growth bumped full-year 2009 earnings up 12 percent from a year ago to $3.72 per share. Revenues grew 4.2 percent over that period. This impressive performance occurred amid a fragile global economy and weak currencies, suggesting that 2010 will be an even better year for the company--especially as its international business continues to grow. Last year Abbott generated more than half its revenues outside the US, and that proportion should increase after the recent acquisition of Solvay.
Although Abbott Laboratories offers strong growth prospects, it would be better classified and as a growth-and-income play; it pays a quarterly dividend of 44 cents, giving the stock a current yield of 3.4 percent.
Why to Buy
ABBOTT LABORATORIES (NYSE: ABT, $52.61)
• Reform boosts consumption of health care products
• Strong pipeline
• No major patent expirations
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Article Republished with permission from www.KCIinvesting.com and www.rukeyser.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One name that stands to benefit is Abbott Laboratories ( ABT ), a leading pharmaceutical company that also offers nutritional, diagnostic and vascular products. Abbott's purchase of Belgian pharmaceutical maker Solvay also deepened its drug pipeline while greatly expanding its presence in Europe and emerging markets. This impressive performance occurred amid a fragile global economy and weak currencies, suggesting that 2010 will be an even better year for the company--especially as its international business continues to grow. | One name that stands to benefit is Abbott Laboratories ( ABT ), a leading pharmaceutical company that also offers nutritional, diagnostic and vascular products. Its most recent acquisition, STARLIMS Technologies, provides entrée into the medical information technology field, and last year's acquisitions of Advanced Medical Optics and Visiogen give Abbott a strong presence in the eye-care market, especially the rapidly growing field of LASIK vision corrective surgery. Although Abbott Laboratories offers strong growth prospects, it would be better classified and as a growth-and-income play; it pays a quarterly dividend of 44 cents, giving the stock a current yield of 3.4 percent. | One name that stands to benefit is Abbott Laboratories ( ABT ), a leading pharmaceutical company that also offers nutritional, diagnostic and vascular products. A diverse product line and strong international business are reason enough to invest in the company, but analysts forecast that health care reform could expand the company's US revenues by as much as 20 percent over the next decade. Its most recent acquisition, STARLIMS Technologies, provides entrée into the medical information technology field, and last year's acquisitions of Advanced Medical Optics and Visiogen give Abbott a strong presence in the eye-care market, especially the rapidly growing field of LASIK vision corrective surgery. | One name that stands to benefit is Abbott Laboratories ( ABT ), a leading pharmaceutical company that also offers nutritional, diagnostic and vascular products. A diverse product line and strong international business are reason enough to invest in the company, but analysts forecast that health care reform could expand the company's US revenues by as much as 20 percent over the next decade. That being said, Abbott does have a strong pipeline of drugs. |
34564.0 | 2010-03-15 00:00:00 UTC | 2 Things Investors Don't Want to See Happen | ABT | https://www.nasdaq.com/articles/2-things-investors-dont-want-see-happen-2010-03-15 | nan | nan | Investors seemed as conflicted as the economic reports on Friday. The major indices closed mixed following a week of gains, and selling in the financial sector halted a 10-day winning streak.
The opening was strong following a 0.3% increase in retail sales and a 0.8% increase ex-autos for February, when economists had been looking for a decline of 0.2% for total retail sales and a 0.1% increase in sales ex-autos.
But the early gains vanished when the University of Michigan's preliminary consumer sentiment survey for March came in at 72.5 instead of the expected 74.
All four of the big financial stocks that led the market earlier in the week turned down. And Citigroup ( C ), which had a good run thanks to rumors that the government was going to unload its shares, fell 5%.
Stocks making large moves included: Aeropostale ( ARO ), up 4.2% on better earnings; Citigroup, off 5% on a "neutral" rating by Oppenheimer; Pall Corp. ( PLL ), down 4.8% after missing analysts' estimates; Abbott Labs ( ABT ), down 1.8% on a rating cut by Citi; and SuperValu ( SVU ), up 6.6% on rumors that it was the target of a leveraged buyout.
The U.S. dollar weakened against the yen and the euro on Friday.
The Dow Jones Industrial Average ( DJI ) gained 13 points to 10,625, the S&P 500 ( SPX ) fell fractionally to 1,150, and the Nasdaq ( NASD ) fell a point to 2,368.
The NYSE traded less than 1.1 billion shares with advancers leading decliners by 8-to-7. On the Nasdaq, decliners were ahead by 7-to-6 on volume of 573 million shares.
Crude oil for April delivery fell 87 cents to $81.24 a barrel because of conflicting signals on the U.S. economy. The Energy Select Sector SPDR ( XLE ) rose 3 cents to $58.50.
April gold fell $6.50 to $1,101.70 an ounce on signs of a stabilization of the economic problem in Greece. The PHLX Gold/Silver Sector Index ( XAU ) fell 1.2 points to 166.04.
What the Markets Are Saying
"What an interesting market," one analyst was heard saying while another opined that he could do with less interest and more gains. I'm sure that's how many investors feel as the S&P 500 has become temporarily "stuck" at the top of its 2010 peak made on Jan. 15 and 18. Friday, the index closed at 1,149.99.
A high-breadth, high-volume advance from here would confirm that the primary uptrend of the market is still intact. But a failure to make a new high could create a double-top with the possible implication of an intermediate turn down or a sideways trend for an indeterminate time -- and no one wants to see either occur.
Initial support for a move down is at 1,125, with major support at the conjunction of the 20- and 50-day moving averages at around 1,112.
The Dow's view is somewhat like the S&P 500, but is weaker since it has not yet reached the January peak of 10,736. However, the Dow did penetrate its March peak Friday, and because that gain keeps the current uptrend intact for the Dow, it is a mild positive.
But there is significant overhead at the former high, and that overhead is greatly influenced by three Dow components: IBM ( IBM ), 3M ( MMM ), and Chevron ( CVX ), and they are the three highest-priced Dow members.
The Nasdaq, of course, has broken its January high and is the strongest of the major indices. But whether this is good news for the market remains to be seen since old-timers (like me) think of Nasdaq as the more "speculative" of the major indices, and therefore is usually bought by the public and traders. In other words, it's in "weaker hands" than the senior indices. But newer theory holds that there are many quality stocks in the Nasdaq, so the old rules no longer apply. We will see.
Meanwhile, lots of other important indices have broken to new highs, including the Dow Jones Transportation Average ( DJT ), technology and financial indices, the Russell 2000 ( RUT ) and the S&P MidCap 400 Index ( MID ).
Stay tuned because the pressure is building, and this could be "the week that was."
Today's Trading Landscape
Earnings to be reported before the opening include: AAON, American Oriental, Global Sources, GTX, Houston Wire & Cable, RadNet, Schawk and Sterling Construction.
Earnings to be reported after the close include: AthenaHealth, Emeritus Corp., Geokinetics, HQ Sustainable Maritime Industries, Medivation, Seaspan and Sequenom.
Economic reports due: Empire State Manufacturing Survey (the consensus expects 22), Treasury International Capital ( TIC ), industrial production (the consensus expects 0% for production and 72.4% for capacity utilization rate), and housing market index.
Related Articles:
Sweet 16 Option Trades
Profit From Greece's Short-Term Recovery With NBG Calls
7 Ways to Tell a Stock is Headed Down
The Options Trader's Guide to Technical Analysis
In his latest report, learn how John Lansing leverages the power of technical analysis to identify the short window when a trade is set to go straight up or down. Get your FREE copy here!
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks making large moves included: Aeropostale ( ARO ), up 4.2% on better earnings; Citigroup, off 5% on a "neutral" rating by Oppenheimer; Pall Corp. ( PLL ), down 4.8% after missing analysts' estimates; Abbott Labs ( ABT ), down 1.8% on a rating cut by Citi; and SuperValu ( SVU ), up 6.6% on rumors that it was the target of a leveraged buyout. Today's Trading Landscape Earnings to be reported before the opening include: AAON, American Oriental, Global Sources, GTX, Houston Wire & Cable, RadNet, Schawk and Sterling Construction. Earnings to be reported after the close include: AthenaHealth, Emeritus Corp., Geokinetics, HQ Sustainable Maritime Industries, Medivation, Seaspan and Sequenom. | Stocks making large moves included: Aeropostale ( ARO ), up 4.2% on better earnings; Citigroup, off 5% on a "neutral" rating by Oppenheimer; Pall Corp. ( PLL ), down 4.8% after missing analysts' estimates; Abbott Labs ( ABT ), down 1.8% on a rating cut by Citi; and SuperValu ( SVU ), up 6.6% on rumors that it was the target of a leveraged buyout. The Dow Jones Industrial Average ( DJI ) gained 13 points to 10,625, the S&P 500 ( SPX ) fell fractionally to 1,150, and the Nasdaq ( NASD ) fell a point to 2,368. Meanwhile, lots of other important indices have broken to new highs, including the Dow Jones Transportation Average ( DJT ), technology and financial indices, the Russell 2000 ( RUT ) and the S&P MidCap 400 Index ( MID ). | Stocks making large moves included: Aeropostale ( ARO ), up 4.2% on better earnings; Citigroup, off 5% on a "neutral" rating by Oppenheimer; Pall Corp. ( PLL ), down 4.8% after missing analysts' estimates; Abbott Labs ( ABT ), down 1.8% on a rating cut by Citi; and SuperValu ( SVU ), up 6.6% on rumors that it was the target of a leveraged buyout. The Dow Jones Industrial Average ( DJI ) gained 13 points to 10,625, the S&P 500 ( SPX ) fell fractionally to 1,150, and the Nasdaq ( NASD ) fell a point to 2,368. Meanwhile, lots of other important indices have broken to new highs, including the Dow Jones Transportation Average ( DJT ), technology and financial indices, the Russell 2000 ( RUT ) and the S&P MidCap 400 Index ( MID ). | Stocks making large moves included: Aeropostale ( ARO ), up 4.2% on better earnings; Citigroup, off 5% on a "neutral" rating by Oppenheimer; Pall Corp. ( PLL ), down 4.8% after missing analysts' estimates; Abbott Labs ( ABT ), down 1.8% on a rating cut by Citi; and SuperValu ( SVU ), up 6.6% on rumors that it was the target of a leveraged buyout. Investors seemed as conflicted as the economic reports on Friday. The Dow's view is somewhat like the S&P 500, but is weaker since it has not yet reached the January peak of 10,736. |
34565.0 | 2010-03-11 00:00:00 UTC | Why the Market is Stuck | ABT | https://www.nasdaq.com/articles/why-market-stuck-2010-03-11 | nan | nan | A choppy day on Wall Street ended mixed to slightly higher. Both financial and technology sectors outperformed their peers -- the highlight of the day being the successful offering of $2 billion of trust preferred securities by Citigroup ( C ). The KBW Bank Index ( BKX ) rose 2.2%.
Google ( GOOG ) rose 2.9% following the conclusion of negotiations with the Chinese government regarding censorship of its Chinese sites. And Facet Biotech ( FACT ) received an offer from Abbott Labs ( ABT ) to acquire the company for $27 a share.
The rise in technology stocks led to a new 52-week high in Nasdaq the ( NASD ).
Wholesale inventories for January fell 0.2% when a gain of 0.2% was expected. Treasury prices fell 6/32 to yield 3.723% on the 10-year note.
At the close, the Dow Jones Industrial Average ( DJI ) was up 3 points to 10,567, the S&P 500 ( SPX ) rose 5 points to 1,146, and the Nasdaq gained 18 points to 2,359.
The NYSE traded 1.1 billion shares, and Nasdaq crossed 702 million shares. Both registered more advancers than decliners by 2-to-1.
April crude oil rose 60 cents to $82.09 a barrel, boosted by data that showed that the U.S. fuel supply is tightening while demand is increasing. The Energy Select Sector SPDR ( XLE ) rose 51 cents to $58.57.
The March gold contract fell $14.20 to $1,107.80 an ounce, and the PHLX Gold/Silver Sector Index ( XAU ) fell $2.39 to $165.83.
What the Markets Are Saying
The market is now just inching forward (except for Nasdaq), and volume is still very light. The Investor Intelligence Advisor Sentiment reporte yesterday showed that advisers have increased their bullishness for four consecutive weeks and now sit at 44.9% bullish and 23.6% bearish. This is a contra-indicator and not supportive of a major market advance from the current price levels.
Michael Ashbaugh of MarketWatch summarizes the current situation:
The case for the bulls: Some important indices have broken out including the Nasdaq, Dow Jones Transportation Average ( DJT ), Russell 2000 ( RUT ), and the S&P MidCap 400 Index ( MID ). Also, retailers and consumer discretionary names are hitting new highs. China is holding up well to significant resistance.
The case for the bears: The S&P 500 hasn't broken out yet, the recent upturn has come on unusually light volume, and investor sentiment measures, like the CBOE Volatility Index ( VIX ), have reached complacent extremes.
As our readers know, I'm more in the camp of the short-term bears. I believe that the market will eventually break to new highs, but conclude from the data I see that even if the S&P 500 was to break to new highs it is unlikely that there would be strong follow-through.
Until the break occurs and vaults through resistance on high volume and strong breadth, it is likely that we will be trading within the current narrow zones of support for several more months.
Today's Trading Landscape
Earnings to be reported before the opening include: Chemspec International, China Sunergy, Delek US Holdings, Imax, Jackson Hewitt, Metalico, NGP Capital Resources, Piedmont Natural Gas, Smithfield Foods, Stewart Enterprises, Sun Communities and The Buckle.
Earnings to be reported after the close: Aeropostale, Air Methods, Clear Channel Outdoor Holdings, GMX Resources, Goldcorp, HQ Sustainable Maritime Industries, Kodiak Oil & Gas, National Semiconductor, NPS Pharmaceuticals, Obagi Medical Products, Optimer Pharmaceuticals, Pacific Sunwear, Pall Corp, PowerSecure, Quiksilver, SeaChange, Shuffle Master, Smith & Wesson, Ulta Salon and Zumiez.
Economic reports due: international trade (the consensus expects -$41 billion), jobless claims (the consensus expects 460,000), EIA natural gas report, Fed balance sheet and money supply.
Related Articles:
An 'Ultra' Risky Bet on the Financials
5 Way to Trade Options for Retirement
The Problem With Put/Call Ratios
Trade Options to Get Richer, Quicker!
There has never been a more exciting time to be an options trader. And now, you can get the option information you need FREE each week. Sign up for your free subscription to Chris Johnson's Market Edge newsletter today!
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And Facet Biotech ( FACT ) received an offer from Abbott Labs ( ABT ) to acquire the company for $27 a share. Michael Ashbaugh of MarketWatch summarizes the current situation: The case for the bulls: Some important indices have broken out including the Nasdaq, Dow Jones Transportation Average ( DJT ), Russell 2000 ( RUT ), and the S&P MidCap 400 Index ( MID ). The case for the bears: The S&P 500 hasn't broken out yet, the recent upturn has come on unusually light volume, and investor sentiment measures, like the CBOE Volatility Index ( VIX ), have reached complacent extremes. | And Facet Biotech ( FACT ) received an offer from Abbott Labs ( ABT ) to acquire the company for $27 a share. Michael Ashbaugh of MarketWatch summarizes the current situation: The case for the bulls: Some important indices have broken out including the Nasdaq, Dow Jones Transportation Average ( DJT ), Russell 2000 ( RUT ), and the S&P MidCap 400 Index ( MID ). Economic reports due: international trade (the consensus expects -$41 billion), jobless claims (the consensus expects 460,000), EIA natural gas report, Fed balance sheet and money supply. | And Facet Biotech ( FACT ) received an offer from Abbott Labs ( ABT ) to acquire the company for $27 a share. Today's Trading Landscape Earnings to be reported before the opening include: Chemspec International, China Sunergy, Delek US Holdings, Imax, Jackson Hewitt, Metalico, NGP Capital Resources, Piedmont Natural Gas, Smithfield Foods, Stewart Enterprises, Sun Communities and The Buckle. Earnings to be reported after the close: Aeropostale, Air Methods, Clear Channel Outdoor Holdings, GMX Resources, Goldcorp, HQ Sustainable Maritime Industries, Kodiak Oil & Gas, National Semiconductor, NPS Pharmaceuticals, Obagi Medical Products, Optimer Pharmaceuticals, Pacific Sunwear, Pall Corp, PowerSecure, Quiksilver, SeaChange, Shuffle Master, Smith & Wesson, Ulta Salon and Zumiez. | And Facet Biotech ( FACT ) received an offer from Abbott Labs ( ABT ) to acquire the company for $27 a share. This is a contra-indicator and not supportive of a major market advance from the current price levels. I believe that the market will eventually break to new highs, but conclude from the data I see that even if the S&P 500 was to break to new highs it is unlikely that there would be strong follow-through. |
34566.0 | 2010-02-25 00:00:00 UTC | Comparing Dividend Aristocrats to Dividend Champions | ABT | https://www.nasdaq.com/articles/comparing-dividend-aristocrats-dividend-champions-2010-02-25 | nan | nan | David Van Knapp submits:
There are two lists that serve as basic source material for investors interested in long-term dividend-raisers. One is the well-known Dividend Aristocrats list published by S&P. (To get the list, click the link here, then Market Attributes, then Dividend Aristocrats. Free registration is required.) The other is the lesser-known Dividend Champions list maintained by The DRiP Investing Resource Center, a non-profit organization.
In my book, the latter list is far more useful than the former. What follows is a comparison between the two lists.
Goals: Both lists, at first glance, appear to have the same goal: To identify companies that have raised their dividends for 25 consecutive years. That would lead one to believe that the lists should be identical. But they are not. The Dividends Aristocrats [DA] list identifies 43 such companies as of February 17, 2010. The Dividend Champions [DC] list names 98 . How can that be? The answer lies in the methods used to compile the lists.
The two organizations use slightly different wording to describe what their lists show. S&P states that the DA list shows companies with "25 consecutive years of increased cash payments." DriP puts it this way: "[C]ompanies that have increased their dividend in at least 25 consecutive years[,…]broadened to include additional companies that [have] paid higher dividends (without necessarily having increased the quarterly rate in every calendar year."
Source Universe: DA uses the S&P 500. If a company is removed from the S&P 500, it is immediately removed from the DA list. If a company is added to the S&P 500, it is not eligible to be included on the DA list until the list is recompiled in mid-December each year. DC does not specify its universe, but it appears simply to be all US-based companies. Note that neither list includes foreign-based companies.
Update Schedule: S&P's DA list is updated once per year, in mid-December. It remains unchanged during the year unless a company is dropped from the S&P 500 as just described. Each month during the year, DA is updated to show whether or not a dividend increase or decrease has been declared by each company on the list. So even if a company declares a decreased dividend early in the year, the company will remain on the DA list for the rest of the year. For example, when GE announced in Feb. 2009 that it intended to cut its dividend, GE remained on the DA list for the rest of 2009, with a notation that its dividend had "decreased in February."
DC is updated every month. GE was deleted from its list at the end of Feb, 2009, as it should have been. DC maintains a running chronology of changes to its list. That chronology notes, "2/27/09: Deleted General Electric (div. reduced)." GE has not appeared on the DC list since that date.
What Qualifies as a Dividend Increase: S&P focuses on "dividend actions." These are positive declarations by a company that it is increasing its dividend.
DriP focuses on the actual dividend paid annually. This introduces another difference between the two lists. A company can increase its dividend distribution year-over-year without declaring a dividend increase. For example, "alternators" are companies that declare a dividend increase every other year, then hold the payment steady between increases. Say that a company pays out four times per year, as is typical of US companies. Then the actual annual dividend distribution will rise each year even if there is a declared increase only every other year. DC picks up such companies, DA does not. (If it is not intuitive to you why every-other-year increases result in annually increasing payouts, see the example in the DC document.)
Another apparent difference is that DC accounts for "special dividends." When a company declares a special dividend, it can appear the following year that it cut its dividend, even though its "regular dividend" has actually increased. DC factors out special dividends for its listing, and therefore it does not drop a company on the basis that it issued a special dividend the preceding year.
Information Provided by Both Lists: Each list gives the company name, ticker symbol, and sector/industry for each company on its list. Each list is available in Excel spreadsheet form. DriP also provides a pdf version of DC. The DA list is alphabetical, while the DC list is in descending order of the dividend streak.
Additional Information Provided: DA provides a year-by-year tabulation (going back 8 years) of dividend actions by the companies on its list. It tells what month the dividend was increased in that year. For the current year, it tells whether a company has decreased its dividend, without removing the stock from the list. If the company has neither increased nor decreased its dividend in the current or preceding year, that cell is left blank in the spreadsheet. Even if a company has declared a decreased dividend, S&P keeps the company on the DA list until the next December update. So, for example, in the list dated 11/11/2009, DA showed 52 companies, even though 8 of them had decreased their dividends (as noted in the document). Two other companies remained on the list even though no increase was noted in either 2008 or 2009. All 10 of those companies have been removed from the 2010 list.
DriP's DC list provides a host of additional information beyond the bare list itself:
Number of years of consecutive dividend increases (the leader = Diebold [DBD] at 56 years)
Whether the company offers a dividend re-investment plan [DRIP]
Price and yield as of the end of each month
The old and new quarterly dividend rate
The percentage of the most recent dividend increase
The ex-dividend, record, and payment dates
DriP's source of information for each stock
Notes, such as whether a stock's information has been adjusted because it issued a stock dividend, or if its payment schedule is other than quarterly
Totals and averages for all the stocks
A chronology of all adds, deletes, and methodology adjustments since the DC list was first published in 2007
The DC list uses colors to flag special situations: It uses green to indicate that an increase announcement is expected in the next 30 days. It uses red to indicate that the last dividend increase was more than a year ago (i.e., that this stock is a candidate to be dropped from the list.)
The DC list drops stocks that freeze their dividend across two consecutive years. For example, Johnson Controls ( JCI ) is one of the companies noted earlier that S&P kept on its list even though their spreadsheet showed blanks for both 2008 and 2009 (i.e., no dividend increases). DRiP, on the other hand, noted in its chronology that Johnson Controls was dropped in 9/2009 because "4 divs. pd. 2009 = 2008."
Finally, the DC list includes an addendum of "contenders," companies that have recorded at least 15 but less than 25 years of dividend growth. Thus, DC is really a source for companies that have increased their dividends for 15 years or more I have seen it said that business cycles typically last for 3-8 years. Therefore, a company with a 15-year history of dividend growth has maintained that record through at least two business cycles, while a company with 25 straight years has done it through at least three cycles. Each is an impressive achievement.
Notes on Use: In my opinion, either list should be used only as a starting point for doing your own due diligence. As many banks proved in 2008-09, just because a company has raised its dividend many years in a row does not mean that it has the financial wherewithal to keep doing so. Some financial institutions raised their dividends (and repurchased shares) just months before failing. Utilize a method for determining the financial soundness of a company, and the sustainability of its business model, before investing in it for increasing dividends. I modestly suggest the method laid out in my own The Top 40 Dividend Stocks for 2010: How to Generate Wealth or Income from Dividend Stocks .
Also, just because a company has been raising its dividend for many years does not mean that it has a good yield. If you have a threshold minimum yield of 2.5% or 3%, some of these companies will not meet it. For example, Parker-Hannifin (52-year streak) yields 1.8% at the moment. Tootsie Roll (44 years) yields 1.2%.
Company Comparison: The following table compares the two lists. It shows vividly the difference between them as sources for 25-year dividend raisers. You will note that just one company-Supervalu-appears on the DA list and not on the DC list. The company cut its dividend last October; it is not clear why S&P kept it on the DA list for 2010.
Company
S&P
Dividend Aristocrat?
DRiP
Dividend Champion?
Abbott Laboratories ( ABT )
Yes
Yes (37 years)
ABM Industries ( ABM )
Yes (43)
Aflac ( AFL )
Yes
Yes (27)
Air Products & Chemicals ( APD )
Yes
Yes (27)
American States Water ( AWR )
Yes (55)
Archer Daniels Midland ( ADM )
Yes
Yes (34)
AT&T ( T )
Yes (26)
Automatic Data Processing ( ADP )
Yes
Yes (35)
Bancorp South ( BXS )
Yes (25)
Bank of Hawaii ( BOH )
Yes (30)
Becton Dickinson ( BDX )
Yes
Yes (37)
Bemis ( BMS )
Yes
Yes (26)
Black Hills ( BKH )
Yes (40)
Bowl America (BWL-A)
Yes (38)
Brown-Forman (BF-B)
Yes
Yes (26)
California Water Service ( CWT )
Yes (43)
Carlisle ( CSL )
Yes (33)
CenturyLink ( CTL )
Yes
Yes (35)
Chubb ( CB )
Yes
Yes (44)
Cincinnati Financial ( CINF )
Yes
Yes (49)
Cintas ( CTAS )
Yes
Yes (27)
Clarcor ( CLC )
Yes (26)
Clorox ( CLX )
Yes
Yes (32)
Coca-Cola ( KO )
Yes
Yes (47)
Colgate-Palmolive ( CL )
Yes (46)
Commerce Bancshares ( CBSH )
Yes (41)
Community Trust Banc. ( CTBI )
Yes (28)
Connecticut Water Services ( CTWS )
Yes (40)
Consolidated Edison ( ED )
Yes
Yes (36)
C. R. Bard ( BCR )
Yes
Yes (38)
Diebold ( DBD )
Yes (56)
Dover ( DOV )
Yes
Yes 54)
Eaton Vance ( EV )
Yes (29)
Eli Lilly ( LLY )
Yes
Yes (42)
Emerson Electric ( EMR )
Yes
Yes (53)
Energen ( EGN )
Yes (28)
ExxonMobil ( XOM )
Yes
Yes (27)
Family Dollar Stores ( FDO )
Yes
Yes (34)
Federal Realty ( FRT )
Yes (42)
Franklin Resources ( BEN )
Yes (29)
Genuine Parts ( GPC )
Yes (53)
Gorman-Rupp ( GRC )
Yes (35)
H. B. Fuller ( FUL )
Yes (40)
Helmerich & Payne ( HP )
Yes (37)
Hormel Foods ( HRL )
Yes (44)
Illinois Tool Works ( ITW )
Yes (45)
Integrys Energy ( TEG )
Yes
Yes (51)
Johnson & Johnson ( JNJ )
Yes
Yes (47)
Kimberly-Clark ( KMB )
Yes
Yes (37)
Lancaster Colony ( LANC )
Yes (47)
Leggett & Platt ( LEG )
Yes
Yes (38)
Lowe's ( LOW )
Yes
Yes (47)
McDonald's ( MCD )
Yes
Yes (33)
McGraw-Hill ( MHP )
Yes
Yes (37)
Medtronic ( MDT )
Yes (32)
MGE Energy ( MGEE )
Yes (34)
Middlesex Water ( MSEX )
Yes (37)
Mine Safety Appliances ( MSA )
Yes (37)
National Fuel Gas ( NFG )
Yes (39)
Nordson ( NDSN )
Yes (46)
Northwest Natural Gas ( NWN )
Yes (54)
Nucor ( NUE )
Yes (37)
Old Republic International ( ORI )
Yes (27)
Parker-Hannifin ( PH )
Yes (52)
Pentair ( PNR )
Yes (34)
Pepsico ( PEP )
Yes
Yes (37)
Piedmont Natural Gas ( PNY )
Yes (31)
Pitney Bowes ( PBI )
Yes
Yes (27)
PPG Industries ( PPG )
Yes
Yes 38)
Procter & Gamble ( PG )
Yes
Yes (53)
Questar ( STR )
Yes
Yes (30)
RLI ( RLI )
Yes (35)
RPM International ( RPM )
Yes (36)
Sherwin-Williams ( SHW )
Yes
Yes (31)
Sigma-Aldrich ( SIAL )
Yes
Yes (33)
SJW ( SJW )
Yes (43)
Sonoco Products ( SON )
Yes (26)
Stanley Works ( SWK )
Yes
Yes (42)
Stepan ( SCL )
Yes (42)
SuperValu ( SVU )
Yes
Sysco ( SYY )
Yes (40)
Target ( TGT )
Yes
Yes (42)
Teleflex ( TFX )
Yes (31)
Telephone & Data Systems ( TDS )
Yes (34)
Tennant ( TNC )
Yes (38)
Three M ( MMM )
Yes
Yes (51)
Tootsie Roll ( TR )
Yes (44)
United Bancshares ( UBSI )
Yes (36)
Universal ( UVV )
Yes (39)
Valspar ( VAL )
Yes (29)
Vectren ( VVC )
Yes (50)
V. F. ( VFC )
Yes
Yes (37)
Walgreen ( WAG )
Yes
Yes (34)
Wal-Mart ( WMT )
Yes
Yes (35)
Washington REIT ( WRE )
Yes (38)
Wesco Financial ( WSC )
Yes (38)
Weyco ( WEYS )
Yes (28)
WGL Holdings ( WGL )
Yes (33)
W. W. Grainger ( GWW )
Yes
Yes (38)
Author's Disclosure: Long PG, EMR, MMM, JNJ, CB, ABT, PEP, CTL, MCD, T, SHW
See also Productivity: Cyclical or Structural? on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) Yes Yes (37 years) ABM Industries ( ABM ) Yes (43) Aflac ( AFL ) Yes Yes (27) Air Products & Chemicals ( APD ) Yes Yes (27) American States Water ( AWR ) Yes (55) Archer Daniels Midland ( ADM ) Yes Yes (34) Yes Yes (37) Walgreen ( WAG ) Yes Yes (34) Wal-Mart ( WMT ) Yes Yes (35) Washington REIT ( WRE ) Yes (38) Wesco Financial ( WSC ) Yes (38) Weyco ( WEYS ) Yes (28) WGL Holdings ( WGL ) Yes (33) W. W. Grainger ( GWW ) Yes Yes (38) Author's Disclosure: Long PG, EMR, MMM, JNJ, CB, ABT, PEP, CTL, MCD, T, SHW See also Productivity: Cyclical or Structural? Yes (26) Automatic Data Processing ( ADP ) Yes Yes (35) Bancorp South ( BXS ) Yes (25) Bank of Hawaii ( BOH ) Yes (30) Becton Dickinson ( BDX ) Yes Yes (37) Bemis ( BMS ) Yes Yes (26) Black Hills ( BKH ) Yes (40) Bowl America (BWL-A) Yes (38) Brown-Forman (BF-B) Yes Yes (26) California Water Service ( CWT ) Yes (43) Carlisle ( CSL ) Yes (33) CenturyLink ( CTL ) Yes Yes (35) Chubb ( CB ) Yes Yes (44) Cincinnati Financial ( CINF ) Yes Yes (49) Cintas ( CTAS ) Yes Yes (27) Clarcor ( CLC ) Yes (26) Clorox ( CLX ) Yes Yes (32) Coca-Cola ( KO ) Yes Yes (47) Colgate-Palmolive ( CL ) Yes (46) Commerce Bancshares ( CBSH ) Yes (41) Community Trust Banc. | Yes Yes (37) Walgreen ( WAG ) Yes Yes (34) Wal-Mart ( WMT ) Yes Yes (35) Washington REIT ( WRE ) Yes (38) Wesco Financial ( WSC ) Yes (38) Weyco ( WEYS ) Yes (28) WGL Holdings ( WGL ) Yes (33) W. W. Grainger ( GWW ) Yes Yes (38) Author's Disclosure: Long PG, EMR, MMM, JNJ, CB, ABT, PEP, CTL, MCD, T, SHW See also Productivity: Cyclical or Structural? Abbott Laboratories ( ABT ) Yes Yes (37 years) ABM Industries ( ABM ) Yes (43) Aflac ( AFL ) Yes Yes (27) Air Products & Chemicals ( APD ) Yes Yes (27) American States Water ( AWR ) Yes (55) Archer Daniels Midland ( ADM ) Yes Yes (34) DriP puts it this way: "[C]ompanies that have increased their dividend in at least 25 consecutive years[,…]broadened to include additional companies that [have] paid higher dividends (without necessarily having increased the quarterly rate in every calendar year." | Abbott Laboratories ( ABT ) Yes Yes (37 years) ABM Industries ( ABM ) Yes (43) Aflac ( AFL ) Yes Yes (27) Air Products & Chemicals ( APD ) Yes Yes (27) American States Water ( AWR ) Yes (55) Archer Daniels Midland ( ADM ) Yes Yes (34) Yes Yes (37) Walgreen ( WAG ) Yes Yes (34) Wal-Mart ( WMT ) Yes Yes (35) Washington REIT ( WRE ) Yes (38) Wesco Financial ( WSC ) Yes (38) Weyco ( WEYS ) Yes (28) WGL Holdings ( WGL ) Yes (33) W. W. Grainger ( GWW ) Yes Yes (38) Author's Disclosure: Long PG, EMR, MMM, JNJ, CB, ABT, PEP, CTL, MCD, T, SHW See also Productivity: Cyclical or Structural? So even if a company declares a decreased dividend early in the year, the company will remain on the DA list for the rest of the year. | Abbott Laboratories ( ABT ) Yes Yes (37 years) ABM Industries ( ABM ) Yes (43) Aflac ( AFL ) Yes Yes (27) Air Products & Chemicals ( APD ) Yes Yes (27) American States Water ( AWR ) Yes (55) Archer Daniels Midland ( ADM ) Yes Yes (34) Yes Yes (37) Walgreen ( WAG ) Yes Yes (34) Wal-Mart ( WMT ) Yes Yes (35) Washington REIT ( WRE ) Yes (38) Wesco Financial ( WSC ) Yes (38) Weyco ( WEYS ) Yes (28) WGL Holdings ( WGL ) Yes (33) W. W. Grainger ( GWW ) Yes Yes (38) Author's Disclosure: Long PG, EMR, MMM, JNJ, CB, ABT, PEP, CTL, MCD, T, SHW See also Productivity: Cyclical or Structural? Each month during the year, DA is updated to show whether or not a dividend increase or decrease has been declared by each company on the list. |
34567.0 | 2009-11-09 00:00:00 UTC | Three Core Biotech Holdings: Isis, Ligand and Vical | ABT | https://www.nasdaq.com/articles/three-core-biotech-holdings-isis-ligand-and-vical-2009-11-09 | nan | nan | Michael Steinberg submits:
Isis ( ISIS ), Ligand ( LGND ) and Vical ( VICL ) have been my core biotech holdings since the mid 1990s and I have been steadily adding to these positions each time the market has lost faith. They share common themes and some differences. Isis and Vical have maintained consistent management throughout the years, whereas Ligand radically changed direction a few years ago when Daniel Loeb's Third Point hedge fund took a stake. Now all three are focused on drug discovery; leaving the marketing to others.
All three have many pharmaceutical partnerships and many shots on goal, so one failure would not be devastating. In order of platform strength and a protective moat around their technology; Isis is the strongest, followed by Vical, with Ligand pulling up the rear.
Ligand has announced a strategy of picking up funded drug candidates through low cost mergers with desperate cash-strapped micro-cap biotechs. They want to partner their internal development candidates at the earliest possible inflection point, but not much past the initial phase 2 "proof of concept" clinical trials.
Historically, Ligand sold over half of its potential royal streams and settled for higher upfronts over royalties to build a commercial sales organization for a few fledging products. Third Point installed new management, sold Ligand's commercial products, declared a special $2.50 dividend and set the company on the path of operating cash flow neutral.
Three potential blockbusters are close to launch by GlaxoSmithKline ( GSK ) and Pfizer ( PFE ) with sacrificed royalties. Now Ligand is showing more emphasis on royalties than the upfront, a better balance. The encouragement is that new deals are being negotiated with mid-teen and higher royalties. Looking back, I had too much faith in Ligand's old management and now I'm solidly on Dan Loeb's team with Ligand.
Isis' years of failure have been legendary, but the Genzyme ( GENZ ) almost $2B deal on the Mipomersen cholesterol drug was the turning point. Together with the $200M sale of Ibis Biosciences to Abbott ( ABT ), Isis has almost as much cash as India has gold. Isis has over 20 drugs in development and repeatedly committed to keeping its employment below 325 while continuing to rev its discovery engine in high gear.
Both Ligand and Isis will be high earners when royalties start flowing and expenses are maintained at a low level. The difference is Isis is willing to take the clinical process to a higher inflection point to get 50% profit sharing whereas Ligand will settle for less risk and investment to get a 15% royalty. But, neither company wants a sales force.
Vical has been more ambiguous about commercialization. Their DNA vaccine platform has some pharmaceutical and government sponsorship, and they are retaining US rights to their cancer vaccine. Vical is the most risky of the three companies with only about 2 years of cash and limited research funding. But, they have some drugs in phase 3. The bet on Vical is that DNA based vaccines are the only way to respond quickly to potential pandemics .
My core biotech holdings are high risk, high reward. What they have in common is no fear of future product discovery. They can partner knowing there are always more drugs to come. I try to avoid all or nothing biotechs.
Don't be fooled by one product cancer companies alleging that they will diversify into other indications for their one drug. Most of the time, other indications fail. Know that a single drug is not a platform. My core biotechs are all platform companies; Isis and Vical are based on solid technical platforms and Ligand is based a solid business platform.
P.S.: PDL Biopharma ( PDLI ) learned it was a mistake to resist Daniel Loeb's advances.
Disclosure:Author is long Isis, Ligand, PDLI, PFE and Vical.
See also IBM Researchers Speed Up Diagnostic Testing in New Breakthrough on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Together with the $200M sale of Ibis Biosciences to Abbott ( ABT ), Isis has almost as much cash as India has gold. Ligand has announced a strategy of picking up funded drug candidates through low cost mergers with desperate cash-strapped micro-cap biotechs. Historically, Ligand sold over half of its potential royal streams and settled for higher upfronts over royalties to build a commercial sales organization for a few fledging products. | Together with the $200M sale of Ibis Biosciences to Abbott ( ABT ), Isis has almost as much cash as India has gold. Third Point installed new management, sold Ligand's commercial products, declared a special $2.50 dividend and set the company on the path of operating cash flow neutral. My core biotech holdings are high risk, high reward. | Together with the $200M sale of Ibis Biosciences to Abbott ( ABT ), Isis has almost as much cash as India has gold. Michael Steinberg submits: Isis ( ISIS ), Ligand ( LGND ) and Vical ( VICL ) have been my core biotech holdings since the mid 1990s and I have been steadily adding to these positions each time the market has lost faith. Isis and Vical have maintained consistent management throughout the years, whereas Ligand radically changed direction a few years ago when Daniel Loeb's Third Point hedge fund took a stake. | Together with the $200M sale of Ibis Biosciences to Abbott ( ABT ), Isis has almost as much cash as India has gold. Historically, Ligand sold over half of its potential royal streams and settled for higher upfronts over royalties to build a commercial sales organization for a few fledging products. My core biotech holdings are high risk, high reward. |
34568.0 | 2009-11-04 00:00:00 UTC | The Entry Point Market Investors May Be Missing | ABT | https://www.nasdaq.com/articles/entry-point-market-investors-may-be-missing-2009-11-04 | nan | nan | Amit Chokshi submits:
Equity Markets De-Risking
The mid-point of September 2009 marked the one year anniversary since the fall of Lehman Brothers. Interestingly enough, since that period many stocks that experienced strong performance since March 2009 have started to experience substantial corrections. The market appears to be de-risking as many small and mid-cap stocks have taken major haircuts, while a number of larger capitalization stocks appear to have held steady, if not improved, illustrated by Exhibits I and II.
EXHIBIT I: SELECTED SMALL CAPITALIZATION NAMES
[click to enlarge]
EXHIBIT II: SELECTED LARGE CAPITALIZATION NAMES
[click to enlarge]
The US economy is facing both cyclical and structural economic issues which in turn has made market participants question the strength of the recovery. This may have led to a shift in risk appetite with investors rotating from higher beta, smaller names into larger companies that offer well recognized products, services, and brands with stronger balance sheets. These companies can presumably withstand further economic pressure compared to smaller companies that may have less dominant market positions and have greater financial leverage.
One big concern is the strength of the recovery and whether the US consumer will be a leader in it. It appears from reviewing economic data, financial media, economist opinions, and anecdotal evidence that this is unlikely to happen. As a result, it's easy to find many skeptics when it comes to equity prices. However, investors may be ignoring the ability of companies to manage the cost items of the income statement as well as the ability of companies to manage working capital accounts on their balance sheets, in essence enhancing their ability to generate cash and profits.
For example, while sales have dropped considerably for many companies, management teams have slashed corporate expenses to such a degree that SG&A has scaled down even more aggressively than sales declines. In addition, with many commodities and input costs declining, gross margins have been able to hold steady. Given the aggressive reduction in corporate expenses, stabilization in sales declines can have a very pronounced impact, even without the benefit of a V-shaped recovery.
Example I provides an illustration of how this can work. In 2008, Company X generated sales of $1B with gross margins of 40%. At the time, due to its scale, SG&A was $250MM resulting in EBIT of $150MM. Assuming there was no financial income or expenses, a 40% tax rate, and 100MM shares, Company X had EPS of $0.90. Now let's fast forward to 2009. Based on three quarters of data, investors can reasonably assume the metrics presented in Example I for 2009.
EXAMPLE I: COMPANY X
Due to lower commodity and input costs, Company X has managed to improve gross margins. In addition, perhaps there is less excess inventory relative to 2008 when the global meltdown occurred, resulting in companies aggressively discounting their products. With Company X controlling its inventory along with reduced input costs, gross margins have actually increased. Keep in mind that H2 2008 resulted in many companies and customers "shutting down" in terms of willingness to purchase just about anything. This was illustrated in the devastating GDP figures in Q3 08 and Q4 08. So with reduced inventory, reduced input prices relative to 2008, and customers feeling that the worst may be behind them, gross margins have improved. Second, Company X has reduced its cost structure at the SG&A level. While sales in 2009 will decline by 20%, SG&A has been stripped out by 30%, resulting in the same EPS despite a much worse economic backdrop.
This has become an issue for many market observers that note that earnings beats have been driven by cost cutting as opposed to top line demand. This may not be as large a problem, however, if even a mild recovery occurs. Example I projects that in 2010, sales may increase by 7.5% from 2009 levels. This is hardly robust growth from an anemic bottom. But assuming gross margins remain level with 2009 and SG&A increases by about 3% as work weeks and worker demand slightly increases, Company X - despite sales levels 14% below 2008 levels - can generate a higher EPS in 2010.
One thing investors should note is that PE contraction likely occurred in 2007 and 2008 such that Company X's 2008 EPS of $0.90 may have been valued at 6.0x EPS, making Company X worth $5.40 early in 2008. Perhaps as 2009 has demonstrated, a severe and complicated recession is what the US is facing as opposed to the Great Depression II and therefore Company X can be valued at 8.0x 2009 EPS of $0.90 or $7.20. This 33% gain may just be part of the normalization process from Armageddon to awful.
However, investors should question how 2010 EPS would be valued. Presumably things should be improving in 2010 and 2011 should have a better outlook as well. Would a 10.0x EPS multiple or 12.0x EPS multiple be warranted or plausible? Even if the market elects to value Company X's 2010 EPS at just 8.0x, the value of the stock would be $8.08, 12% higher than 2009 levels.
Example I is intended to solely provide a back drop for how investors may wish to analyze potential investments on both the long and short side. Indeed, if Company X's valuation rocketed from a PE of 6.0x to 25.0x and was still facing the same, weak future prospects, shorting Company X could make sense. However, across a number of stocks, particularly in the more volatile small and midcap space (the stocks that have acted like those in Exhibit I) which have fallen 20-50% from their recent peaks, market observers may be missing an interesting entry point.
Commercial Real Estate
Shorting equities in 2008 was a slam dunk which has led many pundits and financial media to spend considerable time on items such as levels of government debt and the impending commercial real estate ("CRE") collapse as investment themes for 2009-2010. CRE is a risk but may not be the market killer many fear. This is in part due to the wave of bank consolidation that occurred in the early 1990s through the most recent crisis. Basically the big banks got killed by CRE in the early 90s and actually learned their lesson. The big banks were killed by derivatives and more residential exposure while the smaller banks took on the CRE.
The problem is that CRE is held by regional and smaller banks which is why many have lagged the larger banks in terms of performance. Regionals don't have the capital market businesses that larger banks do, so they are stuck trying to rebuild capital reserves based on the yield curve. In contrast, those with capital market businesses have had the chance to rebuild capital faster given their ability to participate in the volatile markets. What could pose an issue is the new line that the government is drawing between Too Big to Fail ("TBTF") and everyone else. "Everyone else" are those that are holding a lot of bad CRE.
Successfully shorting these types of banks would require examining the CRE exposure of the many small and regional banks. Another possibility could be sifting through the FDIC's Troubled Bank list and finding suitable candidates. Shorting REITs may also be an idea to consider as the stocks have performed extremely well since raising equity in the spring. The risk of a complete failure for many REITs has subsided due to the equity raises. Those actions saved many REITs from the abyss and that, combined with a major contraction in credit spreads, benefited highly levered equities like REITs, propelling those shares. However, given expected occupancy levels, rents, and cap rates that still have not quite blown out, FFO valuation metrics may be ahead of themselves for a number of REITs.
Nonetheless, while many banks will continue to fail due to CRE and other economic problems, investors should note that the impact in terms of managing portfolios could be relegated to specific areas. The major banks control the lion's share of assets such that hundreds of bank failures may have very little overall impact compared to 20 years ago when assets were less concentrated. However, one theme that could play out is that as CRE impacts smaller banks, larger banks could benefit as the supply of available credit continues to contract, further strengthening the banks on the government dole.
Rent It, Don't Own It
US investors have already experienced our first lost decade, and simply holding on to equities since 2000 generated a much different return profile than what investors - and frankly the majority of investment managers - experienced from 1982-2000. Unless certain investments in one's portfolio are designated as extremely high conviction and offer multibagger possibilities, enduring high levels of volatility can be costly. This is not advocating a holding period of just days but investors should remain nimble and focus on both the long and short side of portfolio management.
DISCLAIMER : Any views expressed herein are provided for information purposes only and should not be construed in any way as an offer, an endorsement, or inducement to invest with any fund, manager, or program mentioned here or elsewhere.
See also Don't Expect the Resolution Authority to Be a 'Cure-All' on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | [click to enlarge] The US economy is facing both cyclical and structural economic issues which in turn has made market participants question the strength of the recovery. This may have led to a shift in risk appetite with investors rotating from higher beta, smaller names into larger companies that offer well recognized products, services, and brands with stronger balance sheets. Nonetheless, while many banks will continue to fail due to CRE and other economic problems, investors should note that the impact in terms of managing portfolios could be relegated to specific areas. | The market appears to be de-risking as many small and mid-cap stocks have taken major haircuts, while a number of larger capitalization stocks appear to have held steady, if not improved, illustrated by Exhibits I and II. But assuming gross margins remain level with 2009 and SG&A increases by about 3% as work weeks and worker demand slightly increases, Company X - despite sales levels 14% below 2008 levels - can generate a higher EPS in 2010. Nonetheless, while many banks will continue to fail due to CRE and other economic problems, investors should note that the impact in terms of managing portfolios could be relegated to specific areas. | However, investors may be ignoring the ability of companies to manage the cost items of the income statement as well as the ability of companies to manage working capital accounts on their balance sheets, in essence enhancing their ability to generate cash and profits. But assuming gross margins remain level with 2009 and SG&A increases by about 3% as work weeks and worker demand slightly increases, Company X - despite sales levels 14% below 2008 levels - can generate a higher EPS in 2010. One thing investors should note is that PE contraction likely occurred in 2007 and 2008 such that Company X's 2008 EPS of $0.90 may have been valued at 6.0x EPS, making Company X worth $5.40 early in 2008. | So with reduced inventory, reduced input prices relative to 2008, and customers feeling that the worst may be behind them, gross margins have improved. Even if the market elects to value Company X's 2010 EPS at just 8.0x, the value of the stock would be $8.08, 12% higher than 2009 levels. The problem is that CRE is held by regional and smaller banks which is why many have lagged the larger banks in terms of performance. |
34569.0 | 2023-10-05 00:00:00 UTC | Noteworthy Thursday Option Activity: AMED, SQ, ABUS | ABUS | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-amed-sq-abus | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Amedisys, Inc. (Symbol: AMED), where a total of 7,202 contracts have traded so far, representing approximately 720,200 underlying shares. That amounts to about 164.3% of AMED's average daily trading volume over the past month of 438,425 shares. Especially high volume was seen for the $95 strike call option expiring November 17, 2023, with 3,580 contracts trading so far today, representing approximately 358,000 underlying shares of AMED. Below is a chart showing AMED's trailing twelve month trading history, with the $95 strike highlighted in orange:
Block Inc (Symbol: SQ) options are showing a volume of 174,727 contracts thus far today. That number of contracts represents approximately 17.5 million underlying shares, working out to a sizeable 142.9% of SQ's average daily trading volume over the past month, of 12.2 million shares. Especially high volume was seen for the $100 strike put option expiring January 19, 2024, with 17,946 contracts trading so far today, representing approximately 1.8 million underlying shares of SQ. Below is a chart showing SQ's trailing twelve month trading history, with the $100 strike highlighted in orange:
And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 10,161 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 140.2% of ABUS's average daily trading volume over the past month, of 724,845 shares. Particularly high volume was seen for the $2 strike call option expiring December 15, 2023, with 5,002 contracts trading so far today, representing approximately 500,200 underlying shares of ABUS. Below is a chart showing ABUS's trailing twelve month trading history, with the $2 strike highlighted in orange:
For the various different available expirations for AMED options, SQ options, or ABUS options, visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
Also see:
ETFs Holding USNA
HCKT shares outstanding history
ETFs Holding DXPE
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Particularly high volume was seen for the $2 strike call option expiring December 15, 2023, with 5,002 contracts trading so far today, representing approximately 500,200 underlying shares of ABUS. Below is a chart showing SQ's trailing twelve month trading history, with the $100 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 10,161 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 140.2% of ABUS's average daily trading volume over the past month, of 724,845 shares. | That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 140.2% of ABUS's average daily trading volume over the past month, of 724,845 shares. Below is a chart showing SQ's trailing twelve month trading history, with the $100 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 10,161 contracts thus far today. Particularly high volume was seen for the $2 strike call option expiring December 15, 2023, with 5,002 contracts trading so far today, representing approximately 500,200 underlying shares of ABUS. | Below is a chart showing SQ's trailing twelve month trading history, with the $100 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 10,161 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 140.2% of ABUS's average daily trading volume over the past month, of 724,845 shares. Particularly high volume was seen for the $2 strike call option expiring December 15, 2023, with 5,002 contracts trading so far today, representing approximately 500,200 underlying shares of ABUS. | That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 140.2% of ABUS's average daily trading volume over the past month, of 724,845 shares. Below is a chart showing ABUS's trailing twelve month trading history, with the $2 strike highlighted in orange: For the various different available expirations for AMED options, SQ options, or ABUS options, visit StockOptionsChannel.com. Below is a chart showing SQ's trailing twelve month trading history, with the $100 strike highlighted in orange: And Arbutus Biopharma Corp (Symbol: ABUS) options are showing a volume of 10,161 contracts thus far today. |
34570.0 | 2023-09-13 00:00:00 UTC | HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation | ABUS | https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-arbutus-biopharma-abus-buy-recommendation-4 | nan | nan | Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation.
Analyst Price Forecast Suggests 171.33% Upside
As of August 31, 2023, the average one-year price target for Arbutus Biopharma is 5.51. The forecasts range from a low of 4.04 to a high of $6.30. The average price target represents an increase of 171.33% from its latest reported closing price of 2.03.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is 22MM, a decrease of 6.89%. The projected annual non-GAAP EPS is -0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 221 funds or institutions reporting positions in Arbutus Biopharma. This is a decrease of 16 owner(s) or 6.75% in the last quarter. Average portfolio weight of all funds dedicated to ABUS is 0.12%, a decrease of 48.15%. Total shares owned by institutions increased in the last three months by 5.12% to 69,724K shares.
The put/call ratio of ABUS is 0.28, indicating a bullish outlook.
What are Other Shareholders Doing?
Two Seas Capital holds 8,281K shares representing 4.94% ownership of the company. In it's prior filing, the firm reported owning 7,465K shares, representing an increase of 9.86%. The firm decreased its portfolio allocation in ABUS by 79.94% over the last quarter.
Whitefort Capital Management holds 8,094K shares representing 4.83% ownership of the company. In it's prior filing, the firm reported owning 7,500K shares, representing an increase of 7.34%. The firm decreased its portfolio allocation in ABUS by 17.25% over the last quarter.
Rubric Capital Management holds 3,396K shares representing 2.03% ownership of the company. In it's prior filing, the firm reported owning 4,195K shares, representing a decrease of 23.54%. The firm increased its portfolio allocation in ABUS by 1.34% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,301K shares representing 1.97% ownership of the company. No change in the last quarter.
Hudson Bay Capital Management holds 2,847K shares representing 1.70% ownership of the company. In it's prior filing, the firm reported owning 2,736K shares, representing an increase of 3.88%. The firm decreased its portfolio allocation in ABUS by 30.26% over the last quarter.
Arbutus Biopharma Background Information
(This description is provided by the company.)
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.12%, a decrease of 48.15%. The put/call ratio of ABUS is 0.28, indicating a bullish outlook. | Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.12%, a decrease of 48.15%. The put/call ratio of ABUS is 0.28, indicating a bullish outlook. | Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.12%, a decrease of 48.15%. The put/call ratio of ABUS is 0.28, indicating a bullish outlook. | Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.12%, a decrease of 48.15%. The put/call ratio of ABUS is 0.28, indicating a bullish outlook. |
34571.0 | 2023-09-12 00:00:00 UTC | Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up | ABUS | https://www.nasdaq.com/articles/arbutus-abus-to-focus-on-hepatitis-b-candidates-stock-up | nan | nan | Arbutus Biopharma ABUS announced that it will be focusing its resources on developing hepatitis B virus (HBV) therapies, while discontinuing development of its oral RNA destabilizer, AB-161 and coronavirus combination therapy program. This strategic shift is expected to extend the company's cash runway through the third quarter of 2025. Shares of the company were up 4.8% on Sep 11, following the news.
ABUS is currently developing two candidates to address chronic HBV - imdusiran (AB-729) and AB-101. Imdusiran is an RNA interference (RNAi) designed to target and reduce HBV viral proteins and antigens. The candidate is being currently evaluated in multiple early-to-mid stage combination studies for treatment of chronic HBV infection.
The company recently initiated a phase Ia/Ib study on AB-101, an oral PD-L1 inhibitor. Data from preclinical studies on the candidate have indicated its ability to reactivate exhausted HBV-specific T-cells in chronic HBV patients,potentially restoring the immune response against the virus. Arbutus anticipates to report initial data from the early-stage study in the first half of 2024.
Arbutus’ shares have fallen 5.6% year to date compared with the industry’s 12.8% decline.
Image Source: Zacks Investment Research
Additionally, the company is discontinuing the development of all coronavirus and oral RNA destabilizer programs. It is ending the development of its oral RNA destabilizer,AB-161, due to a pre-clinical toxicology finding, which is unrelated to peripheral neuropathy. AB-161 was being evaluated in an early-stage study for patients with HBV infection. We note that therewere no reported safety issues in healthy subjects who received doses of AB-161 during the early-stage study.
ABUS is also discontinuing the discovery and development of new molecular therapies for treating coronavirus. This program includes AB-343, a coronavirus drug candidate that inhibits the SARS-CoV-2 Mpro and targets treatment of COVID-19 and potential coronavirus outbreaks. This decision was driven by an unfavorable pharmacokinetic profile observed during the investigational new drug-enabling studies for AB-343.
Discontinuation of the studies will provide the company with the financial stability needed to pursue its core HBV-focused programs. As of Jun 30, 2023, the company had cash, cash equivalents and investments in marketable securities of $163.5 million compared with $178.5 million as of Mar 31, 2023.
Hepatitis B is a significant global health concern affecting millions worldwide and leading to severe complications, including cirrhosis and liver cancer. Despite the availability of vaccines and treatment options, chronic HBV infection remains a pressing unmet medical need, resulting in approximately 820,000 deaths annually.
Arbutus Biopharma Corporation Price and Consensus
Arbutus Biopharma Corporation price-consensus-chart | Arbutus Biopharma Corporation Quote
Zacks Rank & Stocks to Consider
Arbutus currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are Anika Therapeutics ANIK, Annovis Bio ANVS and Corcept Therapeutics CORT, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.32 for 2023. The bottom-line estimate has narrowed from a loss of 79 cents to a loss of 64 cents for 2024 during the same time frame. Shares of the company have lost 41.5% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 14.8% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 62.7% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
Free Report: Top EV Battery Stocks to Buy Now
Just-released report reveals 5 stocks to profit as millions of EV batteries are made. Elon Musk tweeted that lithium prices have gone to "insane levels," and they're likely to keep climbing. As a result, a handful of lithium battery stocks are set to skyrocket. Access this report to discover which battery stocks to buy and which to avoid.
Download free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma ABUS announced that it will be focusing its resources on developing hepatitis B virus (HBV) therapies, while discontinuing development of its oral RNA destabilizer, AB-161 and coronavirus combination therapy program. ABUS is currently developing two candidates to address chronic HBV - imdusiran (AB-729) and AB-101. ABUS is also discontinuing the discovery and development of new molecular therapies for treating coronavirus. | Arbutus Biopharma ABUS announced that it will be focusing its resources on developing hepatitis B virus (HBV) therapies, while discontinuing development of its oral RNA destabilizer, AB-161 and coronavirus combination therapy program. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. ABUS is currently developing two candidates to address chronic HBV - imdusiran (AB-729) and AB-101. | Arbutus Biopharma ABUS announced that it will be focusing its resources on developing hepatitis B virus (HBV) therapies, while discontinuing development of its oral RNA destabilizer, AB-161 and coronavirus combination therapy program. Click to get this free report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. ABUS is currently developing two candidates to address chronic HBV - imdusiran (AB-729) and AB-101. | ABUS is currently developing two candidates to address chronic HBV - imdusiran (AB-729) and AB-101. Arbutus Biopharma ABUS announced that it will be focusing its resources on developing hepatitis B virus (HBV) therapies, while discontinuing development of its oral RNA destabilizer, AB-161 and coronavirus combination therapy program. ABUS is also discontinuing the discovery and development of new molecular therapies for treating coronavirus. |
34572.0 | 2023-09-06 00:00:00 UTC | 3 Stocks to Buy For the COVID Resurgence | ABUS | https://www.nasdaq.com/articles/3-stocks-to-buy-for-the-covid-resurgence | nan | nan | The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023. Updated vaccines are awaiting regulatory approval that are effective against the proliferation of various strains, including the Omicron EG.5 variant, which is responsible for 22% of new infections, and the XBB.1.5 subvariant. The new vaccines will be available in late September after the vote recommendations and FDA approval.
The CDC reported that COVID-19 cases have increased 19% since the end of August. Mask mandates have been reenacted in regions with rising COVID cases at offices, schools and healthcare facilities. Lions Gate Entertainment Co. (NYSE: LGF.A) has implemented a mask mandate on two floors of its headquarters in Hollywood.
The pandemic has made people more conscious about healthcare, but complacency may be kicking in. Litigation among the biotechs continues, but it's not stopping the rollout. A new slate of COVID booster vaccines is expected to be rolled out in September 2023. Here are 3 stocks to keep on your watchlist for the upcoming COVID-19 booster season.
Pfizer Inc. (NYSE: PFE)
The most widely used COVID-19 vaccine in the U.S., produced in collaboration with Pfizer and BioNTech SE (NASDAQ: BNTX), received European Commission authorization on its new vaccine targeting the Omicron XBB.1.4 variant. The name of the vaccine is Comirnaty, which is approved for adults, children and infants older than six months.
Comirnaty is a messenger-RNA (mRNA) vaccine. mRNA is a molecule that trains the immune system to fight specific diseases. It carries blueprints for cells to produce the spike protein found on the surface of the COVID-19 virus (SARS-CoV-2), which the immune system attacks by producing antibodies and T-cells that remember how to fight it in the future. This enables the immune system to be able to combat COVID-19 infections.
However, it's worth noting that the mRNA doesn't remain in the body as it breaks down and is disposed of by the body in time. It's important to understand that the vaccine does not introduce the live virus that causes the disease; the mRNA only carries blueprints to identify the protein or spike protein in the case of COVID-19.
Patent Infringement Lawsuits Galore
Many biotechnology companies are suing Pfizer and BioNTech under allegations of patent infringement for lipid nanoparticle technology (LNP). While Moderna is being sued, it is also suing Pfizer and BioNTech. LNP is responsible for delivering the mRNA to cells to create spike proteins for which the immune system will make antibodies to build defenses.
In a nutshell, without LNPs, the mRNA would not be able to reach the cells before being digested and rendered useless. Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arbutus Biopharma Co. (NASDAQ: ABUS), CureVac N.V. (NASDAQ: CVAC) and Genevant Sciences are suing Pfizer, BioNTech and Moderna for various patent infringements. They are seeking a cut of the revenues but not are not attempting to stop vaccine production or distribution. The various stages of the lawsuits may take years to play out.
Pfizer analyst ratings and price targets are at MarketBeat.
Weekly Descending Triangle Pattern
The weekly candlestick chart on PFE illustrates the descending triangle formed after peaking at $43.25 in February 2023. The flat-bottom horizontal trendline of the triangle is at $34.96. The descending trendline has rejected each bounce attempt at a lower high as it gets closer to the apex point. PFE formed a market structure low (MSL) trigger at $39.70, but that's nowhere near triggering.
The relative strength index (RSI) oscillator is stalled at the 40-band. As the apex nears, PFE will break out through the descending or flat-bottom trendlines. Pullback supports are at $34.96, $34.18, $33.10 and $32.07.
Moderna Inc. (NASDAQ: MRNA)
Moderna is the second most widely used COVID-19 vaccine in the country. It's also working on vaccines for Respiratory Syncytial Virus (RSV), influenza and cancer. Moderna stated that its new booster shots were effective against the Omicron subvariants. The variants have changed dramatically to a point where the original vaccinations may no longer be effective as the virus can evade the antibodies.
The new boosters enable protection against the original strain and provide better protection against the BA.4 and BA.5 strains of Omicron to induce broader immunity.
Lawsuits
Pfizer and BioNTech requested the U.S. Patent and Trade Office (USPTO) to reconsider and invalidate Moderna's overly broad mRNA-related patents. They contend that Moderna's patents covering any mRNA sequence encoding any beta coronavirus spike protein, as well as any lipid-based formulation for delivery, are too broad and should be deemed unpatentable.
On August 28, 2023, Alnylam Pharmaceuticals lost on two patent infringement cases against Moderna but still alleges five of its patents related to LNP technology were violated in producing its Spikevax COVID vaccine.
Moderna analyst ratings and price targets are at MarketBeat.
Novavax Inc. (NASDAQ: NVAX)
Novavax was a promising early contender in the race for a COVID-19 vaccine, but delay after delay set the company back. Its vaccine, Nuvaxovid, was limited to distribution in Canada and foreign countries outside the U.S. as Pfizer and Moderna dominated vaccinations domestically. Novavax saw its shares plunge from $331.68 in February 2021 to the $4 range in 2023.
However, this time around, Novavax is trying to stay ahead of the curve, attempting to get a CDC recommendation for its booster in time for the 2023 COVID-19 and influenza season. It is working on a combination of COVID and influenza vaccine in one, which is in phase 2 trials. Shares recently exploded to the upside on a surprise Q2 2023 profit of 58 cents per share when analysts were expecting a loss of $1.33.
Even more surprising was the upbeat guidance for full-year 2023 revenues to come between $1.3 billion and $1.5 billion, beating analyst estimates of $1.44 billion.
Nuvaxovid Effective Against Omicron Variant EG.5
Novavax announced that its COVID booster was proven successful in neutralizing the XBB1.16.5 and EG.5.1 strains in non-human primates. It has filed with the FDA and CDC for approval, along with many foreign health agencies. The company sees a potential of 80 million to 100 million doses in the U.S. if approved.
September 12 will be an important day to mark on the calendar. This underdog has $5.32 in cash and a whopping 42% short interest, which could spark a short squeeze if approved.
Novavax analyst ratings and price targets are at MarketBeat.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arbutus Biopharma Co. (NASDAQ: ABUS), CureVac N.V. (NASDAQ: CVAC) and Genevant Sciences are suing Pfizer, BioNTech and Moderna for various patent infringements. LNP is responsible for delivering the mRNA to cells to create spike proteins for which the immune system will make antibodies to build defenses. They contend that Moderna's patents covering any mRNA sequence encoding any beta coronavirus spike protein, as well as any lipid-based formulation for delivery, are too broad and should be deemed unpatentable. | Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arbutus Biopharma Co. (NASDAQ: ABUS), CureVac N.V. (NASDAQ: CVAC) and Genevant Sciences are suing Pfizer, BioNTech and Moderna for various patent infringements. Patent Infringement Lawsuits Galore Many biotechnology companies are suing Pfizer and BioNTech under allegations of patent infringement for lipid nanoparticle technology (LNP). On August 28, 2023, Alnylam Pharmaceuticals lost on two patent infringement cases against Moderna but still alleges five of its patents related to LNP technology were violated in producing its Spikevax COVID vaccine. | Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arbutus Biopharma Co. (NASDAQ: ABUS), CureVac N.V. (NASDAQ: CVAC) and Genevant Sciences are suing Pfizer, BioNTech and Moderna for various patent infringements. Pfizer Inc. (NYSE: PFE) The most widely used COVID-19 vaccine in the U.S., produced in collaboration with Pfizer and BioNTech SE (NASDAQ: BNTX), received European Commission authorization on its new vaccine targeting the Omicron XBB.1.4 variant. On August 28, 2023, Alnylam Pharmaceuticals lost on two patent infringement cases against Moderna but still alleges five of its patents related to LNP technology were violated in producing its Spikevax COVID vaccine. | Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Arbutus Biopharma Co. (NASDAQ: ABUS), CureVac N.V. (NASDAQ: CVAC) and Genevant Sciences are suing Pfizer, BioNTech and Moderna for various patent infringements. A new slate of COVID booster vaccines is expected to be rolled out in September 2023. LNP is responsible for delivering the mRNA to cells to create spike proteins for which the immune system will make antibodies to build defenses. |
34573.0 | 2023-08-04 00:00:00 UTC | Chardan Capital Reiterates Arbutus Biopharma (ABUS) Buy Recommendation | ABUS | https://www.nasdaq.com/articles/chardan-capital-reiterates-arbutus-biopharma-abus-buy-recommendation | nan | nan | Fintel reports that on August 4, 2023, Chardan Capital reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation.
Analyst Price Forecast Suggests 167.38% Upside
As of August 2, 2023, the average one-year price target for Arbutus Biopharma is 5.51. The forecasts range from a low of 4.04 to a high of $6.30. The average price target represents an increase of 167.38% from its latest reported closing price of 2.06.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is 22MM, a decrease of 6.89%. The projected annual non-GAAP EPS is -0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 237 funds or institutions reporting positions in Arbutus Biopharma. This is an increase of 5 owner(s) or 2.16% in the last quarter. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. Total shares owned by institutions increased in the last three months by 17.29% to 66,361K shares.
The put/call ratio of ABUS is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Whitefort Capital Management holds 7,500K shares representing 4.51% ownership of the company. In it's prior filing, the firm reported owning 3,851K shares, representing an increase of 48.66%. The firm increased its portfolio allocation in ABUS by 202.98% over the last quarter.
Two Seas Capital holds 7,465K shares representing 4.49% ownership of the company. In it's prior filing, the firm reported owning 7,504K shares, representing a decrease of 0.53%. The firm increased its portfolio allocation in ABUS by 24.98% over the last quarter.
Rubric Capital Management holds 4,195K shares representing 2.53% ownership of the company. In it's prior filing, the firm reported owning 3,466K shares, representing an increase of 17.37%. The firm decreased its portfolio allocation in ABUS by 6.40% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,301K shares representing 1.99% ownership of the company. No change in the last quarter.
Hudson Bay Capital Management holds 2,736K shares representing 1.65% ownership of the company. In it's prior filing, the firm reported owning 4,851K shares, representing a decrease of 77.29%. The firm decreased its portfolio allocation in ABUS by 40.99% over the last quarter.
Arbutus Biopharma Background Information
(This description is provided by the company.)
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Additional reading:
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in
NASDAQ: ABUS www.arbutusbio.com August 3, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation
EXECUTIVE EMPLOYMENT AGREEMENT
EXECUTIVE EMPLOYMENT AGREEMENT
OPTION AGREEMENT - EMPLOYEES
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on August 4, 2023, Chardan Capital reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. | Fintel reports that on August 4, 2023, Chardan Capital reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. | Additional reading: Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in NASDAQ: ABUS www.arbutusbio.com August 3, 2023 Corporate Presentation © 2023 Arbutus Biopharma, Inc. Fintel reports that on August 4, 2023, Chardan Capital reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. | Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. Fintel reports that on August 4, 2023, Chardan Capital reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. |
34574.0 | 2023-08-04 00:00:00 UTC | HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation | ABUS | https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-arbutus-biopharma-abus-buy-recommendation-3 | nan | nan | Fintel reports that on August 4, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation.
Analyst Price Forecast Suggests 167.38% Upside
As of August 2, 2023, the average one-year price target for Arbutus Biopharma is 5.51. The forecasts range from a low of 4.04 to a high of $6.30. The average price target represents an increase of 167.38% from its latest reported closing price of 2.06.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is 22MM, a decrease of 6.89%. The projected annual non-GAAP EPS is -0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 237 funds or institutions reporting positions in Arbutus Biopharma. This is an increase of 5 owner(s) or 2.16% in the last quarter. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. Tot | Fintel reports that on August 4, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia. | Fintel reports that on August 4, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. Analyst Price Forecast Suggests 167.38% Upside As of August 2, 2023, the average one-year price target for Arbutus Biopharma is 5.51. | Fintel reports that on August 4, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. Analyst Price Forecast Suggests 167.38% Upside As of August 2, 2023, the average one-year price target for Arbutus Biopharma is 5.51. | Fintel reports that on August 4, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, a decrease of 0.98%. Analyst Price Forecast Suggests 167.38% Upside As of August 2, 2023, the average one-year price target for Arbutus Biopharma is 5.51. |
34575.0 | 2023-08-03 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q2-loss-lags-revenue-estimates | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.10, delivering a surprise of 28.57%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.65 million for the quarter ended June 2023, missing the Zacks Consensus Estimate by 7.39%. This compares to year-ago revenues of $14.24 million. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have lost about 10.7% since the beginning of the year versus the S&P 500's gain of 17.6%.
What's Next for Arbutus?
While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.12 on $5.1 million in revenues for the coming quarter and -$0.44 on $23 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Zymeworks Inc. (ZYME), is yet to report results for the quarter ended June 2023. The results are expected to be released on August 10.
This company is expected to post quarterly loss of $0.51 per share in its upcoming report, which represents a year-over-year change of +47.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Zymeworks Inc.'s revenues are expected to be $12.86 million, up 136.4% from the year-ago quarter.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Zymeworks Inc. (ZYME) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Zymeworks Inc. (ZYME) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Zymeworks Inc. (ZYME) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.65 million for the quarter ended June 2023, missing the Zacks Consensus Estimate by 7.39%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Zymeworks Inc. (ZYME) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $4.65 million for the quarter ended June 2023, missing the Zacks Consensus Estimate by 7.39%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Zymeworks Inc. (ZYME) : Free Stock Analysis Report To read this article on Zacks.com click here. The company has topped consensus revenue estimates just once over the last four quarters. |
34576.0 | 2023-07-07 00:00:00 UTC | JMP Securities Reiterates Arbutus Biopharma (ABUS) Market Outperform Recommendation | ABUS | https://www.nasdaq.com/articles/jmp-securities-reiterates-arbutus-biopharma-abus-market-outperform-recommendation | nan | nan | Fintel reports that on July 6, 2023, JMP Securities reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform recommendation.
Analyst Price Forecast Suggests 147.00% Upside
As of July 6, 2023, the average one-year price target for Arbutus Biopharma is 5.51. The forecasts range from a low of 4.04 to a high of $6.30. The average price target represents an increase of 147.00% from its latest reported closing price of 2.23.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is 22MM, a decrease of 33.85%. The projected annual non-GAAP EPS is -0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 237 funds or institutions reporting positions in Arbutus Biopharma. This is an increase of 9 owner(s) or 3.95% in the last quarter. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 18.85%. Total shares owned by institutions increased in the last three months by 16.09% to 66,318K shares.
The put/call ratio of ABUS is 0.25, indicating a bullish outlook.
What are Other Shareholders Doing?
Whitefort Capital Management holds 7,500K shares representing 4.51% ownership of the company. In it's prior filing, the firm reported owning 3,851K shares, representing an increase of 48.66%. The firm increased its portfolio allocation in ABUS by 202.98% over the last quarter.
Two Seas Capital holds 7,465K shares representing 4.49% ownership of the company. In it's prior filing, the firm reported owning 7,504K shares, representing a decrease of 0.53%. The firm increased its portfolio allocation in ABUS by 24.98% over the last quarter.
Rubric Capital Management holds 4,195K shares representing 2.53% ownership of the company. In it's prior filing, the firm reported owning 3,466K shares, representing an increase of 17.37%. The firm decreased its portfolio allocation in ABUS by 6.40% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,301K shares representing 1.99% ownership of the company. No change in the last quarter.
Hudson Bay Capital Management holds 2,736K shares representing 1.65% ownership of the company. In it's prior filing, the firm reported owning 4,851K shares, representing a decrease of 77.29%. The firm decreased its portfolio allocation in ABUS by 42.31% over the last quarter.
Arbutus Biopharma Background Information
(This description is provided by the company.)
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Additional reading:
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 Treatment was generally well tolerated with continued HBsAg declines in some patients
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
EXHIBIT 10.1 ARBUTUS BIOPHARMA CORPORATION 2016 OMNIBUS SHARE AND INCENTIVE PLAN (as adopted by the board of directors on April 6, 2016 and approved by the shareholders on May 19, 2016; and as supplemented by the Committee on May 9, 2019) Section 1.
Press release dated May 4, 2023
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on July 6, 2023, JMP Securities reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 18.85%. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. | Fintel reports that on July 6, 2023, JMP Securities reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 18.85%. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. | Fintel reports that on July 6, 2023, JMP Securities reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 18.85%. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. | Fintel reports that on July 6, 2023, JMP Securities reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 18.85%. The put/call ratio of ABUS is 0.25, indicating a bullish outlook. |
34577.0 | 2023-06-23 00:00:00 UTC | Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year? | ABUS | https://www.nasdaq.com/articles/are-medical-stocks-lagging-amphastar-pharmaceuticals-amph-this-year-0 | nan | nan | Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Amphastar Pharmaceuticals (AMPH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amphastar Pharmaceuticals is a member of our Medical group, which includes 1139 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Amphastar Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 22.4% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AMPH has returned 108.4% so far this year. Meanwhile, stocks in the Medical group have lost about 1.2% on average. This shows that Amphastar Pharmaceuticals is outperforming its peers so far this year.
Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The stock's year-to-date return is 6%.
For Arbutus Biopharma, the consensus EPS estimate for the current year has increased 22.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, a group that includes 17 individual stocks and currently sits at #79 in the Zacks Industry Rank. On average, stocks in this group have gained 8.8% this year, meaning that AMPH is performing better in terms of year-to-date returns.
On the other hand, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry. This 548-stock industry is currently ranked #111. The industry has moved -7% year to date.
Amphastar Pharmaceuticals and Arbutus Biopharma could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Amphastar Pharmaceuticals (AMPH) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? | Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, a group that includes 17 individual stocks and currently sits at #79 in the Zacks Industry Rank. | Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, a group that includes 17 individual stocks and currently sits at #79 in the Zacks Industry Rank. | Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Amphastar Pharmaceuticals is a member of our Medical group, which includes 1139 different companies and currently sits at #6 in the Zacks Sector Rank. |
34578.0 | 2023-06-07 00:00:00 UTC | Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? | ABUS | https://www.nasdaq.com/articles/is-amphastar-pharmaceuticals-amph-stock-outpacing-its-medical-peers-this-year-0 | nan | nan | Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amphastar Pharmaceuticals (AMPH) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Amphastar Pharmaceuticals is a member of the Medical sector. This group includes 1144 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amphastar Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 20.1% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AMPH has moved about 63.7% on a year-to-date basis. At the same time, Medical stocks have lost an average of 2.9%. This means that Amphastar Pharmaceuticals is outperforming the sector as a whole this year.
Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The stock's year-to-date return is 11.6%.
The consensus estimate for Arbutus Biopharma's current year EPS has increased 22.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, which includes 17 individual stocks and currently sits at #103 in the Zacks Industry Rank. Stocks in this group have gained about 3.3% so far this year, so AMPH is performing better this group in terms of year-to-date returns.
On the other hand, Arbutus Biopharma belongs to the Medical - Biomedical and Genetics industry. This 552-stock industry is currently ranked #98. The industry has moved -6.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Amphastar Pharmaceuticals and Arbutus Biopharma as they could maintain their solid performance.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Going forward, investors interested in Medical stocks should continue to pay close attention to Amphastar Pharmaceuticals and Arbutus Biopharma as they could maintain their solid performance. | Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. | Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. | Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. |
34579.0 | 2023-06-01 00:00:00 UTC | Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates | ABUS | https://www.nasdaq.com/articles/biohaven-bhvn-stock-up-8-on-encouraging-pipeline-updates | nan | nan | Shares of Biohaven Ltd BHVN were up 7.6% on May 31, after it provided an overview of clinical progress and regulatory updates on the company’s pipeline candidates at its R&D Day.
As part of its regulatory updates, Biohaven announced that it submitted a new drug application (“NDA”) in second-quarter 2023 for troriluzole, one of its most advanced pipeline candidates. The NDA seeks approval for troriluzole to treat spinocerebellar ataxia type 3 (“SCA3”), an ultra-rare neurodegenerative disease associated with progressive disability.
This NDA is supported by data from a phase III study (BHV4157-206) wherein treatment with troriluzole demonstrated benefits across multiple outcome measures in study participants. Troriluzole has also been granted fast track and orphan drug designations by the FDA in SCA indication. The candidate is also being developed in two late-stage studies for obsessive-compulsive disorder (“OCD”).
The company also announced that it expects to complete enrolment in the global phase III study evaluating taldefgrobep alfa, another candidate, in spinal muscular atrophy (“SMA”) by this year’s end. Management also intends to start a phase II study later this year to evaluate this drug in metabolic disorders.
In the year so far, shares of Biohaven have increased 26.2% against the industry’s 9.7% fall.
Biohaven also announced several clinical updates on its pre-clinical/early-stage pipeline candidates. It stated that it has advanced BHV-8000, a TYK-1/JAK1 inhibitor for treating brain disorders, to clinical development. Management recently initiated a phase I study to evaluate BHV-8000 in healthy volunteers. The candidate was acquired in March 2023 from China-based Hangzhou Highlightll Pharmaceutical Co. Ltd.
The firm also revealed its plans to start the phase I EEG study to evaluate BHV-7000, a Kv7.2/3 activator in first-half 2023. Management intends to start pivotal clinical studies evaluating the candidate in focal epilepsy and bipolar disorder indications by this year’s end.
Alongside the above updates, BHVN plans to submit investigational new drug (IND) applications to the FDA to start clinical studies on multiple pipeline candidates. This includes BHV-1300, a novel IgG degrader, whose IND application is on track for submission later this year.
Currently, Biohaven has no marketed drugs in its portfolio and is dependent on its pipeline for growth. The company is a new publicly traded company, which has retained the non-calcitonin gene-related peptide (CGRP) development stage pipeline compounds of legacy Biohaven.
Last year, the company turned to a new direction after it announced that its CGRP business was acquired by Pfizer PFE for $148.50 per share or an aggregate equity value of $11.6 billion. Following this acquisition, the newly-incorporated Biohaven has been focused on advancing its non-CGRP pipeline compounds targeting neurological and neuropsychiatric diseases like SMA, SCA and OCD. The acquisition also resulted in Pfizer adding legacy Biohaven’s sole marketed drug Nurtec ODT to its product portfolio. Pfizer also added Biohaven’s other CGRP programs, including zavegepant nasal spray to its product portfolio. Zavegepant received FDA approval in March for the acute treatment of migraine. Pfizer is marketing this spray under the brand name Zavzpret.
Image Source: Zacks Investment Research
Zacks Rank & Stock to Consider
Biohaven currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the overall healthcare sector are Arbutus Biopharma ABUS and Ligand Pharmaceuticals LGND. While Ligand Pharmaceuticals sports a Zacks Rank #1 (Strong Buy) at present, Arbutus Biopharma carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the estimate for Ligand’s 2023 earnings per share has increased from $4.16 to $5.25. During the same period, the earnings estimate per share for 2024 has increased from $4.58 to $4.69. In the year so far, the shares of Ligand have risen 4.9%.
Ligand Pharmaceuticals beat earnings estimates in two of the last four quarters, while missing the mark on the other two occasions. On average, the company’s earnings witnessed an earnings surprise of 21.50%. In the last reported quarter, LGND delivered an earnings surprise of 121.36%.
In the past 30 days, estimates for Arbutus Biopharma’s 2023 loss per share have improved from 57 cents to 44 cents. During the same period, the loss estimates per share for 2024 have narrowed from 61 cents to 53 cents. Shares of Arbutus Biopharma are up 6.9% in the year-to-date period.
Earnings of Arbutus Biopharma beat estimates in two of the last four quarters while meeting the mark twice. On average, the company’s earnings witnessed a surprise of 12.91%. In the last reported quarter, Arbutus Biopharma’searnings beat estimates by 28.57%.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Biohaven Ltd. (BHVN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the overall healthcare sector are Arbutus Biopharma ABUS and Ligand Pharmaceuticals LGND. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Biohaven Ltd. (BHVN) : Free Stock Analysis Report To read this article on Zacks.com click here. The company also announced that it expects to complete enrolment in the global phase III study evaluating taldefgrobep alfa, another candidate, in spinal muscular atrophy (“SMA”) by this year’s end. | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Biohaven Ltd. (BHVN) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the overall healthcare sector are Arbutus Biopharma ABUS and Ligand Pharmaceuticals LGND. Alongside the above updates, BHVN plans to submit investigational new drug (IND) applications to the FDA to start clinical studies on multiple pipeline candidates. | Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Biohaven Ltd. (BHVN) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the overall healthcare sector are Arbutus Biopharma ABUS and Ligand Pharmaceuticals LGND. Shares of Biohaven Ltd BHVN were up 7.6% on May 31, after it provided an overview of clinical progress and regulatory updates on the company’s pipeline candidates at its R&D Day. | A couple of better-ranked stocks in the overall healthcare sector are Arbutus Biopharma ABUS and Ligand Pharmaceuticals LGND. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Biohaven Ltd. (BHVN) : Free Stock Analysis Report To read this article on Zacks.com click here. As part of its regulatory updates, Biohaven announced that it submitted a new drug application (“NDA”) in second-quarter 2023 for troriluzole, one of its most advanced pipeline candidates. |
34580.0 | 2023-05-30 00:00:00 UTC | Valneva (VALN) Stock Down 53% in the Past Year: Here's Why | ABUS | https://www.nasdaq.com/articles/valneva-valn-stock-down-53-in-the-past-year%3A-heres-why | nan | nan | Shares of Valneva VALN have plunged 52.9% in the trailing 12 months compared with the industry’s 33.8% decline.
Image Source: Zacks Investment Research
This substantial decline was caused by the revision of the advance purchase agreement (“APA”) of VLA2001, the company’s inactivated COVID-19 vaccine.
Last year, the European Commission (“EC”) granted marketing authorization to Valneva’s COVID-19 vaccine for use as a primary regimen in adults aged 18 through 50 years in the European Union (EU). Following this approval, VLA2001 became the first COVID-19 vaccine to receive standard marketing authorization in Europe.
The EC’s decision to grant approval to VLA2001 was based on positive top-line data from the pivotal phase III Cov-Compare study, which evaluated VLA2001 against AstraZeneca’s AZN COVID vaccine, AZD1222. The study achieved co-primary endpoints two weeks after the second vaccination dose. Data from this study demonstrated the superiority of VLA2001 over AstraZeneca’s AZD1222. Valneva’s COVID-19 vaccine produced superior neutralizing antibody titer levels to AstraZeneca’s vaccine. VLA2001 demonstrated the same effectiveness as the AstraZeneca vaccine in neutralizing antibody seroconversion rates by more than 95%.
Prior to securing the marketing approval in the EU, Valneva entered into an APA with the EC in November 2021 to supply up to 60 million doses of VLA2001 to the EU member states once the vaccine was granted marketing authorization.
One of the terms of this APA provided the EC the right to terminate the agreement, if VLA2001 failed to receive marketing authorization in the EU by Apr 30, 2022. The EC decided to exercise this right in May 2022 and communicated its intent to terminate the APA. Following remediation discussions between the EC and Valneva, the former approved an amendment to the APA, revising the supply down from 60 million doses of VLA2001 to 1.25 million doses. The amended APA allows EC to purchase another 1.25 million doses.
This reduced order received from the EC resulted in management evaluating its COVID-19 program. Management decided not to continue further investment in VLA2001-related activities unless it has secured a partnership to fund the same. Instead, the company is utilizing its resources towards developing its non-COVID pipeline candidates. The successful development and potential development of these candidates will likely boost the stock’s growth prospects in the long-run.
Currently, Valneva is focused on developing vaccine candidates targeting chikungunya and Lyme disease.
Valneva is developing VLA15, its vaccine candidate for Lyme disease. The candidate is being developed in collaboration with Pfizer PFE. Last year, Pfizer and Valneva initiated a phase III study to evaluate VLA15 in individuals aged five years and older.
In December, Valneva and Pfizer reported six-month antibody persistence data from a phase II study in patients who completed a three-dose or a two-dose vaccination schedule of VLA15. While antibody levels in schedules remained above baseline, they were higher in participants who received the three-dose vaccination schedule. These results validate incorporating a three-dose vaccination schedule in the above-mentioned phase III study.
This February, Valneva announced that the FDA accepted the BLA submission, which seeks approval to use its single-shot chikungunya vaccine, VLA1553, in adults. This filing has been granted priority review and a decision is expected by August 2023-end. If approved, VLA1553 will be the first vaccine for chikungunya and will be eligible for a priority review voucher. A similar regulatory filing for the vaccine in Europe is expected later this year.
Valneva SE Sponsored ADR Price
Valneva SE Sponsored ADR price | Valneva SE Sponsored ADR Quote
Zacks Rank & Stock to Consider
Valneva currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, estimates for Arbutus Biopharma’s 2023 loss per share have improved from 57 cents to 44 cents. During the same period, the loss estimates per share for 2024 have narrowed from 61 cents to 53 cents. Shares of Arbutus Biopharma are up 0.8% in the year-to-date period.
Earnings of Arbutus Biopharma beat estimates in two of the last four quarters while meeting the mark twice. On average, the company’s earnings witnessed a surprise of 12.91%. In the last reported quarter, Arbutus Biopharma’searnings beat estimates by 28.57%.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Valneva SE Sponsored ADR (VALN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Valneva SE Sponsored ADR (VALN) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research This substantial decline was caused by the revision of the advance purchase agreement (“APA”) of VLA2001, the company’s inactivated COVID-19 vaccine. | A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Valneva SE Sponsored ADR (VALN) : Free Stock Analysis Report To read this article on Zacks.com click here. Valneva SE Sponsored ADR Price Valneva SE Sponsored ADR price | Valneva SE Sponsored ADR Quote Zacks Rank & Stock to Consider Valneva currently carries a Zacks Rank #3 (Hold). | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Valneva SE Sponsored ADR (VALN) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Prior to securing the marketing approval in the EU, Valneva entered into an APA with the EC in November 2021 to supply up to 60 million doses of VLA2001 to the EU member states once the vaccine was granted marketing authorization. | A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Valneva SE Sponsored ADR (VALN) : Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Valneva is focused on developing vaccine candidates targeting chikungunya and Lyme disease. |
34581.0 | 2023-05-29 00:00:00 UTC | FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug | ABUS | https://www.nasdaq.com/articles/fda-accepts-iovances-iova-bla-filing-for-melanoma-drug | nan | nan | Shares of Iovance Biotherapeutics IOVA were up 18.0% in after-market trading on May 26 after management announced that the FDA had accepted its biologics license application (BLA) for lifileucel, its lead pipeline candidate, in melanoma indication. A final decision is expected by Nov 25, 2023.
The BLA seeks accelerated approval for lifileucel to treat patients with advanced unresectable or metastatic melanoma, which progressed on or after prior anti-PD-1/L1 therapy.
Per management, the FDA currently has no plan to hold an advisory committee meeting. The BLA has also been granted priority review by the FDA.
If the BLA is approved, lifileucel will be the first FDA-approved individualized, one-time cell therapy for melanoma patients. The approval to lifileucel will cater to the needs of melanoma patients who have already been treated with standard-of-care medications and have limited treatment options.
In the year so far, shares of Iovance have increased 18.2% against the industry’s 9.2% fall.
Image Source: Zacks Investment Research
The BLA filing, which was completed earlier this March, is based on data from cohorts 2 and 4 of the phase II C-144-01 study, which evaluated lifileucel in patients with post-anti-PD1 melanoma. Overall data from these cohorts shows that treatment with lifileucel achieved an objective response rate (ORR) of 31%, with the median duration of the response still not reached at 36.5 months.
In January, management reached an agreement with the FDA on the scope of the phase III TILVANCE-301 study, which will evaluate the combination of lifileucel and Merck’s MRK PD-L1 inhibitor Keytruda (pembrolizumab) against Merck’s Keytruda in frontline metastatic melanoma. This late-stage study, starting later this year, will serve as a confirmatory study for the above BLA. Iovance already evaluated the combination of lifileucel and Merck’s Keytruda for the given indication in a cohort of the phase II IOV-COM-202 study. Data from the cohort demonstrated an overall response rate (ORR) of 67%.
A multi-center study, IOV-COM-202 is composed of seven cohorts evaluating Iovance’s TIL therapies in multiple settings and for several indications, as a monotherapy and in combination with Merck’s Keytruda or Bristol-Myers’ BMY Opdivo/Yervoy.
Opdivo and Yervoy are two of the many blockbuster drugs marketed by Bristol Myers. The drugs are key top-line drivers for Bristol Myers. During first-quarter 2023, Bristol Myers generated $2.2 billion from Opdivo sales and recorded $508 million as product revenues from Yervoy.
Iovance Biotherapeutics, Inc. Price
Iovance Biotherapeutics, Inc. price | Iovance Biotherapeutics, Inc. Quote
Zacks Rank & Stock to Consider
Iovance currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, estimates for Arbutus Biopharma’s 2023 loss per share have improved from 57 cents to 44 cents. During the same period, the loss estimates per share for 2024 have narrowed from 61 cents to 53 cents. Shares of Arbutus Biopharma are up 7.3% in the year-to-date period.
Earnings of Arbutus Biopharma beat estimates in two of the last four quarters while meeting the mark twice. On average, the company’s earnings witnessed a surprise of 12.91%. In the last reported quarter, Arbutus Biopharma’s earnings beat estimates by 28.57%.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Iovance Biotherapeutics IOVA were up 18.0% in after-market trading on May 26 after management announced that the FDA had accepted its biologics license application (BLA) for lifileucel, its lead pipeline candidate, in melanoma indication. | A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report To read this article on Zacks.com click here. Iovance Biotherapeutics, Inc. Price Iovance Biotherapeutics, Inc. price | Iovance Biotherapeutics, Inc. Quote Zacks Rank & Stock to Consider Iovance currently carries a Zacks Rank #3 (Hold). | Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Image Source: Zacks Investment Research The BLA filing, which was completed earlier this March, is based on data from cohorts 2 and 4 of the phase II C-144-01 study, which evaluated lifileucel in patients with post-anti-PD1 melanoma. | A better-ranked stock in the overall healthcare sector is Arbutus Biopharma ABUS, carrying a Zacks Rank #2 (Buy) at present. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research The BLA filing, which was completed earlier this March, is based on data from cohorts 2 and 4 of the phase II C-144-01 study, which evaluated lifileucel in patients with post-anti-PD1 melanoma. |
34582.0 | 2023-05-22 00:00:00 UTC | Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year? | ABUS | https://www.nasdaq.com/articles/is-amphastar-pharmaceuticals-amph-outperforming-other-medical-stocks-this-year-0 | nan | nan | For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Amphastar Pharmaceuticals (AMPH) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amphastar Pharmaceuticals is one of 1144 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amphastar Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 15.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, AMPH has gained about 57.6% so far this year. In comparison, Medical companies have returned an average of -1.7%. This shows that Amphastar Pharmaceuticals is outperforming its peers so far this year.
Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The stock's year-to-date return is 10.3%.
Over the past three months, Arbutus Biopharma's consensus EPS estimate for the current year has increased 24.1%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Amphastar Pharmaceuticals belongs to the Medical - Generic Drugs industry, a group that includes 17 individual stocks and currently sits at #101 in the Zacks Industry Rank. This group has gained an average of 3.9% so far this year, so AMPH is performing better in this area.
Arbutus Biopharma, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 552-stock industry is ranked #114. The industry has moved -6.5% so far this year.
Investors with an interest in Medical stocks should continue to track Amphastar Pharmaceuticals and Arbutus Biopharma. These stocks will be looking to continue their solid performance.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. | Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Over the past 90 days, the Zacks Consensus Estimate for AMPH's full-year earnings has moved 15.7% higher. | Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. | Another stock in the Medical sector, Arbutus Biopharma (ABUS), has outperformed the sector so far this year. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. |
34583.0 | 2023-05-05 00:00:00 UTC | HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation | ABUS | https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-arbutus-biopharma-abus-buy-recommendation-1 | nan | nan | Fintel reports that on May 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation.
Analyst Price Forecast Suggests 126.67% Upside
As of April 24, 2023, the average one-year price target for Arbutus Biopharma is 5.78. The forecasts range from a low of 5.05 to a high of $6.30. The average price target represents an increase of 126.67% from its latest reported closing price of 2.55.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is 22MM, a decrease of 33.85%. The projected annual non-GAAP EPS is -0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 232 funds or institutions reporting positions in Arbutus Biopharma. This is a decrease of 2 owner(s) or 0.85% in the last quarter. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 111.92%. Total shares owned by institutions increased in the last three months by 17.49% to 56,580K shares.
The put/call ratio of ABUS is 0.21, indicating a bullish outlook.
What are Other Shareholders Doing?
Two Seas Capital holds 7,504K shares representing 4.55% ownership of the company. In it's prior filing, the firm reported owning 5,654K shares, representing an increase of 24.66%. The firm increased its portfolio allocation in ABUS by 68.42% over the last quarter.
Hudson Bay Capital Management holds 4,851K shares representing 2.94% ownership of the company. In it's prior filing, the firm reported owning 4,962K shares, representing a decrease of 2.28%. The firm increased its portfolio allocation in ABUS by 37.83% over the last quarter.
Whitefort Capital Management holds 3,851K shares representing 2.33% ownership of the company.
Rubric Capital Management holds 3,466K shares representing 2.10% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,301K shares representing 2.00% ownership of the company. No change in the last quarter.
Arbutus Biopharma Background Information
(This description is provided by the company.)
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
See all Arbutus Biopharma regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on May 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 111.92%. The put/call ratio of ABUS is 0.21, indicating a bullish outlook. | Fintel reports that on May 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 111.92%. The put/call ratio of ABUS is 0.21, indicating a bullish outlook. | Fintel reports that on May 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 111.92%. The put/call ratio of ABUS is 0.21, indicating a bullish outlook. | Fintel reports that on May 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.23%, an increase of 111.92%. The put/call ratio of ABUS is 0.21, indicating a bullish outlook. |
34584.0 | 2023-05-04 00:00:00 UTC | Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? | ABUS | https://www.nasdaq.com/articles/is-arbutus-biopharma-abus-outperforming-other-medical-stocks-this-year | nan | nan | The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Arbutus Biopharma is a member of our Medical group, which includes 1145 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Arbutus Biopharma is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 2.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ABUS has returned about 7.7% since the start of the calendar year. At the same time, Medical stocks have lost an average of 0.5%. This means that Arbutus Biopharma is performing better than its sector in terms of year-to-date returns.
Hologic (HOLX) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 12.4%.
Over the past three months, Hologic's consensus EPS estimate for the current year has increased 3.8%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Arbutus Biopharma is a member of the Medical - Biomedical and Genetics industry, which includes 552 individual companies and currently sits at #93 in the Zacks Industry Rank. On average, stocks in this group have lost 5.8% this year, meaning that ABUS is performing better in terms of year-to-date returns.
On the other hand, Hologic belongs to the Medical - Instruments industry. This 94-stock industry is currently ranked #122. The industry has moved +4.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Arbutus Biopharma and Hologic as they could maintain their solid performance.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past 90 days, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 2.3% higher. Our latest available data shows that ABUS has returned about 7.7% since the start of the calendar year. | On average, stocks in this group have lost 5.8% this year, meaning that ABUS is performing better in terms of year-to-date returns. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? | Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past 90 days, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 2.3% higher. | On average, stocks in this group have lost 5.8% this year, meaning that ABUS is performing better in terms of year-to-date returns. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past 90 days, the Zacks Consensus Estimate for ABUS' full-year earnings has moved 2.3% higher. |
34585.0 | 2023-05-04 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q1-loss-tops-revenue-estimates-0 | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.14 per share when it actually produced a loss of $0.14, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.69 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 47.94%. This compares to year-ago revenues of $12.58 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have added about 7.7% since the beginning of the year versus the S&P 500's gain of 6.5%.
What's Next for Arbutus?
While Arbutus has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $4.59 million in revenues for the coming quarter and -$0.57 on $21.11 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Akoya Biosciences (AKYA), has yet to report results for the quarter ended March 2023. The results are expected to be released on May 8.
This tissue analysis provider is expected to post quarterly loss of $0.46 per share in its upcoming report, which represents a year-over-year change of -4.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Akoya Biosciences' revenues are expected to be $20.37 million, up 20.6% from the year-ago quarter.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. | Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.69 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 47.94%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.69 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 47.94%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
34586.0 | 2023-05-02 00:00:00 UTC | Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates | ABUS | https://www.nasdaq.com/articles/sarepta-therapeutics-srpt-reports-q1-loss-tops-revenue-estimates-0 | nan | nan | Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to loss of $1.20 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 33.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.28 per share when it actually produced a loss of $1.24, delivering a surprise of 3.13%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Sarepta Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $253.5 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 13.60%. This compares to year-ago revenues of $210.83 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Sarepta Therapeutics shares have lost about 3.5% since the beginning of the year versus the S&P 500's gain of 8.6%.
What's Next for Sarepta Therapeutics?
While Sarepta Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Sarepta Therapeutics: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$2.12 on $249.94 million in revenues for the coming quarter and -$4.91 on $1.22 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended March 2023. The results are expected to be released on May 4.
This biopharmaceutical company is expected to post quarterly loss of $0.14 per share in its upcoming report, which represents a year-over-year change of -27.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Arbutus Biopharma's revenues are expected to be $4.52 million, down 64.1% from the year-ago quarter.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended March 2023. Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended March 2023. Sarepta Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $253.5 million for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 13.60%. | Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended March 2023. Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.46. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended March 2023. Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.46. |
34587.0 | 2023-04-29 00:00:00 UTC | HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation | ABUS | https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-arbutus-biopharma-abus-buy-recommendation-0 | nan | nan | Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation.
Analyst Price Forecast Suggests 130.28% Upside
As of April 24, 2023, the average one-year price target for Arbutus Biopharma is 5.78. The forecasts range from a low of 5.05 to a high of $6.30. The average price target represents an increase of 130.28% from its latest reported closing price of 2.51.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is 22MM, a decrease of 43.84%. The projected annual non-GAAP EPS is -0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 228 funds or institutions reporting positions in Arbutus Biopharma. This is a decrease of 6 owner(s) or 2.56% in the last quarter. Average portfolio weight of all funds dedicated to ABUS is 0.24%, an increase of 124.34%. Total shares owned by institutions increased in the last three months by 17.26% to 56,511K shares.
The put/call ratio of ABUS is 0.22, indicating a bullish outlook.
What are Other Shareholders Doing?
Two Seas Capital holds 7,504K shares representing 4.55% ownership of the company. In it's prior filing, the firm reported owning 5,654K shares, representing an increase of 24.66%. The firm increased its portfolio allocation in ABUS by 68.42% over the last quarter.
Hudson Bay Capital Management holds 4,851K shares representing 2.94% ownership of the company. In it's prior filing, the firm reported owning 4,962K shares, representing a decrease of 2.28%. The firm increased its portfolio allocation in ABUS by 37.83% over the last quarter.
Whitefort Capital Management holds 3,851K shares representing 2.33% ownership of the company.
Rubric Capital Management holds 3,466K shares representing 2.10% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,301K shares representing 2.00% ownership of the company. No change in the last quarter.
Arbutus Biopharma Background Information
(This description is provided by the company.)
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
See all Arbutus Biopharma regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.24%, an increase of 124.34%. The put/call ratio of ABUS is 0.22, indicating a bullish outlook. | Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.24%, an increase of 124.34%. The put/call ratio of ABUS is 0.22, indicating a bullish outlook. | Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.24%, an increase of 124.34%. The put/call ratio of ABUS is 0.22, indicating a bullish outlook. | Fintel reports that on April 28, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Average portfolio weight of all funds dedicated to ABUS is 0.24%, an increase of 124.34%. The put/call ratio of ABUS is 0.22, indicating a bullish outlook. |
34588.0 | 2023-04-26 00:00:00 UTC | Second judge says US not liable in Moderna COVID-19 vaccine patent case | ABUS | https://www.nasdaq.com/articles/second-judge-says-us-not-liable-in-moderna-covid-19-vaccine-patent-case-0 | nan | nan | By Blake Brittain
April 26 (Reuters) - Moderna Inc MRNA.O failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine.
Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit.
Connolly did not include the reasoning for his decision in his order, which he announced from the bench following arguments in the case.
A Moderna spokesperson said in a statement that the company "respectfully disagrees" with the decision and is confident that discovery will support its position. Representatives for Alnylam did not immediately respond to a request for comment.
Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.
The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year.
Moderna said in the Alnylam case that the court should dismiss claims that were based on vaccines it sold to the U.S. government and that Alnylam should instead seek damages from the government itself. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH.
U.S. District Judge Mitchell Goldberg rejected Moderna's motion in that case last year and said it had not yet proven the government was more than an "incidental beneficiary" of the shots.
Goldberg denied the motion for a second time last month after the federal government backed Moderna's position.
(Reporting by Blake Brittain in Washington; Editing by Cynthia Osterman)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA. U.S. District Judge Mitchell Goldberg rejected Moderna's motion in that case last year and said it had not yet proven the government was more than an "incidental beneficiary" of the shots. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit. The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. By Blake Brittain April 26 (Reuters) - Moderna Inc MRNA.O failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit. The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year. |
34589.0 | 2023-04-26 00:00:00 UTC | Second judge says US not liable in Moderna COVID-19 vaccine patent case | ABUS | https://www.nasdaq.com/articles/second-judge-says-us-not-liable-in-moderna-covid-19-vaccine-patent-case | nan | nan | By Blake Brittain
April 26 (Reuters) - Moderna Inc MRNA.O failed to persuade a Delaware federal judge on Wednesday to shift liability to the U.S. government for patent infringement allegations based on COVID-19 vaccines it provided for the government's vaccination effort.
Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit.
Connolly did not include the reasoning for his decision in his order, which he announced from the bench following arguments in the case. Representatives for Moderna and Alnylam did not immediately respond to requests for comment.
Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.
The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year.
Moderna said in the Alnylam case that the court should dismiss claims that were based on vaccines it sold to the U.S. government and that Alnylam should instead seek damages from the government itself. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH.
U.S. District Judge Mitchell Goldberg rejected Moderna's motion in that case last year and said it had not yet proven the government was more than an "incidental beneficiary" of the shots.
Goldberg denied the motion for a second time last month after the federal government backed Moderna's position.
(Reporting by Blake Brittain in Washington)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA. U.S. District Judge Mitchell Goldberg rejected Moderna's motion in that case last year and said it had not yet proven the government was more than an "incidental beneficiary" of the shots. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit. The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. By Blake Brittain April 26 (Reuters) - Moderna Inc MRNA.O failed to persuade a Delaware federal judge on Wednesday to shift liability to the U.S. government for patent infringement allegations based on COVID-19 vaccines it provided for the government's vaccination effort. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit. | Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. By Blake Brittain April 26 (Reuters) - Moderna Inc MRNA.O failed to persuade a Delaware federal judge on Wednesday to shift liability to the U.S. government for patent infringement allegations based on COVID-19 vaccines it provided for the government's vaccination effort. Chief Judge Colm Connolly's ruling for Alnylam Pharmaceuticals Inc ALNY.O came just over a month after a different judge in Delaware rejected Moderna's similar motion in another vaccine patent lawsuit. |
34590.0 | 2023-04-25 00:00:00 UTC | Why Arbutus Biopharma Stock Is Sinking Today | ABUS | https://www.nasdaq.com/articles/why-arbutus-biopharma-stock-is-sinking-today | nan | nan | What happened
Shares of Arbutus Biopharma (NASDAQ: ABUS) were trading down by 12.6% as of 11:04 a.m. ET Tuesday. The decline came after the company announced that the Food and Drug Administration (FDA) had placed a clinical hold on its Investigational New Drug (IND) application for AB-101, its experimental chronic hepatitis B virus therapy.
So what
It's unknown at this point exactly why the FDA placed the clinical hold on AB-101. The clinical-stage biopharmaceutical company said that the FDA indicated that it would send an official letter with more details within 30 days.
The company had hoped to advance the oral PD-L1 inhibitor into phase 1 clinical testing quickly enough to report initial data on it in the second half of 2023. Arbutus said it no longer expects to meet that timeline.
This FDA decision put a speed bump in Arbutus' path after what had up until that point been a great year. The biotech stock was up 24% year to date prior to Tuesday's announcement.
Arbutus presented positive preclinical data for experimental COVID-19 therapy AB-343 at the International Conference on Antiviral Research in March. It also dosed the first patient in a phase 1 study evaluating AB-161, an experimental oral therapy that holds the potential to provide a functional cure for patients infected by the hepatitis B virus.
Now what
There should be plenty of developments for investors to watch with Arbutus in the coming months. The company expects to report data from its phase 1 study of AB-161 in the second half of 2023. It also plans to announce preliminary results from a phase 2a study evaluating AB-729, a nucleoside/nucleotide analog therapy, and Vaccitech's VTP-300 in treating hepatitis B virus in the second half of the year as well.
10 stocks we like better than Arbutus Biopharma
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of April 24, 2023
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) were trading down by 12.6% as of 11:04 a.m. The company had hoped to advance the oral PD-L1 inhibitor into phase 1 clinical testing quickly enough to report initial data on it in the second half of 2023. Arbutus presented positive preclinical data for experimental COVID-19 therapy AB-343 at the International Conference on Antiviral Research in March. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) were trading down by 12.6% as of 11:04 a.m. It also dosed the first patient in a phase 1 study evaluating AB-161, an experimental oral therapy that holds the potential to provide a functional cure for patients infected by the hepatitis B virus. The company expects to report data from its phase 1 study of AB-161 in the second half of 2023. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) were trading down by 12.6% as of 11:04 a.m. The decline came after the company announced that the Food and Drug Administration (FDA) had placed a clinical hold on its Investigational New Drug (IND) application for AB-101, its experimental chronic hepatitis B virus therapy. 10 stocks we like better than Arbutus Biopharma When our analyst team has a stock tip, it can pay to listen. | What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) were trading down by 12.6% as of 11:04 a.m. The company expects to report data from its phase 1 study of AB-161 in the second half of 2023. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! |
34591.0 | 2023-04-06 00:00:00 UTC | HC Wainwright & Co. Reiterates Arbutus Biopharma (ABUS) Buy Recommendation | ABUS | https://www.nasdaq.com/articles/hc-wainwright-co.-reiterates-arbutus-biopharma-abus-buy-recommendation | nan | nan | Fintel reports that on April 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation.
Analyst Price Forecast Suggests 99.31% Upside
As of March 30, 2023, the average one-year price target for Arbutus Biopharma is $5.78. The forecasts range from a low of $5.05 to a high of $6.30. The average price target represents an increase of 99.31% from its latest reported closing price of $2.90.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arbutus Biopharma is $22MM, a decrease of 43.84%. The projected annual non-GAAP EPS is -$0.55.
For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia.
What are Other Shareholders Doing? | Fintel reports that on April 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. The projected annual revenue for Arbutus Biopharma is $22MM, a decrease of 43.84%. For more in-depth coverage of Arbutus Biopharma, view the free, crowd-sourced company research report on Finpedia. | Fintel reports that on April 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Analyst Price Forecast Suggests 99.31% Upside As of March 30, 2023, the average one-year price target for Arbutus Biopharma is $5.78. The average price target represents an increase of 99.31% from its latest reported closing price of $2.90. | Fintel reports that on April 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Analyst Price Forecast Suggests 99.31% Upside As of March 30, 2023, the average one-year price target for Arbutus Biopharma is $5.78. The average price target represents an increase of 99.31% from its latest reported closing price of $2.90. | Fintel reports that on April 5, 2023, HC Wainwright & Co. reiterated coverage of Arbutus Biopharma (NASDAQ:ABUS) with a Buy recommendation. Analyst Price Forecast Suggests 99.31% Upside As of March 30, 2023, the average one-year price target for Arbutus Biopharma is $5.78. See our leaderboard of companies with the largest price target upside. |
34592.0 | 2023-04-04 00:00:00 UTC | Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines | ABUS | https://www.nasdaq.com/articles/arbutus-files-patent-lawsuit-against-pfizer-biontech-over-covid-vaccines | nan | nan | Adds BioNTech's and Arbutus's response, updates shares
April 4 (Reuters) - Arbutus Biopharma ABUS.O on Tuesday sued U.S. drugmaker Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.
Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines to carry and transfer genetic material into the body.
The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology but they did not "result in a settlement".
Genevant is a joint venture between Arbutus and Roivant Sciences Ltd ROIV.O.
Arbutus Biopharma had also sued Moderna Inc MRNA.O in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents.
In its lawsuit against Moderna, Arbutus had said it was not looking to block the drugmaker from producing or distributing the vaccines but was seeking monetary damages including a reasonable royalty.
"Pfizer and BioNTech are aware that Arbutus Biopharma and Genevant Sciences have filed an action for infringement with respect to certain U.S. Patents," BioNTech told Reuters, and added that the companies would not comment on their legal strategy.
Pfizer had said earlier in the day that the company "will vigorously defend against the allegations of the lawsuit."
Arbutus declined to comment beyond the press release.
Moderna had sued Pfizer and BioNTech in August 2022 for allegedly infringing three patents related to their multibillion-dollar mRNA COVID-19 vaccines.
Pfizer and BioNtech are facing another patent infringement lawsuit related to the vaccines brought by Alnylam Pharmaceuticals Inc ALNY.Oin March 2022.
Arbutus fell 2.6% to $2.98 on Tuesday, while Pfizer was down 1.2% and U.S.-listed shares of BioNtech dropped almost 3%.
(Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru and Blake Brittain in Washington, D.C; Editing by Krishna Chandra Eluri and Sriraj Kalluvila)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds BioNTech's and Arbutus's response, updates shares April 4 (Reuters) - Arbutus Biopharma ABUS.O on Tuesday sued U.S. drugmaker Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents. Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines to carry and transfer genetic material into the body. Arbutus Biopharma had also sued Moderna Inc MRNA.O in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents. | Adds BioNTech's and Arbutus's response, updates shares April 4 (Reuters) - Arbutus Biopharma ABUS.O on Tuesday sued U.S. drugmaker Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents. Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines to carry and transfer genetic material into the body. Moderna had sued Pfizer and BioNTech in August 2022 for allegedly infringing three patents related to their multibillion-dollar mRNA COVID-19 vaccines. | Adds BioNTech's and Arbutus's response, updates shares April 4 (Reuters) - Arbutus Biopharma ABUS.O on Tuesday sued U.S. drugmaker Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents. Arbutus Biopharma had also sued Moderna Inc MRNA.O in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents. "Pfizer and BioNTech are aware that Arbutus Biopharma and Genevant Sciences have filed an action for infringement with respect to certain U.S. | Adds BioNTech's and Arbutus's response, updates shares April 4 (Reuters) - Arbutus Biopharma ABUS.O on Tuesday sued U.S. drugmaker Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents. Patents," BioNTech told Reuters, and added that the companies would not comment on their legal strategy. Moderna had sued Pfizer and BioNTech in August 2022 for allegedly infringing three patents related to their multibillion-dollar mRNA COVID-19 vaccines. |
34593.0 | 2023-03-10 00:00:00 UTC | Moderna loses bid to shift liability in COVID-19 vaccine patent case | ABUS | https://www.nasdaq.com/articles/moderna-loses-bid-to-shift-liability-in-covid-19-vaccine-patent-case | nan | nan | By Blake Brittain
March 10 (Reuters) - Despite the backing of the U.S. government, Moderna Inc MRNA.O on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States should have been sued instead.
U.S. District Judge Mitchell Goldberg ruled for the second time that Moderna had not yet shown that the government was the proper target of a lawsuit by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH.
A spokesperson for Genevant declined to comment on the decision. Representatives for Moderna, the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services did not immediately respond to requests for comment Friday.
Warminster Township, Pennsylvania-based Arbutus and Genevant — a joint venture between Arbutus and Roivant Sciences Ltd ROIV.O — sued Cambridge, Massachusetts-based Moderna for patent infringement last year, seeking royalties from Moderna's multi-billion-dollar COVID vaccines.
Moderna asked the court to dismiss the case last May. It said the United States was the proper target of the claims because the company made its vaccine for the government's nationwide vaccination effort, citing a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
Goldberg first ruled against Moderna in November. He said Moderna had not yet shown that the shots were made "for the government," and that the government may have been an "incidental beneficiary" instead.
The U.S. Justice Department said in a court filing last month that it supports Moderna's position, arguing that the company should not be liable for shots provided under its contract with the government as part of Operation Warp Speed.
Goldberg ruled Friday that Moderna's request was still premature and said details were still emerging about the scope of the company's government agreements.
The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00252.
(Reporting by Blake Brittain in Washington)
((blake.brittain@tr.com; +1 (202) 938-5713;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | U.S. District Judge Mitchell Goldberg ruled for the second time that Moderna had not yet shown that the government was the proper target of a lawsuit by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. By Blake Brittain March 10 (Reuters) - Despite the backing of the U.S. government, Moderna Inc MRNA.O on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States should have been sued instead. The U.S. Justice Department said in a court filing last month that it supports Moderna's position, arguing that the company should not be liable for shots provided under its contract with the government as part of Operation Warp Speed. | U.S. District Judge Mitchell Goldberg ruled for the second time that Moderna had not yet shown that the government was the proper target of a lawsuit by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. Goldberg ruled Friday that Moderna's request was still premature and said details were still emerging about the scope of the company's government agreements. The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. | U.S. District Judge Mitchell Goldberg ruled for the second time that Moderna had not yet shown that the government was the proper target of a lawsuit by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. By Blake Brittain March 10 (Reuters) - Despite the backing of the U.S. government, Moderna Inc MRNA.O on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States should have been sued instead. Warminster Township, Pennsylvania-based Arbutus and Genevant — a joint venture between Arbutus and Roivant Sciences Ltd ROIV.O — sued Cambridge, Massachusetts-based Moderna for patent infringement last year, seeking royalties from Moderna's multi-billion-dollar COVID vaccines. | U.S. District Judge Mitchell Goldberg ruled for the second time that Moderna had not yet shown that the government was the proper target of a lawsuit by Arbutus Biopharma Corp ABUS.O and Genevant Sciences GmbH. By Blake Brittain March 10 (Reuters) - Despite the backing of the U.S. government, Moderna Inc MRNA.O on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States should have been sued instead. Goldberg ruled Friday that Moderna's request was still premature and said details were still emerging about the scope of the company's government agreements. |
34594.0 | 2023-03-02 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q4-loss-misses-revenue-estimates-0 | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of $0.12, delivering no surprise.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.25 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.03%. This compares to year-ago revenues of $3.21 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have added about 20.6% since the beginning of the year versus the S&P 500's gain of 2.9%.
What's Next for Arbutus?
While Arbutus has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.15 on $3.54 million in revenues for the coming quarter and -$0.58 on $18 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Akoya Biosciences (AKYA), has yet to report results for the quarter ended December 2022. The results are expected to be released on March 6.
This tissue analysis provider is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of +12.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Akoya Biosciences' revenues are expected to be $21 million, up 30% from the year-ago quarter.
Is THIS the Ultimate New Clean Energy Source? (4 Ways to Profit)
The world is increasingly focused on eliminating fossil fuels and ramping up use of renewable, clean energy sources. Hydrogen fuel cells, powered by the most abundant substance in the universe, could provide an unlimited amount of ultra-clean energy for multiple industries.
Our urgent special report reveals 4 hydrogen stocks primed for big gains - plus our other top clean energy stocks.
See Stocks Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. | Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.25 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.03%. | Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.25 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 1.03%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. Click to get this free report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. |
34595.0 | 2023-02-28 00:00:00 UTC | ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates | ABUS | https://www.nasdaq.com/articles/adc-therapeutics-sa-adct-reports-q4-loss-misses-revenue-estimates | nan | nan | ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 38.78%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.65, delivering a surprise of -27.45%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
ADC Therapeutics SA, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $69.8 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 7.58%. This compares to year-ago revenues of $17.01 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
ADC Therapeutics SA shares have added about 6% since the beginning of the year versus the S&P 500's gain of 3.7%.
What's Next for ADC Therapeutics SA?
W | ADC Therapeutics SA, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $69.8 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 7.58%. The company has topped consensus revenue estimates two times over the last four quarters. ADC Therapeutics SA shares have added about 6% since the beginning of the year versus the S&P 500's gain of 3.7%. | ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.49. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.65, delivering a surprise of -27.45%. ADC Therapeutics SA shares have added about 6% since the beginning of the year versus the S&P 500's gain of 3.7%. | ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.49. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.65, delivering a surprise of -27.45%. ADC Therapeutics SA, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $69.8 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 7.58%. | ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.49. This quarterly report represents an earnings surprise of 38.78%. The company has topped consensus revenue estimates two times over the last four quarters. |
34596.0 | 2023-02-23 00:00:00 UTC | Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates | ABUS | https://www.nasdaq.com/articles/kymera-therapeutics-inc.-kymr-reports-q4-loss-misses-revenue-estimates | nan | nan | Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this company would post a loss of $0.70 per share when it actually produced a loss of $0.79, delivering a surprise of -12.86%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Kymera Therapeutics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $16.14 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 37.83%. This compares to year-ago revenues of $15.28 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Kymera Therapeutics, Inc. Shares have added about 26.3% since the beginning of the year versus the S&P 500's gain of 4%.
What's Next for Kymera Therapeutics, Inc.
While Kymera Therapeutics, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Kymera Therapeutics, Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.77 on $10.33 million in revenues for the coming quarter and -$2.17 on $114.02 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2022. The results are expected to be released on March 2.
This biopharmaceutical company is expected to post quarterly loss of $0.14 per share in its upcoming report, which represents a year-over-year change of +6.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Arbutus Biopharma's revenues are expected to be $6.31 million, up 96.6% from the year-ago quarter.
Is THIS the Ultimate New Clean Energy Source? (4 Ways to Profit)
The world is increasingly focused on eliminating fossil fuels and ramping up use of renewable, clean energy sources. Hydrogen fuel cells, powered by the most abundant substance in the universe, could provide an unlimited amount of ultra-clean energy for multiple industries.
Our urgent special report reveals 4 hydrogen stocks primed for big gains - plus our other top clean energy stocks.
See Stocks Now
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2022. Click to get this free report Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. | Click to get this free report Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2022. Kymera Therapeutics, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $16.14 million for the quarter ended December 2022, missing the Zacks Consensus Estimate by 37.83%. | Click to get this free report Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2022. Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.57. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended December 2022. Click to get this free report Kymera Therapeutics, Inc. (KYMR) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. While Kymera Therapeutics, Inc. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? |
34597.0 | 2023-01-11 00:00:00 UTC | Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains? | ABUS | https://www.nasdaq.com/articles/vericel-corporation-vcel-surges-16.3%3A-is-this-an-indication-of-further-gains | nan | nan | Vericel Corporation VCEL shares rallied 16.3% in the last trading session to close at $27.73. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 1.1% gain over the past four weeks.
The company recently announced an accelerated launch timeline for MACI arthroscopic delivery, which is now anticipated to be launched in 2024 along with its preliminary results for the fourth quarter and full year 2022. Investors are also upbeat about the recent approval of NexoBrid.
This company is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of -77.8%. Revenues are expected to be $52.6 million, up 10.5% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Vericel Corporation, the consensus EPS estimate for the quarter has been revised 15.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on VCEL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Vericel Corporation is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Arbutus Biopharma (ABUS), finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month.
Arbutus' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.14. Compared to the company's year-ago EPS, this represents a change of +6.7%. Arbutus currently boasts a Zacks Rank of #3 (Hold).
Free Report: Must-See Energy Stocks for 2023
Record profits at oil companies can mean big gains for you. With soaring demand and elevated prices, oil stocks could be top performers by far in 2023. Zacks has released a special report revealing the 4 oil stocks experts believe will deliver the biggest gains. (You’ll never guess Stock #2!)
Download Oil Market on Fire today, absolutely free.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Vericel Corporation (VCEL) : Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock in the same industry, Arbutus Biopharma (ABUS), finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month. Click to get this free report Vericel Corporation (VCEL) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Vericel Corporation (VCEL) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock in the same industry, Arbutus Biopharma (ABUS), finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month. | Click to get this free report Vericel Corporation (VCEL) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. One other stock in the same industry, Arbutus Biopharma (ABUS), finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month. | One other stock in the same industry, Arbutus Biopharma (ABUS), finished the last trading session 3% higher at $2.75. ABUS has returned -1.5% over the past month. Click to get this free report Vericel Corporation (VCEL) : Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report To read this article on Zacks.com click here. |
34598.0 | 2022-11-09 00:00:00 UTC | Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-reports-q3-loss-lags-revenue-estimates | nan | nan | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.10, delivering a surprise of 23.08%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.95 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 46.45%. This compares to year-ago revenues of $3.34 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Arbutus shares have lost about 36.8% since the beginning of the year versus the S&P 500's decline of -19.7%.
What's Next for Arbutus?
While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Arbutus: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.14 on $10.53 million in revenues for the coming quarter and -$0.44 on $48.07 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Humanigen Inc. (HGEN), has yet to report results for the quarter ended September 2022.
This company is expected to post quarterly loss of $0.21 per share in its upcoming report, which represents a year-over-year change of +81.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Humanigen Inc.'s revenues are expected to be $1.04 million, unchanged compared to the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Humanigen Inc. (HGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.95 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 46.45%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Arbutus, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $5.95 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 46.45%. | Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The company has topped consensus revenue estimates two times over the last four quarters. |
34599.0 | 2022-11-08 00:00:00 UTC | Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates | ABUS | https://www.nasdaq.com/articles/albireo-pharma-albo-reports-q3-loss-tops-revenue-estimates | nan | nan | Albireo Pharma (ALBO) came out with a quarterly loss of $1.89 per share versus the Zacks Consensus Estimate of a loss of $1.86. This compares to loss of $1.26 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -1.61%. A quarter ago, it was expected that this company would post a loss of $1.58 per share when it actually produced a loss of $2.04, delivering a surprise of -29.11%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Albireo Pharma, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.83 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 1.58%. This compares to year-ago revenues of $3.66 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Albireo Pharma shares have lost about 3.9% since the beginning of the year versus the S&P 500's decline of -20.1%.
What's Next for Albireo Pharma?
While Albireo Pharma has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Albireo Pharma: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.71 on $10.42 million in revenues for the coming quarter and -$7.89 on $35.13 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended September 2022. The results are expected to be released on November 9.
This biopharmaceutical company is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Arbutus Biopharma's revenues are expected to be $11.12 million, up 232.8% from the year-ago quarter.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Albireo Pharma (ALBO): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended September 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended September 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Albireo Pharma, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.83 million for the quarter ended September 2022, surpassing the Zacks Consensus Estimate by 1.58%. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended September 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Albireo Pharma (ALBO) came out with a quarterly loss of $1.89 per share versus the Zacks Consensus Estimate of a loss of $1.86. | One other stock from the same industry, Arbutus Biopharma (ABUS), is yet to report results for the quarter ended September 2022. Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report The company has topped consensus revenue estimates two times over the last four quarters. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.